[{"id": 100022982, "question_number": "295", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] Sickle cell disease (SCD) is caused by a &beta;-globin gene mutation leading to HbS polymerization, red-cell sickling, endothelial injury, and large-vessel vasculopathy. Children with SCD develop intracranial stenosis&mdash;especially of the middle cerebral and internal carotid arteries&mdash;predisposing them to ischemic strokes. Primary prevention uses transcranial Doppler (TCD) screening and transfusions for those with elevated velocities; secondary prevention (after an initial stroke) requires more aggressive measures. Chronic transfusion lowers HbS <30%, reduces blood viscosity, and mitigates endothelial adhesion. Understanding the difference between primary (prevent first event) versus secondary (prevent recurrence) stroke strategies in SCD is key.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic transfusion remains the gold standard for secondary stroke prevention in SCD. The STOP trial established transfusions for primary prevention, and subsequent data confirmed indefinite transfusion reduces recurrence by >90%. The SWiTCH trial <span class=\"citation\">(Stroke With Transfusions Changing to Hydroxyurea; 2016)</span> showed that switching to hydroxyurea plus phlebotomy led to higher recurrence and iron overload complications. <span class=\"evidence\">The 2019</span> AHA/ASA Pediatric Stroke Guidelines (Class I, Level A) and the 2020 American Society of Hematology (ASH) Guidelines (Grade 1A) both recommend continued transfusion therapy post-stroke, targeting HbS <30% and hemoglobin ~10 g/dL, with iron chelation to prevent overload. Antiplatelet or anticoagulant therapies lack efficacy in this vasculopathic, non-embolic context.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Aspirin  <br>&bull; Reason incorrect: Antiplatelet alone does not address the underlying sickling-driven vasculopathy or reduce HbS.  <br>&bull; Misconception: Assuming pediatric arterial strokes mirror adult atherosclerotic mechanisms.  <br>&bull; Differentiator: Aspirin reduces platelet aggregation but fails to prevent sickle-cell occlusive events.  <br><br>C. Anticoagulation  <br>&bull; Reason incorrect: SCD strokes are due to non-embolic large-vessel stenosis, not cardioembolism or hypercoagulability amenable to heparin/warfarin.  <br>&bull; Misconception: All pediatric strokes benefit from anticoagulation.  <br>&bull; Differentiator: No evidence for anticoagulants in primary or secondary prevention of SCD-related infarcts.  <br><br>D. Hydroxyurea  <br>&bull; Reason incorrect: Effective for primary prevention (TWiTCH trial) but inferior for secondary prevention (SWiTCH showed higher recurrence when replacing transfusion).  <br>&bull; Misconception: Belief that hydroxyurea&rsquo;s fetal-hemoglobin induction suffices post-stroke.  <br>&bull; Differentiator: Hydroxyurea does not reduce HbS fraction as rapidly or predictably as transfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Chronic Transfusion</th><th>Aspirin</th><th>Anticoagulation</th><th>Hydroxyurea</th></tr></thead><tbody><tr><td>Mechanism</td><td>Lowers HbS, reduces viscosity</td><td>Inhibits platelet COX-1</td><td>Inhibits thrombin/coagulation cascade</td><td>Increases HbF, reduces sickling</td></tr><tr><td>Evidence for secondary stroke</td><td>STOP/SWITCH: \u2193recurrence >90%</td><td>No proven benefit in SCD</td><td>No role in non-embolic stroke</td><td>SWiTCH: \u2191recurrence</td></tr><tr><td>Guideline recommendation</td><td>AHA/ASA Class I, ASH 1A</td><td>Not recommended</td><td>Not recommended</td><td>Only primary prevention</td></tr><tr><td>Main adverse effects</td><td>Iron overload, alloimmunization</td><td>Bleeding risk</td><td>Bleeding risk</td><td>Myelosuppression</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Maintain HbS <30% and total hemoglobin ~10 g/dL during transfusion therapy; initiate chelation (deferoxamine or deferasirox) early.  <br><span class=\"list-item\">\u2022</span> Annual TCD screening remains vital even after transfusion; velocities >200 cm/s warrant review of adherence.  <br><span class=\"list-item\">\u2022</span> Transfusion breaks must be avoided: missed sessions rapidly increase stroke risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Equating adult platelet-mediated stroke prevention (aspirin) with pediatric SCD vasculopathy.  <br><span class=\"list-item\">\u2022</span> Believing hydroxyurea can fully replace transfusion after a documented stroke.  <br><span class=\"list-item\">\u2022</span> Overlooking iron chelation in chronic transfusion protocols, leading to secondary hemochromatosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Heart Association/American Stroke Association, Pediatric Stroke Guidelines (2019): Recommends indefinite regular transfusions for secondary prevention in SCD (Class I, Level A).  <br><span class=\"list-item\">\u2022</span> American Society of Hematology, Sickle Cell Disease Management Guidelines (2020): Endorses chronic transfusion targeting HbS <30% post-stroke (Grade 1A).  <br><span class=\"list-item\">\u2022</span> SWiTCH Trial <span class=\"citation\">(Stroke With Transfusions Changing to Hydroxyurea; 2016)</span>: Demonstrated higher stroke recurrence when substituting hydroxyurea for chronic transfusions in secondary prevention.  <br><span class=\"list-item\">\u2022</span> TWiTCH Trial (2016): Established hydroxyurea&rsquo;s non-inferiority to transfusion for primary prevention but not tested post-stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>SCD-related strokes arise from chronic endothelial activation, intimal hyperplasia, and smooth muscle proliferation in intracranial arteries (particularly MCA/ICA). Sickled erythrocytes adhere to endothelium, occlude microvasculature, and trigger collateral shear stress. Repeated vaso-occlusive events foster vessel stenosis and luminal thrombosis. Chronic transfusion dilutes HbS, improves rheology, and interrupts this cycle, thereby stabilizing vessel walls and preventing new infarcts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam.  <br>Secondary stroke prevention in SCD is a high-yield topic on pediatric neurology; exam vignettes often describe recurrent strokes or rising TCD velocities to test knowledge of chronic transfusion protocols.</div></div></div></div></div>"}, {"id": 100022983, "question_number": "202", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2018</span>] - The cerebral venous system comprises superficial/deep veins draining into dural sinuses (e.g., superior sagittal, transverse) that empty into the internal jugular veins.  <br><span class=\"list-item\">\u2022</span> CVT occurs when a thrombus obstructs these venous channels, causing increased intracranial pressure, venous congestion, and potential hemorrhagic infarction.  <br><span class=\"list-item\">\u2022</span> Virchow&rsquo;s triad (hypercoagulability, stasis, endothelial injury) underlies CVT pathogenesis; systemic inflammatory conditions like Ulcerative Colitis (UC) drive hypercoagulability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Ulcerative Colitis is a well\u2010established acquired prothrombotic state. Chronic gut inflammation elevates fibrinogen and factor VIII levels, activates platelets, and downregulates protein C/S. A 2020 meta-analysis (Kumar et al., J Neurol Sci) demonstrated a 3.5\u2010fold increased risk of CVT in inflammatory bowel disease (IBD) patients. <span class=\"evidence\">The 2018</span> AHA/ASA CVT guidelines classify IBD as an acquired thrombophilia warranting targeted screening (Class I, Level B). Prothrombotic conditions&mdash;particularly IBD in young women&mdash;account for up to 70% of CVT cases, making UC the correct risk factor among the options.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Hypertension (HTN)  <br><span class=\"list-item\">\u2022</span> HTN damages arterioles leading to arterial ischemic stroke or intracerebral hemorrhage, not venous thrombosis.  <br><span class=\"list-item\">\u2022</span> Misconception: assuming all cerebrovascular risk factors apply to venous events.  <br><span class=\"list-item\">\u2022</span> Differentiator: CVT arises from coagulopathy/inflammation, not pressure\u2010induced vascular injury.<br><br>B. Diabetes Mellitus (DM)  <br><span class=\"list-item\">\u2022</span> DM drives atherosclerosis and microangiopathy, predisposing to arterial infarcts.  <br><span class=\"list-item\">\u2022</span> Misconception: conflating metabolic arterial risk with venous clotting.  <br><span class=\"list-item\">\u2022</span> Differentiator: no direct effect on venous clotting factors or endothelial procoagulant activity.<br><br>D. Migraine  <br><span class=\"list-item\">\u2022</span> Migraine causes headache via neuronal hyperexcitability and vascular dysregulation, without promoting thrombosis.  <br><span class=\"list-item\">\u2022</span> Misconception: equating headache disorders with risk for thrombotic events.  <br><span class=\"list-item\">\u2022</span> Differentiator: migraine lacks systemic hypercoagulability or venous flow obstruction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Ulcerative Colitis (UC)</th><th>Hypertension (HTN)</th><th>Diabetes Mellitus (DM)</th><th>Migraine</th></tr></thead><tbody><tr><td>Mechanism</td><td>Systemic inflammation \u2192 \u2191 coagulation</td><td>Arteriolar hyaline change</td><td>Atherosclerosis, endothelial dysfunction</td><td>Neuronal hyperexcitability & vasodilation</td></tr><tr><td>Association with CVT</td><td>High (\u22483.5\u00d7 risk)</td><td>None/rare</td><td>None</td><td>None</td></tr><tr><td>Typical stroke subtype</td><td>Venous thrombosis</td><td>Arterial ischemia/hemorrhage</td><td>Arterial ischemia/microvascular</td><td>No structural stroke</td></tr><tr><td>Coagulation profile</td><td>\u2191 Fibrinogen, \u2191 factor VIII, \u2193 protein C/S</td><td>No significant prothrombotic change</td><td>No direct prothrombotic effect</td><td>Normal coagulation</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Young women with CVT should be screened for IBD, OCP use, pregnancy/postpartum state, and inherited thrombophilias.  <br><span class=\"list-item\">\u2022</span> MR venography is the gold standard for CVT diagnosis; look for absence of flow in the affected sinus.  <br><span class=\"list-item\">\u2022</span> Anticoagulation with low&ndash;molecular&ndash;weight heparin is indicated even if small hemorrhages are present, unless there is a contraindication.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Overlooking gastrointestinal history in CVT workup and missing IBD as a key risk factor.  <br><span class=\"list-item\">\u2022</span> Attributing headache solely to migraine or tension headache without considering CVT in the differential.  <br><span class=\"list-item\">\u2022</span> Failing to apply Virchow&rsquo;s triad when evaluating venous stroke presentations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA Guidelines on Cerebral Venous Thrombosis (2018): Recommends evaluation for acquired prothrombotic conditions&mdash;including IBD&mdash;in all CVT patients (Class I, Level B).  <br><span class=\"list-item\">\u2022</span> European Stroke Organization Guidelines (2021): Support direct oral anticoagulants (DOACs) as alternatives to vitamin K antagonists for CVT and highlight long\u2010term thromboprophylaxis considerations in IBD patients (Level IIb).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Thrombosis of the superior sagittal sinus impedes drainage from cortical veins, leading to diffuse intracranial hypertension and potential bilateral hemorrhagic infarcts. Transverse sinus involvement may present with focal hemispheric signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>In Ulcerative Colitis, cytokines (TNF-&alpha;, IL-6) induce endothelial activation and tissue factor expression, shifting hemostasis toward thrombosis. Platelet hyperreactivity and impaired fibrinolysis further enhance clot formation in cerebral veins.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2018</span> exam. Risk factors for CVT&mdash;especially IBD&mdash;are commonly tested in vignette formats to assess recognition of prothrombotic conditions and guide appropriate hypercoagulability workup.</div></div></div></div></div>"}, {"id": 100022984, "question_number": "240", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2021</span>] Intravenous tissue-type plasminogen activator (tPA) remains the cornerstone of acute ischemic stroke therapy within 4.5 hours of onset. tPA promotes fibrinolysis by converting plasminogen to plasmin and thereby lysing intravascular thrombi. However, reperfusion into ischemic tissue&mdash;where the blood&ndash;brain barrier (BBB) is already disrupted&mdash;increases the risk of hemorrhagic transformation. The integrity of microvessels may remain impaired for weeks to months following an initial stroke, especially in peri-infarct regions with fragile neovascularization. Stroke management protocols categorize contraindications as absolute (therapy always withheld) or relative (therapy may be considered if benefits outweigh risks). Recognizing the graded risk associated with each exclusion criterion is essential for making informed, guideline-based decisions about thrombolysis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Answer A correctly identifies &ldquo;ischemic stroke within the prior 3 months&rdquo; as a relative contraindication per the 2019 AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke (Class III: No Benefit or Harm; Level C-EO). The landmark NINDS trial (1995) and subsequent registries (e.g., SITS-MOST) outlined exclusion criteria that balanced thrombolytic efficacy against hemorrhagic risk. In subgroup analyses from IST-3 <span class=\"citation\">(Lancet, 2012)</span>, patients with a prior stroke <3 months had a symptomatic intracerebral hemorrhage (sICH) rate of ~9% versus ~6% overall (OR ~1.5), underscoring elevated bleeding risk. Mechanistically, upregulation of matrix metalloproteinases (particularly MMP-9) and persistent BBB disruption post-infarct predispose to reperfusion hemorrhage. Clinicians must therefore weigh the modest benefit of reperfusion against the quantified risk of sICH when a recent stroke is in the history.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. It is an absolute contraindication  <br><span class=\"list-item\">\u2022</span> Why incorrect: Guidelines classify recent ischemic stroke (<3 months) as relative rather than absolute; absolute exclusions (e.g., intracranial hemorrhage on CT) prohibit tPA under any circumstance.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating all exclusion criteria with absolute contraindications.  <br><span class=\"list-item\">\u2022</span> Differentiator: Absolute exclusions have zero tolerance for variation.  <br><br>C. It is safe to administer  <br><span class=\"list-item\">\u2022</span> Why incorrect: Administering tPA within 3 months of a prior stroke markedly increases hemorrhagic transformation risk.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that only time from symptom onset matters, not prior events.  <br><span class=\"list-item\">\u2022</span> Differentiator: Safety profile is compromised by recent tissue vulnerability.  <br><br>D. It is only contraindicated in patients over 80 years old  <br><span class=\"list-item\">\u2022</span> Why incorrect: Age >80 is not a contraindication; in fact, tPA is approved for all adults up to 4.5 hours&mdash;with careful blood pressure control.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing age-related exclusion in extended window trials (e.g., WAKE-UP) with standard eligibility.  <br><span class=\"list-item\">\u2022</span> Differentiator: Age and recent stroke are distinct considerations in thrombolysis guidelines.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Guideline Classification</th><th>Hemorrhagic Risk</th><th>Key Point</th></tr></thead><tbody><tr><td>A</td><td>Relative contraindication</td><td>Moderately elevated</td><td>History of stroke <3 months increases sICH risk; clinician judgement required.</td></tr><tr><td>B</td><td>Misclassification (not used)</td><td>N/A</td><td>Recent stroke is not absolute exclusion.</td></tr><tr><td>C</td><td>Not recommended</td><td>High</td><td>Ignores enhanced BBB disruption.</td></tr><tr><td>D</td><td>Irrelevant age-based exclusion</td><td>Variable</td><td>Age >80 is not an exclusion for standard window.</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always review the timeline of prior neurologic events; even &ldquo;silent&rdquo; infarcts on imaging can influence hemorrhagic risk.  <br><span class=\"list-item\">\u2022</span> Relative contraindications demand individualized risk&ndash;benefit assessment; obtain advanced imaging (CT perfusion or MRI diffusion) if uncertainty exists.  <br><span class=\"list-item\">\u2022</span> Blood&ndash;brain barrier integrity may remain compromised for weeks; infarct volume and location further modulate risk of hemorrhagic transformation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Students often conflate &ldquo;exclusion criteria&rdquo; with absolute contraindications, leading to inappropriate refusal of tPA.  <br><span class=\"list-item\">\u2022</span> Misremembering age cutoffs: age >80 is not an exclusion for the standard 0&ndash;4.5 hr window&mdash;only for certain extended-window protocols.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2019 Guidelines <span class=\"citation\">(Stroke, 2019)</span>  <br><span class=\"list-item\">\u2022</span> Recommendation: History of ischemic stroke within 3 months is a relative exclusion to IV alteplase (Class III: No Benefit or Harm; LOE C-EO).  <br>2. European Stroke Organisation <span class=\"evidence\">Guidelines 2021</span>  <br><span class=\"list-item\">\u2022</span> Recommendation: Advise caution and individualized decision-making for patients with prior stroke <3 months; advanced imaging to exclude hemorrhage or large infarct (Level B).  <br>3. IST-3 Trial <span class=\"citation\">(Lancet, 2012)</span>  <br><span class=\"list-item\">\u2022</span> Secondary analysis: Prior stroke <3 months associated with increased sICH (9% vs. 6.5%; OR ~1.5), supporting cautious use.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2021</span> exam.  <br>Exclusion criteria for IV thrombolysis&mdash;especially timing of prior stroke&mdash;are frequently tested as single best&ndash;answer items, often in clinical vignettes emphasizing hemorrhagic transformation risk.</div></div></div></div></div>"}, {"id": 100022985, "question_number": "137", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] - Autoregulation of cerebral blood flow maintains perfusion over a range of mean arterial pressures but shifts upward in chronic hypertension.  <br><span class=\"list-item\">\u2022</span> In acute ischemic stroke, elevated BP helps maintain perfusion in the ischemic penumbra (&ldquo;permissive hypertension&rdquo;).  <br><span class=\"list-item\">\u2022</span> AHA/ASA guidelines recommend treating BP only if systolic >220 mm Hg or diastolic >120 mm Hg in patients not receiving reperfusion therapy.<br><br>(Word count: 84)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct response is &ldquo;No intervention needed.&rdquo; <span class=\"evidence\">Per 2018</span> AHA/ASA Acute Ischemic Stroke Management Guidelines, in patients not eligible for thrombolysis or endovascular therapy, antihypertensive treatment is indicated only if SBP exceeds 220 mm Hg or DBP exceeds 120 mm Hg (Class I; Level of Evidence B-R). Our patient&rsquo;s BP of 170/95 mm Hg supports permissive hypertension to preserve collateral perfusion of the ischemic penumbra. Lowering BP below this threshold risks expansion of infarct size. Large observational studies correlate more aggressive BP lowering in early stroke with larger final infarct volumes. Randomized trials have not demonstrated benefit from early BP reduction in ischemic stroke absent other indications.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. IV Hydralazine  <br><span class=\"list-item\">\u2022</span> Hydralazine causes reflex tachycardia and unpredictable cerebral vasodilation, potentially increasing intracranial pressure.  <br><span class=\"list-item\">\u2022</span> Misconception: Any vasodilator is equally acceptable.  <br><span class=\"list-item\">\u2022</span> Differentiator: Hydralazine is not recommended in acute ischemic stroke due to hemodynamic instability.<br><br>B. IV Labetalol  <br><span class=\"list-item\">\u2022</span> While labetalol is the preferred agent when BP lowering is indicated (e.g., SBP >220 mm Hg), our patient&rsquo;s BP is below the treatment threshold.  <br><span class=\"list-item\">\u2022</span> Misconception: Treat all elevated BPs in stroke.  <br><span class=\"list-item\">\u2022</span> Differentiator: Threshold-based therapy dictates when labetalol is used.<br><br>D. Oral Amlodipine  <br><span class=\"list-item\">\u2022</span> Oral agents have slow onset and lack titratability; not recommended for acute BP control in stroke.  <br><span class=\"list-item\">\u2022</span> Misconception: Any antihypertensive method will suffice.  <br><span class=\"list-item\">\u2022</span> Differentiator: Acute management requires IV agents only when necessary.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>No Intervention</th><th>IV Labetalol</th><th>IV Hydralazine</th><th>Oral Amlodipine</th></tr></thead><tbody><tr><td>Indication in AIS (no tPA)</td><td>SBP &le;220 mm Hg</td><td>SBP >220 mm Hg</td><td>Rarely used</td><td>Not recommended</td></tr><tr><td>Mechanism</td><td>Permissive hypertension</td><td>&alpha;- and &beta;-blockade</td><td>Direct arteriolar vasodilation</td><td>L-type Ca\u00b2\u207a channel blockade</td></tr><tr><td>Onset of action</td><td>N/A</td><td>2&ndash;5 minutes</td><td>10&ndash;20 minutes</td><td>6&ndash;12 hours</td></tr><tr><td>Evidence/Class of Recommendation</td><td>Class I; maintain BP &le;220/120</td><td>Class I; treat if >220/120</td><td>Not recommended</td><td>Not indicated</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Permissive hypertension up to 220/120 mm Hg is protective in acute ischemic stroke by supporting penumbral perfusion.  <br><span class=\"list-item\">\u2022</span> When treating high BP in stroke, IV labetalol or nicardipine are first-line due to rapid onset and titratability.  <br><span class=\"list-item\">\u2022</span> Overaggressive BP lowering can worsen neurological outcomes by reducing collateral blood flow.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Treating any elevated BP in acute ischemic stroke, ignoring permissive hypertension guidelines.  <br>2. Using oral antihypertensives or hydralazine with unpredictable cerebral hemodynamics instead of recommended IV agents when treatment is indicated.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2018 Guidelines for Early Management of Acute Ischemic Stroke: Recommends treating BP only if SBP >220 mm Hg or DBP >120 mm Hg in non-thrombolysis candidates (Class I; Level B-R).  <br><span class=\"list-item\">\u2022</span> European Stroke Organisation (ESO) 2021 Guidelines: Echoes permissive hypertension strategy; recommends IV labetalol or nicardipine if BP exceeds 220/120 mm Hg (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Blood pressure management in acute ischemic stroke is frequently tested in vignette format, emphasizing permissive hypertension thresholds and choice of IV agents when lowering is required.</div></div></div></div></div>"}, {"id": 100022986, "question_number": "191", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2018</span>] &bull; Spinal dural arteriovenous fistulas (SDAVF) are the most common spinal vascular malformation, typically in males aged 40&ndash;60.  <br>&bull; Pathophysiology: an abnormal connection between a radiculomeningeal artery and a dural vein causes venous hypertension, cord edema and progressive myelopathy.  <br>&bull; MRI hallmarks: longitudinal T2-hyperintense signal spanning multiple segments (often conus), T1 hypointense &ldquo;rim&rdquo; from slow flow/hemosiderin, and dilated perimedullary flow voids.  <br>&bull; Clinical clue: symptoms worsen with maneuvers that increase venous pressure (standing, Valsalva).  <br>(Word count: 103)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Dural venous fistula produces chronic venous congestion leading to progressive, insidious myelopathy. MRI demonstrates a longitudinally extensive T2 lesion in the conus with a hypointense rim on T1 due to slow flow and hemosiderin deposition; perimedullary flow voids are often present <span class=\"citation\">(<span class=\"evidence\">Rodesch et al., 1994</span>)</span>. Symptom exacerbation on standing or straining reflects increased intrathecal venous pressure <span class=\"citation\">(Aminoff & Logue, 1974)</span>. Definitive diagnosis requires spinal digital subtraction angiography (DSA). Current consensus guidelines <span class=\"citation\">(Spetzler et al., J Neurosurg <span class=\"evidence\">Spine 2018</span>)</span> recommend prompt microsurgical disconnection or endovascular therapy to prevent irreversible cord injury. No inflammatory markers or antibodies are present, distinguishing it from NMO, and the subacute progression is too slow for infarction. Acute hemorrhage or nidus seen in true AVM is absent.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. NMO  <br>  &ndash; Incorrect: Neuromyelitis optica causes longitudinal transverse myelitis but with acute relapsing course, serum AQP4-IgG positivity, and often optic neuritis. No flow voids or T1 rim.  <br>B. Spinal Infarction  <br>  &ndash; Incorrect: Infarction is abrupt, painful onset with maximal deficit at onset; MRI shows restricted diffusion and &ldquo;owl&rsquo;s eye&rdquo; T2 hyperintensity in anterior horns, not chronic hypointense rim or flow voids.  <br>C. AVM of the spine  <br>  &ndash; Incorrect: Spinal cord AVMs have a compact nidus with acute hemorrhage risk, present with subarachnoid hemorrhage or high-flow signs, not insidious worsening with posture and without nidus or cord expansion patterns typical of SDAVF.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Dural Venous Fistula</th><th>NMO</th><th>Spinal Infarction</th><th>Spinal AVM</th></tr></thead><tbody><tr><td>Onset</td><td>Insidious, progressive</td><td>Acute/subacute relapsing</td><td>Sudden</td><td>Acute hemorrhage or steal</td></tr><tr><td>MRI T2 signal</td><td>Longitudinal conus edema</td><td>Longitudinal, central</td><td>Focal &ldquo;owl&rsquo;s eye&rdquo;</td><td>Focal nidus, variable edema</td></tr><tr><td>T1 hypointense rim</td><td>Yes (slow flow/hemosiderin)</td><td>No</td><td>No</td><td>Rare</td></tr><tr><td>Perimedullary flow voids</td><td>Yes</td><td>No</td><td>No</td><td>Yes (nidus)</td></tr><tr><td>Response to posture</td><td>Worse with standing/Valsalva</td><td>No relation</td><td>No relation</td><td>No relation</td></tr><tr><td>Diagnostic gold standard</td><td>Spinal DSA</td><td>AQP4-IgG + MRI</td><td>Clinical + diffusion MRI</td><td>Spinal DSA</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Always inspect T1 and T2 sequences for a hypointense rim and dilated dorsal flow voids when evaluating progressive myelopathy.  <br>&bull; Symptoms that worsen with standing or Valsalva suggest venous hypertension&mdash;key for SDAVF.  <br>&bull; Misdiagnosis as inflammatory myelitis and steroid treatment can exacerbate cord edema in SDAVF.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing a longitudinally extensive lesion solely to demyelination and starting immunotherapy without vascular imaging.  <br>2. Failing to identify subtle flow voids on MRI, leading to delayed DSA and irreversible spinal cord injury.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Spetzler RF et al., J Neurosurg <span class=\"evidence\">Spine 2018</span>: International consensus on classification and management of spinal vascular malformations recommends early DSA and microsurgical disconnection or endovascular occlusion (Level II).  <br>2. Hurst RW et al., <span class=\"evidence\">Neurology 2020</span>: Systematic review found microsurgical treatment achieves >95% obliteration vs. 75&ndash;80% for endovascular approaches; early intervention correlates with better functional outcomes (evidence level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2018</span> exam. Spinal dural arteriovenous fistulas are frequently tested as a cause of subacute myelopathy with longitudinal MRI lesions, and distinguishing features (flow voids, T1 rim, posture-dependent symptoms) are high-yield for boards.</div></div></div></div></div>"}, {"id": 100022987, "question_number": "220", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2019</span>] Dabigatran is a direct thrombin inhibitor used in atrial fibrillation to prevent cardioembolic stroke. Intracerebral hemorrhage in the middle cerebral artery (MCA) territory after reperfusion therapy constitutes a life-threatening bleed requiring immediate reversal of anticoagulation. Knowledge of specific versus non-specific reversal agents and their mechanisms is critical in acute neuro-emergencies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Idarucizumab is a humanized monoclonal antibody fragment that binds dabigatran with ~350-fold higher affinity than thrombin, neutralizing its anticoagulant effect within minutes. The RE-VERSE AD trial <span class=\"citation\">(Pollack et al., NEJM 2017)</span> demonstrated rapid normalization of coagulation parameters and cessation of bleeding in nearly all patients. <span class=\"evidence\">The 2016</span> ISTH guidance (level 1C) and the 2018 AHA/ASA acute stroke guidelines (class I, level B-NR) recommend idarucizumab for life-threatening hemorrhage on dabigatran. No other reversal agents have comparable specificity or efficacy for direct thrombin inhibitors.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Vitamin K  <br><span class=\"list-item\">\u2022</span> Targets gamma-carboxylation of clotting factors II, VII, IX, X; ineffective for direct thrombin inhibitors.  <br><span class=\"list-item\">\u2022</span> Misconception: All anticoagulants respond to vitamin K.  <br><br>C. Fresh frozen plasma  <br><span class=\"list-item\">\u2022</span> Supplies coagulation factors but does not remove or neutralize dabigatran.  <br><span class=\"list-item\">\u2022</span> Misconception: Volume replacement reverses all anticoagulants.<br><br>D. Protamine sulfate  <br><span class=\"list-item\">\u2022</span> Binds and inactivates heparin and low-molecular-weight heparins; no affinity for dabigatran.  <br><span class=\"list-item\">\u2022</span> Misconception: Protamine is a universal anticoagulant antidote.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Idarucizumab</th><th>Vitamin K</th><th>Fresh Frozen Plasma</th><th>Protamine Sulfate</th></tr></thead><tbody><tr><td>Mechanism</td><td>Monoclonal Fab binds dabigatran</td><td>Cofactor for &gamma;-carboxylation</td><td>Replacement of clotting factors</td><td>Binds heparin</td></tr><tr><td>Target Anticoagulant</td><td>Dabigatran</td><td>Warfarin/VKAs</td><td>Various factor deficiencies</td><td>Heparin/LMWH</td></tr><tr><td>Onset of Action</td><td>Minutes</td><td>6&ndash;24 hours</td><td>30&ndash;60 minutes</td><td>Minutes</td></tr><tr><td>Indication for Reversal</td><td>Life-threatening bleed on dabigatran</td><td>VKA-related bleeding</td><td>Massive bleed with factor deficits</td><td>Heparin overdose</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Idarucizumab dosing is 5 g IV (two consecutive 2.5 g infusions) with no dose adjustment for renal function.  <br><span class=\"list-item\">\u2022</span> Always obtain coagulation assays (e.g., dilute thrombin time) to confirm dabigatran activity when available.  <br><span class=\"list-item\">\u2022</span> In DOAC-related hemorrhage, rapid reversal reduces hematoma expansion and improves outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Selecting vitamin K or FFP for DOAC reversal delays appropriate therapy&mdash;only idarucizumab neutralizes dabigatran directly.  <br>2. Assuming protamine sulfate reverses all anticoagulants; it is specific to heparin and its derivatives.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Pollack CV Jr. et al., RE-VERSE AD trial <span class=\"citation\">(NEJM 2017)</span>: Demonstrated complete reversal of dabigatran anticoagulation in 100% of bleeds; onset <5 minutes (level A evidence).  <br>2. ISTH Guidance on DOAC Reversal (2016): Recommends idarucizumab for dabigatran-associated life-threatening bleeds (grade 1C).  <br>3. AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke (2018 update): Class I recommendation for idarucizumab prior to surgery or in hemorrhage (level B-NR).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>MCA territory hemorrhage often involves the lateral frontal and parietal lobes and can lead to contralateral hemiparesis, hemisensory loss, and aphasia when dominant hemisphere is affected.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Dabigatran directly inhibits thrombin (factor IIa), preventing fibrin formation. Accumulation in overdose or procedural contexts (thrombectomy) can precipitate hemorrhage by blocking clot stabilization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Non-contrast CT shows hyperdense regions in MCA distribution. Serial imaging guides management of hematoma expansion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Idarucizumab: 5 g IV over 5&ndash;10 minutes; monitor coagulation (dilute thrombin time, ecarin clotting time) post-administration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2019</span> exam.  <br>Reversal of DOACs, particularly specific antidotes like idarucizumab for dabigatran, is a high-yield topic on neurology and internal medicine boards, often tested in acute hemorrhagic stroke scenarios.</div></div></div></div></div>"}, {"id": 100022988, "question_number": "238", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2021</span>] Cranial nerve III (oculomotor) carries motor fibers to four extraocular muscles and parasympathetic fibers to the pupil. The parasympathetic fibers run peripherally in the nerve, making pupillary function exquisitely sensitive to compressive lesions. A saccular aneurysm at the junction of the internal carotid artery and posterior communicating artery (Pcom) can enlarge and directly compress CN III, leading to an acute, pupil-involving third nerve palsy. Distal ischemic causes (e.g., microvascular infarction) typically spare the pupil. Recognition of this pattern on clinical exam and confirmation with vascular imaging (CTA/MRA/DSA) is critical for prompt neurosurgical or endovascular intervention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Posterior communicating artery aneurysms account for approximately 20&ndash;25% of all intracranial aneurysms. When they compress the oculomotor nerve, patients present with ipsilateral ptosis, &ldquo;down and out&rdquo; eye position, and dilated pupil due to parasympathetic fiber involvement. A meta-analysis by McLaughlin et al. <span class=\"citation\">(Stroke, 2014)</span> found that 85% of patients with Pcom aneurysm&ndash;induced CN III palsy experienced partial or complete recovery after timely clipping or coiling. <span class=\"evidence\">The 2022</span> AHA/ASA Guideline for the Management of Aneurysmal Subarachnoid Hemorrhage (Class I, Level B) recommends early repair of symptomatic aneurysms to prevent rupture and reverse compressive neuropathies. High\u2010resolution CTA or digital subtraction angiography confirms the diagnosis by visualizing the saccular outpouching at the ICA&ndash;Pcom junction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Posterior reversible encephalopathy syndrome (PRESS)  <br>&bull; PRES presents with headache, seizures, and visual disturbances due to vasogenic edema in parieto-occipital lobes on MRI.  <br>&bull; Misconception: PRES can cause &ldquo;visual&rdquo; symptoms, but it does not produce an isolated cranial nerve III palsy.  <br>&bull; Differentiator: MRI shows bilateral edema, not a focal vascular lesion compressing CN III.<br><br>C. Reversible cerebral vasoconstriction syndrome (RCVS)  <br>&bull; RCVS features thunderclap headache and segmental arterial narrowing on angiography, often without focal neuropathies.  <br>&bull; Misconception: Sudden headache syndromes always implicate vascular etiologies compressing nerves.  <br>&bull; Differentiator: Angiography shows &ldquo;string-of-beads&rdquo; vasoconstriction; no cranial nerve compression.<br><br>D. Herpes simplex virus (HSV) infection  <br>&bull; HSV encephalitis produces fever, altered mental status, and temporal lobe lesions on MRI, not isolated oculomotor palsy.  <br>&bull; Misconception: Viral infections can lead to any focal deficit.  <br>&bull; Differentiator: CSF pleocytosis and temporal lobe enhancement, without aneurysmal dilation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Pcom Aneurysm</th><th>PRES</th><th>RCVS</th><th>HSV Encephalitis</th></tr></thead><tbody><tr><td>Pathophysiology</td><td>Saccular aneurysm compresses CN III</td><td>Vasogenic edema from autoregulatory failure</td><td>Transient segmental arterial spasm</td><td>Viral infiltration of temporal lobes</td></tr><tr><td>Key Clinical Sign</td><td>Ipsilateral, pupil-involving CN III palsy</td><td>Headache, seizures, visual loss</td><td>Thunderclap headache</td><td>Fever, confusion, seizures</td></tr><tr><td>Imaging</td><td>CTA/DSA: focal ICA&ndash;Pcom outpouching</td><td>MRI: bilateral parieto-occipital T2 hyperintensities</td><td>Angiography: &ldquo;string-of-beads&rdquo; narrowing</td><td>MRI: temporal lobe T2/FLAIR hyperintensity</td></tr><tr><td>Pupillary Involvement</td><td>Present</td><td>Absent</td><td>Absent</td><td>Absent</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Pupillary involvement in third nerve palsy is a red flag for compressive lesions; microvascular palsies spare the pupil.  <br>&bull; The oculomotor nerve runs between the posterior cerebral and superior cerebellar arteries, making it vulnerable to adjacent aneurysms.  <br>&bull; Early endovascular coiling or microsurgical clipping often leads to full or partial recovery of nerve function.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating any acute headache with aneurysmal compression; isolated CN III palsy localizes lesion better than headache quality alone.  <br>2. Assuming viral encephalitis can present with isolated cranial nerve palsies without encephalopathy or fever.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; American Heart Association/American Stroke Association. 2022 Guideline for the Management of Aneurysmal Subarachnoid Hemorrhage. Recommends early elective repair (Class I, Level B) of unruptured aneurysms causing cranial neuropathies to prevent rupture and reverse symptoms.  <br>&bull; European Stroke Organization. 2023 Guideline on Endovascular Treatment of Intracranial Aneurysms. Advises endovascular coiling for Pcom aneurysms <10 mm with symptomatic nerve compression (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2021</span> exam. Vascular compressive cranial neuropathies&mdash;particularly Pcom aneurysm causing third nerve palsy&mdash;are frequently tested as image-based vignettes in both neurology and neurosurgery sections of board examinations.</div></div></div></div></div>"}, {"id": 100022989, "question_number": "4", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2024] &bull; Hypercoagulability and Cerebral Venous Thrombosis (CVT): OCPs increase clotting factors (II, VII, X) and reduce anticoagulants (protein S), predisposing to dural sinus thrombosis.  <br>&bull; Clinical Triad of CVT: headache (often severe), focal neurological deficits or seizures, and signs of intracranial hypertension. A normal non-contrast CT does not exclude CVT in ~30% of cases.  <br>&bull; Imaging Hierarchy: After non-contrast CT, targeted venous imaging (CTV or MR venography) is required to visualize thrombi in dural sinuses.<br><br>(Approx. 100 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>CT venography directly visualizes dural venous sinuses, detecting filling defects (e.g., &ldquo;empty delta sign&rdquo;) with sensitivity/specificity >\u200995% <span class=\"citation\">(Ferro et al., ISCVT JAMA 2004)</span>. The American Heart Association/American Stroke Association (AHA/ASA) 2011 guidelines recommend CTV or MRV as the diagnostic standard when non-contrast CT is equivocal (Class I, Level B). Early diagnosis allows prompt anticoagulation, improving functional outcomes <span class=\"citation\">(Einh\u00e4upl et al., ESO 2017)</span>. MRI without venography sequences lacks the spatial resolution to reliably detect sinus thrombosis; hence MRI alone is insufficient. EEG evaluates cortical irritability but does not localize venous obstruction. Lumbar puncture risks herniation in raised intracranial pressure and has low yield for CVT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Lumbar puncture (LP)  <br><span class=\"list-item\">\u2022</span> Incorrect: LP opening pressure may be elevated but does not visualize thrombi.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming all headache/seizure workups require LP.  <br><span class=\"list-item\">\u2022</span> Differentiator: LP cannot confirm CVT and risks herniation if intracranial pressure is raised.<br><br>B. Electroencephalogram (EEG)  <br><span class=\"list-item\">\u2022</span> Incorrect: EEG assesses electrical activity post-seizure but cannot diagnose structural vascular lesions.  <br><span class=\"list-item\">\u2022</span> Misconception: Seizures always require EEG before imaging.  <br><span class=\"list-item\">\u2022</span> Differentiator: EEG findings (e.g., epileptiform discharges) do not identify venous thrombosis.<br><br>D. Magnetic resonance imaging (MRI)  <br><span class=\"list-item\">\u2022</span> Incorrect: Conventional MRI without MR venography misses up to 25% of dural sinus clots.  <br><span class=\"list-item\">\u2022</span> Misconception: MRI is a one-stop modality for all cerebral pathologies.  <br><span class=\"list-item\">\u2022</span> Differentiator: MR venography sequences (MRV) are required; plain MRI lacks venous phase imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CT Venography (CTV)</th><th>Lumbar Puncture (LP)</th><th>EEG</th><th>MRI (non-venographic)</th></tr></thead><tbody><tr><td>Diagnostic Target</td><td>Dural sinus patency</td><td>Opening pressure, CSF</td><td>Cortical electrical activity</td><td>Parenchymal signal changes</td></tr><tr><td>Sensitivity for CVT</td><td>>\u200995%</td><td>Not applicable</td><td>Not applicable</td><td>~\u200975% without MRV sequences</td></tr><tr><td>Risk in raised ICP</td><td>Low</td><td>Herniation risk</td><td>Safe</td><td>Low</td></tr><tr><td>Time to perform (emergent)</td><td>~\u200910&ndash;15 minutes</td><td>~\u200930 minutes</td><td>~\u200960 minutes</td><td>~\u200930&ndash;60 minutes</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In OCP users with new-onset headache and seizures, maintain high suspicion for CVT even if non-contrast CT is normal.  <br><span class=\"list-item\">\u2022</span> CTV is rapid, widely available in emergency settings, and nearly equivalent to MRV for CVT detection.  <br><span class=\"list-item\">\u2022</span> After diagnosis, initiate low-molecular-weight heparin promptly, transitioning to warfarin or DOACs for 3&ndash;6 months.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Over-reliance on a normal non-contrast CT: up to 30% of CVT cases are radiographically occult without venous imaging.  <br>2. Performing LP before vascular imaging: risks herniation and delays definitive diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2011 Guidelines on CVT: Recommend CTV or MRV for diagnosis after non-contrast CT (Class I, Level B).  <br>&bull; European Stroke Organization (ESO) 2017 Guidelines: Endorse CTV as first-line venous imaging in acute settings (Level A evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Thrombosis commonly affects the superior sagittal sinus, transverse sinuses, and sigmoid sinus, impairing cortical venous drainage and causing parenchymal edema or hemorrhage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>OCP-induced hypercoagulability leads to thrombus formation in dural venous sinuses, elevating intracranial pressure and provoking venous infarcts, hemorrhages, and seizures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Non-contrast head CT to exclude hemorrhage.  <br>2. If CT normal/suspicious, perform CTV (or MRV).  <br>3. Confirm CVT \u2192 start anticoagulation.  <br>4. Evaluate for prothrombotic states.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>The &ldquo;empty delta sign&rdquo; on contrast-enhanced CTV indicates a filling defect in the superior sagittal sinus. Direct visualization of thrombus via CTV increases diagnostic confidence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2024 exam. CVT often presents on board exams as OCP-associated headache/seizure vignettes requiring knowledge of CTV/MRV diagnostics.</div></div></div></div></div>"}, {"id": 100022990, "question_number": "30", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Spontaneous intracerebral hemorrhage (ICH) may arise from hypertension (deep nuclei) or amyloid angiopathy/vascular malformations (lobar cortex). Non-contrast CT rapidly confirms hemorrhage. Vascular imaging then seeks treatable lesions (e.g., aneurysm, AVM).  <br>Key points:  <br><span class=\"list-item\">\u2022</span> Lobar hemorrhages warrant early angiographic evaluation for macrovascular causes.  <br><span class=\"list-item\">\u2022</span> CT angiography (CTA) is rapid, noninvasive, and sensitive for aneurysms/AVMs.  <br><span class=\"list-item\">\u2022</span> Digital subtraction angiography (DSA) is gold standard but invasive, reserved when CTA is inconclusive.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>CTA is the recommended first-line vascular study in acute lobar ICH. <span class=\"evidence\">The 2015</span> AHA/ASA ICH guideline <span class=\"citation\">(Hemphill et al., Stroke. 2015;46:2032&ndash;2060)</span> gives CTA a Class I, Level B recommendation to identify structural lesions. CTA sensitivity for aneurysms/AVMs approaches 85&ndash;95%, with sub-5-minute acquisition in most centers. CTA also identifies the &ldquo;spot sign,&rdquo; an independent predictor of hematoma expansion <span class=\"citation\">(Delgado Almandoz JO et al., Radiology. 2009;251(1)</span>:206&ndash;213), guiding hemostatic interventions.  <br>Conventional angiography (DSA) is Class IIa, LOE C&mdash;reserved when CTA is nondiagnostic but suspicion remains high. MRI/MRA, while excellent for cavernomas or amyloid microbleeds, has longer acquisition times, limited acute sensitivity for active bleeding, and often is impractical in unstable patients. Observation without vascular imaging risks missing treatable etiologies that alter management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. MRI  <br><span class=\"list-item\">\u2022</span> Incorrect because acute MRI is time-consuming, less reliable for active vessel bleed detection, and less available in unstable ICH patients.  <br><span class=\"list-item\">\u2022</span> Misconception: MRI is always superior for brain pathology.  <br><span class=\"list-item\">\u2022</span> Differentiator: CTA provides vascular detail in minutes.<br><br>C. Conventional angiography  <br><span class=\"list-item\">\u2022</span> Incorrect as initial test due to invasiveness, higher complication risk (stroke, groin hematoma), and longer procedure time.  <br><span class=\"list-item\">\u2022</span> Misconception: DSA should always precede noninvasive studies.  <br><span class=\"list-item\">\u2022</span> Differentiator: Reserve DSA for CTA-negative cases with ongoing suspicion.<br><br>D. Observation  <br><span class=\"list-item\">\u2022</span> Incorrect because delaying vascular imaging may miss aneurysms/AVMs amenable to intervention, worsening outcomes.  <br><span class=\"list-item\">\u2022</span> Misconception: Small or lobar bleeds in the elderly rarely have structural causes.  <br><span class=\"list-item\">\u2022</span> Differentiator: Early CTA changes management by identifying treatable lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Modality</th><th>Sensitivity for Vascular Lesions</th><th>Invasiveness</th><th>Acquisition Time</th><th>Role in ICH Workup</th></tr></thead><tbody><tr><td>CTA</td><td>~85&ndash;95% for AVM/aneurysm</td><td>Low</td><td>~5 minutes</td><td>First-line vascular imaging</td></tr><tr><td>MRI/MRA</td><td>Moderate for cavernoma, amyloid</td><td>Low</td><td>30&ndash;60 minutes</td><td>Adjunct for microbleeds/cavernomas if stable</td></tr><tr><td>DSA (Conventional angio)</td><td>~98%</td><td>High</td><td>1&ndash;2 hours</td><td>Confirmatory when CTA negative but suspicion persists</td></tr><tr><td>Observation</td><td>N/A</td><td>None</td><td>N/A</td><td>Inappropriate without vascular evaluation</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In lobar ICH without clear hypertension history, always obtain CTA to exclude macrovascular lesions.  <br><span class=\"list-item\">\u2022</span> The CTA &ldquo;spot sign&rdquo; predicts hematoma expansion (OR 4.5), prompting aggressive blood pressure and coagulopathy management.  <br><span class=\"list-item\">\u2022</span> In renal impairment, use low-osmolar contrast and pre-hydrate; benefits of detecting treatable lesions often outweigh nephrotoxicity risks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming MRI is the acute vascular study of choice&mdash;delay in diagnosis and management can occur.  <br>2. Believing that deep hypertensive bleeds never warrant vascular imaging&mdash;atypical presentations (e.g., younger age, lobar location) require CTA.  <br>3. Omitting CTA in elderly lobar hemorrhages, attributing all to amyloid angiopathy without ruling out AVM or aneurysm.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Heart Association/American Stroke Association (AHA/ASA) Guidelines, 2015: Recommends CTA in acute lobar ICH to identify structural lesions (Class I, Level B).  <br><span class=\"list-item\">\u2022</span> European Stroke Organisation (ESO) Guidelines, 2019: Endorses early CTA for spontaneous lobar ICH to exclude macrovascular causes (Grade A recommendation).  <br><span class=\"list-item\">\u2022</span> Delgado Almandoz JO et al., Radiology. 2009: Prospective cohort demonstrating CTA &ldquo;spot sign&rdquo; predicts hematoma expansion (Level II evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Vascular imaging in ICH&mdash;especially the role and timing of CTA versus DSA&mdash;is a high-yield topic, frequently tested as image-based vignettes and single-best-answer questions on neurology and stroke boards.</div></div></div></div></div>"}, {"id": 100022991, "question_number": "141", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] Stroke classification (TOAST) divides ischemic stroke by mechanism: large-artery atherosclerosis, cardioembolism, small-vessel occlusion, other determined, and undetermined. Occipital lobe infarcts produce contralateral homonymous hemianopia. In a young trauma patient, consider vascular injury (dissection) leading to thrombus formation and distal embolization. Dissections most often involve the carotid or vertebral arteries after neck trauma, creating an intimal flap and intramural hematoma that can shed emboli into cerebral circulation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Artery-to-artery embolism is correct: motor vehicle collisions commonly cause cervical artery dissection. An intimal tear in the vertebral or carotid artery produces an intramural thrombus, which embolizes distally to occlude cortical branches of the posterior cerebral artery, resulting in occipital infarction and homonymous hemianopia. A meta-analysis <span class=\"citation\">(Debette et al., <span class=\"evidence\">Neurology 2015</span>)</span> showed 85% of traumatic dissections present with embolic strokes. AHA/ASA 2018 guidelines recommend vascular imaging (CTA/MRA) in suspected dissections and antithrombotic therapy to prevent recurrent embolism (Class I, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Large vessel atherosclerosis  <br><span class=\"list-item\">\u2022</span> Incorrect: Usually chronic plaque in older patients; acute trauma does not induce rapid atherosclerotic plaque rupture.  <br><span class=\"list-item\">\u2022</span> Misconception: Conflating dissection with atherosclerotic plaque disease.  <br><br>C. Cardioembolic  <br><span class=\"list-item\">\u2022</span> Incorrect: No evidence of arrhythmia, intracardiac thrombus, or valvular disease; mechanism here is arterial wall injury, not cardiac source.  <br><span class=\"list-item\">\u2022</span> Misconception: Attributing all cortical strokes to the heart without vascular imaging.  <br><br>D. Small vessel disease  <br><span class=\"list-item\">\u2022</span> Incorrect: Causes lacunar infarcts in deep structures (basal ganglia, pons), not large cortical occipital infarcts.  <br><span class=\"list-item\">\u2022</span> Misconception: Overextending lacunar syndromes to cortical deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Artery-to-Artery Embolism</th><th>Large Vessel Atherosclerosis</th><th>Cardioembolic</th><th>Small Vessel Disease</th></tr></thead><tbody><tr><td>Typical Age</td><td>Young (20&ndash;50) post-trauma</td><td>Older (>60)</td><td>Middle&ndash;elderly (>50)</td><td>Middle&ndash;elderly (>50)</td></tr><tr><td>Imaging Findings</td><td>Cortical infarcts</td><td>Cortical/subcortical border-zone infarcts</td><td>Cortical, multiple territories</td><td>Lacunes (<15 mm) in deep nuclei</td></tr><tr><td>Vascular Pathology</td><td>Dissection \u2192 thrombus</td><td>Atherosclerotic plaque</td><td>Cardiac thrombus</td><td>Lipohyalinosis</td></tr><tr><td>Mechanism</td><td>Embolism from injured artery</td><td>In situ thrombosis</td><td>Embolism from heart</td><td>Occlusion of small penetrating arterioles</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. In trauma patients with focal deficits, always suspect cervical artery dissection and obtain CTA/MRA of head and neck.  <br>2. Occipital lobe strokes manifest as contralateral homonymous hemianopia, often with macular sparing due to dual occipital supply.  <br>3. First-line treatment for cervical artery dissection is antithrombotic therapy (aspirin or anticoagulation), individualized by bleeding risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Assuming trauma must cause hemorrhage; arterial dissections can lead to ischemic stroke without hemorrhage.  <br><span class=\"list-item\">\u2022</span> Misidentifying cortical homonymous deficits as occipital migraines or seizure phenomena.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2018 \"Guidelines for Early Management of Patients With Acute Ischemic Stroke\"  <br><span class=\"list-item\">\u2022</span> Recommendation: Perform CTA/MRA in suspected cervical dissection (Class I, Level B).  <br>2. CADISS Trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurology 2015</span>)</span>  <br><span class=\"list-item\">\u2022</span> Found no significant difference in recurrent stroke between antiplatelet and anticoagulant therapy in cervical artery dissection (Level of Evidence A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The posterior cerebral artery (PCA), a branch of the vertebrobasilar system, supplies the occipital cortex. Emboli lodging in PCA branches produce contralateral visual field deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Trauma \u2192 intimal tear in cervical artery \u2192 intramural hematoma \u2192 luminal stenosis and platelet aggregation \u2192 distal artery-to-artery emboli \u2192 cortical infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect dissection in trauma with focal deficits.  <br>2. Obtain CTA or MRA of head/neck.  <br>3. Identify vessel wall irregularity, &ldquo;string sign,&rdquo; or intramural hematoma.  <br>4. Initiate antithrombotic therapy.  <br>5. Follow-up imaging at 3&ndash;6 months to ensure vessel healing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CT may miss early infarction; diffusion-weighted MRI is more sensitive.  <br><span class=\"list-item\">\u2022</span> CTA/MRA can detect vessel wall hematoma and flap; digital subtraction angiography remains gold standard but is invasive.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Aspirin 75&ndash;325 mg daily is first-line for dissection (Class I, Level B).  <br><span class=\"list-item\">\u2022</span> Consider anticoagulation (e.g., heparin to warfarin) in select cases based on CADISS trial data.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. It exemplifies classic testing on trauma-related arterial dissection, emphasizing TOAST classification and vascular imaging in young stroke patients.</div></div></div></div></div>"}, {"id": 100022992, "question_number": "236", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2021</span>] Giant Cell Arteritis (GCA) is a large-vessel vasculitis affecting branches of the external carotid artery, notably the superficial temporal artery. Key features include:  <br>&bull; Granulomatous inflammation of medium/large arteries leading to luminal narrowing and ischemia  <br>&bull; Jaw claudication and temporal headache from ischemia of masticatory muscles and periosteum  <br>&bull; Ocular involvement (transient or permanent vision changes) due to ophthalmic artery ischemia  <br>Rapid initiation of high-dose corticosteroids is critical to prevent irreversible vision loss; diagnostic biopsy should follow but not delay therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>IV methylprednisolone is the recommended first step in suspected GCA with visual symptoms. EULAR 2018 guidelines <span class=\"citation\">(Hellmich et al., Ann Rheum <span class=\"evidence\">Dis 2018</span>)</span> advise 500&ndash;1000 mg IV for 3 days in ocular involvement, then switch to high-dose oral prednisolone. Immediate therapy before biopsy reduces risk of anterior ischemic optic neuropathy. ACR/Vasculitis <span class=\"evidence\">Foundation 2021</span> recommendations reinforce prompt high-dose steroids and suggest tocilizumab as a steroid-sparing adjunct <span class=\"citation\">(Stone et al., NEJM 2017)</span>. Starting IV methylprednisolone addresses acute ischemia faster than oral prednisone, halting inflammatory arteritis and preserving vision.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Aspirin  <br>&bull; Why incorrect: Low-dose aspirin may reduce ischemic events but is adjunctive, not primary therapy.  <br>&bull; Misconception: Assuming antiplatelet therapy alone can prevent vision loss.  <br>&bull; Differentiator: Does not target granulomatous arterial inflammation.  <br><br>C. Prednisone  <br>&bull; Why incorrect: Oral prednisone (40&ndash;60 mg/day) is standard when no visual symptoms; slower onset in acute visual threat.  <br>&bull; Misconception: Equating any corticosteroid route as equally effective in ocular involvement.  <br>&bull; Differentiator: Delayed peak concentrations vs. IV route.  <br><br>D. Temporal artery biopsy  <br>&bull; Why incorrect: Biopsy confirms diagnosis but should follow, not precede, urgent steroid therapy.  <br>&bull; Misconception: Prioritizing tissue diagnosis over vision preservation.  <br>&bull; Differentiator: Diagnostic tool vs. therapeutic urgency.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>IV Methylprednisolone</th><th>Oral Prednisone</th><th>Aspirin</th><th>Temporal Artery Biopsy</th></tr></thead><tbody><tr><td>Route & Dose</td><td>IV 500&ndash;1000 mg/day \u00d73 days</td><td>PO 40&ndash;60 mg/day</td><td>PO 75&ndash;100 mg/day</td><td>N/A</td></tr><tr><td>Onset of Action</td><td>1&ndash;2 hours</td><td>4&ndash;6 hours</td><td>Days (platelet inhibition)</td><td>N/A</td></tr><tr><td>Indication in GCA</td><td>Visual symptoms or threatened vision</td><td>No ocular involvement</td><td>Adjunctive to reduce ischemic risk</td><td>Diagnostic confirmation</td></tr><tr><td>Guideline Recommendation (LoE)</td><td>EULAR 2018, LoE C</td><td>EULAR 2018, LoE C</td><td>EULAR 2018, LoE B</td><td>Should not delay steroids</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Jaw claudication has ~90% specificity for GCA.  <br>&bull; Always initiate high-dose steroids before temporal artery biopsy to prevent vision loss.  <br>&bull; Consider low-dose aspirin as an adjunct to reduce stroke risk in GCA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Waiting for biopsy results before starting steroids, risking irreversible blindness.  <br>2. Using only oral prednisone in acute visual symptoms, leading to delayed therapeutic levels.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; EULAR <span class=\"evidence\">Recommendations 2018</span> (Hellmich et al.): For GCA with ocular involvement, start IV glucocorticoids <span class=\"citation\">(500&ndash;1000 mg/day for 3 days)</span>; then switch to oral prednisolone (LoE C).  <br>&bull; ACR/Vasculitis <span class=\"evidence\">Foundation 2021</span>: Endorses prompt high-dose steroids; tocilizumab added for steroid sparing <span class=\"citation\">(Level II evidence from Stone et al., NEJM 2017)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Inflammation of the superficial temporal artery (branch of external carotid) and its ophthalmic branch compromises blood flow to the optic nerve head, leading to anterior ischemic optic neuropathy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Granulomatous infiltration of the arterial media and adventitia by multinucleated giant cells and lymphocytes leads to intimal hyperplasia, luminal occlusion, and downstream ischemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion with headache, jaw claudication, visual changes, high ESR/CRP  <br>2. Start high-dose corticosteroids immediately  <br>3. Ultrasound &ldquo;halo sign&rdquo; or MRI angiography if available  <br>4. Temporal artery biopsy within 2 weeks of steroid initiation for confirmation</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Ultrasound of temporal arteries may show a hypoechoic &ldquo;halo sign&rdquo; reflecting vessel wall edema; FDG-PET can detect large-vessel involvement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>IV methylprednisolone: 500&ndash;1000 mg/day for 3 days, then switch to oral prednisolone 1 mg/kg/day. Monitor for steroid side effects; initiate bone protection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2021</span> exam. Giant Cell Arteritis is frequently tested in rapid-recognition vignettes; questions often focus on immediate management to prevent vision loss and the role of temporal artery biopsy.</div></div></div></div></div>"}, {"id": 100022993, "question_number": "234", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2021</span>] - Autoimmune hypercoagulability: Anti-phospholipid syndrome (APS) features autoantibodies (lupus anticoagulant, anti-cardiolipin, anti-&beta;2-glycoprotein I) that activate endothelial cells and platelets, promoting thrombosis.  <br><span class=\"list-item\">\u2022</span> Obstetric manifestations: Recurrent early pregnancy loss results from placental thrombosis and infarction.  <br><span class=\"list-item\">\u2022</span> Dermatologic sign: Livedo reticularis arises from segmental cutaneous vascular occlusion.  <br><span class=\"list-item\">\u2022</span> Diagnostic criteria: Sydney criteria require at least one clinical event (thrombosis or pregnancy morbidity) plus persistent antibody positivity &ge;12 weeks apart.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Anti-phospholipid antibody testing is the definitive laboratory evaluation for suspected APS in patients with thrombotic events or recurrent pregnancy loss. <span class=\"evidence\">The 2006</span> Sydney update <span class=\"citation\">(Miyakis et al., J Thromb <span class=\"evidence\">Haemost 2006</span>)</span> mandates testing for lupus anticoagulant, anticardiolipin IgG/IgM, and anti-&beta;2-glycoprotein I. APS is identified in up to 15% of women with recurrent miscarriages <span class=\"citation\">(Branch et al., <span class=\"evidence\">Blood 1998</span>)</span>. Although lupus anticoagulant prolongs aPTT in vitro, routine coagulation profiles lack specificity and sensitivity for APS. Early diagnosis allows initiation of low-dose aspirin plus heparin, reducing miscarriage recurrence by 70&ndash;80% <span class=\"citation\">(Empson et al., <span class=\"evidence\">Lancet 2005</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Complete blood count  <br><span class=\"list-item\">\u2022</span> Incorrect: Evaluates anemia or thrombocytopenia but does not detect antiphospholipid antibodies or hypercoagulability.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that a normal platelet count excludes clotting disorders.  <br><span class=\"list-item\">\u2022</span> Differentiator: APS diagnosis relies on serologic antibody panels, not cell counts.<br><br>C. Thyroid function tests  <br><span class=\"list-item\">\u2022</span> Incorrect: Hypothyroidism can cause miscarriage but does not explain livedo reticularis or thrombotic risk.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming all recurrent pregnancy losses are endocrine in origin.  <br><span class=\"list-item\">\u2022</span> Differentiator: APS presents with cutaneous vasculopathy and requires antibody detection.<br><br>D. Coagulation profile  <br><span class=\"list-item\">\u2022</span> Incorrect: PT/aPTT may be paradoxically prolonged by lupus anticoagulant yet does not confirm APS.  <br><span class=\"list-item\">\u2022</span> Misconception: Interpreting prolonged aPTT as bleeding tendency rather than thrombosis risk.  <br><span class=\"list-item\">\u2022</span> Differentiator: Specific antiphospholipid antibody assays are necessary for diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Anti-phospholipid Ab Testing</th><th>Complete Blood Count</th><th>Thyroid Function Tests</th><th>Coagulation Profile</th></tr></thead><tbody><tr><td>Clinical purpose</td><td>Confirm APS in thrombosis/pregnancy</td><td>Assess blood cell lines</td><td>Screen thyroid disorders</td><td>Measure PT/aPTT</td></tr><tr><td>Specificity for APS</td><td>High (&ge;99% with combined assays)</td><td>None</td><td>None</td><td>Low</td></tr><tr><td>Sensitivity for pregnancy loss</td><td>85&ndash;90% for APS-related cases</td><td>N/A</td><td>20&ndash;30% for endocrine causes</td><td>N/A</td></tr><tr><td>Diagnostic requirement</td><td>Positive on &ge;2 occasions &ge;12 weeks</td><td>Single sample</td><td>Single sample</td><td>Single sample</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Lupus anticoagulant often prolongs aPTT in vitro but indicates thrombosis risk in vivo.  <br><span class=\"list-item\">\u2022</span> Confirm persistent antibody positivity &ge;12 weeks apart to avoid false positives from transient infections.  <br><span class=\"list-item\">\u2022</span> Combined low-dose aspirin and heparin therapy in pregnant APS patients reduces miscarriage rates by up to 80%.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overreliance on PT/aPTT: Not pursuing specific antiphospholipid antibody testing when aPTT is normal or paradoxically prolonged.  <br>2. Attributing all recurrent miscarriages to endocrine causes: Overlooking hypercoagulable evaluations in patients with livedo reticularis or thrombotic history.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- EULAR 2019 Recommendations for managing APS: Advocate testing for lupus anticoagulant, anticardiolipin, and anti-&beta;2-glycoprotein I in women with &ge;2 unexplained pregnancy losses (Level 1B evidence).  <br><span class=\"list-item\">\u2022</span> ISTH SSC 2013 Guidelines: Recommend using a combination of lupus anticoagulant, anticardiolipin, and anti-&beta;2-glycoprotein I assays to improve diagnostic accuracy (Grade A recommendation).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2021</span> exam. APS evaluation commonly appears in board-style questions linking obstetric morbidity, livedo reticularis, and serologic confirmation with antiphospholipid antibody panels.</div></div></div></div></div>"}, {"id": 100022994, "question_number": "136", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] 1. Oculomotor (III) nerve anatomy: motor fibers (medial) and parasympathetic fibers (superficial) travel together; compressive lesions selectively impair peripheral parasympathetic fibers first, causing pupil dilation.  <br>2. Aneurysmal subarachnoid hemorrhage classically presents with &ldquo;thunderclap&rdquo; headache (&ldquo;worst headache of life&rdquo;) and may produce acute cranial nerve palsies via mass effect.  <br>3. The posterior communicating artery (PCom) arises from the internal carotid and lies adjacent to CN III; aneurysms here compress the nerve and cause an ipsilateral dilated, non-reactive pupil.  <br>(Word count: 102)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Posterior communicating artery aneurysms account for up to 50% of internal carotid aneurysms presenting with oculomotor palsy. The peripheral location of parasympathetic fibers makes them more vulnerable to compression; this explains the early pupillary involvement seen here. Aneurysm rupture into the subarachnoid space produces a sudden, severe headache <span class=\"citation\">(AHA/ASA 2022 guidelines recommend emergent non-contrast CT followed by CT angiography [Class I, Level B])</span>. Early diagnosis and microsurgical clipping or endovascular coiling reduce rebleeding risk <span class=\"citation\">(ISAT trial 2005; long-term follow-up in Lancet <span class=\"evidence\">Neurology 2023</span> confirms coiling superiority in suitable PCom aneurysms)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Anterior communicating artery  <br><span class=\"list-item\">\u2022</span> Incorrect: ACom aneurysms predominantly impinge on the optic chiasm or frontal lobes, causing visual field deficits or personality changes, not CN III palsy.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing location near optic apparatus with oculomotor nerve anatomy.  <br><span class=\"list-item\">\u2022</span> Differentiation: ACom lesions rarely present with isolated third nerve signs.  <br><br>C. Superior cerebellar artery  <br><span class=\"list-item\">\u2022</span> Incorrect: SCA arises from the basilar artery near CN III exit but aneurysms here rarely compress the nerve; patients develop ataxia or cerebellar signs.  <br><span class=\"list-item\">\u2022</span> Misconception: Any posterior circulation aneurysm can involve CN III.  <br><span class=\"list-item\">\u2022</span> Differentiation: SCA aneurysms more often cause cerebellar dysfunction and headache without isolated pupillary dilation.  <br><br>D. Internal carotid artery dissection  <br><span class=\"list-item\">\u2022</span> Incorrect: Dissection causes ipsilateral Horner syndrome (miosis, ptosis), not dilated pupil.  <br><span class=\"list-item\">\u2022</span> Misconception: Attributing sudden headache + oculomotor signs to any ICA pathology.  <br><span class=\"list-item\">\u2022</span> Differentiation: In dissection the pupil is constricted due to sympathetic chain disruption.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PCom Aneurysm (Correct)</th><th>ACom Aneurysm</th><th>SCA Aneurysm</th><th>ICA Dissection</th></tr></thead><tbody><tr><td>Location</td><td>ICA&ndash;PCom junction</td><td>ACom (between ACAs)</td><td>Basilar&ndash;SCA junction</td><td>Cervical ICA</td></tr><tr><td>Cranial nerve III involvement</td><td>Yes (pupil dilatation + palsy)</td><td>No</td><td>Rare</td><td>No (Horner syndrome)</td></tr><tr><td>Headache</td><td>Thunderclap, SAH</td><td>SAH</td><td>SAH or focal headache</td><td>Neck pain, headache</td></tr><tr><td>Other signs</td><td>Ptosis, &ldquo;down and out&rdquo; eye</td><td>Visual field cuts, memory loss</td><td>Ataxia, dysmetria</td><td>Ptosis with miosis</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Compressive III palsy (aneurysm/tumor) = pupil involvement; ischemic (diabetic) III palsy = pupil-sparing.  <br><span class=\"list-item\">\u2022</span> In acute pupil-involving CN III palsy, obtain non-contrast CT &plusmn; CTA emergently to exclude PCom aneurysm.  <br><span class=\"list-item\">\u2022</span> Nimodipine improves outcome in aneurysmal SAH by reducing vasospasm <span class=\"citation\">(AHA/ASA 2022)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing miosis of Horner syndrome (ICA dissection) with dilated pupil in III palsy.  <br>2. Assuming all posterior circulation aneurysms (e.g., SCA, PCA) equally cause oculomotor palsy&mdash;only PCom lies in direct contact with CN III.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2022 Guideline for Management of Aneurysmal Subarachnoid Hemorrhage  <br>   \u00ad&ndash; Recommendation: Non-contrast CT followed by CTA or DSA in any suspected aneurysmal SAH with cranial nerve palsy (Class I, Level B).  <br>2. International Subarachnoid Aneurysm Trial (ISAT) long-term follow-up, Lancet <span class=\"evidence\">Neurol 2023</span>  <br>   \u00ad&ndash; Finding: Endovascular coiling of PCom aneurysms reduces 5-year morbidity compared to clipping in selected patients.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The oculomotor nerve exits the midbrain medial to the superior cerebellar artery and lateral to the PCA, then courses between the PCA and superior cerebellar artery before running adjacent to the PCom; superficial parasympathetic fibers on the nerve&rsquo;s periphery mediate pupillary constriction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Aneurysmal dilation at the PCom segment exerts mass effect on the adjacent oculomotor nerve, compressing peripheral parasympathetic fibers first (causing mydriasis) and then motor fibers (ptosis, &ldquo;down and out&rdquo; deviation).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical identification of pupil-involving CN III palsy + thunderclap headache  <br>2. Immediate non-contrast head CT to detect SAH  <br>3. CT angiography for aneurysm localization  <br>4. Digital subtraction angiography if CTA equivocal  <br>5. Neurosurgical consultation for clipping vs endovascular coiling</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CT\u2009angiography >95% sensitive for aneurysms >3 mm.  <br><span class=\"list-item\">\u2022</span> &ldquo;Fusiform dilation&rdquo; at the ICA&ndash;PCom junction on CTA is pathognomonic.  <br><span class=\"list-item\">\u2022</span> DSA remains gold standard for small aneurysms and surgical planning.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Nimodipine 60 mg orally every 4 hours for 21 days post-SAH to prevent vasospasm.  <br><span class=\"list-item\">\u2022</span> Blood pressure control: systolic 120&ndash;160 mm Hg, avoid hypotension.  <br><span class=\"list-item\">\u2022</span> Analgesia with acetaminophen; avoid NSAIDs to reduce bleeding risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. On neurology board exams, pupil-involving third nerve palsy with &ldquo;thunderclap&rdquo; headache is a classic vignette for PCom aneurysm; students should rapidly differentiate compressive vs ischemic etiologies and know emergent imaging steps.</div></div></div></div></div>"}, {"id": 100022995, "question_number": "226", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2019</span>] Warfarin inhibits vitamin K&ndash;dependent clotting factors II, VII, IX and X, prolonging INR. In ICH, rapid correction is critical to limit hematoma expansion. Prothrombin complex concentrate (PCC) provides concentrated factors II, VII, IX and X for speedy normalization of INR, whereas fresh frozen plasma (FFP) and vitamin K alone act more slowly. Key concepts:  <br><span class=\"list-item\">\u2022</span> Vitamin K antagonist mechanism (warfarin)  <br><span class=\"list-item\">\u2022</span> Hematoma expansion risk correlates with elevated INR  <br><span class=\"list-item\">\u2022</span> Speed of reversal directly impacts clinical outcomes</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>PCC is superior to FFP for warfarin reversal in ICH due to:  <br>1. Faster INR correction: Four-factor PCC normalizes INR within 30&ndash;60\u2009minutes versus 4&ndash;6\u2009hours for FFP.  <br>2. Lower volume: PCC requires <200 mL infusion (vs >1 L for FFP), reducing risk of volume overload and transfusion\u2010related acute lung injury.  <br>3. Guideline support: <span class=\"evidence\">The 2015</span> AHA/ASA ICH guidelines <span class=\"citation\">(Hemphill JC et al., <span class=\"evidence\">Stroke 2015</span>)</span> give Class I, Level A recommendation for four-factor PCC plus IV vitamin K for warfarin\u2010associated ICH.  <br>4. Mortality benefit: Observational studies associate PCC use with reduced hematoma growth and lower 30-day mortality compared with FFP <span class=\"citation\">(Steiner T et al., <span class=\"evidence\">Haematologica 2016</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Fresh frozen plasma (FFP)  <br><span class=\"list-item\">\u2022</span> Incorrect: Slower INR normalization (requires blood typing, thawing, large volumes).  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that broader factor replacement (including fibrinogen) is superior.  <br><span class=\"list-item\">\u2022</span> Differentiator: Volume and time delay vs PCC&rsquo;s rapid, low-volume correction.  <br><br>C. Recombinant activated factor VII (rFVIIa)  <br><span class=\"list-item\">\u2022</span> Incorrect: Off-label for warfarin reversal; limited to hemophilia A with inhibitors.  <br><span class=\"list-item\">\u2022</span> Misconception: Overestimation of clotting boost from single factor.  <br><span class=\"list-item\">\u2022</span> Differentiator: Does not replace factors II, IX, X and carries higher thrombosis risk.  <br><br>D. Vitamin K alone  <br><span class=\"list-item\">\u2022</span> Incorrect: Necessary adjunct but too slow (6&ndash;24\u2009hours) to correct INR acutely.  <br><span class=\"list-item\">\u2022</span> Misconception: Vitamin K monotherapy suffices in emergencies.  <br><span class=\"list-item\">\u2022</span> Differentiator: Enhances endogenous factor synthesis only; no immediate reversal.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PCC (Correct)</th><th>FFP</th><th>rFVIIa</th><th>Vitamin K Alone</th></tr></thead><tbody><tr><td>Time to INR normalization</td><td>30&ndash;60 minutes</td><td>4&ndash;6 hours</td><td>1&ndash;2 hours (factor VII only)</td><td>6&ndash;24 hours</td></tr><tr><td>Volume required</td><td><200 mL</td><td>&ge;1 L</td><td>~50&ndash;100 mL</td><td>Negligible</td></tr><tr><td>Factor replacement</td><td>II, VII, IX, X</td><td>All plasma proteins</td><td>Activated factor VII only</td><td>Promotes synthesis of II, VII, IX, X</td></tr><tr><td>Thrombosis risk</td><td>Low&ndash;moderate</td><td>Low</td><td>High</td><td>None</td></tr><tr><td>Guideline strength (ICH)</td><td>Class I, Level A (AHA)</td><td>Class IIa, Level C (AHA)</td><td>Not recommended</td><td>Adjunct only</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Administer IV vitamin K (5&ndash;10 mg) concurrently with PCC to sustain reversal.  <br><span class=\"list-item\">\u2022</span> Use four-factor PCC rather than three-factor PCC for comprehensive factor replacement.  <br><span class=\"list-item\">\u2022</span> Monitor INR at 30\u2009minutes post\u2010PCC infusion to confirm target <1.4 and repeat as needed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Relying solely on FFP delays reversal and increases volume overload risk.  <br>2. Assuming vitamin K alone is sufficient in acute ICH leads to preventable hematoma expansion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2015 ICH Guidelines <span class=\"citation\">(Hemphill JC et al., <span class=\"evidence\">Stroke 2015</span>)</span>: Class I, Level A for four-factor PCC + IV vitamin K in warfarin\u2010related ICH.  <br><span class=\"list-item\">\u2022</span> ASH 2016 Guidelines on Reversal of Antithrombotics: Recommends four-factor PCC over FFP for vitamin K antagonist reversal (Grade 1B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Warfarin inhibits vitamin K epoxide reductase, depleting reduced vitamin K needed to &gamma;-carboxylate clotting factors. In ICH, continued anticoagulation leads to hematoma growth and raised intracranial pressure. Rapid factor repletion with PCC halts hemorrhage extension by restoring thrombin generation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- PCC dosing: 25&ndash;50 IU/kg based on baseline INR and product specifications.  <br><span class=\"list-item\">\u2022</span> Concurrent vitamin K: 5&ndash;10 mg IV over 30\u2009minutes to support endogenous synthesis.  <br><span class=\"list-item\">\u2022</span> Monitor for thrombosis; consider patient comorbidities (e.g., DVT history).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2019</span> exam.  <br>Warfarin\u2010associated ICH reversal is frequently tested as a single best\u2010answer format, emphasizing PCC&rsquo;s advantage over FFP and the necessity of adjunctive vitamin K.</div></div></div></div></div>"}, {"id": 100022996, "question_number": "222", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2019</span>] Ischemic strokes are classified by mechanism:  <br><span class=\"list-item\">\u2022</span> Lacunar infarcts result from small vessel disease (lipohyalinosis) often due to HTN/DM and local occlusion of penetrating arterioles.  <br><span class=\"list-item\">\u2022</span> Large\u2010artery atherosclerosis (e.g., carotid stenosis) causes cortical or territorial infarcts when high\u2010grade stenosis leads to embolism or hypoperfusion.  <br><span class=\"list-item\">\u2022</span> Cardioembolic strokes (e.g., from PFO or atrial fibrillation) often cause cortical infarcts and may warrant anticoagulation or closure.  <br>Secondary prevention tailors therapy to the dominant mechanism: antiplatelet (small\u2010vessel), endarterectomy (high\u2010grade carotid), or anticoagulation/closure (cardioembolic).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The patient&rsquo;s prior infarct was lacunar in the posterior limb of the internal capsule&mdash;classic for small\u2010vessel lipohyalinosis driven by HTN/DM. CTA showed extracranial atherosclerosis but without mention of &ge;70% stenosis required for endarterectomy (ACAS/ACST trials). PFO closure trials (RESPECT, CLOSE) included cryptogenic cortical strokes in younger patients, not lacunar strokes in older hypertensive diabetics. NAVIGATE ESUS (2018) and RE-SPECT ESUS (2018) trials demonstrated no benefit of anticoagulation over aspirin in embolic\u2010stroke\u2010of\u2010undetermined\u2010source populations. <span class=\"evidence\">The 2019</span> AHA/ASA Secondary Stroke Prevention Guidelines (Class I, Level of Evidence A) recommend antiplatelet monotherapy (aspirin 81&ndash;325 mg daily) for non\u2010cardioembolic ischemic stroke, particularly lacunar subtype.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Closure of PFO  <br><span class=\"list-item\">\u2022</span> Incorrect because PFO closure is indicated in cryptogenic stroke with high\u2010risk PFO anatomy in patients <60 years without alternative mechanisms; lacunar infarct here points to small\u2010vessel disease, not paradoxical embolism.  <br><br>B. Carotid endarterectomy  <br><span class=\"list-item\">\u2022</span> Only indicated for symptomatic carotid stenosis &ge;70% (NASCET criteria) or select 50&ndash;69% cases; &ldquo;extracranial atherosclerosis&rdquo; alone without degree of stenosis &ge;70% does not meet surgical criteria.  <br><br>D. Anticoagulation with warfarin  <br><span class=\"list-item\">\u2022</span> Reserved for cardioembolic sources (e.g., atrial fibrillation, mechanical valves); small\u2010vessel lacunar strokes do not benefit and carry increased hemorrhagic risk (SPA therapy trials).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Aspirin (Correct)</th><th>PFO Closure</th><th>Carotid Endarterectomy</th><th>Warfarin</th></tr></thead><tbody><tr><td>Indication</td><td>Non\u2010cardioembolic ischemic stroke</td><td>Cryptogenic stroke w/ high\u2010risk PFO</td><td>Symptomatic carotid &ge;70% stenosis</td><td>Cardioembolic stroke (AF, valves)</td></tr><tr><td>Key Trial/Evidence</td><td>AHA/ASA 2019 Guidelines (Class I)</td><td>RESPECT, CLOSE</td><td>NASCET, ACAS</td><td>WARSS (no benefit in non\u2010cardioembolic)</td></tr><tr><td>Mechanism</td><td>Inhibits platelet aggregation</td><td>Prevents paradoxical emboli</td><td>Removes atherosclerotic plaque</td><td>Inhibits vitamin K\u2010dependent clotting</td></tr><tr><td>Major Contraindication in This Patient</td><td>None (small\u2010vessel stroke)</td><td>Stroke subtype not cryptogenic</td><td>Stenosis <70%</td><td>No cardioembolic source</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Lacunar infarcts (<15 mm) on MRI DWI in the internal capsule strongly suggest lipohyalinosis from HTN/DM, guiding antiplatelet therapy.  <br><span class=\"list-item\">\u2022</span> Always quantify carotid stenosis by NASCET criteria; incidental &ldquo;atherosclerosis&rdquo; without high\u2010grade narrowing does not warrant surgery.  <br><span class=\"list-item\">\u2022</span> ESUS trials (NAVIGATE, RE-SPECT) reaffirm aspirin as first\u2010line in non\u2010cardioembolic strokes when source remains uncertain.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating any PFO with indication for closure&mdash;only in young cryptogenic cortical strokes after exhaustive workup.  <br>2. Assuming anticoagulation is superior to antiplatelets for all secondary stroke prevention&mdash;true only in atrial fibrillation or prosthetic valves.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. 2019 AHA/ASA Secondary Stroke Prevention Guidelines  <br><span class=\"list-item\">\u2022</span> Recommendation: Aspirin monotherapy (81&ndash;325 mg) for non\u2010cardioembolic ischemic stroke (Class I, LOE A).  <br>2. NAVIGATE ESUS Trial <span class=\"citation\">(<span class=\"evidence\">Hart et al., 2018</span>, NEJM)</span>  <br><span class=\"list-item\">\u2022</span> Rivaroxaban vs aspirin in ESUS: no reduction in recurrent stroke; increased bleeding (Class III recommendation against routine anticoagulation).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The posterior limb of the internal capsule contains corticospinal fibers; lacunar infarcts here produce pure motor hemiparesis without cortical signs, characteristic of small\u2010vessel disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic hypertension and diabetes cause lipohyalinosis and fibrinoid necrosis of penetrating arterioles, leading to small (<15 mm) &ldquo;lacunar&rdquo; infarcts. These do not involve large carotid or cardiac embolic sources.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Brain MRI with DWI to confirm lacunar infarct.  <br>2. Vascular imaging (CTA/MRA) to assess extracranial/intracranial stenosis.  <br>3. Cardiac workup (echo, ECG) to rule out embolic sources.  <br>4. Laboratory risk factor optimization (BP, glucose, lipids).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Lacunes appear as small (<15 mm) cavitary lesions on T1 hypointense/T2 hyperintense sequences.  <br><span class=\"list-item\">\u2022</span> CTA noninvasively evaluates carotid/vertebral stenosis; avoid overcalling mild atherosclerotic plaques as surgical lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Aspirin irreversibly inhibits cyclooxygenase\u20101 (COX\u20101), reducing thromboxane A2&ndash;mediated platelet aggregation. Standard dosing: 81&ndash;325 mg once daily; monitor for gastrointestinal side effects.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2019</span> exam. Secondary stroke prevention questions frequently test matching stroke mechanism to targeted therapy, emphasizing the importance of lacunar vs large\u2010artery vs cardioembolic etiologies.</div></div></div></div></div>"}, {"id": 100022997, "question_number": "34", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Watershed (border-zone) infarctions occur at junctions between major cerebral artery territories (most often ACA-MCA or MCA-PCA). These distal arterioles rely on adequate perfusion pressure and are most vulnerable when systemic or regional blood flow falls. Imaging shows wedge-shaped or linear DWI hyperintensities parallel to the cortical surface. Unilateral watershed patterns typically reflect focal hypoperfusion rather than embolic occlusion. Key terms: perfusion pressure, collateral circulation, hemodynamic stroke. Differentiating hemodynamic from embolic patterns is critical for targeted workup and management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Hypoperfusion is the direct pathophysiologic mechanism in watershed infarcts. <span class=\"evidence\">The 2018</span> AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke classify border-zone infarctions under hemodynamic strokes due to reduced perfusion pressure (Class IIa, Level B-R). Bang et al. <span class=\"citation\">(Stroke.2011;42:391-397)</span> demonstrated that patients with &ge;70% ipsilateral ICA stenosis displayed ACA-MCA watershed infarcts on MRI, correlated with prolonged time-to-peak on CT perfusion. Distal arterioles in these zones have limited collateral support; when systemic blood pressure or carotid inflow drops below autoregulatory thresholds, cytotoxic edema ensues, seen as DWI hyperintensity. Thus, hypoperfusion&mdash;often secondary to large-artery stenosis&mdash;is the immediate mechanism.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Internal carotid artery (ICA) stenosis  <br>&ndash; Incorrect because stenosis is an underlying etiology, not the direct mechanism.  <br>&ndash; Misconception: equating cause with mechanism.  <br>&ndash; Differentiator: steno\u00adsis leads to hypoperfusion; the mechanism is reduced cerebral blood flow.  <br><br>B. Cardiac embolism  <br>&ndash; Emboli lodge in cortical branch arteries causing territorial infarcts, not border-zone patterns.  <br>&ndash; Misconception: assuming all cortical infarcts are embolic.  <br>&ndash; Differentiator: embolic strokes produce wedge-shaped territorial lesions with abrupt diffusion/ADC changes.  <br><br>D. Venous thrombosis  <br>&ndash; Venous outflow obstruction causes hemorrhagic infarcts with vasogenic edema, often in deep or cortical veins.  <br>&ndash; Misconception: conflating venous infarcts with arterial border-zone strokes.  <br>&ndash; Differentiator: venous infarcts show mixed signal on T1/T2 with possible hemorrhage, not pure DWI wedge shapes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Hypoperfusion</th><th>ICA Stenosis</th><th>Cardiac Embolism</th><th>Venous Thrombosis</th></tr></thead><tbody><tr><td>Pathophysiology</td><td>\u2193 Perfusion pressure</td><td>Atherosclerotic narrowing</td><td>Embolic arterial occlusion</td><td>Impaired venous drainage</td></tr><tr><td>MRI DWI Pattern</td><td>Border-zone wedge/linear</td><td>May show border-zone if severe</td><td>Territorial cortical infarct</td><td>Hemorrhagic, ill-defined</td></tr><tr><td>Collateral Dependence</td><td>High in distal arterioles</td><td>Variable based on Circle of Willis</td><td>Not relevant</td><td>Not relevant</td></tr><tr><td>Acute Perfusion Imaging</td><td>Delayed time-to-peak</td><td>Prolonged in ipsilateral hemisphere</td><td>Focal perfusion deficit</td><td>Mixed arterial/venous flow</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In acute watershed infarcts, avoid aggressive antihypertensive therapy to preserve collateral perfusion.  <br><span class=\"list-item\">\u2022</span> Carotid duplex ultrasound is first-line to detect high-grade ICA stenosis in suspected hemodynamic strokes.  <br><span class=\"list-item\">\u2022</span> CT/MR perfusion imaging differentiates hypoperfusion from embolic penumbra, guiding revascularization decisions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mistaking cortical watershed infarcts for lacunar strokes; lacunes are small (<15 mm), subcortical, due to small-vessel lipohyalinosis.  <br>2. Attributing all cortical infarctions to embolism without assessing hemodynamic factors like carotid stenosis or systemic hypotension.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2018 Guideline on Early Management of Acute Ischemic Stroke: Recommends carotid endarterectomy for symptomatic 70&ndash;99% ICA stenosis to prevent recurrent hemodynamic strokes (Class I, Level A).  <br><span class=\"list-item\">\u2022</span> European Stroke Organisation (ESO) 2021 Guideline: Advocates routine perfusion imaging in acute stroke to distinguish hemodynamic from embolic mechanisms, optimizing reperfusion strategies (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Watershed zones lie at the distal territories of ACA-MCA (anterior border zone, &ldquo;V&rdquo;-shaped along the convexity) and MCA-PCA (posterior border zone, occipital\u2010parietal junction). These regions have the lowest perfusion reserve and are first to infarct when cerebral perfusion pressure falls.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Reduced perfusion pressure&mdash;due to systemic hypotension or proximal arterial stenosis&mdash;drops below autoregulatory capacity in distal arterioles. Oxygen deprivation triggers failure of ion pumps, leading to cytotoxic edema and infarction in border-zone territories.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. MRI with DWI/ADC to confirm watershed pattern.  <br>2. CT/MR perfusion imaging to quantify cerebral blood flow/volume and mean transit time.  <br>3. Carotid duplex ultrasound or CT angiography for ICA stenosis.  <br>4. Echocardiography and ECG to exclude cardioembolic sources.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- DWI: Wedge-shaped hyperintensities parallel to cortical surface in border zones.  <br><span class=\"list-item\">\u2022</span> MR angiography/CTA: Identifies high-grade carotid stenosis or occlusion.  <br><span class=\"list-item\">\u2022</span> Perfusion maps: Show prolonged time-to-peak and decreased cerebral blood flow in affected regions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Watershed infarction patterns are frequently tested to assess differentiation between hemodynamic and embolic stroke mechanisms; examine imaging distribution and clinical context to select the appropriate pathophysiologic explanation.</div></div></div></div></div>"}, {"id": 100022998, "question_number": "31", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Malignant MCA infarction involves extensive cortical and subcortical ischemia leading to cytotoxic and vasogenic edema that peaks 48&ndash;72 h after onset. Because the skull is a fixed volume (Monro-Kellie doctrine), this edema causes intracranial hypertension, midline shift, and risk of transtentorial herniation. Decompressive hemicraniectomy (DHC) removes a large bone flap and opens the dura to accommodate swollen brain tissue, rapidly lowering intracranial pressure (ICP) and preventing secondary ischemic injury. Key concepts: 1) Pathophysiology of cytotoxic vs vasogenic edema; 2) ICP dynamics and herniation syndromes; 3) Time-dependent intervention within 48 h.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Decompressive hemicraniectomy within 48 h for malignant MCA infarction in patients &le;60 years reduces 12-month mortality from ~80 % to ~30&ndash;40 % and increases chances of favorable functional outcome (mRS 0&ndash;4). This is supported by three randomized controlled trials&mdash;DECIMAL (2007), DESTINY (2007), HAMLET (2009)&mdash;and a pooled meta-analysis <span class=\"citation\">(<span class=\"evidence\">Vahedi et al., 2009</span>)</span>. <span class=\"evidence\">The 2018</span> AHA/ASA guidelines give DHC a Class I, Level A recommendation for these patients. By providing immediate relief of ICP, DHC preserves cerebral perfusion and prevents fatal herniation, benefits not matched by medical therapy alone.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Medical management with osmotic agents  <br>  &bull; Only provides transient ICP reduction, without expanding intracranial volume capacity.  <br>  &bull; Common misconception: osmotherapy suffices to manage malignant edema.  <br>  &bull; Does not lower mortality or improve functional outcomes significantly.<br><br>C. Anticoagulation therapy  <br>  &bull; High risk of hemorrhagic transformation in large infarcts; no role in acute malignant MCA.  <br>  &bull; Misconception: extending cardioembolic stroke protocols to massive infarctions.  <br>  &bull; Fails to address life-threatening mass effect.<br><br>D. Thrombolysis  <br>  &bull; Therapeutic window is &le;4.5 h; at 48 h post-stroke, tPA is contraindicated.  <br>  &bull; Misconception: tPA can reverse established edema.  <br>  &bull; Does not mitigate cytotoxic and vasogenic edema once infarction is completed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Intervention</th><th>Mechanism</th><th>Timing Window</th><th>Mortality Benefit</th><th>Evidence Level</th></tr></thead><tbody><tr><td>Decompressive hemicraniectomy</td><td>Surgical decompression \u2193ICP</td><td>&le;48 h</td><td>\u2193Mortality by ~50 %</td><td>Class I, Level A</td></tr><tr><td>Osmotic agents (mannitol/hypertonic)</td><td>Osmotic dehydration</td><td>Any</td><td>No significant mortality \u2193</td><td>Class IIb, Level C</td></tr><tr><td>Anticoagulation (heparin/warfarin)</td><td>Thrombosis prevention</td><td>Acute</td><td>\u2191Hemorrhage risk</td><td>Not recommended</td></tr><tr><td>Thrombolysis (tPA)</td><td>Fibrinolysis</td><td>&le;4.5 h</td><td>\u2193Disability in small strokes</td><td>Class I, Level A</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Initiate neurosurgical consultation within 24 h in suspected malignant MCA infarction.  <br><span class=\"list-item\">\u2022</span> DHC offers greatest benefit in patients &le;60 years; DESTINY II supports selective use in older patients.  <br><span class=\"list-item\">\u2022</span> A bone flap &ge;12 cm with duraplasty maximizes decompression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Waiting for clinical deterioration rather than acting on imaging-based criteria may miss the surgical window.  <br><span class=\"list-item\">\u2022</span> Overreliance on hyperosmolar therapy can delay definitive treatment.  <br><span class=\"list-item\">\u2022</span> Misapplication of thrombolysis or anticoagulation beyond approved time windows in large infarcts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2018 Guidelines for Early Management of Acute Ischemic Stroke: Class I, Level A recommendation for DHC in malignant MCA infarction &le;48 h in patients &le;60 years.  <br>2. DESTINY II Trial (2019): Demonstrated mortality reduction with DHC in patients >60 years, supporting Class IIa, Level B recommendation for selected older adults.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Malignant MCA infarction and indication/timing for decompressive hemicraniectomy are frequently tested as single-best-answer items, often incorporating patient age, imaging criteria, and outcome data.</div></div></div></div></div>"}, {"id": 100022999, "question_number": "63", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] &bull; Intracerebral hemorrhage (ICH) involves bleeding into brain parenchyma, causing mass effect, tissue injury, and perihematomal edema.  <br>&bull; VKAs (e.g., warfarin) inhibit vitamin K epoxide reductase, reducing &gamma;-carboxylation of clotting factors II, VII, IX, and X, thereby elevating INR and exacerbating bleeding.  <br>&bull; Rapid normalization of INR is critical to limit hematoma expansion and improve outcomes; this requires both vitamin K (to restore endogenous factor synthesis) and factor replacement (PCC preferred).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option A is correct because withholding the VKA and administering vitamin K addresses the root cause (vitamin K&ndash;dependent factor deficiency) and begins synthesis of new clotting factors within hours. <span class=\"evidence\">The 2015</span> AHA/ASA ICH guidelines (Class I, Level A) mandate immediate reversal of VKA-associated coagulopathy with IV vitamin K (5&ndash;10 mg) plus four-factor PCC. Trials such as Sarode et al. <span class=\"citation\">(NEJM 2013)</span> demonstrated that four-factor PCC normalizes INR in a median of 30 minutes in 70% of patients versus 10% with FFP (p<0.001), reducing hematoma growth without increased thrombosis. Neither rFVIIa (off-label, high thrombosis risk, no functional benefit) nor FFP alone (slow infusion, large volume, delayed INR correction) substitute for targeted vitamin K&ndash;mediated factor regeneration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Continue VKA therapy  <br>&bull; Incorrect: perpetuates coagulopathy, risking hematoma expansion.  <br>&bull; Misconception: maintaining anticoagulation for stroke prevention outweighs acute hemorrhage risk.  <br>&bull; Differentiator: acute ICH management prioritizes hemostasis over long-term anticoagulation.<br><br>C. Administer rFVIIa  <br>&bull; Incorrect: rFVIIa can transiently correct INR but has no proven outcome benefit in ICH and carries a high arterial and venous thrombosis risk (up to 10%).  <br>&bull; Misconception: any factor concentrate is equally safe/effective.  <br>&bull; Differentiator: rFVIIa lacks vitamin K&ndash;dependent factor support and is not guideline-endorsed for VKA reversal in ICH.<br><br>D. Administer fresh frozen plasma  <br>&bull; Incorrect as sole therapy: FFP requires blood typing, thawing, and large volumes (\u224815 mL/kg), delaying reversal; slower INR correction compared to PCC.  <br>&bull; Misconception: FFP is first-line when PCC is unavailable.  <br>&bull; Differentiator: FFP is a backup when PCC is unavailable; vitamin K remains mandatory.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Vitamin K (withhold VKA)</th><th>Continue VKA</th><th>rFVIIa</th><th>FFP</th></tr></thead><tbody><tr><td>INR Correction Onset</td><td>6&ndash;12 h (endogenous)</td><td>None</td><td>Immediate, short-lived</td><td>4&ndash;6 h (volume-dependent)</td></tr><tr><td>Hematoma Expansion Risk</td><td>\u2193</td><td>\u2191</td><td>\u2194/\u2191 (thrombosis)</td><td>\u2193 (slower than PCC)</td></tr><tr><td>Volume Requirement</td><td>Minimal</td><td>N/A</td><td>Minimal</td><td>High (\u224815 mL/kg)</td></tr><tr><td>Thrombosis Risk</td><td>Low</td><td>N/A</td><td>High</td><td>Moderate</td></tr><tr><td>Guideline Endorsement (ICH)</td><td>I (Class I, LOE A)</td><td>Contraindicated</td><td>IIb/C</td><td>IIb/C</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; In warfarin-related ICH, always co-administer IV vitamin K with factor replacement (PCC preferred).  <br>&bull; Four-factor PCC achieves INR <1.4 within 30 minutes in most patients; FFP is only if PCC is unavailable.  <br>&bull; Subcutaneous vitamin K is too slow; always use the IV route (5&ndash;10 mg) for acute ICH.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Relying solely on FFP delays INR normalization and risks volume overload in older or heart-failure patients.  <br>2. Assuming rFVIIa is safer than PCC; it increases arterial thromboses without improving neurologic outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA ICH <span class=\"evidence\">Guidelines 2015</span>: &ldquo;IV vitamin K (5&ndash;10 mg) plus four-factor PCC for VKA reversal in ICH&rdquo; (Class I, LOE A).  <br>&bull; Sarode R. et al., NEJM 2013: Four-factor PCC achieved rapid INR reversal (median 30 min vs 4 h with FFP; p<0.001) with fewer transfusion complications.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Warfarin blocks vitamin K epoxide reductase \u2192 insufficient &gamma;-carboxylation of clotting factors II, VII, IX, X \u2192 impaired prothrombin activation \u2192 prolonged INR \u2192 unchecked bleeding in ruptured cerebral vessels \u2192 hematoma growth exacerbates intracranial pressure and secondary injury.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Vitamin K (IV 5&ndash;10 mg): restores &gamma;-carboxylation of vitamin K&ndash;dependent factors over 6&ndash;12 h.  <br>&bull; Four-factor PCC (25&ndash;50 IU/kg): provides immediate clotting factors II, VII, IX, X; normalizes INR within 30 min.  <br>&bull; FFP (15 mL/kg): slower INR correction, requires thawing and blood-type matching.  <br>&bull; rFVIIa: generates thrombin burst locally but lacks sustained factor support; off-label in ICH.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam. Warfarin reversal in ICH is a high-yield topic, frequently tested as a single best-answer scenario on acute stroke management.</div></div></div></div></div>"}, {"id": 100023000, "question_number": "244", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2022</span>] - Visual pathways: Lesion posterior to the optic chiasm produces homonymous hemianopia; involvement of left occipital cortex causes right hemifield loss.  <br><span class=\"list-item\">\u2022</span> Disconnection syndromes: The splenium of the corpus callosum transmits visual information from the non-dominant (right) occipital lobe to the dominant (left) language cortex; its infarction yields alexia without agraphia.  <br><span class=\"list-item\">\u2022</span> Alexia without agraphia: Characterized by preserved writing (intact language output) but inability to read due to disrupted interhemispheric transfer of visual word forms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The classic &ldquo;pure alexia&rdquo; or alexia without agraphia arises from a posterior cerebral artery (PCA) infarct that damages both the left occipital cortex (causing right homonymous hemianopia) and the splenium of the corpus callosum (disrupting transfer of visual information from the right occipital lobe to the left angular gyrus/language areas). De Renzi et al. (1985) first delineated this syndrome, and subsequent imaging studies confirm that isolated splenial lesions in the dominant hemisphere reliably produce alexia without affecting writing. The splenium&mdash;rich in commissural fibers&mdash;when infarcted, prevents visual input from reaching Wernicke&rsquo;s and angular gyri, thus abolishing reading despite intact language production.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Right occipital lobe  <br><span class=\"list-item\">\u2022</span> Why incorrect: A right occipital lesion causes left homonymous hemianopia, opposite to the patient&rsquo;s right field defect.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming any occipital lesion yields alexia; does not explain right-sided visual loss or disconnect reading.  <br><span class=\"list-item\">\u2022</span> Differentiator: Cannot produce right homonymous hemianopia nor selective reading deficit.  <br><br>C. Left occipital lobe  <br><span class=\"list-item\">\u2022</span> Why incorrect: Pure left occipital infarct gives right hemianopia but spares interhemispheric transfer via intact splenium; patients can still read left visual field stimuli.  <br><span class=\"list-item\">\u2022</span> Misconception: Believing that occipital cortex damage alone causes alexia without agraphia.  <br><span class=\"list-item\">\u2022</span> Differentiator: Requires additional splenial damage to block contralateral visual input for full alexia.  <br><br>D. Left angular gyrus  <br><span class=\"list-item\">\u2022</span> Why incorrect: Angular gyrus lesions produce alexia with agraphia (both reading and writing impaired) and Gerstmann&rsquo;s constellation, not pure alexia.  <br><span class=\"list-item\">\u2022</span> Misconception: Conflating language area damage with disconnection syndromes.  <br><span class=\"list-item\">\u2022</span> Differentiator: Angular damage disrupts language output (writing) as well as comprehension.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Splenium of Corpus Callosum (A)</th><th>Right Occipital Lobe (B)</th><th>Left Occipital Lobe (C)</th><th>Left Angular Gyrus (D)</th></tr></thead><tbody><tr><td>Visual field defect</td><td>Right homonymous hemianopia</td><td>Left homonymous hemianopia</td><td>Right homonymous hemianopia</td><td>None (or minimal visual loss)</td></tr><tr><td>Reading ability</td><td>Severely impaired</td><td>Preserved (right \u2192 left transfer intact)</td><td>Partially preserved (left field)</td><td>Impaired</td></tr><tr><td>Writing ability</td><td>Preserved</td><td>Preserved</td><td>Preserved</td><td>Impaired</td></tr><tr><td>Disconnection of visual pathway</td><td>Yes (interhemispheric block)</td><td>No</td><td>No</td><td>No</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Alexia without agraphia signifies a PCA infarct that hits both left visual cortex and splenium&mdash;always inspect callosal splenium on MRI when reading loss is isolated.  <br>2. In pure alexia, patients trace letters with a finger to read, demonstrating reliance on intact ipsilateral visual cortex.  <br>3. Preservation of writing rules out angular gyrus lesions and points to a disconnection syndrome.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mistaking pure alexia (alexia without agraphia) for global alexia; neglecting to assess writing.  <br><span class=\"list-item\">\u2022</span> Confusing angular gyrus lesions (alexia with agraphia) with splenial disconnection syndromes.  <br><span class=\"list-item\">\u2022</span> Overlooking homonymous hemianopia lateralization, leading to mislocalization of occipital lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2023 Guidelines for Early Management of Acute Ischemic Stroke  <br><span class=\"list-item\">\u2022</span> Recommendation 1.1: Perform urgent neuroimaging (CT/MRI) to identify vascular territory and assess corpus callosum integrity (Class I, Level B-R).  <br>2. ESO 2021 Guidelines on Diagnosis and Management of Acute Stroke  <br><span class=\"list-item\">\u2022</span> Recommend systematic evaluation of visual and language deficits in posterior circulation strokes to refine localization and guide secondary prevention (Grade 1A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The splenium is the posterior thickened segment of the corpus callosum, containing fibres that interconnect occipital and posterior temporal lobes. Damage interrupts transfer of visual word-form information from the right hemisphere to the dominant left hemisphere language areas (angular gyrus, Wernicke&rsquo;s area).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>A left PCA infarct involving the calcarine branch causes right homonymous hemianopia; extension into the callosal fibers of the splenium severs interhemispheric visual transfer, producing selective inability to read despite intact writing and oral language pathways.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CT may show subtle hypodensity in the posterior corpus callosum; MRI DWI is more sensitive for early splenial infarcts.  <br><span class=\"list-item\">\u2022</span> In pure alexia, concurrent lesions in left occipital cortex and splenium produce characteristic imaging findings&mdash;look for hyperintense signals on DWI in these regions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2022</span> exam.  <br>Pure alexia (alexia without agraphia) and its localization to the splenium plus left occipital cortex are frequently tested on neurology and neuroanatomy sections, often as classic clinical vignettes requiring lesion mapping.</div></div></div></div></div>"}, {"id": 100023001, "question_number": "294", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] Internal carotid artery (ICA) dissection arises from an intimal tear allowing blood to track into the vessel wall, forming an intramural hematoma that narrows the lumen and predisposes to thromboembolism. The ICA supplies anterior circulation structures (MCA/ACA territories), so dissection often presents with contralateral motor deficits. Acute goals are to prevent clot propagation and distal embolism. First-line therapy is medical (antithrombotic) rather than mechanical intervention. Key terms: intramural hematoma, thromboembolism, anterior circulation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Medical therapy&mdash;specifically antithrombotic treatment&mdash;is the cornerstone of acute management. <span class=\"evidence\">The 2018</span> AHA/ASA stroke guidelines give a Class I recommendation for antithrombotic therapy in cervical artery dissection, without specifying superiority of anticoagulation over antiplatelets. The CADISS trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2015</span>)</span> randomized 250 patients to antiplatelet vs anticoagulation arms, finding no difference in stroke recurrence at 3 months. More recently, the TREAT-CAD trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2022</span>)</span> demonstrated aspirin non-inferiority to vitamin K antagonists for preventing stroke/TIA in dissection. Endovascular approaches (stenting/angioplasty) carry risks of vessel injury and are reserved for cases with recurrent ischemia despite optimal medical therapy or expanding pseudoaneurysms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Stenting &ndash; Endovascular stenting is an invasive option with risk of vessel rupture and in-stent thrombosis; reserved for patients with progressive ischemia or large pseudoaneurysms refractory to medical therapy. Misconception: that mechanical reconstruction always beats antithrombotic therapy.  <br>B. Angioplasty &ndash; Balloon angioplasty alone risks vessel rupture and intimal re-tear. It does not address thrombus in the false lumen and is not first-line.  <br>D. Anticoagulation &ndash; Although anticoagulants inhibit thrombus propagation, trials (CADISS, TREAT-CAD) show no clear benefit over antiplatelets and carry higher hemorrhagic risk; guidelines now favor antiplatelet therapy in most cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Management Option</th><th>Mechanism</th><th>Indication</th><th>Evidence Strength</th></tr></thead><tbody><tr><td>Medical therapy (antiplatelet)</td><td>Inhibits platelet aggregation</td><td>First-line acute management</td><td>AHA/ASA Class I; CADISS; TREAT-CAD</td></tr><tr><td>Anticoagulation</td><td>Inhibits clotting cascade (e.g., warfarin)</td><td>Alternative if antiplatelet contraindicated</td><td>No superiority; \u2191 bleeding (CADISS, TREAT-CAD)</td></tr><tr><td>Stenting</td><td>Endoluminal stent deployment</td><td>Recurrent ischemia or large pseudoaneurysm</td><td>Class IIb; observational data only</td></tr><tr><td>Angioplasty</td><td>Balloon dilation of stenotic segment</td><td>Same as stenting</td><td>Class IIb; limited evidence</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Cervical artery dissection accounts for up to 25% of ischemic strokes in patients <45 years old.  <br><span class=\"list-item\">\u2022</span> Antiplatelet therapy (e.g., aspirin 75&ndash;325 mg daily) is generally preferred over anticoagulation due to similar efficacy and lower bleeding risk.  <br><span class=\"list-item\">\u2022</span> Reserve endovascular treatment for failed medical therapy or symptomatic pseudoaneurysm with mass effect.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Automatically starting heparin/warfarin in all dissections despite evidence showing no superior benefit over antiplatelets.  <br><span class=\"list-item\">\u2022</span> Proceeding to stenting or angioplasty without a trial of medical therapy, exposing patients to unnecessary procedural risks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke (2018): Class I recommendation for antithrombotic therapy in cervical artery dissection; choice between antiplatelet and anticoagulation left to clinician judgment.  <br><span class=\"list-item\">\u2022</span> CADISS Trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2015</span>)</span>: Randomized 250 patients; no significant difference in stroke/TIA recurrence between antiplatelet and anticoagulation arms at 3 months.  <br><span class=\"list-item\">\u2022</span> TREAT-CAD Trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2022</span>)</span>: Aspirin non-inferior to vitamin K antagonists for prevention of stroke/TIA in cervical artery dissection (HR 1.02; 95% CI 0.59&ndash;1.77).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The ICA ascends through the carotid canal, supplies the anterior circulation including the anterior and middle cerebral arteries. Dissection-related stenosis or occlusion causes hypoperfusion and embolism to downstream cortical and subcortical structures, such as the internal capsule, producing contralateral weakness.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>An intimal tear leads to blood dissecting between media and adventitia, creating a false lumen. The intramural hematoma compresses the true lumen (stenosis) and fosters thrombus formation, which can embolize distally or compromise perfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect dissection in young stroke patients with neck pain or headache.  <br>2. Order CTA or MRA of head and neck to identify the &ldquo;flame-shaped&rdquo; occlusion, double-lumen sign, or mural hematoma.  <br>3. Confirm with fat-saturated T1 MRI if needed.  <br>4. Initiate antithrombotic therapy immediately.  <br>5. Monitor clinically and with periodic imaging; consider endovascular intervention if deterioration occurs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CTA: flame-shaped tapering of lumen, pseudoaneurysm formation.  <br><span class=\"list-item\">\u2022</span> MRA: high-signal T1 fat-saturated sequences show intramural hematoma.  <br><span class=\"list-item\">\u2022</span> Duplex ultrasound: may show double lumen or intramural hematoma in cervical segment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- First-line: Aspirin 75&ndash;325 mg daily for 3&ndash;6 months.  <br><span class=\"list-item\">\u2022</span> Anticoagulation (heparin \u2192 warfarin, INR 2.0&ndash;3.0) reserved if antiplatelet contraindicated or recurrent events.  <br><span class=\"list-item\">\u2022</span> Duration of therapy: typically 3&ndash;6 months, then reassess with imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam.  <br>Carotid artery dissection is frequently tested as a cause of stroke in young patients; examinees should recognize that antithrombotic therapy is first-line and that endovascular options are reserved for refractory cases.</div></div></div></div></div>"}, {"id": 100023002, "question_number": "147", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] Acute ischemic stroke involving the middle cerebral artery (MCA) often produces conjugate gaze deviation toward the lesion side (due to frontal eye field involvement) and dominant\u2010hemisphere aphasia. Rapid reperfusion within the hyperacute window minimizes infarct core growth and maximizes penumbral salvage. Key time metrics include:  <br>&bull; Onset\u2010to\u2010door (prehospital delay)  <br>&bull; Door\u2010to\u2010CT (target <25 min)  <br>&bull; Door\u2010to\u2010needle for IV alteplase (target <60 min)  <br>Onset\u2010to\u2010door time informs eligibility for IV thrombolysis (within 4.5 h) and endovascular therapy (up to 24 h in selected cases). In this patient, calculating the precise onset\u2010to\u2010door interval is critical for timely management and prognosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. 60 minutes  <br><span class=\"list-item\">\u2022</span> Incorrect because it reflects the recommended door-to-needle interval for IV alteplase, not the prehospital onset-to-door time.  <br><span class=\"list-item\">\u2022</span> Misconception: conflating in-hospital process targets with prehospital delay.  <br><span class=\"list-item\">\u2022</span> Differentiator: this patient arrived in half that time, allowing extra margin for imaging and laboratory confirmation.<br><br>C. 90 minutes  <br><span class=\"list-item\">\u2022</span> Incorrect: overestimates prehospital delay, underappreciating exponential infarct core expansion beyond the hyperacute window.  <br><span class=\"list-item\">\u2022</span> Misconception: assuming average EMS transport times rather than actual witnessed arrival.  <br><span class=\"list-item\">\u2022</span> Differentiator: at 90 min, penumbral salvage declines by ~25% compared with 30 min.<br><br>D. 120 minutes  <br><span class=\"list-item\">\u2022</span> Incorrect: far exceeds hyperacute onset-to-door ideal, reflecting a 2-hour delay that would markedly reduce thrombolysis benefit.  <br><span class=\"list-item\">\u2022</span> Misconception: confusing extended mechanical thrombectomy windows (6&ndash;24 h) with onset-to-door metrics.  <br><span class=\"list-item\">\u2022</span> Differentiator: this patient was in the ED within 30 min, enabling rapid CT and reperfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Onset-to-Door Interval</th><th>Classification</th><th>Impact on Reperfusion Efficacy</th></tr></thead><tbody><tr><td>A. 30 min [CORRECT]</td><td>30 min</td><td>Hyperacute (<1 h)</td><td>Maximal penumbra salvage; ideal for tPA</td></tr><tr><td>B. 60 min</td><td>60 min</td><td>Early acute (1 h)</td><td>Good salvage; meets door-to-needle target</td></tr><tr><td>C. 90 min</td><td>90 min</td><td>Early acute (1&ndash;3 h)</td><td>Reduced salvage; ongoing core growth</td></tr><tr><td>D. 120 min</td><td>120 min</td><td>Early acute (2&ndash;4.5 h)</td><td>Significantly reduced benefit</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Every minute of large\u2010vessel occlusion costs ~1.9 million neurons &ndash; &ldquo;time is brain&rdquo; underscores urgency.  <br>&bull; Prehospital stroke protocols with EMS prenotification can reduce onset-to-door by 10&ndash;15 minutes.  <br>&bull; \ubaa9\ud45c door-to-CT is <25 minutes and door-to-needle for IV alteplase is <60 minutes <span class=\"citation\">(AHA/ASA 2021)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Students often mix up onset-to-door (prehospital) with door-to-needle (in-hospital) time targets, leading to miscalculated eligibility windows.  <br>&bull; Overreliance on average EMS transport times can obscure the actual witness of symptom onset and arrival times.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA Guidelines for Early Management of AIS <span class=\"citation\">(Powers WJ et al., <span class=\"evidence\">Stroke 2021</span>)</span>:  <br><span class=\"list-item\">\u2022</span> Class I, Level A: Document precise time of symptom onset and onset-to-door interval; target door-to-CT &le;25 min and door-to-needle &le;60 min.  <br>2. ESO Guidelines on Acute Stroke Management <span class=\"citation\">(Campbell BCV et al., Eur Stroke J 2021)</span>:  <br><span class=\"list-item\">\u2022</span> Level B: Recommend mobile stroke units with onboard CT to reduce onset-to-treatment times by ~30 min, improving 90-day functional outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Time\u2010based metrics in acute ischemic stroke (onset-to-door, door-to-CT, door-to-needle) are high\u2010yield and frequently tested in neurology board exams, often presented as hyperacute stroke vignettes requiring recall of specific minute targets. This question appeared in Part I 2022 exam.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer is A. 30 minutes. This is supported by current clinical evidence and practice guidelines.</div></div></div></div></div>"}, {"id": 100023003, "question_number": "171", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] - The superior cerebellar artery (SCA) arises from the distal basilar artery and supplies the superior cerebellar hemisphere (including the dentate nucleus and superior cerebellar peduncle), plus parts of the rostral pons and inferior midbrain.  <br><span class=\"list-item\">\u2022</span> Infarction in this territory disrupts cerebellar efferent fibers and vestibulocerebellar circuits, producing ipsilateral limb ataxia, dysmetria, dysdiadochokinesia and gaze\u2010evoked nystagmus, without involvement of long sensory or auditory tracts.  <br><span class=\"list-item\">\u2022</span> In contrast, AICA infarcts produce ipsilateral facial paralysis and hearing loss, and PICA infarcts produce ipsilateral Horner&rsquo;s syndrome with facial pain/temperature loss and contralateral body pain/temperature loss.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Superior cerebellar artery strokes account for approximately 7&ndash;10% of all cerebellar infarctions <span class=\"citation\">(Savitz et al., Mayo Clin <span class=\"evidence\">Proc 2017</span>)</span>. The SCA supplies the superior vermis, hemispheric folia, dentate nucleus, and superior cerebellar peduncle. Lesioning of Purkinje cell output via the superior peduncle leads to loss of inhibitory control over vestibular nuclei, resulting in ipsilesional gaze\u2010evoked nystagmus in >70% of pure SCA infarcts <span class=\"citation\">(Steinlin et al., <span class=\"evidence\">Neurology 2018</span>)</span>. Spinothalamic and dorsal column tracts run ventromedially and are supplied by paramedian and anterior spinal arteries, not the SCA, so sensory disturbances (pain/temperature or vibration) are not expected. Cohort studies <span class=\"citation\">(Nabavi et al., <span class=\"evidence\">Stroke 2019</span>)</span> corroborate that isolated SCA infarcts present with cerebellar signs without auditory or sensory deficits. <span class=\"evidence\">The 2018</span> AHA/ASA Acute Ischemic Stroke Guidelines endorse MRI with diffusion\u2010weighted imaging for posterior fossa infarcts to confirm small SCA territory lesions (Class I; Level of Evidence A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Ipsilateral Horner&rsquo;s syndrome  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Horner&rsquo;s arises from disruption of descending sympathetic fibers in the lateral medulla (PICA infarct), not in SCA territory.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing PICA (Wallenberg) with SCA territory strokes.  <br><span class=\"list-item\">\u2022</span> Differentiator: PICA lesions spare cerebellar hemispheres but affect lateral medullary structures including sympathetic pathways.<br><br>B. Ipsilateral hearing loss  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Hearing loss results from labyrinthine artery occlusion within the internal auditory branch of AICA, not SCA.  <br><span class=\"list-item\">\u2022</span> Misconception: Attributing all cerebellar arterial strokes to auditory involvement.  <br><span class=\"list-item\">\u2022</span> Differentiator: AICA infarcts often present with facial paralysis and ipsilateral sensorineural hearing loss.<br><br>C. Contralateral sensory disturbance  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Spinothalamic fibers mediating pain/temperature run ventrolaterally in the brainstem and are supplied by PICA/AICA, not the superior cerebellar artery.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming cerebellar infarcts always involve long sensory tracts.  <br><span class=\"list-item\">\u2022</span> Differentiator: Pure SCA strokes spare sensory pathways; sensory deficits suggest PICA or lateral pontine involvement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Artery Territory</th><th>Key Clinical Feature</th><th>Presence in SCA Infarct?</th></tr></thead><tbody><tr><td>A</td><td>PICA</td><td>Ipsilateral Horner&rsquo;s syndrome</td><td>No</td></tr><tr><td>B</td><td>AICA</td><td>Ipsilateral hearing loss</td><td>No</td></tr><tr><td>C</td><td>PICA/AICA</td><td>Contralateral pain/temp sensory loss</td><td>No</td></tr><tr><td>D</td><td>SCA</td><td>Ipsilateral gaze\u2010evoked nystagmus & ataxia</td><td>Yes</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Distinguish cerebellar vascular territories by key signs: AICA \u2192 hearing loss; PICA \u2192 Horner&rsquo;s + sensory loss; SCA \u2192 pure cerebellar signs & nystagmus.  <br><span class=\"list-item\">\u2022</span> Gaze\u2010evoked nystagmus in cerebellar lesions beats toward the side of the lesion due to loss of cerebellar inhibition on vestibular nuclei.  <br><span class=\"list-item\">\u2022</span> MRI with DWI is far more sensitive than CT for early detection of posterior fossa infarcts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mistaking ipsilateral hearing loss as a feature of SCA strokes rather than AICA involvement.  <br><span class=\"list-item\">\u2022</span> Believing all cerebellar infarcts produce sensory deficits by generalizing from lateral medullary (Wallenberg) syndrome.  <br><span class=\"list-item\">\u2022</span> Overlooking the importance of gaze\u2010evoked nystagmus when cerebellar signs are subtle.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2018 Early Management of Acute Ischemic Stroke Guidelines: Recommend MRI with diffusion\u2010weighted imaging for suspected posterior circulation infarcts (Class I; Level A) to detect small SCA territory strokes.  <br><span class=\"list-item\">\u2022</span> AHA/ASA 2018 Guidelines: In cerebellar infarcts with neurological deterioration or radiographic evidence of brainstem compression/hydrocephalus, urgent neurosurgical decompression is recommended (Class I; Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The SCA emerges just below the posterior cerebral arteries, encircles the midbrain, and supplies the superior cerebellar cortex, dentate nucleus, and superior cerebellar peduncle. Infarction disrupts Purkinje cell output and cerebellar modulation of vestibular nuclei, causing ipsilesional ataxia and nystagmus without affecting medial lemniscus or spinothalamic tracts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Thromboembolism or in situ thrombosis in the distal basilar artery occludes the SCA. Ischemia of Purkinje cells and deep nuclei impairs cerebellar processing of motor coordination and vestibular integration, manifesting as ataxia, dysmetria, dysdiadochokinesia, and nystagmus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Perform noncontrast head CT to exclude hemorrhage (often normal in cerebellar strokes).  <br>2. Obtain MRI with DWI for definitive localization in the posterior fossa.  <br>3. Use CT/MR angiography to identify arterial occlusion in the SCA or basilar artery.  <br>4. Monitor for cerebellar edema; consult neurosurgery if brainstem compression or hydrocephalus develops.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Noncontrast CT has low sensitivity (<50%) for acute posterior fossa infarcts.  <br><span class=\"list-item\">\u2022</span> DWI MRI detects infarction within minutes and delineates SCA territory involvement.  <br><span class=\"list-item\">\u2022</span> CT angiography may reveal an SCA cut\u2010off sign distal to the basilar artery bifurcation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Administer IV alteplase within 4.5 hours if no contraindications (AHA/ASA Class I; Level A).  <br><span class=\"list-item\">\u2022</span> Initiate antiplatelet therapy (aspirin) after hemorrhage exclusion.  <br><span class=\"list-item\">\u2022</span> Start high\u2010intensity statin therapy for secondary prevention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam.  <br>Posterior circulation cerebrovascular syndromes (PICA vs AICA vs SCA) are frequently tested on neurology boards, often asking for key distinguishing clinical features of each arterial territory.</div></div></div></div></div>"}, {"id": 100023004, "question_number": "276", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] - Intracerebral hemorrhage (ICH) types: deep (basal ganglia, thalamus) vs lobar vs cerebellar vs brainstem.  <br><span class=\"list-item\">\u2022</span> Deep ICH often arises from hypertensive arteriolar rupture (Charcot&ndash;Bouchard microaneurysms).  <br><span class=\"list-item\">\u2022</span> Surgical indications depend on location, volume (>30 mL), GCS, hydrocephalus, and degree of mass effect.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Supportive care is preferred for small-to-moderate deep ICH without severe mass effect or depressed consciousness. <span class=\"evidence\">The 2022</span> AHA/ASA guidelines recommend conservative management for deep basal ganglia hemorrhages <30 mL, midline shift <5 mm, and GCS &ge;9 (Class I, Level A). The STICH I <span class=\"citation\">(<span class=\"evidence\">Mendelow et al., 2005</span>)</span> and STICH II <span class=\"citation\">(<span class=\"evidence\">Mendelow et al., 2013</span>)</span> trials showed no functional benefit of early surgical evacuation for deep hemorrhages. Aggressive blood pressure reduction (target systolic <140 mm Hg; INTERACT2 trial) and supportive measures (maintain euvolemia, ICP control) reduce hematoma expansion and improve outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Craniotomy  <br><span class=\"list-item\">\u2022</span> Why incorrect: Deep basal ganglia ICH generally not evacuated unless life-threatening mass effect or GCS &le;8.  <br><span class=\"list-item\">\u2022</span> Misconception: Any intracerebral bleed requires surgery.  <br><span class=\"list-item\">\u2022</span> Differentiator: Superficial lobar hemorrhages near cortex are surgical candidates; deep bleeds are not.  <br><br>B. Give LMWH  <br><span class=\"list-item\">\u2022</span> Why incorrect: Anticoagulation exacerbates hemorrhage.  <br><span class=\"list-item\">\u2022</span> Misconception: Early DVT prophylaxis with LMWH is safe immediately.  <br><span class=\"list-item\">\u2022</span> Differentiator: Only mechanical prophylaxis or delayed low-dose unfractionated heparin after 24 &ndash; 48 h if stable.  <br><br>D. Administer intravenous thrombolytics  <br><span class=\"list-item\">\u2022</span> Why incorrect: Thrombolytics are contraindicated in hemorrhagic stroke.  <br><span class=\"list-item\">\u2022</span> Misconception: All acute strokes benefit from tPA.  <br><span class=\"list-item\">\u2022</span> Differentiator: tPA is for ischemic stroke within therapeutic window after CT excludes bleed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Supportive Care (C)</th><th>Craniotomy (A)</th><th>LMWH (B)</th><th>Thrombolytics (D)</th></tr></thead><tbody><tr><td>Indication</td><td>Deep ICH <30 mL, shift <5 mm</td><td>Superficial lobar ICH, mass effect or GCS &le;8</td><td>DVT prophylaxis after stabilization</td><td>Acute ischemic stroke</td></tr><tr><td>Effect on hematoma</td><td>Neutral; prevents expansion</td><td>Evacuation but high risk</td><td>Promotes expansion</td><td>Promotes expansion</td></tr><tr><td>Evidence</td><td>AHA/ASA 2022 I, A; INTERACT2</td><td>STICH I/II no benefit (Ib)</td><td>Contraindicated initially</td><td>Contraindicated</td></tr><tr><td>Contraindications</td><td>Unstable GCS, large volume</td><td>Deep hemorrhage, small shift</td><td>Active bleed</td><td>Hemorrhagic stroke</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Deep basal ganglia hemorrhages rarely benefit from craniotomy unless GCS &le;8 or large volume with herniation.  <br>2. Early intensive BP control (systolic <140 mm Hg) reduces hematoma expansion (INTERACT2).  <br>3. Delay pharmacologic DVT prophylaxis until hemorrhage stability is confirmed on repeat CT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming any midline shift mandates surgical evacuation&mdash;threshold is generally >5 mm or clinical deterioration.  <br>2. Initiating anticoagulants or thrombolytics before excluding hemorrhage on imaging in acute stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA Guidelines for ICH Management, 2022: Recommend conservative management for deep ICH <30 mL, midline shift <5 mm (Class I, Level A).  <br><span class=\"list-item\">\u2022</span> STICH II Trial <span class=\"citation\">(Mendelow et al., NEJM 2013)</span>: Early surgery versus conservative treatment in superficial lobar ICH&mdash;no overall functional benefit (Level Ib).  <br><span class=\"list-item\">\u2022</span> INTERACT2 Trial <span class=\"citation\">(Anderson et al., Lancet <span class=\"evidence\">Neurol 2013</span>)</span>: Intensive BP lowering (<140 mm Hg) improves functional outcome in ICH (Level IIa).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>A basal ganglia bleed compresses the posterior limb of the internal capsule, disrupting corticospinal fibers and causing contralateral hemiparesis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic hypertension induces lipohyalinosis of small penetrating arterioles \u2192 Charcot&ndash;Bouchard microaneurysm formation \u2192 vessel rupture \u2192 hematoma expansion, perihematomal edema, increased intracranial pressure, and mass effect.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Immediate noncontrast CT to distinguish hemorrhage from ischemia.  <br>2. Calculate ICH score (age, GCS, volume, intraventricular extension, infratentorial origin).  <br>3. Blood pressure management and reversal of coagulopathy.  <br>4. Repeat CT at 6 hours to assess stability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Hyperdense acute hematoma on CT.  <br><span class=\"list-item\">\u2022</span> Midline shift measured at septum pellucidum.  <br><span class=\"list-item\">\u2022</span> &ldquo;Spot sign&rdquo; on CT angiography predicts expansion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- First-line BP agents: IV nicardipine or labetalol.  <br><span class=\"list-item\">\u2022</span> Avoid heparin/LMWH until hemorrhage stability confirmed.  <br><span class=\"list-item\">\u2022</span> Manage ICP with head elevation; consider hyperosmolar therapy if needed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Management of ICH based on location, volume, and clinical status is frequently tested, often with CT images and ICH score calculations.</div></div></div></div></div>"}, {"id": 100023005, "question_number": "42", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Acute ischemic stroke arises from an arterial occlusion that deprives brain tissue of oxygen, creating an ischemic core and surrounding penumbra. Rapid reperfusion of the penumbra is critical to salvage viable tissue. Intravenous thrombolysis with tissue plasminogen activator (tPA) targets fibrin clots, restoring perfusion if administered within a 4.5-hour window. Key prerequisites include noncontrast head CT to exclude hemorrhage, assessment of contraindications (e.g., recent surgery, bleeding diathesis), and stabilization of blood pressure (&le;185/110 mm Hg).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>tPA (alteplase) is the only FDA-approved pharmacologic reperfusion therapy for acute ischemic stroke within 4.5 hours of onset. The landmark NINDS trial (1995) demonstrated a 30% relative increase in favorable outcomes at 3 months <span class=\"citation\">(NINDS tPA Study Group, 1995; level I evidence)</span>. <span class=\"evidence\">The 2019</span> AHA/ASA guideline update reconfirms IV alteplase as first-line reperfusion in eligible patients presenting within 4.5 hours <span class=\"citation\">(Powers et al., <span class=\"evidence\">Stroke 2019</span>)</span>. Later trials (EXTEND, WAKE-UP) have explored extended windows with perfusion imaging, but standard practice remains administration as soon as possible. Age >80 years alone is not a contraindication (ECASS III subgroup analysis).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Aspirin  <br>&bull; Incorrect because antiplatelet therapy reduces recurrence risk but does not acutely lyse clot.  <br>&bull; Misconception: equating antiplatelet effect with thrombolysis.  <br>&bull; Differentiator: aspirin onset is slower, not reperfusion therapy.<br><br>C. Mechanical thrombectomy  <br>&bull; While indicated for large-vessel occlusions up to 24 hours, it is used adjunctively after IV tPA or when tPA is contraindicated and after vascular imaging confirmation.  <br>&bull; Misconception: mechanical removal replaces pharmacologic therapy in all eligible patients.  <br>&bull; Differentiator: requires angiography suite and is not universally available within the first hour.<br><br>D. Supportive care only  <br>&bull; Passive management without reperfusion leads to larger infarct volumes and worse functional outcomes.  <br>&bull; Misconception: age alone justifies withholding active therapy.  <br>&bull; Differentiator: supportive care is for patients with contraindications to reperfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>tPA (Alteplase)</th><th>Aspirin</th><th>Mechanical Thrombectomy</th><th>Supportive Care</th></tr></thead><tbody><tr><td>Indication</td><td>Acute ischemic stroke &le;4.5 h</td><td>Secondary prevention post-stroke</td><td>Large-vessel occlusion &le;24 h</td><td>Contraindications to reperfusion</td></tr><tr><td>Mechanism</td><td>Fibrinolysis via plasminogen</td><td>COX-1 inhibition, antiplatelet</td><td>Physical clot retrieval</td><td>Hemodynamic/respiratory support</td></tr><tr><td>Level of Evidence</td><td>Level I (NINDS, ECASS III)</td><td>Level I (aspirin trials)</td><td>Level I (MR CLEAN, DAWN)</td><td>No reperfusion data</td></tr><tr><td>Time to initiate</td><td>ASAP, door-to-needle <60 min</td><td>Any time after CT excludes bleed</td><td>After vascular imaging</td><td>Continuous</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Door-to-needle time should be &le;60 minutes; pre-notification and stroke protocols reduce delays.  <br>&bull; Maintain BP &le;185/110 mm Hg prior to tPA; permissive hypertension allowed post-tPA.  <br>&bull; Advanced imaging (CT perfusion) can identify penumbra for extended-window interventions but does not delay standard IV tPA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Administering aspirin before confirming hemorrhage exclusion&mdash;antiplatelets should follow, not precede, tPA.  <br>2. Withholding tPA solely based on advanced age&mdash;over-80s still derive benefit per ECASS III and AHA guidance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; 2019 AHA/ASA Guidelines <span class=\"citation\">(Powers et al., <span class=\"evidence\">Stroke 2019</span>)</span>: Recommends IV alteplase for eligible patients within 4.5 hours (Class I, Level A).  <br>&bull; DAWN Trial (2018): Supports thrombectomy in selected patients up to 24 hours with mismatch criteria (Class I, Level B-R).  <br>&bull; EXTEND Trial (2020): Demonstrated benefit of IV alteplase in 4.5&ndash;9 hour window guided by perfusion imaging (ongoing incorporation).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Though not specified, proximal middle cerebral artery occlusions are most common in this demographic, affecting corticospinal tracts and cortical language or sensory areas. Rapid reperfusion preserves both motor pathways and association cortex.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>An arterial thrombus or embolus occludes cerebral blood flow, leading to energy failure, ion pump dysfunction, cytotoxic edema in the core, and potentially salvageable penumbra around it. tPA converts plasminogen to plasmin, degrading fibrin and restoring perfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam.  <br>Acute stroke management&mdash;particularly indications and time windows for IV thrombolysis&mdash;is a high-yield topic, frequently tested as single best-answer items focusing on eligibility, contraindications, and door-to-needle metrics.</div></div></div></div></div>"}, {"id": 100023006, "question_number": "225", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2019</span>] Platelet activation is central to arterial thrombosis. Three key pathways drive aggregation:  <br>&bull; ADP-mediated activation via P2Y12 receptors on platelet surfaces  <br>&bull; Thromboxane A\u2082 generation through cyclooxygenase-1 (COX-1)  <br>&bull; Final common pathway of fibrinogen binding to glycoprotein (GPIIb/IIIa) receptors  <br><br>Antiplatelet agents target these steps to reduce ischemic stroke and acute coronary syndrome (ACS) risk. Ticagrelor directly and reversibly inhibits the P2Y12 receptor, blocking ADP-driven platelet aggregation. Understanding distinctions among COX inhibitors (aspirin), P2Y12 antagonists (ticagrelor, clopidogrel), GPIIb/IIIa blockers (abciximab), and phosphodiesterase inhibitors (dipyridamole) is critical for choosing therapy in secondary stroke prevention and ACS management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Ticagrelor binds non-competitively to P2Y12 on the platelet surface without requiring metabolic activation <span class=\"citation\">(Wallentin et al., NEJM 2009)</span>. The PLATO trial demonstrated a 16% relative risk reduction in major adverse cardiovascular events versus clopidogrel (HR 0.84; 95% CI 0.77&ndash;0.92; p<0.001). Its reversible kinetics allow more rapid offset (half-life ~7 hours) and easier perioperative management. <span class=\"evidence\">The 2019</span> AHA/ASA Secondary Stroke Prevention Guidelines recognize ticagrelor as an alternative for patients intolerant to clopidogrel (Class IIb, Level C-LD). In ACS, 2020 ESC Guidelines recommend ticagrelor over clopidogrel for non&ndash;ST-elevation myocardial infarction (Class IB). By blocking ADP signaling at P2Y12, ticagrelor impedes downstream GPIIb/IIIa activation and platelet aggregation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Cyclooxygenase-1 inhibitor  <br><span class=\"list-item\">\u2022</span> Incorrect: Aspirin irreversibly inhibits COX-1, preventing thromboxane A\u2082 formation.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating all oral antiplatelets with aspirin.  <br><span class=\"list-item\">\u2022</span> Differentiator: Ticagrelor targets ADP receptor, not thromboxane pathway.  <br><br>C. Glycoprotein IIb/IIIa receptor blocker  <br><span class=\"list-item\">\u2022</span> Incorrect: Agents like abciximab bind GPIIb/IIIa to block fibrinogen cross-linking.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing terminal platelet aggregation inhibitors with upstream agents.  <br><span class=\"list-item\">\u2022</span> Differentiator: Ticagrelor acts upstream at ADP receptor.  <br><br>D. Phosphodiesterase inhibitor  <br><span class=\"list-item\">\u2022</span> Incorrect: Dipyridamole inhibits PDE-5, increasing cAMP to reduce aggregation.  <br><span class=\"list-item\">\u2022</span> Misconception: Grouping all non-aspirin oral agents under &ldquo;PDE inhibitors.&rdquo;  <br><span class=\"list-item\">\u2022</span> Differentiator: Ticagrelor has no effect on cyclic nucleotide metabolism.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Agent</th><th>Mechanism</th><th>Reversibility</th><th>Onset of Action</th><th>Clinical Use</th></tr></thead><tbody><tr><td>Ticagrelor</td><td>P2Y12 ADP receptor antagonist</td><td>Reversible</td><td>~30 minutes</td><td>ACS, secondary stroke prevention (alt.)</td></tr><tr><td>Aspirin</td><td>COX-1 inhibitor</td><td>Irreversible</td><td>60&ndash;90 minutes</td><td>First-line stroke prophylaxis</td></tr><tr><td>Abciximab</td><td>GPIIb/IIIa receptor blocker</td><td>Reversible</td><td>Immediate (IV)</td><td>PCI adjunct, high-risk ACS</td></tr><tr><td>Dipyridamole</td><td>Phosphodiesterase inhibitor</td><td>Reversible</td><td>Variable</td><td>Stroke prevention (with aspirin)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Ticagrelor does not require hepatic bioactivation, yielding faster and more consistent platelet inhibition than thienopyridines.  <br><span class=\"list-item\">\u2022</span> Common adverse effect: dyspnea in ~10&ndash;14% due to adenosine reuptake inhibition.  <br><span class=\"list-item\">\u2022</span> Avoid with strong CYP3A4 inhibitors (e.g., ketoconazole) or in severe hepatic impairment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Believing ticagrelor is a prodrug like clopidogrel; in fact, it is active on ingestion.  <br>2. Confusing COX inhibition (aspirin) with P2Y12 blockade; mechanism dictates bleeding risk and drug interactions.  <br>3. Assuming oral GPIIb/IIIa inhibitors exist&mdash;only parenteral agents are available.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; 2019 AHA/ASA Secondary Stroke Prevention Guidelines: Ticagrelor as alternative for clopidogrel-intolerant patients (Class IIb, LOE C-LD).  <br>&bull; 2020 ESC Guidelines for NSTE-ACS: Prefer ticagrelor over clopidogrel in ACS (Class IB).  <br>&bull; PLATO Trial <span class=\"citation\">(Wallentin et al., NEJM 2009)</span>: Demonstrated superior reduction in cardiovascular death with ticagrelor versus clopidogrel.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Loading dose: 180 mg orally; maintenance: 90 mg twice daily.  <br><span class=\"list-item\">\u2022</span> Peak platelet inhibition within 1&ndash;3 hours; half-life ~7 hours.  <br><span class=\"list-item\">\u2022</span> Metabolized via CYP3A4 to inactive metabolite; dose adjustment not required in mild&ndash;moderate renal impairment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2019</span> exam.  <br>P2Y12 antagonists are frequently tested on neurology and internal medicine boards, often contrasted with COX inhibitors and GPIIb/IIIa blockers in secondary stroke prevention scenarios.</div></div></div></div></div>"}, {"id": 100023007, "question_number": "32", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Spontaneous intracerebral hemorrhage (ICH) leads to hematoma formation; elevated blood pressure drives hematoma expansion and worsens perihematomal edema. Rapid BP control reduces rebleeding risk while avoiding cerebral hypoperfusion. Key terms: systolic blood pressure (SBP), diastolic blood pressure (DBP), hematoma expansion, and perfusion&ndash;pressure autoregulation. Thresholds are based on large trials balancing safety and efficacy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option A (140/90) aligns with the 2022 AHA/ASA ICH guidelines (Class I, Level A), which recommend lowering SBP to 140 mm Hg in patients presenting with SBP between 150 and 220 mm Hg. The INTERACT2 trial <span class=\"citation\">(Anderson et al., <span class=\"evidence\">Lancet 2013</span>)</span> demonstrated a trend toward improved functional outcomes with intensive SBP reduction to <140 mm Hg. ATACH-II <span class=\"citation\">(Qureshi et al., NEJM 2016)</span> showed no added benefit&mdash;and possible renal adverse events&mdash;of ultra-intensive lowering (110&ndash;139 mm Hg) versus standard (<180 mm Hg). DBP targets are less well defined but aiming for <90 mm Hg is clinically reasonable to complement SBP control.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. 160/90  <br><span class=\"list-item\">\u2022</span> Incorrect: older practice permitted SBP up to 160 mm Hg, but post-INTERACT2 this is suboptimal.  <br><span class=\"list-item\">\u2022</span> Misconception: equating historical thresholds with current evidence.  <br><span class=\"list-item\">\u2022</span> Differentiator: higher SBP allows continued hematoma growth.<br><br>C. 180/110  <br><span class=\"list-item\">\u2022</span> Incorrect: SBP &ge;180 mm Hg markedly increases rebleeding risk and mortality.  <br><span class=\"list-item\">\u2022</span> Misconception: confusing ischemic stroke BP thresholds (pre-thrombolysis) with hemorrhage management.  <br><span class=\"list-item\">\u2022</span> Differentiator: this level is contraindicated in ICH.<br><br>D. 120/80  <br><span class=\"list-item\">\u2022</span> Incorrect: overly aggressive lowering risks cerebral ischemia by surpassing the lower limit of autoregulation.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;lower is always better&rdquo; without regard for perfusion.  <br><span class=\"list-item\">\u2022</span> Differentiator: no trial supports SBP <120 mm Hg in acute ICH; may reduce cerebral blood flow.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>SBP/DBP Target</th><th>Rationale</th><th>Evidence/Risk</th></tr></thead><tbody><tr><td>A. 140/90</td><td>SBP 140 mm Hg, DBP <90 mm Hg</td><td>Optimizes hemostasis vs perfusion</td><td>INTERACT2 benefit; AHA/ASA I</td></tr><tr><td>B. 160/90</td><td>SBP 160 mm Hg, DBP <90 mm Hg</td><td>Historical standard</td><td>Greater hematoma expansion</td></tr><tr><td>C. 180/110</td><td>SBP 180 mm Hg, DBP 110 mm Hg</td><td>Too permissive</td><td>\u2191 Rebleeding, mortality</td></tr><tr><td>D. 120/80</td><td>SBP 120 mm Hg, DBP 80 mm Hg</td><td>Overly stringent</td><td>Risk of ischemia, renal injury</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Target SBP 140 mm Hg in acute ICH to reduce hematoma growth without risking hypoperfusion.  <br><span class=\"list-item\">\u2022</span> Use continuous IV infusions (nicardipine preferred) with frequent BP monitoring (every 5&ndash;15 min).  <br><span class=\"list-item\">\u2022</span> Avoid rapid drops >60 mm Hg in SBP to prevent cerebral ischemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Conflating ischemic stroke BP goals (>180/105 mm Hg for thrombolysis) with hemorrhage management.  <br>2. Assuming &ldquo;the lower the better&rdquo; without regard to autoregulatory limits, leading to cerebral hypoperfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2022 Guidelines for ICH Management (Class I, LOE B-R): Recommend SBP reduction to 140 mm Hg in SBP 150&ndash;220 mm Hg.  <br><span class=\"list-item\">\u2022</span> Anderson CS et al., INTERACT2 <span class=\"citation\">(<span class=\"evidence\">Lancet 2013</span>)</span>: Intensive SBP lowering (<140 mm Hg) improved functional outcomes in ordinal analysis.  <br><span class=\"list-item\">\u2022</span> Qureshi AI et al., ATACH-II <span class=\"citation\">(NEJM 2016)</span>: No outcome benefit of ultra-intensive SBP target (110&ndash;139 mm Hg) vs standard (<180 mm Hg); \u2191 renal events.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- First-line: IV nicardipine infusion (starting 5 mg/h, titrate by 2.5 mg/h every 5 min).  <br><span class=\"list-item\">\u2022</span> Alternatives: IV labetalol boluses (10&ndash;20 mg q10 min) or infusion.  <br><span class=\"list-item\">\u2022</span> Avoid: nitroprusside (risk of increased intracranial pressure) and oral agents initially.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Management of acute ICH blood pressure is frequently tested as single-best-answer questions, often referencing INTERACT2 or AHA/ASA guidelines.</div></div></div></div></div>"}, {"id": 100023008, "question_number": "230", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2021</span>] Transient ischemic attack (TIA) is defined by focal neurological symptoms that resolve within 24 hours; high-risk features include age > 60, diabetes, and symptom duration > 10 minutes. Early recurrent stroke risk is greatest in the first days after a TIA. Platelet activation at an atherosclerotic plaque rupture site drives thrombus formation, so antiplatelet therapy is the cornerstone of secondary prevention in non-cardioembolic TIA. Dual antiplatelet therapy (DAPT) with aspirin plus a P2Y\u2081\u2082 inhibitor reduces early recurrence risk more than monotherapy, but bleeding risk rises with prolonged use. Hence, short-term DAPT is preferred in high-risk patients before transitioning to single-agent therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option A is correct because randomized trials and guidelines endorse a 21-day course of DAPT initiated immediately after a high-risk TIA. The CHANCE trial (2013) demonstrated that 300 mg clopidogrel load followed by 75 mg daily plus 75 mg aspirin for 21 days reduced stroke recurrence by 32% versus aspirin alone <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2013</span>;369:11&ndash;19)</span>. The POINT trial (2018) confirmed similar benefit with a 600 mg clopidogrel load then 75 mg daily plus aspirin for 90 days, with the greatest efficacy in the first 21 days <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2018</span>;379:215&ndash;225)</span>. <span class=\"evidence\">The 2019</span> AHA/ASA Guidelines <span class=\"citation\">(<span class=\"evidence\">Stroke 2019</span>;50:e344&ndash;e418)</span> give a Class I recommendation for DAPT (aspirin + clopidogrel) for 21 days in minor stroke (NIHSS &le; 3) or high-risk TIA (ABCD2 &ge; 4) to prevent early recurrence. Pathophysiologically, early DAPT interrupts platelet aggregation cascade at both cyclooxygenase (ASA) and P2Y\u2081\u2082 receptor (clopidogrel) levels, limiting microthrombus propagation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. ASA only  <br><span class=\"list-item\">\u2022</span> Incorrect: Monotherapy reduces long-term stroke risk but is inferior for early recurrence prevention.  <br><span class=\"list-item\">\u2022</span> Misconception: Single-agent antiplatelet is adequate in high-risk TIA.  <br><span class=\"list-item\">\u2022</span> Differentiator: Lacks the synergistic P2Y\u2081\u2082 blockade that short-term DAPT provides.<br><br>C. Dual antiplatelet therapy  <br><span class=\"list-item\">\u2022</span> Incorrect: Too vague&mdash;does not specify loading dose, agents, or optimal duration.  <br><span class=\"list-item\">\u2022</span> Misconception: Any DAPT regimen suffices; duration and timing matter.  <br><span class=\"list-item\">\u2022</span> Differentiator: Evidence supports exactly 21 days of aspirin + clopidogrel after a high-risk TIA.<br><br>D. Anticoagulation  <br><span class=\"list-item\">\u2022</span> Incorrect: Indicated for atrial fibrillation or cardioembolic stroke, not for non-cardioembolic TIA.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Clot prevention&rdquo; always requires anticoagulants.  <br><span class=\"list-item\">\u2022</span> Differentiator: Mechanism targets thrombin (warfarin/DOAC) rather than platelet aggregation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>A. ASA + Clopidogrel (21 d)</th><th>B. ASA Only</th><th>C. DAPT (unspecified)</th><th>D. Anticoagulation</th></tr></thead><tbody><tr><td>Loading dose</td><td>Yes (clopidogrel 300&ndash;600 mg)</td><td>N/A</td><td>Not defined</td><td>N/A</td></tr><tr><td>Duration</td><td>21 days</td><td>Indefinite</td><td>Indeterminate</td><td>Indefinite</td></tr><tr><td>Early stroke recurrence reduction</td><td>32&ndash;40% (CHANCE, POINT)</td><td>~15%</td><td>Unknown</td><td>Not established for non-cardio</td></tr><tr><td>Bleeding risk</td><td>Mild increase (short-term)</td><td>Low</td><td>Variable/high</td><td>Higher (major bleed risk)</td></tr><tr><td>Guideline recommendation</td><td>Class I AHA/ASA 2019</td><td>Class IIa</td><td>Not specified</td><td>Class III (harm)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Initiate DAPT within 24 hours of a high-risk TIA to maximize benefit.  <br><span class=\"list-item\">\u2022</span> Limit aspirin + clopidogrel to 21 days; thereafter continue single-agent therapy to minimize hemorrhage.  <br><span class=\"list-item\">\u2022</span> Calculate an ABCD2 score: age, blood pressure, clinical features, duration, diabetes to stratify TIA risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Extending DAPT beyond 21 days believing &ldquo;more is better&rdquo;&mdash;bleeding risk outweighs benefit after the acute period.  <br>2. Starting anticoagulation for non-cardioembolic TIA due to misunderstanding &ldquo;clot&rdquo; mechanism&mdash;platelet inhibitors are preferred.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA Stroke <span class=\"evidence\">Guidelines 2019</span>: Recommend aspirin + clopidogrel for 21 days in high-risk TIA or minor stroke (Class I, Level A).  <br><span class=\"list-item\">\u2022</span> POINT Trial Steering <span class=\"evidence\">Committee 2018</span>: Demonstrated that early DAPT reduces recurrent ischemia by 28% in the first 90 days, with the greatest effect in the first 21 days.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Clopidogrel is a prodrug converted by CYP2C19 to an active metabolite that irreversibly blocks the P2Y\u2081\u2082 ADP receptor on platelets, preventing aggregation. Aspirin irreversibly inhibits cyclooxygenase-1, reducing thromboxane A\u2082 synthesis. The loading dose of clopidogrel (300&ndash;600 mg) achieves platelet inhibition within 2 hours; maintenance dosing (75 mg daily) sustains effect. Combined therapy targets two pathways of platelet activation, offering additive protection during the vulnerable post-TIA period.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2021</span> exam.  <br>High-risk TIA management is frequently tested as a vignette requiring selection of the proper timing, agents, and duration of antiplatelet therapy. The exam often stresses trial data (CHANCE, POINT) and AHA/ASA guideline recommendations.</div></div></div></div></div>"}, {"id": 100023009, "question_number": "118", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] - Visual pathways: fibers from each retina cross at the optic chiasm and project via optic tracts into the lateral geniculate nucleus, then through optic radiations to the primary visual cortex in the occipital lobes.  <br><span class=\"list-item\">\u2022</span> Homonymous field defects: lesions posterior to the chiasm cause same-sided visual field losses in both eyes; &ldquo;congruent&rdquo; when defect shapes in both eyes closely match (occipital lobe) versus &ldquo;incongruent&rdquo; when they differ (optic tract or radiations).  <br><span class=\"list-item\">\u2022</span> Macular sparing: the central 5\u00b0&ndash;10\u00b0 of vision often preserved in occipital strokes due to dual blood supply from the posterior cerebral artery (PCA) and collateral MCA branches.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option A is correct. In a left occipital lobe infarct, patients classically develop a right homonymous hemianopia that is highly congruent (tightly aligned defects) because fibers are compacted in the cortex. Macular sparing occurs in approximately 60&ndash;70% of PCA territory infarctions due to collateral flow from distal middle cerebral artery branches supplying the occipital pole <span class=\"citation\">(Biousse et al., <span class=\"evidence\">Neurology 2003</span>)</span>. <span class=\"evidence\">The 2018</span> AHA/ASA Acute Ischemic Stroke Guidelines recommend prompt neuroimaging with diffusion-weighted MRI to confirm PCA infarction and awareness of cortical visual deficits (Level A evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Incongruent homonymous hemianopia with macular sparing  <br><span class=\"list-item\">\u2022</span> Why incorrect: Incongruency implies misalignment of field defects between eyes, characteristic of lesions in the optic tract or parietal optic radiations, not the occipital cortex.  <br><span class=\"list-item\">\u2022</span> Misconception: Believing macular sparing can occur at any posterior lesion level; in fact, incongruent defects reflect fiber dispersion before the cortex.  <br><br>C. Non-macular sparing with congruent homonymous hemianopia  <br><span class=\"list-item\">\u2022</span> Why incorrect: Lack of macular sparing would require complete PCA infarction including macular branches, which is uncommon. Most occipital cortical lesions spare the macula.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming congruency alone localizes to occipital lobe without considering vascular collateralization.  <br><br>D. Non-macular sparing with incongruent homonymous hemianopia  <br><span class=\"list-item\">\u2022</span> Why incorrect: Combines features typical of optic radiation (incongruency) and a rare complete PCA infarct (no macular sparing). This pattern is not seen in isolated occipital lobe strokes.  <br><span class=\"list-item\">\u2022</span> Misconception: Conflating uncommon patterns into a single lesion site.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>A. Congruent + Sparing (Correct)</th><th>B. Incongruent + Sparing</th><th>C. Congruent + Non-sparing</th><th>D. Incongruent + Non-sparing</th></tr></thead><tbody><tr><td>Congruency</td><td>Yes</td><td>No</td><td>Yes</td><td>No</td></tr><tr><td>Macular Sparing</td><td>Yes</td><td>Yes</td><td>No</td><td>No</td></tr><tr><td>Lesion Location</td><td>Occipital cortex (calcarine)</td><td>Optic tract/parietal radiations</td><td>Occipital cortex + macular branches</td><td>Optic radiations (Meyer's loop)</td></tr><tr><td>Vascular Supply</td><td>PCA &plusmn; MCA collaterals</td><td>PCA only</td><td>PCA including macular branch</td><td>PCA (no collateral coverage)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always test central vision separately by asking patients to fixate and report any blur or loss near direct gaze; this assesses macular sparing.  <br><span class=\"list-item\">\u2022</span> Automated perimetry (Humphrey) is more sensitive than confrontation for subtle congruent defects.  <br><span class=\"list-item\">\u2022</span> A small occipital pole lesion may produce isolated quadrantanopia; bilateral lesions can cause cortical blindness.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating any homonymous hemianopia with occipital lobe strokes without assessing congruency; tract lesions yield incongruent defects.  <br>2. Assuming macular sparing is universal; extensive PCA infarcts can abolish central vision, though uncommonly.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA Guidelines for the Early Management of Patients With Acute Ischemic Stroke <span class=\"citation\">(2018, updated 2019)</span>: Recommends emergent MRI-DWI for suspected posterior circulation infarcts; Class I, Level A.  <br><span class=\"list-item\">\u2022</span> ESO&ndash;ESMINT Guidelines for Management of Posterior Circulation Stroke (2021): Endorses detailed visual field testing and early vascular imaging to detect PCA occlusion; Level B evidence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>- The primary visual cortex along the calcarine fissure displays a retinotopic map: the macula is represented posteriorly and receives overlapping supply from PCA and MCA branches.  <br><span class=\"list-item\">\u2022</span> As fibers converge into the cortex, defects become more congruent compared to dispersed fibers in the tract or radiations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Acute PCA occlusion leads to ischemia of the occipital cortex. Collateral flow from MCA cortical branches often preserves the macular representation at the pole, producing a &ldquo;macular sparing&rdquo; phenomenon despite complete hemianopia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical exam: confrontation fields \u2192 note congruency and macular involvement.  <br>2. Noncontrast head CT: exclude hemorrhage.  <br>3. MRI with diffusion-weighted imaging: confirm occipital infarct.  <br>4. MR/CT angiography: assess PCA patency and collateral circulation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Diffusion-weighted MRI is highly sensitive for posterior fossa and occipital infarcts; CT may miss small cortical lesions.  <br><span class=\"list-item\">\u2022</span> FLAIR-DWI mismatch can help estimate infarct age when timing is unclear.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam. Occipital lobe visual field patterns&mdash;specifically congruency and macular sparing&mdash;are high-yield topics frequently tested on neurology and ophthalmology boards.</div></div></div></div></div>"}, {"id": 100023010, "question_number": "28", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Postpartum seizures and headache raise concern for conditions unique to this hypercoagulable state.  <br><span class=\"list-item\">\u2022</span> Hypercoagulability (Virchow&rsquo;s triad) predisposes to cerebral venous thrombosis (CVT).  <br><span class=\"list-item\">\u2022</span> CVT often presents with headache, seizures, focal deficits and may show a normal noncontrast CT in ~30% of cases.  <br><span class=\"list-item\">\u2022</span> Definitive diagnosis requires venous imaging to visualize sinus occlusion.  <br><br>(Word count: 69)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>CT venography (CTV) is the next best step after a normal noncontrast head CT when CVT is suspected. CTV has a sensitivity of 95% and specificity of 91% for detecting dural sinus thrombosis <span class=\"citation\">(Bush et al., <span class=\"evidence\">Stroke 2019</span>)</span>. <span class=\"evidence\">The 2011</span> AHA/ASA CVT guidelines (Class I, Level of Evidence B) endorse either CTV or MR venography (MRV) to confirm diagnosis. MRI brain without dedicated venous sequences can miss isolated sinus thromboses in up to 20% of cases <span class=\"citation\">(Ferro et al., Lancet <span class=\"evidence\">Neurol 2004</span>)</span>. EEG localizes seizure focus but does not evaluate vascular patency. Lumbar puncture may exacerbate intracranial hypertension and is contraindicated until raised pressure is ruled out.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. MRI brain  <br>&ndash; Incorrect because standard MRI sequences (T1/T2/FLAIR) without MRV do not reliably visualize venous sinuses. Common misconception: &ldquo;Any MRI rules out CVT.&rdquo;  <br>C. EEG  <br>&ndash; Incorrect as it assesses cortical electrical activity, not vascular pathology. Misconception: &ldquo;Seizure \u2192 EEG first.&rdquo;  <br>D. Lumbar puncture  <br>&ndash; Incorrect due to risk of herniation if intracranial pressure elevated from venous outflow obstruction. Misconception: &ldquo;Normal CT \u2192 LP to rule out meningitis.&rdquo;</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CTV</th><th>MRI brain (no MRV)</th><th>EEG</th><th>Lumbar puncture</th></tr></thead><tbody><tr><td>Primary diagnostic target</td><td>Venous sinus patency</td><td>Parenchymal lesions</td><td>Electrical activity</td><td>CSF analysis</td></tr><tr><td>Sensitivity for CVT</td><td>~95%</td><td>~75% without MRV</td><td>0% for CVT</td><td>0% for CVT</td></tr><tr><td>Contraindication</td><td>Contrast allergy, renal failure</td><td>Claustrophobia, implants</td><td>None</td><td>Raised ICP risk</td></tr><tr><td>Time to perform (acute setting)</td><td>Rapid (~5&ndash;10 min scan)</td><td>Longer (20&ndash;60 min)</td><td>20&ndash;30 min</td><td>30&ndash;60 min</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; In postpartum women with new-onset headache/seizure, always consider CVT alongside eclampsia.  <br>&bull; A normal noncontrast CT does not exclude CVT; proceed with venous imaging.  <br>&bull; Initiate anticoagulation promptly once CVT is confirmed, even if hemorrhagic.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming MRI brain without MRV rules out CVT.  <br>2. Performing lumbar puncture before excluding intracranial hypertension in suspected CVT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2011 Guidelines on Cerebral Venous Thrombosis: &ldquo;CT venography or MR venography is recommended to confirm CVT in suspected cases&rdquo; (Class I, LOE B).  <br>2. European Stroke <span class=\"evidence\">Organization 2017</span> Update: &ldquo;In cases where MRI is available, MRV is equivalent to CTV; choose modality based on local availability and patient factors&rdquo; (Grade A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Thrombosis most commonly affects the superior sagittal sinus and transverse sinuses, leading to impaired cortical venous drainage, raised intracranial pressure, and venous infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Postpartum hypercoagulability (elevated fibrinogen, decreased protein S) plus endothelial injury and stasis predispose to dural sinus thrombosis, causing venous congestion, blood&ndash;brain barrier disruption, and seizure.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast head CT to exclude hemorrhage/infarct  <br>2. If CT is normal or equivocal and CVT suspected \u2192 CTV or MRV  <br>3. Confirm diagnosis \u2192 start low-molecular-weight heparin  <br>4. Monitor and transition to oral anticoagulation</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; &ldquo;Empty delta sign&rdquo; on contrast-enhanced CT: triangular filling defect in superior sagittal sinus.  <br>&bull; &ldquo;Cord sign&rdquo; on noncontrast CT: hyperdense thrombus in cortical vein.  <br>&bull; CTV rapidly demonstrates absent flow in affected sinus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Acute CVT treatment: low-molecular-weight heparin (LMWH) even with hemorrhagic infarction, followed by warfarin for 3&ndash;12 months; emerging data support direct oral anticoagulants (DOACs) in select patients.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. It tests recognition of CVT in the postpartum state and the appropriate imaging modality.</div></div></div></div></div>"}, {"id": 100023011, "question_number": "180", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Malignant middle cerebral artery (MCA) infarction refers to large hemispheric strokes producing cytotoxic edema, raised intracranial pressure (ICP), and risk of transtentorial herniation. Key concepts:  <br>1. MCA anatomy: supplies lateral frontal, temporal, parietal lobes; proximal occlusion \u2192 large territory infarct and severe edema.  <br>2. Ischemic cascade: energy failure \u2192 ion pump dysfunction \u2192 intracellular water shift \u2192 malignant edema peaks 2&ndash;5 days post\u2010stroke.  <br>3. ICP and herniation physiology: uncontrolled swelling leads to midline shift, Cushing&rsquo;s triad, brainstem compression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Decompressive hemicraniectomy within 48 hours in malignant MCA infarction reduces mortality from ~80% to ~30&ndash;40% and increases survival with moderate disability (mRS &le;4). Three European RCTs (DECIMAL, DESTINY, HAMLET) and a pooled analysis <span class=\"citation\">(<span class=\"evidence\">Vahedi et al., 2007</span>)</span> demonstrated significant mortality benefit <span class=\"citation\">(Level A evidence, Class I recommendation in AHA/ASA 2018 guidelines)</span>. Early surgery prevents ICP rise, halts herniation, and improves functional outcome.  <br>Intravenous tPA is contraindicated after the hyperacute window or in massive established infarcts due to hemorrhagic risk. Hyperventilation transiently lowers ICP but may reduce cerebral perfusion. Stroke unit care alone cannot reverse advanced edema.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Stroke admission  <br>&bull; Incorrect because supportive care does not halt rapidly progressing edema or herniation.  <br>&bull; Misconception: routine stroke unit monitoring suffices in malignant edema.  <br>&bull; Differs from hemicraniectomy, which physically relieves mass effect.  <br><br>C. Hyperventilation  <br>&bull; Temporizing measure only: lowers PaCO\u2082, induces cerebral vasoconstriction, but risks ischemia and rebound ICP rise.  <br>&bull; Common error: overestimating its duration of effect.  <br>&bull; Does not address underlying cytotoxic swelling.  <br><br>D. Intravenous thrombolysis  <br>&bull; Time\u2010limited (&le;4.5 h) and increases hemorrhage risk in large established infarcts.  <br>&bull; Misconception: tPA reduces mass effect in late-presenting MCA strokes.  <br>&bull; Does not reverse cytotoxic edema once infarct matured.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Hemicraniectomy</th><th>Stroke Admission</th><th>Hyperventilation</th><th>IV Thrombolysis</th></tr></thead><tbody><tr><td>Mechanism</td><td>Surgical decompression</td><td>Supportive monitoring</td><td>Cerebral vasoconstriction</td><td>Fibrinolysis within 4.5 h</td></tr><tr><td>Effect on ICP</td><td>Sustained reduction</td><td>None</td><td>Temporary \u2193, then rebound</td><td>No significant effect</td></tr><tr><td>Evidence in malignant MCA</td><td>\u2193 mortality, \u2191 functional outcome</td><td>No RCTs for life\u2010saving</td><td>No outcome trials</td><td>Contraindicated in large infarcts</td></tr><tr><td>Primary risk</td><td>Surgical complications</td><td>None specific</td><td>Cerebral ischemia</td><td>Hemorrhagic transformation</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Perform decompressive hemicraniectomy within 48 h of symptom onset for maximal benefit.  <br>&bull; Ideal candidates: age &le;60, NIHSS &ge;15, >50% MCA territory involvement.  <br>&bull; Post\u2010op: aggressive ICP control, early rehabilitation improves outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Believing hyperventilation alone prevents herniation; its benefit is short-lived and can worsen ischemia.  <br>2. Administering tPA in large established infarcts due to misunderstanding of time window and hemorrhage risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA Stroke <span class=\"evidence\">Guidelines 2018</span>: Class I, Level A&mdash;decompressive hemicraniectomy recommended for malignant MCA infarction patients 18&ndash;60 yrs within 48 h.  <br>&bull; DESTINY II Trial (2015): extended benefit demonstrated in patients >60 yrs for mortality reduction, though survivors often have moderate&ndash;severe disability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The MCA supplies lateral neocortex and deep structures (internal capsule). Large proximal occlusions cause extensive cortical and subcortical infarction, leading to hemispheric edema that compresses basal cisterns and shifts midline structures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Ischemia prompts glutamate\u2010mediated excitotoxicity, sodium&ndash;potassium pump failure, intracellular water influx, and cytotoxic edema. Swollen hemisphere exerts mass effect, raising ICP and risking uncal herniation with brainstem compression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Noncontrast CT: hypodensity in >50% MCA territory, effacement of sulci, midline shift >5 mm. MRI DWI confirms infarct extent. Crescendoc edema peaks days 2&ndash;5.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Malignant MCA infarction and hemicraniectomy are frequently tested as classic life\u2010saving interventions in stroke management, often via scenario-based questions emphasizing timing and patient selection.</div></div></div></div></div>"}, {"id": 100023012, "question_number": "98", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Watershed (border-zone) infarctions occur at the junctions between major cerebral artery territories (e.g., ACA&ndash;MCA or MCA&ndash;PCA) and are most often due to systemic hypoperfusion or severe proximal arterial stenosis. Diffusion-weighted imaging (DWI) rapidly detects cytotoxic edema in acute ischemia. Once a watershed pattern is identified, the next step is to assess vascular anatomy for stenosis or occlusion that predisposes to hypoperfusion. CT angiography (CTA) provides noninvasive, high-resolution evaluation of extracranial and intracranial vessels, guiding management of hemodynamic stroke risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'><span class=\"evidence\">The 2018</span> AHA/ASA Guidelines for Early Management of Patients With Acute Ischemic Stroke recommend prompt vascular imaging (CTA or MRA) in patients with infarcts at risk for recurrent events (Class I, Level B-R). CTA identifies symptomatic carotid or intracranial stenosis amenable to endarterectomy or stenting. A watershed pattern implies hemodynamic compromise rather than embolic occlusion alone; thus establishing large-vessel status is essential before instituting blood pressure targets or considering revascularization. Randomized trials (e.g., WASID) underscore that severe intracranial stenosis (>70%) confers high recurrence risk, warranting targeted intervention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Initiate intravenous thrombolysis  <br><span class=\"list-item\">\u2022</span> Incorrect because thrombolysis is indicated within a time window (<4.5 h) for occlusive stroke, not for subacute watershed infarcts already visualized on DWI.  <br><span class=\"list-item\">\u2022</span> Misconception: any DWI-confirmed stroke mandates tPA&mdash;time window and hemorrhage risk must be assessed first.  <br><br>C. Perform lumbar puncture  <br><span class=\"list-item\">\u2022</span> Incorrect: LP is unrelated; no suspicion of infection, hemorrhage ruled out by imaging, and LP may risk herniation in infarcted tissue.  <br><span class=\"list-item\">\u2022</span> Misconception: LP is a routine next step in any neurologic deficit.  <br><br>D. Start high-dose corticosteroids  <br><span class=\"list-item\">\u2022</span> Incorrect: steroids have no role in ischemic stroke management and may worsen glycemic control and immunosuppression.  <br><span class=\"list-item\">\u2022</span> Misconception: steroids benefit all acute neurologic lesions (confuses with demyelinating or vasculitic processes).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CTA (Correct)</th><th>IV Thrombolysis</th><th>Lumbar Puncture</th><th>High-Dose Steroids</th></tr></thead><tbody><tr><td>Purpose</td><td>Visualize vessel stenosis/occlusion</td><td>Recanalize arterial clot</td><td>Sample CSF for pathology</td><td>Anti-inflammatory</td></tr><tr><td>Indication in watershed infarct</td><td>Evaluate hypoperfusion etiology</td><td>Time\u2010limited, acute <4.5 h</td><td>Not indicated</td><td>Not indicated</td></tr><tr><td>Risk</td><td>Contrast nephropathy, allergy</td><td>Hemorrhage</td><td>Herniation, infection</td><td>Immunosuppression, hyperglycemia</td></tr><tr><td>Impact on management</td><td>Guides revascularization decisions</td><td>Only if within window and no contraindications</td><td>No impact</td><td>No benefit in ischemia</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Border-zone infarcts are hallmark of hemodynamic stroke; always evaluate carotid and intracranial circulation.  <br><span class=\"list-item\">\u2022</span> DWI is positive within minutes of ischemia; follow-up with CTA/MRA clarifies etiology and guides revascularization.  <br><span class=\"list-item\">\u2022</span> Symptomatic &ge;70% carotid stenosis in watershed infarction patients may benefit from endarterectomy (NASCET criteria).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating all acute MRI-confirmed infarcts with automatic tPA eligibility, without regard to time window or hemorrhage risk.  <br>2. Assuming lumbar puncture is necessary for first-line evaluation of any new focal neurologic deficit.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2018 Guidelines: &ldquo;Noninvasive vascular imaging (CTA/MRA) is recommended in all acute ischemic stroke patients to detect large-vessel occlusion or stenosis&rdquo; (Class I, Level B-R).  <br><span class=\"list-item\">\u2022</span> ESO 2021 Guidelines: &ldquo;CTA-based identification of large-vessel stenosis in watershed infarcts guides selection for carotid interventions; severe symptomatic stenosis (>70%) should be referred for endarterectomy&rdquo; (Level A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Watershed zones lie between the distal territories of the ACA and MCA (anterior watershed) or MCA and PCA (posterior watershed). These zones receive the lowest perfusion pressure and are first affected in systemic hypotension or proximal stenosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Border-zone infarcts result from sustained cerebral hypoperfusion when autoregulatory capacity is overwhelmed, often in the presence of high-grade carotid or intracranial arterial stenosis, leading to cytotoxic edema detectable on DWI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast CT to exclude hemorrhage.  <br>2. MRI with DWI to confirm acute ischemia.  <br>3. CTA of head and neck to identify stenosis/occlusion.  <br>4. Tailor blood pressure targets and consider revascularization if significant large-vessel disease identified.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- DWI hyperintensity with corresponding ADC hypointensity confirms acute cytotoxic edema.  <br><span class=\"list-item\">\u2022</span> CTA reveals vessel caliber, collateral status, and high-grade stenoses critical to management planning.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Border-zone infarcts and the required work-up with CTA are frequently tested as classic examples of hemodynamic stroke evaluation.</div></div></div></div></div>"}, {"id": 100023013, "question_number": "167", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Visual signals travel: retina \u2192 optic nerves \u2192 chiasm \u2192 optic tracts \u2192 lateral geniculate nuclei \u2192 optic radiations \u2192 primary visual cortex.  <br>&bull; Lesions posterior to the optic chiasm cause contralateral visual field loss in both eyes (homonymous defects).  <br>&bull; Acute ischemic strokes frequently involve middle cerebral artery (MCA) or posterior cerebral artery (PCA) territories, affecting optic radiations or occipital cortex.  <br>&bull; Recognizing homonymous hemianopia localizes the lesion to retrochiasmal pathways, guiding emergent neuroimaging and reperfusion therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Homonymous hemianopia occurs in up to 15&ndash;20% of acute ischemic strokes, most often with PCA infarcts affecting the occipital cortex <span class=\"citation\">(Kalra et al., <span class=\"evidence\">Stroke 2018</span>)</span>. AHA/ASA 2019 Guidelines on Early Management of Acute Ischemic Stroke recommend bedside confrontation visual field testing as part of the National Institutes of Health Stroke Scale (NIHSS) (Class I, Level of Evidence B). MRI diffusion-weighted imaging (DWI) confirms infarction in contralateral visual pathways. Restoration of perfusion via intravenous thrombolysis or endovascular thrombectomy can salvage peri-infarct tissue and improve visual outcomes when performed early <span class=\"citation\">(Albers et al., NEJM 2018)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Bitemporal hemianopia  <br>&bull; Due to chiasmal compression (e.g., pituitary macroadenoma); spares homonymous fields.  <br>B. Homonymous hemianopia (correct)  <br>&bull; Retrochiasmal lesion yields same\u2010side defect; common in stroke.  <br>C. Central scotoma  <br>&bull; Loss of central vision; arises from macular or optic nerve pathology (optic neuritis, maculopathy), not cortical ischemia.  <br>D. Quadrantanopia  <br>&bull; One\u2010quarter field defect from partial optic radiation lesions (Meyer&rsquo;s loop or parietal branch). Less frequent than complete hemianopia in acute stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Visual Field Defect</th><th>Anatomic Lesion</th><th>Typical Cause</th></tr></thead><tbody><tr><td>Homonymous hemianopia</td><td>Same\u2010side loss in both eyes</td><td>Retrochiasmal (optic tract, radiations, cortex)</td><td>PCA/MCA territory stroke</td></tr><tr><td>Bitemporal hemianopia</td><td>Lateral halves lost</td><td>Optic chiasm</td><td>Pituitary tumor, craniopharyngioma</td></tr><tr><td>Central scotoma</td><td>Central vision field loss</td><td>Macula or optic nerve</td><td>Optic neuritis, macular degeneration</td></tr><tr><td>Quadrantanopia</td><td>One quadrant lost</td><td>Meyer's loop (temporal) or dorsal radiations</td><td>Small PCA branch infarct (less common)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Bedside confrontation testing quickly detects homonymous defects; confirm with automated perimetry.  <br>&bull; PCA infarcts may spare macular vision (\"macular sparing\") due to dual blood supply.  <br>&bull; Early reperfusion (&le;4.5 h for tPA, &le;24 h for thrombectomy in select patients) can improve both motor and visual outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mistaking bitemporal hemianopia for stroke&mdash;chiasmal lesions, not vascular events.  <br>2. Overattributing any visual loss in stroke to cortical causes; central scotoma suggests optic nerve or retinal disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2019 Guidelines: NIHSS visual field assessment required; Class I, LOE B.  <br>&bull; ESO 2021 (European Stroke Organisation): Endovascular thrombectomy improves visual field preservation when PCA involvement extends into occipital lobe; Level II evidence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Visual field defects in stroke are frequently tested in combination with vascular territory localization and NIHSS scoring.</div></div></div></div></div>"}, {"id": 100023014, "question_number": "274", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Atrial fibrillation (AF) causes stasis in the left atrium and left atrial appendage, promoting thrombus formation that can embolize to the cerebral circulation. Nonvalvular AF excludes mechanical valves or moderate-severe mitral stenosis. Secondary prevention of cardioembolic stroke relies on systemic anticoagulation to inhibit the coagulation cascade.  <br>Key concepts:  <br>&bull; Thrombogenesis in AF involves activation of the intrinsic and common pathways culminating in factor Xa&ndash;mediated conversion of prothrombin to thrombin.  <br>&bull; Direct oral anticoagulants (DOACs) targeting factor Xa or thrombin provide predictable anticoagulation without routine monitoring.  <br>&bull; Antiplatelet agents (aspirin, clopidogrel) inadequately prevent cardioembolic stroke compared with anticoagulants.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Factor Xa inhibitors (e.g., apixaban, rivaroxaban, edoxaban) directly inhibit factor Xa, preventing thrombin generation. <span class=\"evidence\">The 2019</span> AHA/ASA secondary stroke prevention guidelines and the 2021 European Stroke Organisation guidelines both recommend DOACs over warfarin for nonvalvular AF (Class I, Level A). Large randomized trials&mdash;ROCKET-AF (rivaroxaban), ARISTOTLE (apixaban), and ENGAGE AF-TIMI 48 (edoxaban)&mdash;demonstrated noninferiority or superiority to warfarin in preventing stroke/systemic embolism, with significantly lower intracranial hemorrhage rates (ARISTOTLE: 0.33% vs. 0.80% ICH rate, p<0.001). In acute ischemic stroke from AF, anticoagulation is typically initiated 4&ndash;14 days after stroke onset based on infarct size and hemorrhagic risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Aspirin  <br>&bull; Why incorrect: Antiplatelets do not inhibit thrombin-mediated clot formation central to cardioembolism.  <br>&bull; Misconception: Confusing atherosclerotic versus cardioembolic stroke prevention.  <br>&bull; Differentiator: Aspirin reduces platelet aggregation, not coagulation factor activity.<br><br>B. Warfarin  <br>&bull; Why incorrect: Although effective, warfarin requires INR monitoring, has variable pharmacokinetics, and higher intracranial hemorrhage risk compared to DOACs.  <br>&bull; Misconception: Belief that warfarin remains first-line for all AF.  <br>&bull; Differentiator: DOACs have fewer dietary/drug interactions and reduced ICH.<br><br>D. Clopidogrel  <br>&bull; Why incorrect: Similar to aspirin, clopidogrel targets P2Y12 receptors on platelets, ineffective for preventing clot formation in high-flow stasis conditions of AF.  <br>&bull; Misconception: Using dual antiplatelet therapy for stroke prevention in AF.  <br>&bull; Differentiator: No direct effect on factor Xa or thrombin.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Factor Xa Inhibitor</th><th>Warfarin</th><th>Aspirin</th><th>Clopidogrel</th></tr></thead><tbody><tr><td>Mechanism</td><td>Direct Xa inhibition</td><td>Vitamin K antagonist</td><td>COX-1 inhibition</td><td>P2Y12 receptor block</td></tr><tr><td>Indication in NVAF</td><td>First-line</td><td>Alternative (valvular)</td><td>Not recommended</td><td>Not recommended</td></tr><tr><td>Monitoring</td><td>None routine</td><td>INR checks</td><td>None</td><td>None</td></tr><tr><td>ICH risk</td><td>Lower</td><td>Higher</td><td>Lower</td><td>Lower</td></tr><tr><td>Efficacy vs warfarin</td><td>Noninferior/superior</td><td>N/A</td><td>Inferior</td><td>Inferior</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; In nonvalvular AF, DOACs reduce intracranial hemorrhage by ~50% versus warfarin.  <br>&bull; Initiate anticoagulation 4&ndash;14 days post-stroke; delay longer for large infarcts.  <br>&bull; Check renal function before choosing a DOAC; dose adjust in CKD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Starting aspirin instead of anticoagulation in AF-related stroke.  <br>2. Presuming warfarin is superior in all stroke patients with AF, ignoring DOAC benefits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA Secondary Stroke Prevention (2019): Recommends DOACs over warfarin for nonvalvular AF (Class I, Level A).  <br>2. European Stroke Organisation Guideline (2021): Endorses factor Xa inhibitors as first-line in nonvalvular AF to reduce stroke and ICH risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam.  <br>Nonvalvular AF management is frequently tested as single-best-answer questions on stroke prevention.</div></div></div></div></div>"}, {"id": 100023015, "question_number": "169", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Intracerebral hemorrhage (ICH) management balances preventing secondary complications (hematoma expansion, edema) and avoiding treatment-related risks.  <br>&bull; VTE risk rises soon after ICH due to immobility and inflammation; early pharmacologic prophylaxis reduces DVT/PE without increasing hematoma growth once the bleed is stable.  <br>&bull; Surgical interventions (EVD, evacuation) are reserved for large hemorrhages, significant mass effect, hydrocephalus, or cerebellar locations.  <br>&bull; Blood pressure control is crucial if hypertensive; with normotension, aggressive lowering may compromise cerebral perfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Prophylactic low-molecular-weight heparin (LMWH) initiated 24&ndash;48 hours after ICH onset is supported by the 2022 AHA/ASA Guidelines (Class I, Level B-R). The landmark PREVENT trial and subsequent meta-analyses show no increase in hematoma expansion when heparin is started after CT stability is confirmed. In contrast, EVD is indicated only for intraventricular hemorrhage with hydrocephalus; surgical evacuation benefits superficial lobar bleeds >30 mL but not small deep hemorrhages; strict BP control applies only when systolic >180 mm Hg (ICH ATACH-II criteria).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. External ventricular drain (EVD) placement  <br>&ndash; Incorrect: No intraventricular extension or hydrocephalus reported.  <br>&ndash; Misconception: Belief that all thalamic bleeds cause hydrocephalus.  <br>&ndash; Differentiator: EVD only for obstructive hydrocephalus.<br><br>C. Immediate surgical evacuation  <br>&ndash; Incorrect: Small deep hemorrhages (<10 mL) in thalamus lack surgical benefit.  <br>&ndash; Misconception: All ICH require evacuation.  <br>&ndash; Differentiator: Evacuation reserved for superficial lobar bleeds >30 mL or deteriorating neurologic status.<br><br>D. Strict blood pressure control  <br>&ndash; Incorrect: Patient is normotensive; aggressive lowering risks ischemia.  <br>&ndash; Misconception: &ldquo;Lower is always better&rdquo; in ICH.  <br>&ndash; Differentiator: Target SBP <140 mm Hg only if admission SBP >180 mm Hg per AHA/ASA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>LMWH Prophylaxis</th><th>EVD Placement</th><th>Surgical Evacuation</th><th>BP Control</th></tr></thead><tbody><tr><td>Primary indication</td><td>VTE prevention</td><td>Hydrocephalus relief</td><td>Large/superficial ICH</td><td>Acute SBP >180 mm Hg</td></tr><tr><td>Timing</td><td>24&ndash;48 h post-ICH after CT</td><td>Immediately if hydrocephalus</td><td>Typically within 24 h</td><td>Immediately upon SBP >180</td></tr><tr><td>Hematoma expansion risk</td><td>No increase if stable</td><td>Neutral</td><td>May worsen deep bleeds</td><td>Potential cerebral hypoperfusion</td></tr><tr><td>Supporting guideline level</td><td>Class I, Level B-R (AHA)</td><td>Class I, Level C-LD</td><td>Class IIb, Level B-R</td><td>Class I, Level A (if >180)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Initiate mechanical VTE prophylaxis immediately and add LMWH at 24&ndash;48 h if repeat CT shows no hematoma growth.  <br>&bull; Small deep ICH (<10 mL) are managed medically; avoid neurosurgical interventions unless clinical deterioration.  <br>&bull; BP goal in ICH: systolic 140&ndash;160 mm Hg if initial SBP 150&ndash;220 mm Hg; avoid aggressive lowering in normotensive patients.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Delaying all pharmacologic prophylaxis for >7 days due to fear of expansion&mdash;increases VTE risk.  <br>2. Assuming any thalamic bleed causes hydrocephalus and warrants EVD&mdash;requires radiographic/intracranial pressure evidence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2022 ICH Guideline: Recommend starting prophylactic LMWH 24&ndash;48 h after ICH onset once hematoma stability confirmed (Class I, Level B-R).  <br>&bull; European Stroke <span class=\"evidence\">Organisation 2021</span>: Supports combined mechanical and low-dose pharmacologic VTE prophylaxis in ICH patients at low bleeding risk (Level A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Management of small deep ICH and VTE prophylaxis timing is frequently tested, often contrasting medical versus surgical interventions and blood pressure targets.</div></div></div></div></div>"}, {"id": 100023016, "question_number": "52", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] Intracerebral hemorrhage causes direct parenchymal injury and secondary damage via hematoma expansion. Elevated systemic blood pressure increases transmural pressure across cerebral vessels, promoting further bleeding. According to the Monro&ndash;Kellie doctrine, intracranial volume is fixed; reducing arterial pressure limits hematoma growth while maintaining cerebral perfusion pressure (CPP = mean arterial pressure \u2212 intracranial pressure). In ICH, autoregulatory mechanisms are often impaired in perihematomal tissue, so cerebral blood flow becomes pressure\u2010dependent. The goal is a rapid, controlled reduction of systolic BP to about 140 mm Hg to minimize expansion without inducing ischemia in vulnerable areas.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The AHA/ASA 2015 Guidelines for Management of Spontaneous ICH (Class I, Level A) recommend lowering systolic BP to 140 mm Hg in patients presenting with initial SBP 150&ndash;220 mm Hg, based on INTERACT2 <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2013</span>)</span> which showed a shift toward better functional outcomes. ATACH-II <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2016</span>)</span> compared intensive (<140 mm Hg) versus standard (<180 mm Hg) SBP targets; intensive lowering did not increase adverse events significantly and remains the recommended target in international guidelines. Diastolic goals are less well defined; 90 mm Hg is a practical upper limit when paired with SBP 140 mm Hg.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. 160/90  <br>&ndash; Too permissive: allows ongoing hematoma expansion.  <br>&ndash; Reflects older acute stroke thresholds (SBP <160) but fails to optimize functional outcome in ICH.  <br>&ndash; Does not align with Class I guideline recommendation for SBP 140 mm Hg.<br><br>C. 180/105  <br>&ndash; Matches general ischemic stroke or hypertensive emergency protocols but is excessive in ICH.  <br>&ndash; Associated with higher rates of hematoma growth and worse prognosis.  <br>&ndash; Represents a misunderstanding of ICH-specific BP targets versus ischemic stroke.<br><br>D. 120/80  <br>&ndash; Overly aggressive lowering risks cerebral hypoperfusion and ischemia, especially with impaired autoregulation.  <br>&ndash; Below the lower limit of recommended SBP (130&ndash;150 mm Hg) range in trials.  <br>&ndash; Misconception: &ldquo;lower is always better&rdquo; without regard to CPP.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>140/90 (A)</th><th>160/90 (B)</th><th>180/105 (C)</th><th>120/80 (D)</th></tr></thead><tbody><tr><td>Guideline Recommendation</td><td>SBP \u2248140 mm Hg</td><td>Not recommended</td><td>Not recommended</td><td>Too low (<130)</td></tr><tr><td>Risk of Hematoma Expansion</td><td>Minimized</td><td>Moderate</td><td>High</td><td>Low</td></tr><tr><td>Risk of Hypoperfusion</td><td>Low if monitored</td><td>Low&ndash;moderate</td><td>Low</td><td>High</td></tr><tr><td>Evidence Base</td><td>INTERACT2, ATACH-II</td><td>None in ICH</td><td>None in ICH</td><td>No trial data</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Initiate IV nicardipine or labetalol infusion for rapid, titratable SBP control.  <br>2. Monitor neurological status and CPP; avoid SBP fluctuations >20 mm Hg.  <br>3. Distinguish BP targets: ischemic stroke (often permissive hypertension) versus ICH (aggressive lowering).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Confusing BP goals in ischemic stroke (allow SBP &le;220 mm Hg) with ICH (target &ge;140 mm Hg).  <br><span class=\"list-item\">\u2022</span> Focusing on diastolic rather than systolic BP as the primary driver of hematoma expansion.  <br><span class=\"list-item\">\u2022</span> Overzealously lowering SBP below 120 mm Hg, precipitating perihematomal ischemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA Guidelines for ICH Management, 2015 (Class I, Level A): Rapid SBP lowering to 140 mm Hg in patients with admission SBP 150&ndash;220 mm Hg.  <br>&bull; INTERACT2 Trial, 2013 (Level I evidence): SBP target <140 mm Hg showed improved functional outcomes (ordinal analysis p=0.04).  <br>&bull; ATACH-II Trial, 2016 (Level I evidence): Intensive SBP lowering (<140 mm Hg) vs standard (<180 mm Hg) did not increase adverse events; supports guideline target.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam. Blood pressure management in acute ICH is frequently tested as a direct MCQ or within clinical vignettes, emphasizing target SBP \u2248140 mm Hg to prevent hematoma expansion while preserving cerebral perfusion.</div></div></div></div></div>"}, {"id": 100023017, "question_number": "207", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2018</span>] Reversible cerebral vasoconstriction syndrome (RCVS) is characterized by transient, segmental narrowing of cerebral arteries leading to ischemic or hemorrhagic complications.  <br>1. Pathophysiology: Dysregulated cerebrovascular tone&mdash;often endothelial dysfunction&mdash;provokes multifocal arterial constriction.  <br>2. Triggers: Physical exertion, emotional stress, vasoactive substances, or minor trauma can precipitate RCVS, especially in migraineurs.  <br>3. Clinical features: Thunderclap headaches are classic; focal deficits (e.g., visual field cuts) may appear hours to days later due to ischemia in posterior circulation territories (occipital lobes).  <br><br>(Word count: 106)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>RCVS is confirmed by angiographic &ldquo;string\u2010of\u2010beads&rdquo; appearance and reversibility within 12 weeks <span class=\"citation\">(Calabrese et al., <span class=\"evidence\">Neurology 2007</span>)</span>. In this patient:  <br><span class=\"list-item\">\u2022</span> Trigger: Intense exertion (tennis) and minor trauma with transient hypertension.  <br><span class=\"list-item\">\u2022</span> Delayed deficit: Hemianopia arises 2 hours after normal CT&mdash;typical of ischemic events secondary to vasoconstriction rather than immediate hemorrhage or dissection.  <br><span class=\"list-item\">\u2022</span> Migraine history: Migraineurs have up to a 20% higher risk of RCVS <span class=\"citation\">(Singhal et al., <span class=\"evidence\">Stroke 2016</span>)</span>.  <br>Current AHA guidelines (2021) recommend noninvasive vascular imaging (MRA) initially, reserving catheter angiography for equivocal cases (Class IIa, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Vertebral dissection  <br><span class=\"list-item\">\u2022</span> Incorrect: Dissection often causes neck pain, immediate focal signs (e.g., lateral medullary syndrome), and visible vessel wall defect on CTA.  <br><span class=\"list-item\">\u2022</span> Misconception: All trauma-related strokes stem from dissection.  <br><span class=\"list-item\">\u2022</span> Differentiation: No cervical pain or hyperintense vessel wall on imaging; delayed isolated hemianopia is atypical.  <br><br>C. Posterior reversible encephalopathy syndrome (PRES)  <br><span class=\"list-item\">\u2022</span> Incorrect: PRES presents with headache, seizures, altered mental status, and bilateral parieto-occipital vasogenic edema on MRI/FLAIR.  <br><span class=\"list-item\">\u2022</span> Misconception: Acute hypertension in trauma always equals PRES.  <br><span class=\"list-item\">\u2022</span> Differentiation: CT was normal; PRES shows diffuse edema rather than focal arterial narrowing.  <br><br>D. Internal carotid artery (ICA) stenosis  <br><span class=\"list-item\">\u2022</span> Incorrect: Typically chronic atherosclerosis in older patients causing TIA or watershed infarcts, not acute hemianopia post-trauma.  <br><span class=\"list-item\">\u2022</span> Misconception: Any visual field cut equals carotid pathology.  <br><span class=\"list-item\">\u2022</span> Differentiation: No bruit, no ulcerated plaque on ultrasound; ICA stenosis rarely causes isolated homonymous hemianopia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>RCVS</th><th>Vertebral Dissection</th><th>PRES</th><th>ICA Stenosis</th></tr></thead><tbody><tr><td>Onset</td><td>Thunderclap headache; delayed focal deficits</td><td>Immediate post-trauma focal signs</td><td>Acute headache, seizures, encephalopathy</td><td>Insidious TIAs; chronic deficits</td></tr><tr><td>Imaging</td><td>MRA: multifocal vasoconstriction; normal CT early</td><td>CTA/MRA: intimal flap, pseudoaneurysm</td><td>MRI FLAIR: bilateral vasogenic edema</td><td>Duplex US/CTA: plaque, stenosis</td></tr><tr><td>Risk factors</td><td>Migraine, exertion, vasoactive drugs</td><td>Neck trauma, cervical manipulation</td><td>Hypertensive crisis, immunosuppression</td><td>Atherosclerosis, hyperlipidemia</td></tr><tr><td>Typical deficits</td><td>PCA territory ischemia (hemianopia)</td><td>Posterior fossa signs, lateral medullary syndrome</td><td>Global or bilateral visual disturbance</td><td>MCA/ACA watershed TIA symptoms</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- RCVS often presents with recurrent thunderclap headaches over 1&ndash;4 weeks; seek delayed ischemic events on imaging.  <br><span class=\"list-item\">\u2022</span> Migraine history is a strong predisposing factor; differentiate from primary migraine aura by the severity and sudden onset.  <br><span class=\"list-item\">\u2022</span> &ldquo;String-of-beads&rdquo; on angiography is pathognomonic; follow-up imaging at 6&ndash;12 weeks should show resolution.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating any acute visual field defect post-trauma with carotid or vertebral dissection without angiography.  <br>2. Misdiagnosing PRES when only focal deficits occur; PRES is a diffuse vasogenic edema syndrome with seizures or encephalopathy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA Scientific Statement on RCVS (2021): Recommends early noninvasive vascular imaging (MRA/CTA) for suspected RCVS (Class IIa, Level B).  <br><span class=\"list-item\">\u2022</span> International Headache Society, ICHD-3 (2018): Classifies RCVS under headache disorders, emphasizing thunderclap onset and reversible angiographic changes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Left homonymous hemianopia localizes to the right occipital cortex (PCA territory). RCVS\u2010induced vasoconstriction in the distal PCA leads to focal ischemia here.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Sympathetic overactivity or endothelial dysfunction \u2192 segmental cerebral arterial constriction \u2192 transient ischemia or hemorrhage. Exposure to triggers (e.g., exertion, trauma) precipitates acute vasospasm.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast head CT to exclude hemorrhage.  <br>2. MRI brain with DWI/FLAIR to detect early ischemia or edema.  <br>3. MRA/CTA to identify multifocal cerebral vasoconstriction.  <br>4. Consider digital subtraction angiography if noninvasive imaging is inconclusive.  <br>5. Follow-up imaging at 6&ndash;12 weeks to confirm reversibility.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Early CT is often normal; use MRI/MRA to detect both parenchymal changes and vascular narrowing.  <br><span class=\"list-item\">\u2022</span> DSA remains gold standard for detailing segmental vasoconstriction (&ldquo;string-of-beads&rdquo;).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>First\u2010line: Oral nimodipine or verapamil to alleviate vasospasm (off\u2010label). Avoid sympathomimetics. Supportive blood pressure control without precipitous drops.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2018</span> exam. RCVS is frequently tested as a cause of thunderclap headache with delayed ischemia; examine triggers, imaging findings, and timing of focal deficits for differentiation from dissection and PRES.</div></div></div></div></div>"}, {"id": 100023018, "question_number": "224", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2019</span>] Warfarin inhibits vitamin K&ndash;dependent &gamma;-carboxylation of clotting factors II, VII, IX, X, leading to coagulopathy. In ICH, rapid INR normalization is critical to prevent hematoma expansion.  <br>&bull; Prothrombin complex concentrate (PCC) provides immediate factor replacement (II, VII, IX, X).  <br>&bull; Intravenous vitamin K is required to sustain synthesis of functional clotting factors by the liver.  <br>&bull; CT imaging confirms hemorrhage; INR guides reversal strategy.  <br>Understanding these principles underpins safe, effective management of warfarin-associated ICH. (\u2248100 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Vitamin K is the only agent that restores endogenous synthesis of clotting factors, ensuring durable INR correction after PCC&rsquo;s transient effect. <span class=\"evidence\">The 2015</span> AHA/ASA ICH guidelines (Class I, LOE B) and 2016 Neurocritical Care Society guidelines (Grade 1B) recommend IV vitamin K (5&ndash;10 mg) concurrently with PCC for warfarin reversal. Sarode et al. <span class=\"citation\">(NEJM 2013)</span> demonstrated faster INR normalization and fewer volume\u2010related complications with 4\u2010factor PCC + vitamin K versus FFP. Without vitamin K, PCC&rsquo;s half\u2010life (8&ndash;24 hours) leads to rebound coagulopathy as factors are consumed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Fresh frozen plasma (FFP)  <br>&ndash; Incorrect because PCC is superior: FFP requires large volumes, slower infusion, and carries risk of transfusion\u2010related acute lung injury.  <br>&ndash; Misconception: FFP alone suffices for emergent reversal; in fact, it&rsquo;s second\u2010line if PCC unavailable.  <br><br>C. Platelet transfusion  <br>&ndash; Incorrect: platelets address thrombocytopenia or antiplatelet therapy; warfarin impairs clotting factors, not platelet function.  <br>&ndash; Misconception: any bleed mandates platelets&mdash;only indicated if platelet count <50\u00d710^9/L or platelet dysfunction.  <br><br>D. Desmopressin  <br>&ndash; Incorrect: desmopressin raises vWF/Factor VIII, useful in von Willebrand disease or platelet dysfunction, not vitamin K antagonist reversal.  <br>&ndash; Misconception: desmopressin reverses all coagulopathies&mdash;its role is limited to specific platelet/vWF defects.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Vitamin K (Correct)</th><th>FFP</th><th>Platelet Transfusion</th><th>Desmopressin</th></tr></thead><tbody><tr><td>Mechanism</td><td>Cofactor for &gamma;-carboxylation of II, VII, IX, X</td><td>Supplies all clotting factors</td><td>Increases platelet count/function</td><td>Releases vWF & factor VIII</td></tr><tr><td>Onset of Action</td><td>6&ndash;12 h (peak 24 h)</td><td>1&ndash;4 h (infusion time)</td><td>Immediately raises platelets</td><td>30&ndash;60 min</td></tr><tr><td>Role in Warfarin ICH</td><td>Sustains INR correction post-PCC</td><td>Emergent but inferior to PCC</td><td>Not indicated if platelets normal</td><td>Not indicated</td></tr><tr><td>Volume/Risk</td><td>Minimal volume; low risk</td><td>High volume; risk of overload</td><td>Transfusion reactions</td><td>Hyponatremia, hypotension risk</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Always administer IV vitamin K alongside PCC to prevent INR rebound after the exogenous factors degrade.  <br>2. Use 4-factor PCC over FFP for faster, lower-volume warfarin reversal in ICH (Class I recommendation).  <br>3. Avoid platelet transfusion or desmopressin in warfarin\u2010only coagulopathy; they address platelet/vWF defects.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Forgetting vitamin K after PCC leads to transient correction and risk of delayed hematoma expansion.  <br>2. Choosing FFP over PCC due to hospital tradition delays reversal and increases fluid overload risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2015 ICH Guidelines (Class I, LOE B): Recommend 4-factor PCC + IV vitamin K for rapid warfarin reversal.  <br>&bull; Neurocritical Care <span class=\"evidence\">Society 2016</span> (Grade 1B): Endorse IV vitamin K (5&ndash;10 mg) with PCC; FFP only if PCC unavailable.  <br>&bull; Sarode et al., NEJM 2013: 4-factor PCC achieved INR <1.4 in 70% within 30 min vs. 9% with FFP (p<0.001).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Warfarin&rsquo;s inhibition of vitamin K epoxide reductase prevents &gamma;-carboxylation of clotting factors, reducing their coagulant function. Elevated INR reflects decreased factor activity. PCC rapidly supplies functional factors, but without vitamin K, endogenous synthesis remains impaired, leading to factor depletion as PCC factors decay.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Vitamin K: 5&ndash;10 mg IV infusion over 30 min to avoid anaphylactoid reactions; recheck INR at 6 h.  <br>&bull; 4-factor PCC dosing based on INR and weight (e.g., 25&ndash;50 IU/kg).  <br>&bull; FFP: 10&ndash;20 mL/kg if PCC unavailable; slow infusion risks volume overload.  <br>&bull; Platelets and desmopressin have no role in isolated warfarin reversal.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2019</span> exam. Reversal of warfarin\u2010related ICH is frequently tested as a rapid\u2010management algorithm question, often requiring knowledge of PCC dosing and the adjunctive role of vitamin K.</div></div></div></div></div>"}, {"id": 100023019, "question_number": "283", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Sneddon disease (syndrome) is a noninflammatory thrombotic vasculopathy affecting small\u2010 and medium\u2010sized arteries in skin and brain, classically presenting with livedo reticularis and recurrent ischemic strokes.  <br><span class=\"list-item\">\u2022</span> Livedo reticularis: a lace\u2010like, violaceous skin mottling due to dermal arteriolar occlusion and capillary dilation.  <br><span class=\"list-item\">\u2022</span> Cerebrovascular involvement: multiple cortical infarcts, often in watershed areas, with normal conventional angiography early on.  <br><span class=\"list-item\">\u2022</span> Differential diagnosis hinges on distinguishing thrombotic noninflammatory arteriopathy (Sneddon) from systemic vasculitis (e.g., polyarteritis nodosa), autoimmune coagulopathies (APS, SLE), and embolic sources.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Sneddon disease is defined by the coexistence of persistent livedo reticularis and ischemic strokes without evidence of systemic inflammatory vasculitis or cardioembolism. Histopathology reveals intimal hyperplasia, luminal thrombosis, and minimal inflammatory infiltrate in small/medium dermal and leptomeningeal vessels <span class=\"citation\">(Bourgeois et al., J Neurol Neurosurg <span class=\"evidence\">Psychiatry 2020</span>)</span>.  <br>A systematic review <span class=\"citation\">(Caetano et al., <span class=\"evidence\">Stroke 2022</span>)</span> showed that 80% of patients with livedo and stroke fulfilling Sneddon criteria had negative inflammatory markers (ESR, CRP) and normal ANCA/ANA panels, distinguishing it from PAN or SLE. Advanced vessel wall MRI may demonstrate concentric wall thickening and enhancement without vessel wall edema <span class=\"citation\">(class IIa, LOE C; ESO 2021 guidelines on cryptogenic stroke)</span>.  <br>Screening for antiphospholipid antibodies is recommended <span class=\"citation\">(Gianni et al., J <span class=\"evidence\">Neurol 2022</span>)</span>, but aPL positivity alone without the livedo&ndash;stroke syndrome fits primary APS, not Sneddon.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Polyarteritis nodosa  <br><span class=\"list-item\">\u2022</span> Why incorrect: PAN is a necrotizing medium\u2010vessel vasculitis with systemic features (renal microaneurysms, mononeuritis multiplex), not isolated livedo reticularis with recurrent cortical strokes.  <br><span class=\"list-item\">\u2022</span> Misconception: conflating livedo reticularis with vasculitis rather than thrombotic arteriopathy.  <br><span class=\"list-item\">\u2022</span> Differentiator: PAN shows elevated ESR/CRP, tissue biopsy reveals fibrinoid necrosis and inflammatory infiltrate.  <br><br>C. Antiphospholipid syndrome  <br><span class=\"list-item\">\u2022</span> Why incorrect: APS causes hypercoagulability with stroke and can produce livedo, but livedo in APS is transient and serology (lupus anticoagulant, aCL, &beta;2\u2010GP1) is persistently positive.  <br><span class=\"list-item\">\u2022</span> Misconception: equating any livedo\u2010stroke association with APS rather than Sneddon&rsquo;s distinctive noninflammatory arteriopathy.  <br><span class=\"list-item\">\u2022</span> Differentiator: APS often has obstetric morbidity and venous thromboses; Sneddon lacks systemic coagulopathy criteria.  <br><br>D. Systemic lupus erythematosus  <br><span class=\"list-item\">\u2022</span> Why incorrect: SLE may have livedo and stroke, but it manifests with multi\u2010organ autoimmunity, hypocomplementemia, positive ANA/dsDNA, and immune complex vasculitis.  <br><span class=\"list-item\">\u2022</span> Misconception: attributing livedo reticularis in any autoimmune disease to SLE.  <br><span class=\"list-item\">\u2022</span> Differentiator: SLE shows broad serologic profile and inflammatory markers, unlike the noninflammatory histology of Sneddon.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Sneddon Disease</th><th>Polyarteritis Nodosa</th><th>Antiphospholipid Syndrome</th><th>Systemic Lupus Erythematosus</th></tr></thead><tbody><tr><td>Vessel involvement</td><td>Small/medium, noninflammatory</td><td>Medium, necrotizing vasculitis</td><td>Small/medium, thrombosis</td><td>Small, immune complex vasculitis</td></tr><tr><td>Livedo Pattern</td><td>Persistent, bilateral, widespread</td><td>Rare, transient</td><td>Transient, patchy</td><td>Occasional, variable</td></tr><tr><td>Serology</td><td>Negative ANA/ANCA/ESR</td><td>Elevated ESR/CRP, negative ANCA</td><td>Positive lupus anticoagulant, aCL, &beta;2\u2010GP1</td><td>Positive ANA, dsDNA, low C3/C4</td></tr><tr><td>Stroke characteristics</td><td>Recurrent cortical infarcts</td><td>Rare cerebral involvement</td><td>Arterial/venous thromboses</td><td>Multifactorial (vasculitis, thrombosis)</td></tr><tr><td>Histopathology</td><td>Intimal proliferation, thrombosis</td><td>Fibrinoid necrosis, inflammation</td><td>Thrombosis, no necrosis</td><td>Immune complex deposition</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Sneddon disease should be suspected in young/middle\u2010aged adults with livedo reticularis and &ldquo;cryptogenic&rdquo; strokes refractory to standard cardioembolic work\u2010up.  <br><span class=\"list-item\">\u2022</span> Skin biopsy of livedo reticularis lesions with deep dermal sampling increases diagnostic yield (>80% sensitivity).  <br><span class=\"list-item\">\u2022</span> Vessel wall MRI shows concentric concentric enhancement without edema in Sneddon vs. vasculitis\u2010associated edema in PAN/SLE.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mistaking livedo reticularis in APS for Sneddon: always confirm aPL serology and obstetric/venous thrombosis history.  <br>2. Assuming all livedo\u2010stroke syndromes are inflammatory: check ESR/CRP and biopsy for inflammatory infiltrates vs. thrombotic arteriopathy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- European Stroke Organisation (ESO) 2021 Guidelines on Cryptogenic Stroke: Recommend (Class IIa, LOE C) screening for nonatherosclerotic vasculopathies (e.g., Sneddon) with skin examination and high\u2010resolution vessel wall imaging when livedo reticularis is present.  <br><span class=\"list-item\">\u2022</span> EULAR 2019 Recommendations for Antiphospholipid Syndrome: In stroke patients with persistent aPL positivity, lifelong anticoagulation with warfarin (INR 2.0&ndash;3.0) is advised (Grade C), underscoring the need to differentiate APS from Sneddon&rsquo;s non\u2010inflammatory arteriopathy.  <br><span class=\"list-item\">\u2022</span> Gianni et al., J <span class=\"evidence\">Neurol 2022</span> (n=48): Found 35% of Sneddon patients had transient aPL positivity but lacked obstetric/venous thrombotic events, reinforcing that isolated livedo&ndash;stroke without full APS criteria indicates Sneddon.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Sneddon disease arises from a primary arteriopathy of dermal and cerebral vessels characterized by endothelial dysfunction, intimal hyperplasia, and in situ thrombosis without significant inflammatory cell infiltration. The precise trigger is unknown; hypotheses include genetic predisposition (e.g., PTHR1 mutations) and endothelial prothrombotic activation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical: Identify persistent livedo reticularis + unexplained ischemic strokes.  <br>2. Labs: ESR/CRP, ANA/ANCA, aPL panel, complement levels.  <br>3. Imaging: Brain MRI for multifocal infarcts; vessel wall MRI to distinguish thrombotic arteriopathy vs. vasculitis.  <br>4. Biopsy: Deep skin biopsy of livedo lesions&mdash;look for intimal thickening and thrombosis without vasculitis.  <br>5. Exclude: Cardioembolic sources, atherosclerosis, systemic vasculitis, APS/SLE.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- MRI: Multiple small cortical/subcortical infarcts, often in watershed zones.  <br><span class=\"list-item\">\u2022</span> Vessel wall MRI: Concentric wall thickening with homogeneous enhancement; lack of mural edema distinguishes from inflammatory vasculitis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Livedo reticularis with recurrent strokes is a high\u2010yield topic on neurology boards, frequently tested in single\u2010best\u2010answer format requiring differentiation between thrombotic arteriopathies and vasculitides.</div></div></div></div></div>"}, {"id": 100023020, "question_number": "61", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Acute ischemic stroke workup hinges on rapid imaging to differentiate hemorrhage from infarction and to identify large\u2010vessel occlusion (LVO).  <br><span class=\"list-item\">\u2022</span> Neuroanatomy: The centrum semiovale is supplied by penetrating branches of the anterior cerebral and middle cerebral arteries; hypodensity there on noncontrast CT suggests early ischemia.  <br><span class=\"list-item\">\u2022</span> Pathophysiology: Vessel occlusion creates a core infarct and surrounding penumbra; timely recanalization preserves at\u2010risk tissue.  <br><span class=\"list-item\">\u2022</span> Imaging Strategy: Noncontrast CT excludes hemorrhage; CT angiography (CTA) of head/neck is the next step to detect LVO and guide thrombolysis or thrombectomy.  <br>(105 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>CTA is the optimal emergent vascular study after noncontrast CT in suspected acute ischemic stroke. <span class=\"evidence\">The 2018</span> AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke (Class I, Level of Evidence B-R) recommend CTA or MRA of head/neck immediately after hemorrhage exclusion to identify LVO and select patients for endovascular therapy. Goyal et al.&rsquo;s meta-analysis <span class=\"citation\">(<span class=\"evidence\">Lancet 2016</span>)</span> demonstrated that CTA\u2010guided selection for mechanical thrombectomy yields a number needed to treat of 2.6 for functional independence. In late windows (6&ndash;24 h), the DAWN <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2018</span>)</span> and DEFUSE 3 <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2018</span>)</span> trials further underscore CTA plus perfusion imaging to expand thrombectomy candidacy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. MRI brain  <br><span class=\"list-item\">\u2022</span> Incorrect because DWI/MRA, while sensitive, delays time to reperfusion. MRI is used when CT findings are equivocal or for subacute stroke characterization.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that MRI must confirm infarct before vessel imaging; in hyperacute stroke, speed supersedes marginal sensitivity gains.  <br><br>C. Start antiplatelet therapy  <br><span class=\"list-item\">\u2022</span> Premature: Antiplatelet agents (e.g., aspirin) are initiated after vascular imaging and consideration of IV thrombolysis; starting without LVO assessment risks mismanagement if thrombectomy or tPA is indicated.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Aspirin immediately&rdquo; overlooks the priority of reperfusion strategies in LVO.  <br><br>D. Carotid Doppler ultrasound  <br><span class=\"list-item\">\u2022</span> Limited to extracranial carotid bifurcation; cannot visualize intracranial arteries or circle of Willis.  <br><span class=\"list-item\">\u2022</span> Slower and operator\u2010dependent; CTA offers comprehensive, rapid head\u2010to\u2010neck evaluation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CTA of Head/Neck</th><th>MRI Brain</th><th>Antiplatelet Therapy</th><th>Carotid Doppler US</th></tr></thead><tbody><tr><td>Vessel visualization</td><td>Intracranial + extracranial</td><td>Intracranial (MRA needed)</td><td>None</td><td>Extracranial only</td></tr><tr><td>Time to perform</td><td>~2&ndash;5 minutes post-CT</td><td>15&ndash;30 minutes</td><td>Immediate</td><td>15&ndash;20 minutes</td></tr><tr><td>Role in LVO detection</td><td>Gold standard</td><td>Adjunct if CT contraind.</td><td>None</td><td>Poor for intracranial LVO</td></tr><tr><td>Guides thrombectomy decision</td><td>Yes</td><td>No (requires additional)</td><td>No</td><td>No</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In acute stroke (<24 h), always obtain emergent CTA following noncontrast CT to assess for endovascular therapy candidacy.  <br><span class=\"list-item\">\u2022</span> Perfusion imaging (CTP or MR perfusion) refines patient selection in extended windows (6&ndash;24 h) per DAWN/DEFUSE 3.  <br><span class=\"list-item\">\u2022</span> Carotid ultrasound is indicated later in subacute stroke to evaluate extracranial stenosis but is not a substitute for CTA in the hyperacute setting.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating MRI with first\u2010line acute stroke imaging, causing critical delays.  <br>2. Initiating antiplatelet therapy before vascular imaging, potentially missing a thrombectomy window.  <br>3. Overreliance on carotid Doppler in lieu of comprehensive CTA, risking undetected intracranial occlusions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2018 Guidelines for Early Management of Acute Ischemic Stroke: Class I recommendation for CTA or MRA immediately after noncontrast CT to detect LVO (Level B-R).  <br><span class=\"list-item\">\u2022</span> DAWN Trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2018</span>)</span>: Demonstrated benefit of EVT up to 24 h in patients with mismatch profiles on CTA/perfusion (NIHSS 6&ndash;25, infarct core <70 mL).  <br><span class=\"list-item\">\u2022</span> DEFUSE 3 <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2018</span>)</span>: Confirmed endovascular benefit in 6&ndash;16 h window using perfusion imaging selection (Class I, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam.  <br>Vascular imaging strategy in acute ischemic stroke is a high\u2010yield topic on neurology boards and STEP exams, frequently tested as a sequence: noncontrast CT \u2192 CTA (or MRA) \u2192 thrombolysis/thrombectomy decision.</div></div></div></div></div>"}, {"id": 100023021, "question_number": "119", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] The cerebellum&rsquo;s superior surface and deep nuclei are supplied by the superior cerebellar artery (SCA). Lesions here produce ipsilateral cerebellar hemisphere signs&mdash;especially limb ataxia&mdash;due to involvement of the dentate nucleus and superior cerebellar peduncle. By contrast, PICA infarction (lateral medullary) yields ipsilateral facial sensory loss and Horner&rsquo;s syndrome; AICA infarction often causes ipsilateral hearing loss via labyrinthine artery involvement. Recognizing these distinct syndromes allows localization to specific posterior circulation territories.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Superior cerebellar artery infarcts account for ~7% of cerebellar strokes <span class=\"citation\">(Schmahmann & Pandya, <span class=\"evidence\">Brain 2018</span>)</span>. In SCA territory strokes, the most consistent exam finding is ipsilateral appendicular ataxia, dysmetria, and dysdiadochokinesia, reflecting dentate nucleus and cerebellar hemisphere dysfunction <span class=\"citation\">(Siepmann et al., Neurol Clin <span class=\"evidence\">Pract 2018</span>)</span>. There is no interruption of descending sympathetic fibers (located in lateral medulla) to cause Horner&rsquo;s syndrome. Nor is the cochlear apparatus affected&mdash;hearing loss is characteristic of AICA <span class=\"citation\">(Hutchinson & Schmidek, Neurosurg Clin N <span class=\"evidence\">Am 2019</span>)</span>. Truncal hyperalgesia is not a recognized feature of SCA infarction. Current AHA/ASA guidelines (2019) emphasize bedside localization of posterior circulation stroke syndromes to guide urgent imaging and revascularization (Class I, Level B-R).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Ipsilateral truncal hyperalgesia  <br><span class=\"list-item\">\u2022</span> Why incorrect: Hyperalgesia implies enhanced pain perception; SCA infarcts spare spinothalamic tracts.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing pain/temperature loss in lateral medullary (PICA) with cerebellar lesions.  <br><span class=\"list-item\">\u2022</span> Differentiator: PICA causes analgesia (not hyperalgesia) of ipsilateral face and contralateral body.<br><br>B. Ipsilateral Horner&rsquo;s syndrome  <br><span class=\"list-item\">\u2022</span> Why incorrect: Horner&rsquo;s arises from disruption of sympathetic fibers in lateral brainstem/upper cervical cord (PICA/Wallenberg), not SCA.  <br><span class=\"list-item\">\u2022</span> Misconception: Attributing all cerebellar infarcts to autonomic signs.  <br><span class=\"list-item\">\u2022</span> Differentiator: Only lateral medullary (PICA) lesions interrupt hypothalamospinal tract causing ptosis, miosis.<br><br>C. Hearing loss  <br><span class=\"list-item\">\u2022</span> Why incorrect: Cochlear structures are supplied by the internal auditory (labyrinthine) artery branching from AICA, not SCA.  <br><span class=\"list-item\">\u2022</span> Misconception: Generalizing brainstem infarcts to include cranial nerve VIII involvement.  <br><span class=\"list-item\">\u2022</span> Differentiator: AICA infarcts produce labyrinthine signs&mdash;vertigo, tinnitus, sensorineural hearing loss.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>SCA Infarct (D)</th><th>PICA Infarct (A/B)</th><th>AICA Infarct (C)</th></tr></thead><tbody><tr><td>Primary artery</td><td>Superior cerebellar artery</td><td>Posterior inferior cerebellar</td><td>Anterior inferior cerebellar</td></tr><tr><td>Key presenting sign</td><td>Ipsilateral limb ataxia</td><td>Ipsilateral facial analgesia<br>&plusmn; Horner&rsquo;s</td><td>Ipsilateral hearing loss<br>facial paralysis</td></tr><tr><td>Autonomic involvement</td><td>None</td><td>Horner&rsquo;s syndrome</td><td>Possible facial numbness</td></tr><tr><td>Vestibular signs</td><td>Possible nystagmus</td><td>Vertigo, nystagmus</td><td>Severe vertigo, tinnitus</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Superior cerebellar artery strokes classically produce ipsilateral appendicular (limb) ataxia, not truncal ataxia (more midline vermian infarcts).  <br><span class=\"list-item\">\u2022</span> Horner&rsquo;s syndrome localizes to lesions interrupting the descending sympathetic pathway in the lateral medulla (Wallenberg), not the cerebellum.  <br><span class=\"list-item\">\u2022</span> Hearing loss in a cerebellar territory stroke strongly suggests AICA involvement&mdash;prompt audiometry may aid early differentiation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing truncal versus appendicular ataxia: vermian lesions cause truncal instability, SCA lesions cause limb dysmetria.  <br>2. Believing all posterior circulation infarcts can produce Horner&rsquo;s syndrome; only lateral medullary (PICA) disrupts sympathetic outflow.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2019 Guidelines for Early Management of Acute Ischemic Stroke: Recommends emergent neuroimaging within 20 minutes for posterior fossa syndromes (Class I, Level B-R).  <br><span class=\"list-item\">\u2022</span> ESO 2021 Guidelines on Mechanical Thrombectomy in Posterior Circulation: Suggest benefit of endovascular therapy in basilar artery occlusion; data for branch occlusions (e.g., SCA) remain limited (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The SCA arises just caudal to the posterior cerebral artery from the basilar artery. It courses around the midbrain to supply the superior cerebellar hemisphere, dentate nucleus, and superior cerebellar peduncle. Damage disrupts purkinje-to-deep-nuclei signaling, producing ipsilateral limb incoordination.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Identify acute cerebellar signs (ataxia, dysmetria).  <br>2. Differentiate vermian (truncal) vs hemispheric (limb) ataxia.  <br>3. Evaluate for cranial nerve involvement (hearing, facial sensation).  <br>4. Obtain MRI brain with DWI to localize infarct.  <br>5. Correlate vessel territory to clinical signs (SCA vs AICA vs PICA).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI diffusion-weighted imaging is superior to CT for detecting posterior fossa strokes. SCA infarcts appear as focal diffusion restriction in the superior cerebellar hemispheres, often sparing inferior folia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam. Posterior circulation stroke syndromes&mdash;especially distinguishing SCA, AICA, and PICA&mdash;are frequently tested by correlating vascular territories with specific clinical and imaging findings.</div></div></div></div></div>"}, {"id": 100023022, "question_number": "59", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] Acute ischemic stroke results from arterial occlusion leading to brain tissue hypoperfusion. Intravenous tissue plasminogen activator (tPA) can lyse fibrin clots if given early, reducing infarct size. Eligibility hinges on a narrow therapeutic window (&le;4.5 hours) and strict exclusion criteria to minimize hemorrhagic transformation. Key concepts:  <br><span class=\"list-item\">\u2022</span> Neurovascular unit: ischemia causes excitotoxicity and blood&ndash;brain barrier disruption, raising hemorrhage risk.  <br><span class=\"list-item\">\u2022</span> NIH Stroke Scale (NIHSS): quantifies severity; very mild or rapidly improving deficits predict good outcome without tPA.  <br><span class=\"list-item\">\u2022</span> Inclusion/exclusion criteria balance salvageable penumbra vs bleeding complications.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>&ldquo;Rapid improvement&rdquo; of neurological deficits&mdash;often defined as complete or near-complete resolution before tPA infusion&mdash;is a relative exclusion per 2019 AHA/ASA Guidelines (Class III: No Benefit; Level B-R). In the NINDS rt-PA Stroke Trial, patients with minor or rapidly improving symptoms had low baseline disability and low subsequent benefit but similar hemorrhage risk. Excluding them reduces unnecessary exposure to ICH risk without compromising outcomes. AHA/ASA explicitly lists &ldquo;mild or rapidly improving stroke symptoms&rdquo; among exclusion criteria. Other options either do not meet current thresholds (C, D) or are modifiable with aggressive management (A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Blood pressure >200 mm Hg  <br>  &bull; Why it&rsquo;s incorrect: Hypertension above 185/110 mm Hg is an exclusion until corrected, but >200/110 is modifiable with IV antihypertensives.  <br>  &bull; Misconception: Treatable elevated BP is often mistaken for an absolute contraindication.  <br>  &bull; Differentiator: Only uncontrolled BP after treatment remains an exclusion.  <br><br>C. Platelet count <150,000/mm\u00b3  <br>  &bull; Why it&rsquo;s incorrect: tPA contraindicates platelet count <100,000/mm\u00b3; values between 100,000&ndash;150,000 are acceptable.  <br>  &bull; Misconception: Confusing exclusion threshold for spontaneous ICH risk vs procedural bleeding risk.  <br>  &bull; Differentiator: The critical cutoff is <100\u2009\u00d7\u200910^3/\u00b5L.  <br><br>D. Recent major surgery within 14 days  <br>  &bull; Why it&rsquo;s incorrect: Only intracranial or spinal surgery/head trauma within 3 months is an absolute exclusion; most non\u2010neurosurgical procedures pose lower risk.  <br>  &bull; Misconception: Equating all &ldquo;major&rdquo; surgeries with neurosurgical bleeding risk.  <br>  &bull; Differentiator: Time window and type of surgery (intracranial vs peripheral) matter.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Exclusion Type</th><th>Modifiable?</th><th>Guideline Threshold</th><th>Notes</th></tr></thead><tbody><tr><td>A. BP >200 mm Hg</td><td>Relative exclusion</td><td>Yes</td><td>BP &le;185/110 mm Hg before tPA</td><td>Use IV labetalol/nicardipine to lower BP</td></tr><tr><td>B. Rapid improvement [CORRECT]</td><td>Relative exclusion</td><td>No</td><td>Mild/improving NIHSS symptoms</td><td>Low benefit, similar hemorrhage risk</td></tr><tr><td>C. Platelets <150,000/mm\u00b3</td><td>Not exclusion</td><td>N/A</td><td>Platelets &ge;100,000/mm\u00b3</td><td>Only <100,000/mm\u00b3 contraindicates tPA</td></tr><tr><td>D. Recent major surgery within 14 days</td><td>Not standard</td><td>N/A</td><td>Intracranial surgery <3 months</td><td>Peripheral surgery outside CNS is not excluded</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always lower systolic BP to &le;185 mm Hg prior to tPA; target labetalol bolus or nicardipine infusion.  <br><span class=\"list-item\">\u2022</span> NIHSS &le;5 with rapidly resolving deficits often indicates minor stroke or TIA; withholding tPA avoids hemorrhage risk.  <br><span class=\"list-item\">\u2022</span> Distinguish intracranial from extracranial surgery when assessing bleeding risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Treating any elevated BP >180 as permanent exclusion rather than a modifiable parameter.  <br>2. Believing all recent surgeries&mdash;regardless of type or timing&mdash;preclude tPA, when only intracranial/spinal operations within 3 months do.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2019 Guidelines for Early Management of AIS <span class=\"citation\">(Stroke. 2019;50:e344&ndash;e418)</span>:  <br>   &ndash; Recommendation: Exclude patients with &ldquo;mild or rapidly improving stroke symptoms&rdquo; (Class III: No Benefit; Level B-R).  <br>2. ECASS III Trial <span class=\"citation\">(N Engl J Med. 2008;359:1317&ndash;29)</span>:  <br>   &ndash; Extended tPA window to 4.5 hours; reaffirmed exclusion of minor/rapidly improving deficits to minimize hemorrhagic complications.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mechanism: tPA converts plasminogen to plasmin, degrading fibrin within thrombi.  <br><span class=\"list-item\">\u2022</span> Dosing: 0.9 mg/kg (maximum 90 mg); 10% as bolus over 1 minute, remainder over 60 minutes.  <br><span class=\"list-item\">\u2022</span> Monitoring: Assess neurological status every 15 minutes during infusion; watch for bleeding signs and perform follow-up CT if deterioration occurs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam.  <br>High-yield: Boards frequently test tPA inclusion/exclusion, emphasizing blood pressure thresholds, platelet counts, and the concept of rapidly improving symptoms as an exclusion criterion.</div></div></div></div></div>"}, {"id": 100023023, "question_number": "53", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] Intracranial atherosclerotic stenosis (ICAS) of the middle cerebral artery (MCA) is a common cause of ischemic stroke, especially in patients with diabetes and vascular risk factors. Symptomatic ICAS (>50% stenosis) leads to stroke via artery-to-artery embolism, in situ thrombosis, or hypoperfusion. Key management principles include aggressive medical therapy (antiplatelet agents, statins, blood pressure and glycemic control) versus endovascular or surgical intervention. Understanding that trials in extracranial carotid disease (e.g., NASCET) do not apply directly to intracranial vessels is critical.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Medical management is preferred for symptomatic ICAS based on robust randomized trials and guideline recommendations:<br><span class=\"list-item\">\u2022</span> SAMMPRIS <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2011</span>)</span>: 451 patients with 70&ndash;99% ICAS randomized to aggressive medical therapy versus angioplasty\u2009+\u2009stenting showed 30-day stroke/death 5.8% vs. 14.7% (HR 0.39, p=0.002).  <br><span class=\"list-item\">\u2022</span> VISSIT <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2015</span>)</span>: Similar higher periprocedural risk with stenting.  <br><span class=\"list-item\">\u2022</span> AHA/ASA 2014 Secondary Stroke Prevention Guidelines: Class I recommendation for intensive medical therapy (dual antiplatelet for 90 days then single; high-intensity statin; BP <140/90; glycemic control). Level of Evidence A.  <br>By contrast, endarterectomy is for extracranial carotid lesions; stenting carries high periprocedural risks; anticoagulation (warfarin) showed no benefit over aspirin in the WASID trial and increased hemorrhagic risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>- B. Endarterectomy  <br>  &bull; Reason incorrect: Reserved for extracranial carotid stenosis >70%.  <br>  &bull; Misconception: Applying carotid endarterectomy data (NASCET/ECST) to intracranial vessels.  <br>  &bull; Differentiator: Surgical access and vessel anatomy make intracranial endarterectomy infeasible with high complication rates.  <br><span class=\"list-item\">\u2022</span> C. Stenting  <br>  &bull; Reason incorrect: High periprocedural stroke/death in SAMMPRIS (14.7%) and VISSIT (24.1%).  <br>  &bull; Misconception: Interventional approaches always yield better revascularization outcomes.  <br>  &bull; Differentiator: Intracranial vessel tortuosity and perforator risk zones increase complications.  <br><span class=\"list-item\">\u2022</span> D. Anticoagulation therapy  <br>  &bull; Reason incorrect: WASID <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2005</span>)</span> showed warfarin no better than aspirin and more hemorrhage.  <br>  &bull; Misconception: Extrapolating benefits of anticoagulation in cardioembolic stroke to atherosclerotic stroke.  <br>  &bull; Differentiator: Plaque stabilization and antiplatelet effects, not anticoagulation, reduce recurrent atherothrombotic events.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Approach</th><th>Indication</th><th>Key Evidence</th><th>Periprocedural Risk</th><th>Recommendation</th></tr></thead><tbody><tr><td>Medical management</td><td>Symptomatic intracranial stenosis</td><td>SAMMPRIS (2011)</td><td>Low</td><td>First-line</td></tr><tr><td>Endarterectomy</td><td>Extracranial carotid stenosis</td><td>NASCET/ECST</td><td>Moderate (1&ndash;3%)</td><td>Not for ICAS</td></tr><tr><td>Stenting</td><td>Intracranial stenosis</td><td>SAMMPRIS & VISSIT</td><td>High (14&ndash;36%)</td><td>Contraindicated as routine</td></tr><tr><td>Anticoagulation</td><td>Atherosclerotic stroke (non-cardio)</td><td>WASID (2005)</td><td>Elevated hemorrhage risk</td><td>Not recommended</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Initiate dual antiplatelet therapy (aspirin\u2009+\u2009clopidogrel) for 90 days in symptomatic ICAS, then continue single-agent therapy.  <br>&bull; High-intensity statin therapy (e.g., atorvastatin 80 mg) aiming for LDL <70 mg/dL reduces recurrent stroke risk.  <br>&bull; Aggressive management of hypertension (target <140/90 mm Hg) and diabetes (HbA1c <7%) is essential alongside antithrombotic therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing extracranial carotid endarterectomy criteria with intracranial stenosis management, leading to inappropriate surgical referral.  <br>2. Believing anticoagulation is superior to antiplatelets in atherosclerotic intracranial disease, despite WASID evidence.  <br>3. Underestimating the high periprocedural complication rates associated with intracranial stenting.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA Secondary Stroke Prevention Guidelines (2014): Class I, LOE A for aggressive medical management over endovascular therapy in symptomatic ICAS.  <br>2. SAMMPRIS Trial <span class=\"citation\">(NEJM 2011)</span>: First-line medical therapy (dual antiplatelet\u2009+\u2009statin\u2009+\u2009risk factor control) superior to stenting for 70&ndash;99% ICAS (Level of Evidence: I).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam. Symptomatic intracranial atherosclerotic stenosis management is frequently tested to distinguish medical therapy from interventional options based on SAMMPRIS and AHA/ASA guidelines.</div></div></div></div></div>"}, {"id": 100023024, "question_number": "115", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] &bull; Intracerebral hemorrhage (ICH) morphology on CT: homogeneous hyperdensity vs. heterogeneous with layering.  <br>&bull; Fluid&ndash;fluid levels (&ldquo;hematocrit effect&rdquo;): layering of red cells below plasma due to impaired clot formation.  <br>&bull; Warfarin anticoagulation effects: vitamin K epoxide reductase inhibition \u2192 reduced factors II, VII, IX, X \u2192 coagulopathy predisposes to noncohesive bleed with sedimentation.  <br><br>(Word count: 69)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Fluid&ndash;fluid levels on noncontrast CT are highly specific (>90%) for anticoagulation\u2010related hemorrhage <span class=\"citation\">(Delgado Almandoz et al., AJNR 2010)</span>. In coagulopathic bleeding, inadequate thrombin generation prevents solid clot formation; red cells settle under gravity, creating a hyperdense layer over a hypodense plasma layer. <span class=\"evidence\">The 2022</span> AHA/ASA ICH guidelines recommend rapid reversal of VKA-associated ICH with four-factor prothrombin complex concentrate (PCC) and intravenous vitamin K (Class I, Level A). Early reversal (<1 hour) reduces hematoma expansion and improves functional outcome <span class=\"citation\">(Wilson et al., <span class=\"evidence\">Stroke 2019</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Hypertensive hemorrhage  <br>&ndash; Incorrect: Typically deep basal ganglia/thalamic bleed without fluid levels; clot forms rapidly due to normal coagulation.  <br>&ndash; Misconception: All spontaneous ICH in elderly hypertensives show layering.  <br>&ndash; Differentiator: Homogeneous hyperdense appearance, no sedimentation.  <br><br>C. Arteriovenous malformation rupture  <br>&ndash; Incorrect: Presents with heterogeneous hyperdensity only if long-standing bleed; angiography shows nidus.  <br>&ndash; Misconception: AVM bleeds always show mixed densities.  <br>&ndash; Differentiator: Contrast angiography evidence, no classic fluid&ndash;fluid levels.  <br><br>D. Cerebral amyloid angiopathy  <br>&ndash; Incorrect: Lobar hemorrhages in elderly with microbleeds on MRI; coagulation normal, clot solidifies.  <br>&ndash; Misconception: CAA bleeds layer on CT like coagulopathy.  <br>&ndash; Differentiator: Superficial cortical bleed distribution, positive Congo red pathology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Coagulopathy (Correct)</th><th>Hypertensive Hemorrhage</th><th>AVM Rupture</th><th>CAA Hemorrhage</th></tr></thead><tbody><tr><td>Anticoagulation status</td><td>Positive (e.g., warfarin)</td><td>Usually negative</td><td>Variable</td><td>Negative</td></tr><tr><td>CT appearance</td><td>Fluid&ndash;fluid level (hematocrit)</td><td>Homogeneous hyperdensity</td><td>Heterogeneous without layering</td><td>Homogeneous or lobar bleed</td></tr><tr><td>Clotting factor levels</td><td>Reduced II, VII, IX, X</td><td>Normal</td><td>Normal</td><td>Normal</td></tr><tr><td>Anatomy</td><td>Anywhere (often lobar)</td><td>Deep grey nuclei (basal ganglia, thalamus)</td><td>Any AVM location, cortical/deep</td><td>Lobar (cortical/subcortical)</td></tr><tr><td>Diagnostic confirmation</td><td>Coagulation panel, reversal test</td><td>Clinical & imaging</td><td>Angiography, MRI</td><td>MRI microbleeds, pathology</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Fluid&ndash;fluid levels on CT should prompt urgent INR measurement and reversal in VKA-associated ICH.  <br>2. Four-factor PCC reverses warfarin in <15 minutes vs. FFP in &ge;30 minutes, reducing hematoma growth.  <br>3. Not all heterogeneous-appearing bleeds are neoplastic or vascular malformations; consider coagulopathy first.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Students often attribute any mixed-density hemorrhage to an AVM rather than checking anticoagulation status.  <br>&bull; Belief that CAA bleeds always have layering; in reality, CAA bleeds clot normally, appearing uniformly hyperdense.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2022 ICH Guideline: Class I recommendation for rapid VKA reversal with PCC + IV vitamin K (Level A).  <br>2. Wilson et al., <span class=\"evidence\">Stroke 2019</span>: Early (<1 h) PCC administration in VKA-ICH reduced hematoma expansion by 50% (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Fluid&ndash;fluid levels (&ldquo;hematocrit effect&rdquo;) are best seen on noncontrast CT within hours of bleed onset.  <br>&bull; Susceptibility-weighted MRI shows blooming but cannot distinguish layering as CT does.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Warfarin reversal: four-factor PCC (25&ndash;50 IU/kg) + 10 mg IV vitamin K.  <br>&bull; Avoid FFP in urgent reversal unless PCC unavailable; risk of volume overload and delayed effect.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam. Anticoagulation-related hemorrhages with CT fluid&ndash;fluid levels are frequently tested as a specific imaging sign of coagulopathy.</div></div></div></div></div>"}, {"id": 100023025, "question_number": "288", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Ischemic strokes are classified by etiology (cardioembolic vs. atherothrombotic) and severity (NIHSS). An NIHSS score &le;3 designates a non-disabling (minor) stroke. In atherothrombotic strokes, platelet aggregation on a ruptured plaque drives early recurrence risk. Early initiation of antiplatelet therapy (within 24&ndash;48 hours) significantly lowers recurrence. Recognizing stroke severity via NIHSS informs whether to choose monotherapy versus short-term dual therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Aspirin irreversibly inhibits cyclooxygenase-1, reducing thromboxane A2&ndash;mediated platelet aggregation. The AHA/ASA 2018 Guidelines (Class I, Level A) recommend starting 160&ndash;325 mg aspirin within 24&ndash;48 hours of non-cardioembolic ischemic stroke onset, followed by 75&ndash;100 mg daily. The International Stroke Trial (IST) and CAST demonstrated ~15&ndash;20% reduction in recurrent events with early aspirin. While CHANCE (2013) and POINT (2018) support 21-day dual antiplatelet therapy for minor stroke/TIA (NIHSS &le;3), aspirin monotherapy remains foundational, particularly if bleeding risk is elevated or dual therapy contraindicated. Clopidogrel monotherapy is reserved for true aspirin allergy (CAPRIE trial). Anticoagulants (warfarin, factor Xa inhibitors) are indicated only when a clear cardioembolic source (e.g., atrial fibrillation) is identified.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Warfarin  <br><span class=\"list-item\">\u2022</span> Incorrect: A vitamin K antagonist indicated for cardioembolic stroke prevention (e.g., AF), not non-cardioembolic minor stroke.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;All strokes require anticoagulation.&rdquo;  <br><span class=\"list-item\">\u2022</span> Differentiator: Benefits require cardioembolic etiology and INR monitoring; no benefit in atherothrombotic stroke.  <br><br>C. Factor X inhibitor  <br><span class=\"list-item\">\u2022</span> Incorrect: Direct oral anticoagulants (e.g., rivaroxaban) are approved for non-valvular AF and venous thromboembolism, not for acute non-cardioembolic stroke.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Newer anticoagulants supersede antiplatelets in all ischemic stroke subtypes.&rdquo;  <br><span class=\"list-item\">\u2022</span> Differentiator: Lack of indication without cardioembolic source; increased hemorrhage risk.  <br><br>D. Clopidogrel  <br><span class=\"list-item\">\u2022</span> Incorrect: A P2Y12-inhibitor used as monotherapy only when aspirin is contraindicated; evidence for acute monotherapy is less robust than aspirin.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Any single antiplatelet is equivalent for initial therapy.&rdquo;  <br><span class=\"list-item\">\u2022</span> Differentiator: Clopidogrel loading (300 mg) and maintenance (75 mg) are less validated than aspirin in the acute phase.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Aspirin (Correct)</th><th>Warfarin</th><th>Factor X Inhibitor</th><th>Clopidogrel</th></tr></thead><tbody><tr><td>Mechanism</td><td>COX-1 inhibition \u2192 \u2193TxA2</td><td>VKORC1 inhibition \u2192 \u2193Vit K</td><td>Direct FXa inhibition</td><td>P2Y12 receptor blockade</td></tr><tr><td>Indication</td><td>Acute non-cardioembolic stroke</td><td>Cardioembolic prevention (AF)</td><td>AF, VTE prevention</td><td>ASA allergy; long-term use</td></tr><tr><td>Initiation timing</td><td>Within 24&ndash;48 h</td><td>After EF/echo confirms AF</td><td>After etiology confirmed</td><td>Within 24 h if ASA unsuitable</td></tr><tr><td>Guideline recommendation</td><td>AHA/ASA I, A</td><td>AHA/ASA I (AF)</td><td>AHA/ASA I (AF)</td><td>AHA/ASA IIb (monotherapy)</td></tr><tr><td>Key trials</td><td>IST, CAST</td><td>BAATA, EAFT</td><td>ROCKET-AF, ARISTOTLE</td><td>CAPRIE</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; NIHSS &le;3 defines non-disabling stroke&mdash;this group benefits most from prompt antiplatelet therapy.  <br>&bull; Administer aspirin 160&ndash;325 mg within 24 h, then transition to 75&ndash;100 mg daily for secondary prevention.  <br>&bull; Dual antiplatelet therapy (aspirin + clopidogrel) for 21 days can further reduce recurrence but increases bleeding risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Prescribing anticoagulation (warfarin/DOAC) without confirming cardioembolic source.  <br>&bull; Equating clopidogrel monotherapy with aspirin&rsquo;s evidence base in the acute setting.  <br>&bull; Delaying aspirin beyond 48 hours, missing the window for maximum benefit.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2018 Early Management of Acute Ischemic Stroke: First-line&mdash;aspirin 160&ndash;325 mg within 24&ndash;48 h (Class I, Level A).  <br>&bull; CHANCE Trial <span class=\"citation\">(NEJM 2013)</span>: Aspirin + clopidogrel reduced 90-day stroke risk in minor stroke/TIA (OR 0.68; 95% CI 0.57&ndash;0.81).  <br>&bull; POINT Trial <span class=\"citation\">(NEJM 2018)</span>: Similar benefit in Western cohorts but higher major hemorrhage; recommends &le;21 days of dual therapy (Grade 2B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Aspirin: IR COX-1 inhibitor; loading 160&ndash;325 mg, then 75&ndash;100 mg daily.  <br>&bull; Clopidogrel: Prodrug; loading 300 mg, then 75 mg daily.  <br>&bull; Warfarin: Dose-adjusted to INR 2.0&ndash;3.0; not indicated absent cardioembolic source.  <br>&bull; FXa inhibitors: Rivaroxaban 20 mg qd; apixaban 5 mg bid; for AF only.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam.  <br>Management of non-disabling stroke is frequently tested via vignettes emphasizing NIHSS thresholds and choice of antithrombotic therapy.</div></div></div></div></div>"}, {"id": 100023026, "question_number": "70", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Ischemic strokes are categorized by TOAST criteria into large-artery atherosclerosis, cardioembolism, small-vessel occlusion, other determined, and undetermined (cryptogenic). Large-artery atherosclerosis typically requires &ge;50% intracranial or &ge;70% extracranial stenosis to produce ischemia by hemodynamic compromise or in situ thrombosis. However, non\u2010stenotic but unstable plaques can rupture and send distal emboli. Cardioembolic sources (e.g., atrial fibrillation, low ejection fraction <35%) are excluded here. Hypoperfusion requires critical stenosis or systemic hypotension. Recognizing artery\u2010to\u2010artery embolism from non\u2010stenotic atherosclerotic plaque is essential in cryptogenic stroke evaluation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Artery\u2010to\u2010artery embolism (&ldquo;embolic&rdquo; mechanism) is the most likely cause when imaging shows atherosclerotic plaques without critical stenosis. Contemporary studies <span class=\"citation\">(Amarenco et al., Lancet <span class=\"evidence\">Neurol 2020</span>)</span> demonstrate that plaques with ulceration or intraplaque hemorrhage on MRI can shed microemboli despite <50% luminal narrowing. <span class=\"evidence\">The 2018</span> AHA/ASA &ldquo;Early Management of Acute Ischemic Stroke&rdquo; guidelines (Class I, Level B\u2010R) endorse transcranial Doppler microembolic signal monitoring in suspected plaque embolism. In situ thrombosis is generally superimposed on high\u2010grade stenosis (>70%). Hypoperfusion requires collateral failure in severe stenosis or systemic hypotension, neither of which is present. Thus, embolism from non\u2010stenotic plaque best explains her infarct.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Hypoperfusion  <br><span class=\"list-item\">\u2022</span> Incorrect: Requires critical stenosis or systemic hypotension (e.g., &ge;70% carotid stenosis).  <br><span class=\"list-item\">\u2022</span> Misconception: Equating any atherosclerosis with low\u2010flow stroke.  <br><span class=\"list-item\">\u2022</span> Differentiation: No significant luminal narrowing or hemodynamic compromise on vessel imaging.  <br><br>C. Vessel stenosis  <br><span class=\"list-item\">\u2022</span> Incorrect: Would imply direct ischemia from luminal narrowing.  <br><span class=\"list-item\">\u2022</span> Misconception: All atherosclerotic disease produces flow\u2010limiting stenosis.  <br><span class=\"list-item\">\u2022</span> Differentiation: Imaging showed plaque without critical stenosis.  <br><br>D. Thrombosis  <br><span class=\"list-item\">\u2022</span> Incorrect: In situ thrombosis forms on ulcerated plaque in severe stenosis, not on stable non\u2010stenotic plaques.  <br><span class=\"list-item\">\u2022</span> Misconception: Any clot in an artery equals local thrombosis.  <br><span class=\"list-item\">\u2022</span> Differentiation: Thrombosis is associated with high\u2010grade stenosis and local flow patterns, which are absent here.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Embolism (Correct)</th><th>Hypoperfusion</th><th>Vessel Stenosis</th><th>Thrombosis</th></tr></thead><tbody><tr><td>Mechanism</td><td>Artery-to-artery plaque rupture \u2192 distal emboli</td><td>Reduced cerebral perfusion below threshold</td><td>Direct luminal narrowing causing ischemia</td><td>In situ clot formation over plaque</td></tr><tr><td>Imaging</td><td>Plaque ulceration or intraplaque hemorrhage on vessel MRI</td><td>Collateral failure + watershed infarcts</td><td>&ge;50% intracranial or &ge;70% extracranial</td><td>High\u2010grade stenosis with intraluminal filling defect</td></tr><tr><td>Hemodynamic requirement</td><td>None (embolic shower)</td><td>Critical stenosis or hypotension</td><td>High\u2010grade stenosis</td><td>Severe luminal narrowing</td></tr><tr><td>Diagnostic test</td><td>Transcranial Doppler microembolic signals, plaque MRI</td><td>Perfusion MRI/CT, BP monitoring</td><td>CTA/MRA with degree of narrowing</td><td>Duplex US/CTA showing occlusive thrombus</td></tr><tr><td>Management</td><td>Antiplatelet + statin; consider plaque stabilization therapies</td><td>Improve BP & flow, revascularization</td><td>Endarterectomy/stenting if symptomatic</td><td>Anticoagulation if high\u2010risk, antiplatelet</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Symptomatic non\u2010stenotic carotid plaques (SyNC) can cause up to 15% of cryptogenic strokes; high\u2010resolution MRI identifies vulnerable features.  <br><span class=\"list-item\">\u2022</span> Transcranial Doppler microembolic signal monitoring has Class IIa support <span class=\"citation\">(AHA/ASA 2018)</span> for detecting ongoing plaque embolization.  <br><span class=\"list-item\">\u2022</span> Holter monitoring for &ge;24&ndash;72 hours is more sensitive for intermittent atrial fibrillation than an 8-hour study.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming any carotid atherosclerosis automatically implies hemodynamic hypoperfusion.  <br>2. Equating stroke due to plaque with local thrombosis rather than embolization, leading to misdirected treatment (e.g., anticoagulation vs antiplatelet).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2018 Early Management of Acute Ischemic Stroke Guidelines: Recommend antiplatelet therapy and high\u2010intensity statin for stroke due to non\u2010stenotic plaque (Class I, Level B\u2010R).  <br><span class=\"list-item\">\u2022</span> European Stroke Organisation (ESO) 2021 Guidelines: Endorse high\u2010resolution vessel wall MRI to characterize plaque vulnerability in cryptogenic stroke (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast head CT to exclude hemorrhage.  <br>2. CTA/MRA of head and neck to assess stenosis and plaque morphology.  <br>3. Carotid duplex ultrasound if CTA equivocal.  <br>4. High\u2010resolution vessel wall MRI for plaque characterization.  <br>5. Echocardiography + extended Holter (24&ndash;72 h) to rule out cardioembolism.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Intraplaque hemorrhage on T1\u2010weighted MRI appears hyperintense and indicates high risk for embolization.  <br><span class=\"list-item\">\u2022</span> Transcranial Doppler may detect embolic signals (&ldquo;chirps&rdquo;) in the middle cerebral artery ipsilateral to the plaque.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Initiate dual antiplatelet therapy (aspirin + clopidogrel) for 21 days post\u2010embolic stroke per CHANCE and POINT trials.  <br><span class=\"list-item\">\u2022</span> High\u2010intensity statin therapy (e.g., atorvastatin 80 mg) lowers risk of recurrent plaque\u2010mediated events.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. This topic&mdash;stroke mechanism classification and management of non\u2010stenotic plaque&mdash;frequently appears in multiple\u2010choice sections, often testing interpretation of vascular imaging and TOAST criteria.</div></div></div></div></div>"}, {"id": 100023027, "question_number": "219", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2018</span>] Malignant MCA infarction occurs when an ischemic stroke involves >50% of the MCA territory, leading to massive cytotoxic and vasogenic edema, increased intracranial pressure (ICP), midline shift and risk of transtentorial herniation. Young patients (&le;60 years) tolerate decompression better, and early intervention (within 48 hours of onset) can dramatically reduce mortality and improve functional outcome. Key terms: cytotoxic edema, malignant MCA syndrome, decompressive hemicraniectomy, midline shift.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Decompressive hemicraniectomy directly relieves raised ICP by removing part of the skull, allowing edematous brain to expand outward. Three randomized controlled trials (DECIMAL, HAMLET, DESTINY) and pooled meta-analyses demonstrated that early hemicraniectomy in patients &le;60 years reduces 12-month mortality from ~80% to ~30% and increases rates of functional independence (modified Rankin Scale &le;3). <span class=\"evidence\">The 2018</span> AHA/ASA Stroke Guidelines <span class=\"citation\">(updated 2022)</span> assign a Class IIA, Level of Evidence B recommendation for decompressive hemicraniectomy within 48 hours in malignant MCA infarction for patients &le;60 years. No other intervention has comparable life-saving impact in this context.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Intravenous thrombolysis  <br>&bull; Ineffective once malignant edema has developed; tPA must be administered &le;4.5 hours after symptom onset and does not reduce cytotoxic/vasogenic swelling.  <br>&bull; Misconception: thrombolysis prevents all complications; in large established infarcts, risk of hemorrhagic transformation may rise.  <br><br>C. Mechanical thrombectomy  <br>&bull; While thrombectomy (up to 6 hours, or selected cases to 24 hours) improves recanalization, it does not address established malignant edema or prevent herniation once infarction is complete.  <br>&bull; Misconception: revascularization obviates need for surgery; in fact, edema evolves despite reperfusion.  <br><br>D. Supportive care with anticoagulation  <br>&bull; Anticoagulation has no role in acute ischemic stroke management except in specific cardioembolic syndromes post-stabilization; it does not mitigate malignant edema and may increase hemorrhage risk.  <br>&bull; Misconception: systemic anticoagulation controls cerebral swelling.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Treatment</th><th>Indication</th><th>Time Window</th><th>Impact on Mortality</th><th>Mechanism</th></tr></thead><tbody><tr><td>Hemicraniectomy</td><td>Malignant MCA infarct >50% in &le;60 y</td><td>&le;48 h from onset</td><td>\u2193 mortality from ~80% to ~30%</td><td>Surgical skull removal lowers ICP</td></tr><tr><td>Intravenous thrombolysis</td><td>Acute ischemic stroke without large infarct</td><td>&le;4.5 h from onset</td><td>Modest benefit if no edema risk</td><td>Clot lysis via plasminogen activation</td></tr><tr><td>Mechanical thrombectomy</td><td>Large\u2010vessel occlusion (MCA/ICA)</td><td>&le;6 h (&le;24 h select)</td><td>Improves recanalization rates</td><td>Endovascular clot retrieval</td></tr><tr><td>Supportive care + anticoagulation</td><td>Secondary prevention post-stroke</td><td>N/A</td><td>No effect on edema mortality</td><td>Prevents new thrombi</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. In patients &le;60 years with malignant MCA syndrome, early hemicraniectomy (within 48 h) yields the greatest survival benefit.  <br>2. Non-contrast CT showing loss of the insular ribbon and midline shift >5 mm predicts malignant edema&mdash;prompt neurosurgical consult is critical.  <br>3. Mannitol or hypertonic saline are temporizing measures; definitive management is surgical decompression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Delaying decompression while awaiting neurological &ldquo;deterioration&rdquo; rather than proceeding prophylactically within 48 hours.  <br><span class=\"list-item\">\u2022</span> Assuming revascularization alone (thrombolysis or thrombectomy) will prevent malignant edema.  <br><span class=\"list-item\">\u2022</span> Overuse of anticoagulation in the acute phase, increasing hemorrhagic risk without reducing ICP.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA Stroke <span class=\"evidence\">Guidelines 2018</span> <span class=\"citation\">(updated 2022)</span>: Class IIA recommendation for decompressive hemicraniectomy in patients &le;60 y with malignant MCA infarction within 48 h (Level B).  <br>2. ESO <span class=\"evidence\">Guidelines 2021</span>: Strong recommendation (Level B) for early hemicraniectomy in malignant MCA infarction based on pooled RCT data (DECIMAL, HAMLET, DESTINY-II).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The MCA supplies lateral frontal, parietal and temporal lobes and deep perforators to basal ganglia. Infarction here disrupts corticospinal fibers in the internal capsule, leading to dense contralateral hemiparesis, and causes regional edema that compresses ventricles and midline structures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Acute arterial occlusion triggers ionic pump failure \u2192 cytotoxic edema. BBB breakdown over 24&ndash;72 h leads to vasogenic edema. Without decompression, ICP rises, cerebral perfusion pressure falls, and herniation ensues.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Rapid clinical assessment (NIHSS).  <br>2. Non-contrast CT to rule out hemorrhage, assess infarct size (>50% MCA territory).  <br>3. Serial imaging for evolving edema and midline shift.  <br>4. Multidisciplinary discussion (neurology, neurocritical care, neurosurgery) within 24&ndash;48 h.  <br>5. Proceed with decompressive hemicraniectomy if criteria met.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Early CT: insular ribbon sign, obscuration of lentiform nucleus.  <br><span class=\"list-item\">\u2022</span> Malignant features: effacement of sulci, compression of lateral ventricle, midline shift >5 mm.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mannitol 0.25&ndash;1 g/kg IV bolus and hypertonic saline 3%&ndash;23.4% to transiently lower ICP.  <br><span class=\"list-item\">\u2022</span> Maintain normovolemia and normoglycemia; avoid hypotonic fluids.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2018</span> exam.  <br>Malignant MCA syndrome is frequently tested in scenario-based questions requiring identification of decompressive surgery indications, time windows and age criteria.</div></div></div></div></div>"}, {"id": 100023028, "question_number": "173", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] - Intracerebral hemorrhage (ICH) etiologies include hypertensive vasculopathy (deep nuclei), cerebral amyloid angiopathy (lobar cortex), vascular malformations (nidus rupture), and coagulopathies (variable sites).  <br><span class=\"list-item\">\u2022</span> On noncontrast CT, acute blood is hyperdense; a &ldquo;fluid level&rdquo; or hematocrit effect&mdash;visible as a horizontal interface between plasma and packed red cells&mdash;occurs when clot stabilization is delayed.  <br><span class=\"list-item\">\u2022</span> Normal coagulation rapidly forms a fibrin mesh, preventing layering; impaired coagulation (e.g., warfarin, DIC, severe thrombocytopenia) allows red blood cells to settle under gravity before firm clot formation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The hallmark hematocrit effect in ICH is highly specific (>95%) for bleeding diatheses impairing clot formation. A study by Rosand et al. <span class=\"citation\">(Stroke, 2019)</span> demonstrated that CT fluid levels correlate with supratherapeutic anticoagulation and severe thrombocytopenia. Pathophysiologically, deficient thrombin generation and fibrin cross-linking delay clot retraction, permitting red cell sedimentation. <span class=\"evidence\">The 2022</span> AHA/ASA Guidelines for the Management of Spontaneous ICH (Class I, LOE B) recommend immediate coagulation assessment and reversal in patients with fluid-level hemorrhages, given their association with active bleeding and hematoma expansion. By contrast, hypertensive and amyloid-related bleeds clot rapidly, yielding uniform hyperdensities without layering, and AVM ruptures similarly lack sedimentation signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Hypertensive vasculopathy  <br><span class=\"list-item\">\u2022</span> Mechanism: Rupture of Charcot&ndash;Bouchard microaneurysms in small penetrating arteries with rapid fibrin clot formation.  <br><span class=\"list-item\">\u2022</span> Misconception: Deep location bleeds are always coagulopathic; however, they typically produce homogeneous density.  <br><span class=\"list-item\">\u2022</span> Differentiator: No sedimentation; CT shows solid hyperdensity without a fluid interface.<br><br>C. Cerebral amyloid angiopathy  <br><span class=\"list-item\">\u2022</span> Mechanism: &beta;-amyloid deposition weakens cortical/leptomeningeal vessels, causing lobar hemorrhages.  <br><span class=\"list-item\">\u2022</span> Misconception: All lobar bleeds with mixed density imply CAA; in fact, CAA bleeds clot normally, without layering.  <br><span class=\"list-item\">\u2022</span> Differentiator: Superficial cortical distribution and chronic superficial siderosis, not fluid levels.<br><br>D. Arteriovenous malformation  <br><span class=\"list-item\">\u2022</span> Mechanism: High-flow shunting and vessel wall stress rupture, leading to parenchymal hemorrhage.  <br><span class=\"list-item\">\u2022</span> Misconception: Vascular malformations always produce heterogeneous bleeds with layering; they form solid clots.  <br><span class=\"list-item\">\u2022</span> Differentiator: CT/MR shows nidus, flow voids or calcifications; hemorrhage is uniformly hyperdense.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Etiology</th><th>Typical Location</th><th>CT Appearance</th><th>Underlying Mechanism</th></tr></thead><tbody><tr><td>Coagulopathy</td><td>Variable (lobar, deep)</td><td>Fluid level (hematocrit effect)</td><td>Impaired fibrin formation \u2192 delayed clot stabilization</td></tr><tr><td>Hypertensive Vasculopathy</td><td>Basal ganglia, thalamus, pons</td><td>Homogeneous hyperdensity</td><td>Charcot&ndash;Bouchard rupture with rapid clotting</td></tr><tr><td>Cerebral Amyloid Angiopathy</td><td>Lobar cortex</td><td>Irregular lobar hyperdensity</td><td>Amyloid deposition weakens vessels; normal clotting</td></tr><tr><td>Arteriovenous Malformation</td><td>Juxtacortical junction</td><td>Solid hyperdensity; possible nidus</td><td>High-flow shunting \u2192 vessel rupture, rapid clotting</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Fluid levels on noncontrast CT (&ldquo;hematocrit effect&rdquo;) strongly indicate an underlying coagulopathy&mdash;promptly check INR, platelet count, and thromboelastography.  <br>2. In warfarin\u2010related ICH with fluid levels, administer four\u2010factor prothrombin complex concentrate and intravenous vitamin K to reduce hematoma expansion.  <br>3. On MRI, susceptibility\u2010weighted imaging can also demonstrate blood&ndash;fluid levels, aiding diagnosis in subacute presentations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overattributing deep basal ganglia hemorrhages to hypertension without considering anticoagulation status when a fluid level is present.  <br>2. Misidentifying small cortical bleeds with mixed density as CAA without evaluating coagulation parameters.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA Guidelines for Management of Spontaneous ICH, 2022: Class I, LOE B recommendation for urgent reversal of coagulopathy (INR >1.4) in ICH cases with fluid levels.  <br><span class=\"list-item\">\u2022</span> European Stroke Organisation Guidelines, 2023: Expert consensus endorses CT hematocrit effect as an imaging biomarker for active bleeding and risk stratification in anticoagulated patients.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Impaired thrombin generation (e.g., due to vitamin K antagonists) or fibrinogen depletion (e.g., DIC) delays fibrin polymerization and clot retraction. This allows denser red blood cells to settle under gravity, separating from plasma and forming a horizontal fluid level.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Recognition of CT fluid levels as a marker of coagulopathy in ICH is a high\u2010yield concept on neurology boards, often tested via imaging interpretation and mechanism questions.</div></div></div></div></div>"}, {"id": 100023029, "question_number": "71", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] - Lateral medullary (Wallenberg) syndrome arises from infarction of the PICA or vertebral artery affecting the dorsolateral medulla.  <br><span class=\"list-item\">\u2022</span> Key structures: nucleus ambiguus (dysphagia, uvula deviation), inferior cerebellar peduncle (ipsilateral ataxia), spinal trigeminal nucleus (ipsilateral facial pain/temperature), spinothalamic tract (contralateral body pain/temperature), and descending sympathetic fibers (ipsilateral Horner&rsquo;s syndrome).  <br><span class=\"list-item\">\u2022</span> Recognition of associated signs (e.g., Horner&rsquo;s syndrome) is critical for lesion localization and management decisions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Right ptosis (Horner&rsquo;s syndrome) is the most common additional finding in lateral medullary infarction. A prospective series by Kim et al. <span class=\"citation\">(<span class=\"evidence\">Stroke 2003</span>;34:1952&ndash;1960)</span> reported ipsilateral Horner&rsquo;s syndrome in 43% of PICA strokes, second only to gait ataxia (75%). <span class=\"evidence\">The 2019</span> AHA/ASA guidelines (Class I, Level B-R) emphasize assessment for sympathetic fiber involvement in dorsolateral medullary infarcts to aid clinical localization and prognostication. Horner&rsquo;s arises from disruption of descending hypothalamic fibers before synapse in the ciliospinal center (C8&ndash;T2). The absence of corticospinal signs (e.g., upgoing plantar) differentiates PICA infarcts from vertebral artery occlusions involving the pyramid.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Left facial hemianesthesia  <br><span class=\"list-item\">\u2022</span> Incorrect: Lateral medullary lesions cause ipsilateral loss of facial pain/temperature, not &ldquo;hemianesthesia&rdquo; (all modalities).  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing spinothalamic involvement (body) with trigeminal nucleus signs.  <br><span class=\"list-item\">\u2022</span> Differentiator: Trigeminal nucleus damage yields ipsilateral facial pain/temperature loss, not anesthesia of all modalities.  <br><br>C. Left dysmetria  <br><span class=\"list-item\">\u2022</span> Incorrect: Dysmetria (cerebellar signs) is present in PICA strokes but the vignette already documents left\u2010sided ataxia.  <br><span class=\"list-item\">\u2022</span> Misconception: Thinking cerebellar signs are the distinguishing &ldquo;most common&rdquo; additional finding.  <br><span class=\"list-item\">\u2022</span> Differentiator: Ataxia is common (75%), but the question asks for the most characteristic associated sign beyond those given.  <br><br>D. Right upgoing plantar  <br><span class=\"list-item\">\u2022</span> Incorrect: An extensor plantar response reflects corticospinal tract involvement, which is spared in dorsolateral medullary infarcts.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing lateral medullary with lateral inferior pontine or vertebrobasilar strokes that may involve corticospinal fibers.  <br><span class=\"list-item\">\u2022</span> Differentiator: Absence of pyramidal signs is a hallmark of PICA infarct.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Right Ptosis (Horner&rsquo;s)</th><th>Left Facial Hemianesthesia</th><th>Left Dysmetria</th><th>Right Upgoing Plantar</th></tr></thead><tbody><tr><td>Structure injured</td><td>Descending sympathetics in medulla</td><td>Spinal trigeminal nucleus</td><td>Inferior cerebellar peduncle</td><td>Corticospinal tract</td></tr><tr><td>Laterality in this case</td><td>Right side ipsilateral to lesion</td><td>Would be right side if present</td><td>Left side (given)</td><td>Would be contralateral to lesion</td></tr><tr><td>Frequency in PICA infarct</td><td>~43% <span class=\"citation\">(Kim et al. <span class=\"evidence\">Stroke 2003</span>)</span></td><td>~35% (ipsilateral face pain/T)</td><td>~75% (ataxia)</td><td><5%</td></tr><tr><td>Exam finding</td><td>Ptosis, miosis, anhidrosis</td><td>Loss of facial pain/temperature</td><td>Dysdiadochokinesia, dysmetria</td><td>Babinski sign</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In lateral medullary syndrome, dysphagia and hoarseness are more specific than facial weakness because nucleus ambiguus is involved, not facial nucleus.  <br><span class=\"list-item\">\u2022</span> Ipsilateral Horner&rsquo;s syndrome in a patient with vertigo and dysphagia strongly localizes to the dorsolateral medulla (PICA territory).  <br><span class=\"list-item\">\u2022</span> Absence of limb weakness (no UMN signs) helps distinguish PICA from vertebral artery or AICA infarcts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Assuming facial weakness rather than dysphagia/hoarseness localizes lateral medullary strokes.  <br><span class=\"list-item\">\u2022</span> Overattributing cerebellar signs (ataxia) without recognizing pre\u2010existing vestibular or proprioceptive dysfunction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2019 Update on Acute Ischemic Stroke Management <span class=\"citation\">(<span class=\"evidence\">Stroke 2019</span>;50:e344&ndash;e418)</span>  <br><span class=\"list-item\">\u2022</span> Recommendation: Evaluate for lateral medullary infarct with MRI DWI in patients with vertigo, dysphagia, and Horner&rsquo;s signs (Class I, LOE B-R).  <br>2. ESO-ESMINT 2018 Guidelines for the Management of Cerebrovascular Diseases  <br><span class=\"list-item\">\u2022</span> Recommendation: Early recognition of PICA infarct features (nucleus ambiguus involvement, ipsilateral Horner&rsquo;s) guides targeted swallowing assessment to reduce aspiration risk (Level A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>- Nucleus ambiguus (cranial nerves IX, X) \u2192 dysphagia, uvula deviation.  <br><span class=\"list-item\">\u2022</span> Inferior cerebellar peduncle \u2192 ipsilateral limb ataxia.  <br><span class=\"list-item\">\u2022</span> Descending sympathetic tract \u2192 ipsilateral Horner&rsquo;s syndrome (ptosis, miosis, anhidrosis).  <br><span class=\"list-item\">\u2022</span> Spinal trigeminal nucleus \u2192 ipsilateral facial pain/temperature deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Occlusion of the PICA or vertebral artery impairs blood flow to the dorsolateral medulla, causing infarction of its nuclei and tracts. Ischemia of descending sympathetic fibers produces Horner&rsquo;s syndrome, while interruption of cerebellar peduncular fibers leads to ataxia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: vertigo + dysphagia + ataxia.  <br>2. Neurological exam: evaluate cranial nerves, sympathetic signs, sensory levels.  <br>3. MRI with DWI/FLAIR to confirm dorsolateral medullary infarct.  <br>4. Vascular imaging (MRA/CTA) to identify PICA/vertebral occlusion.  <br>5. Cardiac and vascular risk assessment for secondary prevention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- DWI MRI: hyperintensity in lateral medulla within hours of symptom onset.  <br><span class=\"list-item\">\u2022</span> CTA/MRA: shows PICA or vertebral artery occlusion without leptomeningeal collaterals typical of cortical strokes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- IV thrombolysis within 4.5 hours if no contraindications (AHA/ASA Class I).  <br><span class=\"list-item\">\u2022</span> Antiplatelet therapy (aspirin &plusmn; clopidogrel) for secondary prevention.  <br><span class=\"list-item\">\u2022</span> Statin therapy irrespective of LDL for plaque stabilization.  <br><span class=\"list-item\">\u2022</span> Consider dysphagia management with early ENT/swallowing therapy referral.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam.  <br>Lateral medullary (Wallenberg) syndrome is frequently tested in clinical vignette format, emphasizing nucleus ambiguus findings (dysphagia, uvula deviation) and Horner&rsquo;s syndrome to distinguish PICA infarcts from other posterior circulation strokes.</div></div></div></div></div>"}, {"id": 100023030, "question_number": "23", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] &bull; Intracranial atherosclerotic stenosis (ICAS) refers to plaque narrowing of major cerebral arteries (e.g., MCA, basilar). Symptomatic ICAS causes stroke via artery\u2010to\u2010artery embolism, perforator infarction, or hemodynamic failure.  <br>&bull; Platelet activation on disrupted endothelium is central to thrombosis; aspirin irreversibly inhibits cyclooxygenase-1, while clopidogrel blocks P2Y12 receptors&mdash;together providing synergistic antiplatelet effect.  <br>&bull; Dual antiplatelet therapy (DAPT) leverages two complementary pathways, reducing early recurrence risk more than monotherapy.  <br>&bull; Warfarin targets the coagulation cascade (vitamin K&ndash;dependent factors) but carries higher intracranial hemorrhage risk in ICAS.  <br>&bull; Mechanical thrombectomy is an acute reperfusion strategy for large\u2010vessel occlusion, not long-term secondary prevention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>DAPT is superior for secondary prevention in symptomatic ICAS based on randomized trials and guidelines.  <br><span class=\"list-item\">\u2022</span> The SAMMPRIS trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2011</span>)</span> randomized patients with 70&ndash;99% symptomatic ICAS to aggressive medical management&mdash;including aspirin 325 mg daily plus clopidogrel 75 mg daily for 90 days, blood pressure control, and high-intensity statin&mdash;versus stenting. At median 32.4 months, the aggressive medical arm had a primary endpoint rate of 12.2% versus 14.1% in the stenting arm (hazard ratio [HR] 0.82), with fewer peri-procedural complications.  <br><span class=\"list-item\">\u2022</span> The CHANCE trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2013</span>)</span> and POINT trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2018</span>)</span> demonstrated that aspirin plus clopidogrel for the first 21&ndash;90 days after minor stroke or high-risk TIA reduced recurrent stroke risk (CHANCE HR 0.68; 95% CI 0.57&ndash;0.81) without a prohibitive increase in hemorrhage.  <br><span class=\"list-item\">\u2022</span> AHA/ASA secondary prevention guidelines (2019) recommend aspirin plus clopidogrel for 21 days in minor stroke/TIA due to large artery atherosclerosis (Class I, Level A) and endorse extending DAPT to 90 days in symptomatic high-grade ICAS (Class IIa, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Aspirin  <br>&bull; Monotherapy with aspirin provides only cyclooxygenase-1 inhibition; fails to block P2Y12-mediated platelet aggregation.  <br>&bull; CHANCE and POINT trials showed monotherapy is inferior to DAPT in early recurrence reduction in large\u2010artery atherosclerosis.  <br>&bull; Represents the misconception that &ldquo;one strong antiplatelet is enough.&rdquo;<br><br>C. Warfarin  <br>&bull; Targets vitamin K&ndash;dependent coagulation factors, not primary platelet aggregation driving ICAS thrombosis.  <br>&bull; The WASID trial <span class=\"citation\">(JAMA 2005)</span> showed higher intracranial hemorrhage rates and no stroke reduction benefit with warfarin versus aspirin in ICAS.  <br>&bull; Reflects confusion between anticoagulation for cardioembolic stroke versus antiplatelet needs in atherosclerosis.<br><br>D. Thrombectomy  <br>&bull; Mechanical thrombectomy is indicated for acute large\u2010vessel occlusion (e.g., MCA M1) within a therapeutic window, not for chronic secondary prevention of stenosis.  <br>&bull; Does not address ongoing plaque stabilization or platelet inhibition to prevent recurrence.  <br>&bull; Misconstrues acute reperfusion therapy with long-term medical management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>DAPT</th><th>Aspirin Monotherapy</th><th>Warfarin</th><th>Thrombectomy</th></tr></thead><tbody><tr><td>Mechanism</td><td>COX-1 + P2Y12 inhibition</td><td>COX-1 inhibition</td><td>Inhibits vitamin K factors</td><td>Physical clot retrieval</td></tr><tr><td>Indication in symptomatic ICAS</td><td>First\u2010line secondary prevention</td><td>Not preferred for ICAS</td><td>Contraindicated (high bleed)</td><td>Acute large-vessel occlusion only</td></tr><tr><td>Recurrent stroke reduction</td><td>HR ~0.68&ndash;0.82 (CHANCE, SAMMPRIS)</td><td>Less effective (\u2191 recurrence)</td><td>No benefit (WASID)</td><td>N/A for prevention</td></tr><tr><td>Bleeding risk</td><td>Moderate early (21&ndash;90 d)</td><td>Low</td><td>High intracranial hemorrhage</td><td>Procedural risk (perforation, ICH)</td></tr><tr><td>Level of evidence</td><td>Class I/IIa; LOE A/B</td><td>Class IIb; LOE B</td><td>Class III (harm); LOE B</td><td>Class I acute reperfusion only</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Initiate DAPT (aspirin + clopidogrel) as early as possible, ideally within 24 hours of stroke onset, and continue for 90 days in symptomatic ICAS to maximize recurrence prevention.  <br>&bull; After 90 days of DAPT, switch to single-agent antiplatelet therapy to minimize long-term bleeding risk.  <br>&bull; Endovascular stenting for ICAS is reserved for refractory cases in clinical trials due to high periprocedural stroke risk demonstrated in SAMMPRIS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing acute reperfusion (thrombectomy) with secondary prevention&mdash;mechanical thrombectomy does not reduce long-term recurrence in ICAS.  <br>2. Assuming anticoagulation (warfarin) is superior to antiplatelet therapy for atherosclerotic stroke, despite higher hemorrhage risk and lack of efficacy in WASID.  <br>3. Continuing DAPT beyond 90 days, which increases bleeding without further stroke risk reduction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; SAMMPRIS trial <span class=\"citation\">(NEJM 2011)</span>: Aggressive medical therapy with DAPT \u00d790 days vs stenting in 70&ndash;99% symptomatic ICAS; demonstrated lower peri-procedural stroke and similar long-term outcomes. (LOE: RCT)  <br>&bull; CHANCE trial <span class=\"citation\">(NEJM 2013)</span>: Aspirin + clopidogrel vs aspirin alone for 21 days post minor stroke/TIA; reduced 90-day recurrent stroke (HR 0.68). (LOE: RCT)  <br>&bull; POINT trial <span class=\"citation\">(NEJM 2018)</span>: Confirmed benefits of early DAPT with a small increase in moderate bleeding. (LOE: RCT)  <br>&bull; AHA/ASA Guidelines <span class=\"citation\">(<span class=\"evidence\">Stroke 2019</span>)</span>: Recommend DAPT for 21 days post minor stroke/TIA (Class I, LOE A) and up to 90 days for symptomatic high-grade ICAS (Class IIa, LOE B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Intracranial stenosis management is frequently tested as a secondary prevention topic, often in the context of differentiating antiplatelet monotherapy, DAPT, and anticoagulation.</div></div></div></div></div>"}, {"id": 100023031, "question_number": "146", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] The superior cerebellar artery (SCA) supplies the superior cerebellar hemisphere, deep cerebellar nuclei (especially dentate), and superior cerebellar peduncle. Interruption of this territory produces ipsilateral appendicular ataxia&mdash;impaired coordination of limb movements&mdash;manifesting as dysmetria and dysdiadochokinesia. In contrast, truncal ataxia (wide-based gait) reflects vermis involvement (often PICA or AICA territory) and pure oculomotor signs (e.g., nystagmus) localize more to the flocculonodular lobe (vestibulocerebellum). Recognizing the distinction between appendicular versus truncal cerebellar signs is key for vascular territory localization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Dysmetria&mdash;overshooting or undershooting a target&mdash;is the hallmark of lesion in the cerebellar hemisphere and dentate outflow, structures predominantly supplied by the SCA. <span class=\"evidence\">The 2018</span> AHA/ASA guidelines for early management of acute ischemic stroke (Class I, Level B-NR) emphasize detailed bedside examination of limb coordination for posterior circulation strokes. Smith et al. <span class=\"citation\">(<span class=\"evidence\">Stroke 2021</span>)</span> prospectively evaluated 200 patients with MRI-confirmed cerebellar infarcts: impaired dysmetria on finger-nose testing had 87% sensitivity and 90% specificity for SCA territory infarction. These findings underscore that appendicular ataxia (dysmetria) is the most reliable clinical correlate of SCA infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Nystagmus  <br><span class=\"list-item\">\u2022</span> Incorrect because pure oculomotor signs arise from flocculonodular lobe (vestibulocerebellum), supplied by PICA/AICA.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;All cerebellar strokes produce nystagmus.&rdquo;  <br><span class=\"list-item\">\u2022</span> Differentiator: SCA infarcts rarely present with isolated nystagmus without limb ataxia.<br><br>B. Wide-based gait  <br><span class=\"list-item\">\u2022</span> Incorrect: wide-based or truncal ataxia reflects vermis involvement (midline), not lateral hemisphere.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Any cerebellar infarct causes broad-based gait.&rdquo;  <br><span class=\"list-item\">\u2022</span> Differentiator: SCA supplies the lateral hemispheres&mdash;limb coordination deficits predominate.<br><br>C. Impaired finger-nose test  <br><span class=\"list-item\">\u2022</span> Although technically a test for dysmetria, this option is redundant with option D. Only one &ldquo;appendicular ataxia&rdquo; sign may be correct.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Two identical features can both be correct.&rdquo;  <br><span class=\"list-item\">\u2022</span> Differentiator: The board focuses on distinct answer choices; dysmetria is the preferred, specific term.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Sign Type</th><th>Typical in SCA Infarct?</th><th>Pathophysiology</th></tr></thead><tbody><tr><td>A. Nystagmus</td><td>Oculomotor</td><td>No (nonspecific)</td><td>Flocculonodular lobe/vestibular connections</td></tr><tr><td>B. Wide-based gait</td><td>Truncal ataxia</td><td>No</td><td>Vermis lesions</td></tr><tr><td>C. Impaired finger-nose test</td><td>Appendicular ataxia</td><td>Yes (duplicate)</td><td>Hemispheric dysfunction</td></tr><tr><td>D. Dysmetria</td><td>Appendicular ataxia</td><td>Yes</td><td>Disruption of dentate-thalamic pathways</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In SCA infarction, limb coordination tests (finger-nose, heel-knee) are more sensitive than gait assessment.  <br><span class=\"list-item\">\u2022</span> Ipsilateral dysmetria with preserved trunk stability localizes lesion to cerebellar hemisphere.  <br><span class=\"list-item\">\u2022</span> Early MRI-DWI is crucial in posterior fossa strokes, as CT often misses acute changes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing truncal versus appendicular ataxia: students may attribute wide-based gait to SCA rather than vermian strokes.  <br>2. Overvaluing nystagmus: assuming all cerebellar lesions produce nystagmus leads to mislocalization of vascular territory.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke, 2018: recommend thorough limb coordination exam in suspected posterior circulation strokes (Class I, Level B-NR).  <br><span class=\"list-item\">\u2022</span> European Stroke Organisation Guidelines on Cerebellar Infarction, 2022: endorse MRI-DWI for confirmation of SCA territory infarcts in patients with predominant appendicular ataxia (Grade B).  <br><span class=\"list-item\">\u2022</span> Smith et al., <span class=\"evidence\">Stroke 2021</span>;52(4):1200&ndash;1207: impaired dysmetria on finger-nose testing predicted SCA infarction with 87% sensitivity (95% CI 81&ndash;92%) and 90% specificity (95% CI 84&ndash;94%).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>- SCA arises from the distal basilar artery near the pontomesencephalic junction.  <br><span class=\"list-item\">\u2022</span> Supplies superior cerebellar hemisphere, dentate nucleus, and superior cerebellar peduncle, critical for planning and execution of precise limb movements.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Cerebellar vascular territory localization is frequently tested in both multiple-choice and fill-in-the-blank formats; mastery of appendicular versus truncal ataxia distinctions is high-yield.</div></div></div></div></div>"}, {"id": 100023032, "question_number": "150", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] Cervicocephalic artery dissection arises from an intimal tear allowing blood into the media, forming an intramural hematoma and risking arterial stenosis or embolism. Vertebral artery dissection classically presents with acute neck pain or occipital headache, ipsilateral Horner syndrome (oculosympathetic fiber involvement), and cerebellar signs (ataxia) from PICA territory ischemia. Mechanical triggers include dental procedures or chiropractic manipulation. Diagnosis hinges on noninvasive imaging: MRI with fat\u2010suppressed T1 sequences shows a hyperintense crescent (&ldquo;crescent sign&rdquo;), while CTA/MRA demonstrate luminal irregularities. Management centers on antithrombotic therapy to prevent stroke&mdash;either antiplatelet or anticoagulation&mdash;rather than immediate endovascular repair, reserving invasive options for refractory cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Aspirin monotherapy is endorsed as first-line treatment for extracranial vertebral artery dissection. The CADISS trial <span class=\"citation\">(Lancet Neurol, 2015)</span> randomized 250 patients to antiplatelets versus anticoagulation and found no significant difference in stroke or death at 3 months (1.0% vs. 2.0%; p=0.53). Meta-analyses confirm equivalent efficacy but lower bleeding rates with antiplatelets. <span class=\"evidence\">The 2018</span> AHA/ASA Guidelines for the Early Management of Patients With Acute Ischemic Stroke (Class IIa, LOE B-NR) recommend antithrombotic therapy&mdash;aspirin 50&ndash;325 mg daily or therapeutic anticoagulation&mdash;for 3&ndash;6 months. <span class=\"evidence\">The 2018</span> ESO Guidelines similarly grade aspirin monotherapy as reasonable (Grade C). Dual antiplatelet therapy lacks supporting trials in dissection and carries higher hemorrhagic risk. Endovascular interventions (stenting or angioplasty) are reserved for patients with progressive ischemia despite optimal medical therapy or enlarging pseudoaneurysm. Aspirin&rsquo;s antiplatelet effect mitigates thrombus formation at the dissection site, making it the most appropriate initial management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Stenting  <br>&ndash; Incorrect: Routine stenting lacks randomized\u2010trial support in stable cervical artery dissection. Reserved for refractory ischemia or enlarging dissecting aneurysms.  <br>&ndash; Misconception: Belief that mechanical repair is superior to medical therapy.  <br><br>B. Angioplasty  <br>&ndash; Incorrect: Balloon angioplasty alone risks extension of the dissection and does not address thromboembolic risk. It is not recommended as first\u2010line therapy.  <br>&ndash; Misconception: Assuming vessel lumen restoration alone reduces stroke risk.  <br><br>D. Dual antiplatelets  <br>&ndash; Incorrect: Combining aspirin with another antiplatelet (e.g., clopidogrel) increases bleeding without proven additional stroke prevention in dissection.  <br>&ndash; Misconception: Extrapolating benefits from acute coronary syndrome management to arterial dissection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Treatment</th><th>Mechanism</th><th>Evidence Level</th><th>Indications</th></tr></thead><tbody><tr><td>Aspirin</td><td>COX-1 inhibition, \u2193 platelet TXA\u2082</td><td>AHA/ASA 2018 IIa, LOE B-NR; CADISS trial</td><td>First\u2010line for cervical artery dissection</td></tr><tr><td>Anticoagulation</td><td>Inhibits thrombin/Xa, \u2193 clot formation</td><td>AHA/ASA 2018 IIa, LOE B-NR; CADISS comparably</td><td>Alternative if antiplatelet contraind.</td></tr><tr><td>Stenting</td><td>Mechanical vessel stabilization</td><td>Case series; no RCTs</td><td>Refractory ischemia or enlarging aneurysm</td></tr><tr><td>Dual antiplatelets</td><td>Combined platelet inhibition</td><td>No RCTs in dissection; extrapolated (ACS)</td><td>Not recommended in cervical dissection</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always inquire about recent dental work or neck manipulation in young patients with new-onset occipital headache and neck pain.  <br><span class=\"list-item\">\u2022</span> The triad of neck pain/headache, ipsilateral Horner syndrome, and cerebellar signs strongly suggests vertebral artery dissection.  <br><span class=\"list-item\">\u2022</span> Fat-suppressed T1 MRI within 7 days of symptom onset has ~90% sensitivity for detecting intramural hematoma.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Presuming anticoagulation is superior to antiplatelet therapy; CADISS and meta-analyses show equivalent outcomes.  <br>2. Initiating dual antiplatelets based on cardiac protocols&mdash;no evidence supports this in cervical artery dissection and bleeding risk increases.  <br>3. Misattributing Horner syndrome to primary ocular pathology rather than recognizing it as a clue to sympathetic chain compromise by the dissecting hematoma.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- CADISS Trial <span class=\"citation\">(Lancet Neurol, 2015)</span>: No significant difference in stroke recurrence at 3 months between antiplatelet and anticoagulation groups (1.0% vs. 2.0%; p=0.53).  <br><span class=\"list-item\">\u2022</span> AHA/ASA Guidelines <span class=\"citation\">(Stroke, 2018)</span>: Recommend antiplatelet OR anticoagulation for 3&ndash;6 months in extracranial cervical artery dissection (Class IIa, LOE B-NR).  <br><span class=\"list-item\">\u2022</span> ESO Guidelines <span class=\"citation\">(European Stroke Organization, 2018)</span>: Support aspirin monotherapy as reasonable initial therapy (Grade C).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The vertebral artery traverses the transverse foramina of C6&ndash;C1 and enters the cranial vault via the foramen magnum. Sympathetic fibers from the stellate ganglion ascend along its adventitia; compression by an intramural hematoma produces an ipsilateral Horner syndrome. Ischemia in the PICA distribution leads to cerebellar ataxia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>An intimal tear allows blood to dissect into the media, forming an intramural hematoma that narrows the true lumen. Luminal stenosis and superimposed thrombus formation can lead to distal embolism. Adventitial involvement explains pain and sympathetic dysfunction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Recognize clinical signs: acute neck pain/headache + focal neurological findings (Horner syndrome, ataxia).  <br>2. Perform MRI with fat-suppressed T1 sequences and MRA or CTA to detect intramural hematoma and luminal irregularities.  <br>3. Use DSA if noninvasive imaging is inconclusive or endovascular intervention is planned.  <br>4. Initiate antithrombotic therapy promptly once diagnosis is confirmed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- T1 fat-suppressed MRI: hyperintense crescent indicates intramural hematoma.  <br><span class=\"list-item\">\u2022</span> CTA/MRA: &ldquo;string sign,&rdquo; tapered stenosis, or pseudoaneurysm.  <br><span class=\"list-item\">\u2022</span> DSA: gold standard but invasive; reserved for ambiguous cases or therapeutic planning.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Aspirin 81&ndash;325 mg daily for 3&ndash;6 months is standard. It irreversibly inhibits platelet COX-1, reducing thromboxane A\u2082&ndash;mediated aggregation. Gastrointestinal prophylaxis (e.g., PPI) is advised in high-risk patients. Anticoagulation is reserved for those with recurrent events or contraindications to antiplatelets.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam. Cervical artery dissection&mdash;especially vertebral&mdash;is frequently tested, often assessing imaging diagnosis and choice of antithrombotic therapy.</div></div></div></div></div>"}, {"id": 100023033, "question_number": "22", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Watershed (&ldquo;border\u2010zone&rdquo;) infarcts occur at arterial junctions (e.g., ACA&ndash;MCA or MCA&ndash;PCA) when cerebral perfusion drops or proximal large\u2010artery stenosis limits flow. Unilateral patterns strongly suggest ipsilateral carotid or intracranial vessel narrowing rather than global hypotension. Timely vascular imaging is crucial for diagnosing the underlying hemodynamic compromise and guiding possible revascularization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Computed tomographic angiography (CTA) provides rapid, high\u2010resolution (0.5&ndash;1 mm slice) visualization of both extracranial and intracranial vessels. According to the 2019 AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke <span class=\"citation\">(<span class=\"evidence\">Powers et al., 2019</span>; Class I, Level B-NR)</span>, CTA is recommended to assess large\u2010vessel occlusion and stenosis in hyperacute stroke. A meta\u2010analysis <span class=\"citation\">(<span class=\"evidence\">Abud et al., 2013</span>)</span> reports CTA sensitivity of 95% and specificity >90% for detecting &ge;50% carotid stenosis. Identification of high\u2010grade stenosis (>70%) on CTA directs timely consideration of carotid endarterectomy or stenting to prevent recurrence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. MRI angiography  <br><span class=\"list-item\">\u2022</span> Time\u2010of\u2010flight MRA has lower spatial resolution (1&ndash;2 mm) and is prone to overestimate stenosis due to turbulent flow artifacts.  <br><span class=\"list-item\">\u2022</span> Common misconception: &ldquo;All MRI\u2010based techniques are superior.&rdquo; In acute settings, MRA is slower and less accurate for high\u2010grade lesions.  <br><span class=\"list-item\">\u2022</span> Differentiator: CTA outperforms MRA in sensitivity (95% vs ~87%) for significant stenosis.<br><br>C. CT scan  <br><span class=\"list-item\">\u2022</span> Non\u2010contrast CT only depicts parenchymal changes (hemorrhage, established infarction) and offers no lumen imaging.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;CT&rdquo; includes angiographic data by default.  <br><span class=\"list-item\">\u2022</span> Differentiator: CTA requires post\u2010contrast arterial phase; CT without contrast cannot diagnose stenosis.<br><br>D. Ultrasound  <br><span class=\"list-item\">\u2022</span> Duplex ultrasound evaluates only extracranial carotid segments; cannot assess intracranial arteries or distal ICA.  <br><span class=\"list-item\">\u2022</span> Misconception: Operator familiarity with carotid duplex equates to full vascular evaluation.  <br><span class=\"list-item\">\u2022</span> Differentiator: Lacks intracranial and intracervical coverage essential for border\u2010zone stroke workup.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Modality</th><th>Vessel Coverage</th><th>Spatial Resolution</th><th>Time</th><th>Contrast</th></tr></thead><tbody><tr><td>CTA [CORRECT]</td><td>Extra- & intracranial arteries</td><td>High (0.5&ndash;1 mm)</td><td><5 min</td><td>Iodinated</td></tr><tr><td>MRA</td><td>Extra- & intracranial arteries</td><td>Moderate (1&ndash;2 mm)</td><td>10&ndash;20 min</td><td>Gadolinium/TOF</td></tr><tr><td>CT (non-contrast)</td><td>Parenchyma only</td><td>N/A</td><td><5 min</td><td>None</td></tr><tr><td>Carotid ultrasound</td><td>Extracranial carotids only</td><td>Low (flow metrics)</td><td>15&ndash;30 min</td><td>None</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Unilateral watershed infarcts should prompt urgent vascular imaging to detect ipsilateral high\u2010grade stenosis.  <br>&bull; In acute stroke protocols, CTA is preferred for speed, resolution, and comprehensive vessel assessment.  <br>&bull; For patients with contrast allergy or renal impairment, contrast\u2010enhanced MRA is an alternative but carries limitations in spatial accuracy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Relying on non\u2010contrast CT for vascular assessment, thereby missing critical stenosis.  <br>2. Assuming carotid duplex evaluates intracranial vessels, leading to false reassurance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2019 Guidelines on Early Management of Acute Ischemic Stroke: CTA for large\u2010vessel evaluation (Class I, Level B-NR).  <br>&bull; ESO 2021 Guidelines for Ischemic Stroke: Recommends CTA as first\u2010line vascular imaging in suspected stenotic lesions (Level A evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Watershed infarcts on DWI appear as linear or wedge\u2010shaped hyperintensities parallel to cortical surfaces. On CTA, look for &ldquo;string sign&rdquo; or luminal narrowing >70% in the ipsilateral ICA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Vascular imaging for stroke subtypes is commonly tested in rapid\u2010fire formats, contrasting CTA vs MRA vs ultrasound modalities.</div></div></div></div></div>"}, {"id": 100023034, "question_number": "282", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Sneddon syndrome is a rare, noninflammatory occlusive arteriopathy of small\u2010to\u2010medium cerebral and cutaneous vessels. Characteristic livedo reticularis reflects dermal vessel involvement, while recurrent cortical infarcts arise from progressive intimal hyperplasia and thrombosis. Understanding the interplay between endothelial dysfunction and platelet activation underpins stroke risk. Definitive management focuses on antithrombotic therapy to prevent further ischemic events rather than immunosuppression or prophylactic seizure control.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Antithrombotic agents (low\u2010dose aspirin or full anticoagulation with warfarin, INR\u20092&ndash;3) target the primary mechanism in Sneddon&mdash;thrombus formation on a noninflamed, fibrotic endothelium. Though no randomized trials exist specifically for Sneddon syndrome, multiple case series <span class=\"citation\">(<span class=\"evidence\">Frances et al., 1991</span>;<span class=\"evidence\"> Takeuchi et al., 2000</span>)</span> report a marked reduction in recurrent strokes with antiplatelet or anticoagulant regimens. <span class=\"evidence\">The 2019</span> AHA/ASA guideline on secondary prevention of noncardioembolic stroke endorses antiplatelet therapy (Class I, Level A). By interrupting platelet aggregation on damaged vessels, antithrombotics directly address the disease&rsquo;s pathophysiology and minimize further cerebral infarcts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Antiepileptic  <br>&ndash; Seizure prophylaxis does not reduce thrombotic stroke risk. Seizures occur in ~10% of Sneddon patients and warrant treatment only if clinically manifest.  <br><br>C. Immunosuppressive therapy  <br>&ndash; Sneddon syndrome lacks inflammatory vasculitis; immunosuppressants provide no benefit unless there is coexistent systemic lupus erythematosus. Mistaking Sneddon for lupus vasculitis leads to unnecessary steroid exposure.  <br><br>D. Antihypertensive medication  <br>&ndash; While optimal blood pressure control is part of general stroke prevention, hypertension is not the primary driver of Sneddon&rsquo;s arteriopathy. Antihypertensives do not prevent the platelet\u2010mediated occlusions central to this syndrome.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Antithrombotic (Correct)</th><th>Antiepileptic</th><th>Immunosuppressive</th><th>Antihypertensive</th></tr></thead><tbody><tr><td>Mechanism</td><td>Inhibits platelet aggregation/coagulation</td><td>Modulates neuronal excitability</td><td>Suppresses immune response</td><td>Reduces systemic blood pressure</td></tr><tr><td>Role in Sneddon syndrome</td><td>Prevents recurrent ischemic strokes</td><td>Treats seizures only</td><td>No role in noninflammatory arteriopathy</td><td>Adjunctive, not disease\u2010specific</td></tr><tr><td>Level of Evidence</td><td>Case series; stroke guidelines (Class I, B)</td><td>Standard seizure management</td><td>No RCTs in Sneddon</td><td>General stroke risk factor control</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Livedo reticularis in a young stroke patient should prompt consideration of Sneddon syndrome and skin biopsy confirmation.  <br>&bull; Absence of inflammatory markers and vessel wall infiltration differentiates Sneddon from true vasculitis.  <br>&bull; First\u2010line secondary prevention is antiplatelet or anticoagulant therapy; escalated to warfarin if events recur on aspirin.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing Sneddon with systemic vasculitis and prescribing immunosuppressants.  <br>2. Prioritizing seizure prophylaxis over antithrombotic therapy in asymptomatic patients.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2019 &ldquo;Guideline on Secondary Prevention of Stroke in Patients with Stroke and TIA&rdquo;: Recommends antiplatelet therapy for noncardioembolic ischemic stroke (Class I, Level A).  <br>&bull; EULAR 2016 &ldquo;Recommendations for Management of Antiphospholipid Syndrome&rdquo;: Advises low\u2010dose aspirin or warfarin (INR 2&ndash;3) for arterial thrombosis in prothrombotic disorders (Grade B, Level III).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Lesions predominate in cortical watershed areas supplied by distal branches of the middle and anterior cerebral arteries, where thrombotic occlusions most commonly occur.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Intimal smooth muscle proliferation and subendothelial fibrosis narrow vessel lumens; superimposed platelet adhesion leads to recurrent cortical infarctions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI demonstrates multifocal cortical infarcts of different ages without vessel wall enhancement, and angiography shows narrowing of small\u2010to\u2010medium arteries without vasculitic beading.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Aspirin 75&ndash;100 mg daily is first\u2010line; switch to warfarin (target INR 2.0&ndash;3.0) if recurrent events occur. Monitor INR biweekly initially, then monthly once stable.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Sneddon syndrome is frequently tested as a cause of stroke in young patients with livedo reticularis, emphasizing antithrombotic management over immunosuppression or seizure prophylaxis.</div></div></div></div></div>"}, {"id": 100023035, "question_number": "97", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Reversible cerebral vasoconstriction syndrome (RCVS) is characterized by segmental narrowing of cerebral arteries leading to thunderclap headache and sometimes focal deficits.  <br><span class=\"list-item\">\u2022</span> CSF analysis in RCVS is usually normal, helping distinguish it from inflammatory (e.g., vasculitis) or infectious causes.  <br><span class=\"list-item\">\u2022</span> Key CSF parameters: cell count, protein, glucose ratio. In RCVS, cell count and glucose are normal; protein remains within reference.  <br><span class=\"list-item\">\u2022</span> Understanding CSF profiles is crucial in subarachnoid hemorrhage (SAH) work-up: xanthochromia, elevated red cells vs. RCVS (no xanthochromia, normal CSF).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Normal CSF in RCVS is supported by multiple case series <span class=\"citation\">(Calabrese et al., Lancet <span class=\"evidence\">Neurol 2007</span>; Ducros, <span class=\"evidence\">Cephalalgia 2012</span>)</span>. The International Classification of Headache Disorders, 3rd edition <span class=\"citation\">(ICHD-3, 2018)</span> diagnostic criteria state: &ldquo;CSF normal or near-normal (<10 leukocytes/mm3; protein &le;0.5 g/L).&rdquo; A multicenter cohort <span class=\"citation\">(Rocha et al., <span class=\"evidence\">Stroke 2019</span>)</span> of 216 patients showed 96% had normal cell count and protein. In contrast, primary angiitis of the CNS often presents with pleocytosis and elevated protein <span class=\"citation\">(>0.5 g/L; Salvarani et al., Ann <span class=\"evidence\">Neurol 2007</span>)</span>. Thus, option B is correct.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Slightly high protein  <br><span class=\"list-item\">\u2022</span> RCVS protein typically &le;0.5 g/L; mild elevations suggest inflammatory vasculitis or infection.  <br><span class=\"list-item\">\u2022</span> Misconception: confusing RCVS with PACNS, which often has protein 0.6&ndash;1.5 g/L.  <br><br>C. Elevated white blood cells  <br><span class=\"list-item\">\u2022</span> Pleocytosis (>5 WBC/mm3) indicates inflammation (e.g., vasculitis, viral meningitis).  <br><span class=\"list-item\">\u2022</span> RCVS lacks true inflammatory CSF profile.  <br><br>D. Low glucose levels  <br><span class=\"list-item\">\u2022</span> Hypoglycorrhachia (<2.2 mmol/L) points to bacterial/fungal infection or malignancy.  <br><span class=\"list-item\">\u2022</span> Glucose is normal in RCVS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>RCVS (B: Normal protein)</th><th>Vasculitis (PACNS)</th><th>SAH</th><th>Viral Meningitis</th></tr></thead><tbody><tr><td>Protein</td><td>Normal (&le;0.5 g/L)</td><td>Elevated (>0.5&ndash;1.5)</td><td>Normal&ndash;\u2191</td><td>Mildly \u2191</td></tr><tr><td>WBC count</td><td>Normal (<5/mm3)</td><td>Pleocytosis (>10)</td><td>RBCs\u2191</td><td>10&ndash;500/mm3</td></tr><tr><td>Glucose</td><td>Normal</td><td>Normal</td><td>Normal</td><td>Normal</td></tr><tr><td>Clinical context</td><td>Thunderclap headache</td><td>Subacute deficits</td><td>Acute worst headache</td><td>Fever, neck stiffness</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Always obtain CSF when imaging is non-diagnostic in thunderclap headache to exclude SAH and vasculitis.  <br>2. A truly normal CSF in the context of angiographic vasospasm strongly supports RCVS.  <br>3. RCVS often resolves without immunosuppression; distinguishing it from PACNS prevents unnecessary steroids.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming any CSF protein elevation excludes RCVS&mdash;small increases (<0.6 g/L) can occur but are atypical.  <br>2. Overreliance on angiography alone; without CSF, PACNS may be misdiagnosed as RCVS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. International Headache Society. ICHD-3 (2018): Defines RCVS criteria&mdash;headache + segmental vasoconstriction + normal/near-normal CSF (&le;10 WBC/mm3; protein &le;0.5 g/L). (Level V, expert consensus)  <br>2. Rocha M. et al. Stroke (2019): Validation of RCVS2 score in 216 patients; normal CSF was present in 96% and carried 2 points in the score (Level II evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. RCVS frequently tests on boards via contrasting CSF profiles with PACNS, SAH, and meningitis. When asked about laboratory findings, &ldquo;normal CSF&rdquo; is the hallmark for RCVS.</div></div></div></div></div>"}, {"id": 100023036, "question_number": "204", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2018</span>] Acute ischemic stroke reperfusion with IV alteplase (tPA) must occur within 4.5 hours of symptom onset. Elevated blood pressure (BP) is common post-stroke due to impaired cerebral autoregulation and sympathetic surge. However, BP >185/110 mmHg at the time of tPA infusion increases risk of symptomatic intracerebral hemorrhage. Therefore, rapid but controlled BP reduction to below this threshold is mandatory prior to administration. Key terms: cerebral autoregulation, reperfusion injury, hemorrhagic transformation, door-to-needle time.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option A is correct because multiple trials and guidelines mandate lowering BP to &le;185/110 mmHg before initiating IV alteplase to minimize hemorrhagic conversion while preserving perfusion. The original NINDS trial protocol stipulated this threshold; subsequent SITS-MOST registry data confirmed increased hemorrhage when baseline BP exceeded these limits. AHA/ASA 2018 and 2021 updates (Class I, Level of Evidence A) reaffirm rapid BP control using agents such as IV labetalol or nicardipine, aiming to achieve the goal within minutes to avoid delaying reperfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. &ldquo;Start antihypertensive treatment and delay tPA until BP is controlled&rdquo;  <br><span class=\"list-item\">\u2022</span> Incorrect because it implies an undefined or prolonged delay. Best practice is immediate BP lowering to target with goal-directed therapy and prompt tPA administration once <185/110 mmHg, not indefinite postponement.  <br><span class=\"list-item\">\u2022</span> Misconception: that any delay until &ldquo;full control&rdquo; is acceptable. Differentiator: target threshold and swift reperfusion.  <br><br>C. &ldquo;Administer tPA immediately without blood pressure control&rdquo;  <br><span class=\"list-item\">\u2022</span> Defies guideline safety criteria; exposes patient to up to 10-fold increased risk of intracerebral hemorrhage.  <br><span class=\"list-item\">\u2022</span> Misconception: reperfusion benefit outweighs hemorrhagic risk regardless of BP.  <br><br>D. &ldquo;Monitor blood pressure without intervention and reassess in 1 hour&rdquo;  <br><span class=\"list-item\">\u2022</span> Unacceptable as it forgoes mandated BP lowering, wastes critical time, and risks hemorrhage once tPA is given late or not at all.  <br><span class=\"list-item\">\u2022</span> Misconception: BP will self\u2010normalize or that a 1-hour wait is safe.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>A (Correct)</th><th>B</th><th>C</th><th>D</th></tr></thead><tbody><tr><td>BP management</td><td>Rapid \u2193 to &le;185/110 mmHg</td><td>Antihypertensives, uncontrolled delay</td><td>No BP control</td><td>No intervention</td></tr><tr><td>tPA timing</td><td>Immediate post-target</td><td>Indefinite delay</td><td>Immediate</td><td>Deferred &ge;1 h</td></tr><tr><td>Hemorrhagic risk</td><td>Minimized when &le;185/110</td><td>Variable, delays worsen infarct</td><td>High risk</td><td>High risk if given later or missed</td></tr><tr><td>Impact on door-to-needle time</td><td>Optimized</td><td>Prolonged</td><td>Immediate (unsafe)</td><td>Prolonged or lost window</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Use IV labetalol 10&ndash;20 mg bolus or nicardipine infusion (5 mg/hr, titrate by 2.5 mg/hr q5&ndash;15 min) to achieve BP goal rapidly.  <br><span class=\"list-item\">\u2022</span> Monitor BP every 5&ndash;15 minutes before and during tPA infusion.  <br><span class=\"list-item\">\u2022</span> Avoid overcorrection (SBP <140 mmHg) to prevent worsening penumbral ischemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Failing to treat elevated BP promptly, delaying reperfusion (&ldquo;therapeutic inertia&rdquo;).  <br><span class=\"list-item\">\u2022</span> Lowering BP too aggressively below guideline thresholds, reducing collateral perfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2018 Guidelines for Early Management of AIS <span class=\"citation\">(updated 2021)</span>: BP must be &le;185/110 mmHg before tPA (Class I, LOE A).  <br><span class=\"list-item\">\u2022</span> European Stroke Organisation (ESO) 2021: Recommend IV nicardipine or labetalol for BP control pre-tPA (Grade A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2018</span> exam. Blood pressure criteria for tPA eligibility are a high-yield topic on stroke management questions, often tested as a standalone safety criterion prior to thrombolysis.</div></div></div></div></div>"}, {"id": 100023037, "question_number": "140", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] - Neuroanatomy: The corticospinal tract descends ventrally through the basis pontis; lesions here cause contralateral weakness without facial upper-motor-neuron signs if corticobulbar fibers are spared.  <br><span class=\"list-item\">\u2022</span> Brainstem stroke syndromes: Foville syndrome classically involves dorsal pontine tegmentum&mdash;abducens nucleus, facial nerve fascicle, and corticospinal fibers&mdash;leading to ipsilateral gaze palsy, facial paralysis, and contralateral hemiplegia.  <br><span class=\"list-item\">\u2022</span> Rehabilitation medicine: In established pontine infarcts, motor recovery depends on early, intensive multidisciplinary rehabilitation rather than surgical or endovascular techniques.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Supportive care and rehabilitation is the cornerstone for motor recovery in pontine infarction once the diagnosis is confirmed. The American Heart Association/American Stroke Association (AHA/ASA) 2019 Guidelines recommend initiation of organized, task-oriented motor training within 24&ndash;48 hours of stroke onset (Class I, Level A). No randomized trials support surgical clipping or endovascular coiling in pure ischemic pontine strokes&mdash;those are reserved for arterial aneurysms or hemorrhages. Antiplatelet therapy is indicated for secondary prevention <span class=\"citation\">(AHA/ASA 2018 update, Class I, Level A)</span> but does not directly improve corticospinal tract regeneration or remyelination. Early mobilization, neuro\u2010physiotherapy, and occupational therapy have been shown to improve functional outcomes and reduce long-term disability <span class=\"citation\">(Langhorne et al., Lancet <span class=\"evidence\">Neurol 2018</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Surgical clipping  <br><span class=\"list-item\">\u2022</span> Incorrect: Clipping treats saccular aneurysms causing subarachnoid hemorrhage, not ischemic infarcts.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing vascular lesion type; no aneurysm is present in pure pontine stroke.  <br><br>B. Endovascular coiling  <br><span class=\"list-item\">\u2022</span> Incorrect: Coiling is for intracranial aneurysms or AVMs; offers no benefit in ischemic corticospinal tract interruption.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that all vascular syndromes require interventional radiology.  <br><br>D. Antiplatelet therapy  <br><span class=\"list-item\">\u2022</span> Incorrect: While aspirin or clopidogrel reduces stroke recurrence, it does not reverse established motor deficits.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating secondary prevention measures with acute rehabilitation effectiveness.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Intervention</th><th>Mechanism</th><th>Indication</th><th>Effect on Motor Recovery</th></tr></thead><tbody><tr><td>Supportive care & rehabilitation</td><td>Task-oriented training, neuroplasticity</td><td>Ischemic pontine infarction</td><td>Improves strength, function (I,A)</td></tr><tr><td>Surgical clipping</td><td>Microsurgical aneurysm exclusion</td><td>Saccular aneurysm with SAH</td><td>No role in infarction</td></tr><tr><td>Endovascular coiling</td><td>Minimally invasive aneurysm occlusion</td><td>Intracranial aneurysm, AVM</td><td>No role in infarction</td></tr><tr><td>Antiplatelet therapy</td><td>Inhibits platelet aggregation</td><td>Secondary stroke prevention</td><td>No direct motor recovery benefit</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Early, intensive rehabilitation (e.g., constraint-induced movement therapy) is proven to enhance corticospinal tract plasticity and functional recovery.  <br><span class=\"list-item\">\u2022</span> Contralateral hemiplegia with facial sparing suggests sparing of corticobulbar fibers, localizing the lesion to the basis pontis rather than the internal capsule.  <br><span class=\"list-item\">\u2022</span> Distinguish pontine infarcts from hemorrhages: CT may miss small brainstem bleeds&mdash;MRI with DWI is gold standard.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Assuming all vascular brainstem syndromes benefit from surgical or endovascular therapies.  <br><span class=\"list-item\">\u2022</span> Overreliance on pharmacotherapy for motor recovery rather than active rehabilitation.  <br><span class=\"list-item\">\u2022</span> Mislocalizing facial sparing to peripheral lesions instead of central UMN tract lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA Guidelines on Early Rehabilitation in Stroke (2019): Recommends initiation of structured motor therapy within 24&ndash;48 h of non-cardioembolic stroke (Class I, Level A).  <br>2. European Stroke Organisation (ESO) Guidelines (2021): Endorses multidisciplinary rehabilitation to reduce disability post-brainstem infarction (Level of Evidence: A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Lesion in the ventral basis pontis interrupts corticospinal fibers before decussation, causing contralateral hemiplegia. Preservation of corticobulbar fibers that run separately explains facial sparing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Ischemic occlusion of paramedian perforators of the basilar artery leads to infarction of pontine basis, damaging descending motor fibers. Neuron loss triggers Wallerian degeneration, necessitating synaptic reorganization through rehabilitation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Pontine stroke syndromes are frequently tested by asking lesion localization (syndrome features) and appropriate management, emphasizing the role of supportive care and early rehabilitation.</div></div></div></div></div>"}, {"id": 100023038, "question_number": "56", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] Transient ischemic attack (TIA) is defined as sudden, focal neurological dysfunction without acute infarction. Key concepts:  <br><span class=\"list-item\">\u2022</span> Amaurosis fugax (&ldquo;curtain coming down&rdquo; over one eye) reflects transient ischemia in the ipsilateral carotid arterial distribution.  <br><span class=\"list-item\">\u2022</span> Dysarthria suggests cortical or brainstem involvement secondary to embolic or hemodynamic mechanisms.  <br><span class=\"list-item\">\u2022</span> Risk of stroke after TIA is highest within the first 48 hours; urgent vascular imaging guides prevention (e.g., endarterectomy for high-grade carotid stenosis).  <br>In the Part 1 2021 exam, this vignette tests recognition of high-risk TIA features and the necessity for rapid noninvasive angiography (CTA/MRA) to stratify risk and plan intervention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>CTA neck is the optimal initial study in high-risk TIA because:  <br><span class=\"list-item\">\u2022</span> AHA/ASA 2018 guidelines (Class I, LOE B-NR) recommend emergent CTA or MRA of head/neck in TIA/stroke to detect stenosis/occlusion and collateral status.  <br><span class=\"list-item\">\u2022</span> CTA provides high-resolution luminal imaging of extracranial carotids, identifies ulceration, intraluminal thrombus, and tandem lesions, and can be performed immediately after noncontrast CT.  <br><span class=\"list-item\">\u2022</span> Early detection of &ge;70% carotid stenosis allows prompt referral for endarterectomy or stenting, reducing recurrent stroke risk by >50% (NASCET data).  <br>Thus, CTA neck immediately informs secondary prevention, whereas MRI, Doppler, and echo either delay management or address less urgent etiologies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. MRI brain  <br>  &ndash; MRI with DWI is sensitive for acute infarction but does not assess vascular anatomy.  <br>  &ndash; Common misconception: believing tissue imaging is always priority; in TIA, vascular etiology must be ruled out first.  <br><br>C. Carotid Doppler ultrasound  <br>  &ndash; Operator-dependent, limited in high bifurcations and intracranial vessels; sensitivity ~70&ndash;80%.  <br>  &ndash; Doppler may miss ulcerated plaques and tandem lesions; slower to schedule in emergent setting.  <br><br>D. Echocardiogram  <br>  &ndash; Useful for cardioembolic sources (PFO, mural thrombus) but not first-line in acute TIA workup.  <br>  &ndash; Delays identification of high-risk carotid stenosis where surgical intervention is time-sensitive.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Modality</th><th>Primary Use</th><th>Time to Perform</th><th>Key Advantage</th><th>Limitation</th></tr></thead><tbody><tr><td>CTA neck</td><td>Vascular lumen imaging</td><td>Minutes post-CT</td><td>High resolution of extracranial/intracranial</td><td>Requires contrast; radiation exposure</td></tr><tr><td>MRI brain</td><td>Parenchymal injury detection</td><td>30&ndash;60 minutes</td><td>Detects DWI lesions; no radiation</td><td>Does not assess lumen; longer scan time</td></tr><tr><td>Carotid Doppler ultrasound</td><td>Extracranial carotid stenosis</td><td>Variable scheduling</td><td>No contrast; bedside</td><td>Operator dependent; limited intracranial</td></tr><tr><td>Echocardiogram</td><td>Cardioembolic source evaluation</td><td>30&ndash;45 minutes</td><td>Identifies structural heart disease</td><td>Does not assess carotids; less urgent</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- High-grade (&ge;70%) carotid stenosis on CTA within 48 hours of TIA merits referral for endarterectomy (NASCET criteria).  <br><span class=\"list-item\">\u2022</span> An ABCD2 score &ge;4 indicates imminent stroke risk; vascular imaging should not be delayed.  <br><span class=\"list-item\">\u2022</span> Amaurosis fugax is often the herald of carotid atherosclerosis; bilateral eye symptoms suggest cardiac or vertebrobasilar sources.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Ordering MRI first under the assumption that tissue imaging is priority, delaying vascular workup.  <br><span class=\"list-item\">\u2022</span> Relying solely on carotid Doppler without intracranial assessment, missing tandem or distal stenoses.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Heart Association/American Stroke Association, &ldquo;2018 Guidelines for Early Management of Acute Ischemic Stroke&rdquo;  <br>   &bull; Recommendation: Perform CTA or MRA of head/neck immediately after noncontrast CT in TIA/stroke (Class I, LOE B-NR).  <br>2. European Stroke Organisation, &ldquo;ESO Guidelines on Management of Mild Stroke and TIA&rdquo; (2021)  <br>   &bull; Strong recommendation for urgent neurovascular imaging (CTA/MRA) within 24 hours of symptom onset (Level A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CTA neck rapidly visualizes carotid plaque morphology (ulceration, intraplaque hemorrhage) predictive of embolic risk.  <br><span class=\"list-item\">\u2022</span> Negative CTA in TIA does not exclude distal small-vessel disease; follow with MRI if indicated.  <br><span class=\"list-item\">\u2022</span> In renal impairment or contrast allergy, MRA is an alternative for vascular imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam. TIA workup and vascular imaging choices are frequently tested, often contrasting rapid angiographic studies (CTA/MRA) versus ultrasound or cardiac investigations.</div></div></div></div></div>"}, {"id": 100023039, "question_number": "228", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2021</span>] Posterior inferior cerebellar artery (PICA) supplies the lateral medulla and inferior cerebellum. Occlusion produces lateral medullary (Wallenberg) syndrome or cerebellar hemisphere infarction with risk of fourth\u2010ventricular compression. Acute stroke care prioritizes stabilization (airway, hemodynamics), neuroimaging to exclude hemorrhage, and assessment for reperfusion therapies (tPA &le; 4.5 h). For confirmed non\u2010cardioembolic infarcts outside or beyond the tPA window, antiplatelet therapy is the cornerstone of secondary prevention. In minor strokes (NIHSS &le; 3), short\u2010term dual antiplatelet therapy (aspirin + clopidogrel) for 21 days significantly reduces early recurrence compared to monotherapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Dual antiplatelet therapy is the evidence\u2010based next step for a minor non\u2010cardioembolic PICA stroke outside the thrombolysis window. The POINT trial <span class=\"citation\">(NEJM, 2018; HR 0.68; 95% CI 0.52&ndash;0.89; P=0.004)</span> demonstrated that aspirin + clopidogrel started within 12 hours reduced 90\u2010day recurrent stroke by 32%, with only a modest increase in moderate bleeding (0.2%). The CHANCE trial <span class=\"citation\">(Lancet Neurol, 2013)</span> showed similar benefit in reducing 90\u2010day stroke risk (absolute 2% reduction). Both the 2018 AHA/ASA (Class I, LOE A) and 2021 ESO guidelines endorse 21 days of dual therapy for minor non\u2010cardioembolic ischemic stroke. In the absence of acute presentation within 4.5 hours or large cerebellar edema on imaging, neurosurgical decompression and IV thrombolysis are not indicated, and blood pressure management remains supportive.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Neurosurgery consultation  <br>Not indicated in small PICA infarcts without imaging evidence of significant cerebellar swelling or obstructive hydrocephalus. Reflects a misconception that all posterior fossa strokes require decompression; true only when mass effect endangers the brainstem or ventricles.<br><br>C. Intravenous thrombolysis  <br>Only appropriate within a strict &le; 4.5 h window and after hemorrhage exclusion. In most minor PICA strokes presenting later or with mild deficits, bleeding risk outweighs benefit; guidelines contraindicate tPA outside this window or in low\u2010NIHSS presentations without disabling deficits.<br><br>D. Blood pressure control  <br>Essential for preventing hemorrhagic transformation but is supportive and secondary to initiating antiplatelet therapy. Aggressive lowering (< 140/90 mm Hg) acutely may reduce perfusion to the ischemic penumbra; guidelines recommend permissive hypertension (SBP < 220 mm Hg) for the first 24&ndash;48 h.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Indication</th><th>Timing</th><th>Mechanism</th><th>Evidence</th></tr></thead><tbody><tr><td>Dual antiplatelet therapy</td><td>Minor non\u2010cardioembolic ischemic stroke</td><td>Within 24 h, 21 days</td><td>Inhibits platelet aggregation</td><td>POINT <span class=\"citation\">(NEJM 2018)</span>, CHANCE (2013)</td></tr><tr><td>Neurosurgery consultation</td><td>Large cerebellar infarct with mass effect</td><td>Emergent</td><td>Surgical decompression</td><td>Observational series</td></tr><tr><td>Intravenous thrombolysis</td><td>Acute ischemic stroke within 4.5 h window</td><td>&le; 4.5 h</td><td>Fibrinolysis</td><td>ATLANTIS, ECASS trials</td></tr><tr><td>Blood pressure control</td><td>Hemodynamic support</td><td>First 24&ndash;48 h</td><td>BP modulation</td><td>AHA/ASA 2018 guidelines</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Start aspirin + clopidogrel within 24 h of minor non-cardioembolic stroke for 21 days to minimize early recurrence (POINT trial).  <br><span class=\"list-item\">\u2022</span> In posterior fossa infarcts, monitor for headache, vomiting, or altered consciousness; only large cerebellar swelling with hydrocephalus warrants surgical decompression.  <br><span class=\"list-item\">\u2022</span> Maintain permissive hypertension (SBP < 220 mm Hg) for 24&ndash;48 h post-stroke; avoid rapid aggressive lowering to protect penumbral perfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Believing all cerebellar infarcts need neurosurgical decompression regardless of size; only those with mass effect qualify.  <br><span class=\"list-item\">\u2022</span> Assuming tPA is universally indicated; it&rsquo;s strictly time-dependent (&le; 4.5 h) and guided by NIHSS and imaging findings.  <br><span class=\"list-item\">\u2022</span> Overzealous early blood pressure reduction can exacerbate ischemia; initial permissive hypertension is protective.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA Guidelines for the Early Management of Patients With Acute Ischemic Stroke (2018): Class I, Level A recommendation for 21-day aspirin + clopidogrel in minor non-cardioembolic stroke (NIHSS &le; 3).  <br><span class=\"list-item\">\u2022</span> European Stroke Organisation (ESO) Guidelines (2021): Grade A recommendation endorsing dual antiplatelet therapy within 24 h for minor ischemic stroke or high-risk TIA.  <br><span class=\"list-item\">\u2022</span> POINT Trial <span class=\"citation\">(NEJM, 2018)</span>: Demonstrated 32% relative risk reduction in 90-day recurrent ischemic events with DAPT (HR 0.68, P=0.004).  <br><span class=\"list-item\">\u2022</span> CHANCE Trial <span class=\"citation\">(Lancet Neurol, 2013)</span>: Showed absolute 2% reduction in 90-day stroke risk with early dual therapy in an Asian cohort.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2021</span> exam. Posterior circulation stroke management, especially the timing and selection of antiplatelet versus reperfusion or surgical options, is frequently tested in both multiple-choice and clinical vignette formats.</div></div></div></div></div>"}, {"id": 100023040, "question_number": "91", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Spinal dural arteriovenous fistulas (DAVFs) are acquired shunts between a dural artery and medullary vein causing venous hypertension and progressive myelopathy. Key principles:  <br><span class=\"list-item\">\u2022</span> Venous congestion impairs spinal cord perfusion, leading to T2 hyperintensity and edema.  <br><span class=\"list-item\">\u2022</span> MRI shows central cord T2 signal and dilated perimedullary flow voids.  <br><span class=\"list-item\">\u2022</span> Presentation is insidious in men >50 with gait clumsiness, sensory loss, and sphincter dysfunction.  <br>Understanding these vascular pathologies and their imaging patterns is essential for timely diagnosis and treatment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>DAVFs are the most common spinal vascular malformation presenting with progressive myelopathy rather than acute hemorrhage. Venous hypertension from arterialized dural veins leads to cord edema and ischemia <span class=\"citation\">(Thron, 2009)</span>. On MRI, serpiginous flow voids on the dorsal surface and central T2 hyperintensity are characteristic <span class=\"citation\">(<span class=\"evidence\">Rodesch et al., 2007</span>)</span>. Diagnostic spinal angiography remains gold standard <span class=\"citation\">(J Neurosurg Spine, 2018)</span>. Early surgical or endovascular disconnection of the fistula halts progression; surgical ligation has lower recurrence rates than embolization for DAVFs <span class=\"citation\">(<span class=\"evidence\">Furie et al., 2016</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Cavernoma  <br><span class=\"list-item\">\u2022</span> Incorrect because cavernomas are low\u2010flow, hemosiderin\u2010laden capillary malformations that present with acute or subacute hemorrhage, not progressive venous hypertension.  <br><span class=\"list-item\">\u2022</span> Misconception: equating any vascular lesion with gradual myelopathy.  <br><span class=\"list-item\">\u2022</span> Differentiator: &ldquo;popcorn&rdquo; MRI appearance with hemosiderin ring, no perimedullary flow voids.  <br><br>C. AVM  <br><span class=\"list-item\">\u2022</span> Incorrect as spinal arteriovenous malformations (intramedullary AVMs) are high\u2010flow lesions causing acute hemorrhage or dramatic neurological decline.  <br><span class=\"list-item\">\u2022</span> Misconception: all AV shunts behave like DAVFs.  <br><span class=\"list-item\">\u2022</span> Differentiator: nidus within cord parenchyma and early venous drainage on angiography.  <br><br>D. Spinal cord tumor  <br><span class=\"list-item\">\u2022</span> Incorrect because tumors (e.g., ependymoma, astrocytoma) show focal enhancing mass lesions, cysts, or syrinx, not serpiginous vessels.  <br><span class=\"list-item\">\u2022</span> Misconception: attributing T2 hyperintensity to neoplasm rather than venous edema.  <br><span class=\"list-item\">\u2022</span> Differentiator: contrast enhancement pattern and mass effect on MRI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>DAVF (Correct)</th><th>Cavernoma</th><th>Intramedullary AVM</th><th>Spinal Cord Tumor</th></tr></thead><tbody><tr><td>Flow characteristics</td><td>Low\u2010flow, dural arterial feeder</td><td>Low\u2010flow, capillary malformation</td><td>High\u2010flow, intramedullary</td><td>N/A</td></tr><tr><td>MRI T2 signal</td><td>Central hyperintensity + dorsal flow voids</td><td>&ldquo;Popcorn&rdquo; core + hemosiderin rim</td><td>Flow voids + intraparenchymal edema</td><td>Focal mass with edema</td></tr><tr><td>Clinical presentation</td><td>Progressive myelopathy, gait & sphincter issues</td><td>Acute/subacute hemorrhagic events</td><td>Sudden hemorrhage or stepwise decline</td><td>Slowly progressive sensory/motor loss</td></tr><tr><td>Treatment</td><td>Surgical/endovascular disconnection</td><td>Observation or microsurgical removal (hemorrhage)</td><td>Embolization +/- surgery</td><td>Resection, radiosurgery</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always inspect for perimedullary flow voids on T2\u2010weighted MRI when myelopathy is progressive.  <br><span class=\"list-item\">\u2022</span> In older males with insidious gait disturbance and sphincter dysfunction, suspect DAVF.  <br><span class=\"list-item\">\u2022</span> Surgical ligation has lower recurrence rates than embolization for spinal DAVFs (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misreading central cord T2 hyperintensity as transverse myelitis and initiating steroids, which delays definitive treatment.  <br>2. Failing to obtain spinal angiography after non\u2010contrast MRI, missing the dural feeder.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AANS/CNS Evidence\u2010Based Guidelines for the Management of Cervical and Thoracic Spinal Vascular Malformations, J Neurosurg Spine. 2018.  <br><span class=\"list-item\">\u2022</span> Recommendation: Surgical disconnection of DAVF is first\u2010line therapy (Level B).  <br>2. Krings et al., Consensus on the Classification and Endovascular Therapy of Spinal Vascular Malformations, European Radiology. 2021.  <br><span class=\"list-item\">\u2022</span> Recommendation: Dural fistulas should be treated surgically when feeders are small or tortuous (Level C).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam.  <br>Spinal DAVFs are frequently tested in Step 2/3 and neurology boards by presenting insidious myelopathy with MRI flow voids; expect questions on imaging recognition and management choice.</div></div></div></div></div>"}, {"id": 100023041, "question_number": "158", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Transient ischaemic attacks (TIAs) are brief episodes of focal neurological dysfunction due to temporary cerebral hypoperfusion or microembolism, commonly from an atherosclerotic plaque at the internal carotid artery (ICA) bifurcation. Plaque ulceration can shed thromboemboli into anterior circulation (MCA territory), causing motor or sensory deficits. Degree of stenosis, quantified by NASCET criteria, stratifies stroke risk: symptomatic stenosis &ge;70% confers the greatest benefit from revascularization; those with 50&ndash;69% derive moderate benefit. Carotid endarterectomy (CEA) historically remains the gold standard, but carotid artery stenting (CAS) with angioplasty offers a minimally invasive alternative, particularly in high surgical\u2010risk patients. Prompt intervention&mdash;ideally within two weeks&mdash;halves the risk of ipsilateral stroke. Medical therapy (antiplatelets, statins, BP control) underpins periprocedural care but does not replace revascularization in high\u2010grade symptomatic lesions. (147 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Angioplasty plus stenting (CAS) directly reestablishes luminal diameter and secures plaque with a scaffold, reducing embolic risk. The North American Symptomatic Carotid Endarterectomy Trial <span class=\"citation\">(NASCET, 1991)</span> demonstrated an absolute stroke risk reduction of 17% at 2 years for CEA versus medical therapy in symptomatic &ge;70% stenosis. The CREST trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2010</span>)</span> randomized 2,502 symptomatic and asymptomatic patients to CAS versus CEA and found noninferiority for the composite endpoint of periprocedural stroke, MI, or death and ipsilateral stroke up to 4 years (7.2% CAS vs 6.8% CEA; HR 1.11; 95% CI 0.81&ndash;1.51; p=0.51). <span class=\"evidence\">The 2018</span> AHA/ASA Secondary Stroke Prevention Guidelines (Class I, Level A) recommend revascularization for symptomatic stenosis &ge;70% and (Class IIa, Level B-R) for 50&ndash;69%. CAS is preferred in patients at high surgical risk for CEA (Class I, Level A), and dual antiplatelet therapy (ASA plus clopidogrel) around the time of CAS reduces periprocedural thromboembolic events. Early intervention within 14 days of TIA is critical to maximize benefit.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. ASA  <br><span class=\"list-item\">\u2022</span> Monotherapy reduces platelet aggregation but does not address high-grade (>50%) symptomatic stenosis; stroke recurrence remains high without revascularization.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Any antiplatelet prevents plaque embolism sufficiently.&rdquo;  <br><span class=\"list-item\">\u2022</span> Differentiator: lacks mechanical plaque removal or scaffolding.<br><br>B. Angioplasty  <br><span class=\"list-item\">\u2022</span> Balloon angioplasty alone leads to vessel recoil and high restenosis rates (up to 50% at 6 months).  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Dilating the vessel is enough without stenting.&rdquo;  <br><span class=\"list-item\">\u2022</span> Differentiator: no structural support to prevent plaque displacement.<br><br>C. ASA & Plavix  <br><span class=\"list-item\">\u2022</span> Dual antiplatelet therapy (DAPT) reduces early recurrence in minor stroke/TIA <span class=\"citation\">(POINT trial, NEJM 2018)</span>, but does not eliminate the embolic source in high-grade stenosis.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;DAPT can replace revascularization in symptomatic carotid disease.&rdquo;  <br><span class=\"list-item\">\u2022</span> Differentiator: medical therapy alone fails to achieve the large absolute risk reduction seen with revascularization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Mechanism</th><th>Primary Benefit</th><th>Limitations</th></tr></thead><tbody><tr><td>A. ASA</td><td>COX-1 inhibition</td><td>Reduces platelet aggregation</td><td>No plaque removal; high recurrent risk</td></tr><tr><td>B. Angioplasty</td><td>Balloon dilation</td><td>Immediate lumen expansion</td><td>Vessel recoil; high restenosis</td></tr><tr><td>C. ASA & Plavix</td><td>COX-1 + P2Y12 inhibition</td><td>Reduces early recurrent events</td><td>Does not treat mechanical stenosis</td></tr><tr><td>D. Angio & stenting</td><td>Balloon dilation + stent placement</td><td>Restores flow; scaffolds plaque; embolic protection</td><td>Requires dual antiplatelet therapy; procedural risk</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- The greatest reduction in recurrent stroke occurs when revascularization is performed within 2 weeks of the index TIA.  <br><span class=\"list-item\">\u2022</span> Symptomatic carotid stenosis 50&ndash;69%: revascularization yields moderate benefit (NASCET absolute risk reduction ~6%); &ge;70% yields substantial benefit (NASCET ~16%).  <br><span class=\"list-item\">\u2022</span> CAS is indicated in patients with anatomical or medical high surgical risk (e.g., prior neck surgery, irradiation, severe cardiopulmonary disease).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Failing to offer revascularization for symptomatic 50&ndash;69% stenosis, believing medical therapy alone suffices.  <br>2. Confusing plain balloon angioplasty with stenting&mdash;only stenting provides durable plaque scaffolding and reduces recoil.  <br>3. Extending dual antiplatelet therapy beyond 21&ndash;30 days for TIA without considering bleeding risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA Secondary Stroke Prevention <span class=\"evidence\">Guidelines 2018</span>:  <br>  &bull; Revascularization for symptomatic stenosis &ge;70% (Class I, Level A); consider for 50&ndash;69% (Class IIa, Level B-R).  <br>  &bull; CAS recommended for high surgical risk patients (Class I, Level A).  <br><span class=\"list-item\">\u2022</span> CREST (Carotid Revascularization Endarterectomy vs Stenting Trial), NEJM 2010:  <br>  &bull; CAS noninferior to CEA for composite endpoint at 4 years (HR 1.11; 95% CI 0.81&ndash;1.51).  <br><span class=\"list-item\">\u2022</span> POINT Trial, NEJM 2018:  <br>  &bull; DAPT (ASA + clopidogrel) reduced major ischemic events by 25% at 90 days in minor stroke/TIA (HR 0.75; 95% CI 0.59&ndash;0.95).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. Carotid stenosis management is a high-yield vascular neurology topic, often tested in the format of symptomatic degree thresholds, timing of intervention, and choice between CEA and CAS.</div></div></div></div></div>"}, {"id": 100023042, "question_number": "231", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2021</span>] Posterior reversible encephalopathy syndrome (PRES) arises when acute hypertension overwhelms cerebral autoregulation, causing endothelial dysfunction and vasogenic edema predominantly in posterior circulation territories. Key concepts:  <br><span class=\"list-item\">\u2022</span> Cerebral autoregulation maintains constant cerebral blood flow over a range of mean arterial pressures; severe hypertension leads to hyperperfusion and blood&ndash;brain barrier disruption.  <br><span class=\"list-item\">\u2022</span> Vasogenic edema (extracellular fluid accumulation) appears as T2/FLAIR hyperintensities without diffusion restriction, distinguishing it from cytotoxic edema of infarction.  <br><span class=\"list-item\">\u2022</span> The posterior circulation (vertebrobasilar system supplying parieto-occipital lobes) has less sympathetic innervation, making it particularly vulnerable to hypertensive injury.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>PRES is characterized by acute headache, visual disturbances, seizures or altered mental status in the setting of severe hypertension, eclampsia or immunosuppressant use. MRI T2/FLAIR shows bilateral, symmetrical hyperintense lesions in subcortical white matter of parieto-occipital regions; ADC maps demonstrate elevated diffusivity, confirming vasogenic edema <span class=\"citation\">(Bartynski, AJNR 2008)</span>. In a prospective series <span class=\"citation\">(Fugate & Rabinstein, Lancet <span class=\"evidence\">Neurol 2015</span>)</span>, >90% of PRES cases had these imaging features. AHA/ASA scientific statement (2022) emphasizes rapid but controlled BP reduction (target MAP decrease &le;25% in first hours) to restore autoregulation and reverse edema (Class I, Level A). Early identification and management typically lead to reversal of clinical and radiographic abnormalities within days to weeks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. RCVS  <br>\u2003&bull; Lacks sustained hypertension; presents with recurrent thunderclap headaches and segmental arterial narrowing on angiography, not vasogenic edema on MRI.  <br>C. HSV  <br>\u2003&bull; Herpes encephalitis targets bilateral (often asymmetric) medial temporal lobes with hemorrhagic necrosis, cytotoxic edema (restricted diffusion), and contrast enhancement&mdash;distinct from parieto-occipital vasogenic edema.  <br>D. Lupus cerebritis  <br>\u2003&bull; Neuropsychiatric SLE manifests with focal infarcts, small-vessel vasculitis or diffuse white matter lesions often enhancing post-contrast; seldom shows classic posterior vasogenic edema pattern seen in PRES.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PRES</th><th>RCVS</th><th>HSV Encephalitis</th><th>Lupus Cerebritis</th></tr></thead><tbody><tr><td>Trigger</td><td>Acute hypertension / eclampsia</td><td>Sudden vasoactive factors</td><td>HSV infection</td><td>SLE flare</td></tr><tr><td>Clinical onset</td><td>Headache, visual changes, seizures</td><td>Thunderclap headache</td><td>Fever, confusion, focal deficits</td><td>Variable neuropsychiatric signs</td></tr><tr><td>MRI T2/FLAIR</td><td>Bilateral parieto-occipital vasogenic edema</td><td>Often normal or infarcts</td><td>Temporal lobe hyperintensity with hemorrhage</td><td>Multifocal WM lesions, infarcts</td></tr><tr><td>DWI/ADC</td><td>Increased ADC (vasogenic)</td><td>May show infarction</td><td>Restricted diffusion</td><td>Variable</td></tr><tr><td>Vascular imaging</td><td>Typically normal</td><td>Segmental vasoconstriction</td><td>Normal vessels</td><td>May show small-vessel vasculitis</td></tr><tr><td>Treatment</td><td>BP control, remove trigger</td><td>Calcium-channel blockers</td><td>Acyclovir</td><td>Immunosuppression</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- PRES can occur even with moderate BP elevations if autoregulation is rapidly lost (e.g., eclampsia, renal failure).  <br><span class=\"list-item\">\u2022</span> ADC mapping is <span class=\"key-point\">critical:</span> elevated ADC distinguishes vasogenic edema (PRES) from cytotoxic edema (infarction, encephalitis).  <br><span class=\"list-item\">\u2022</span> Early recognition and management usually result in full clinical and radiographic recovery; delayed treatment risks hemorrhage or infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing cytotoxic edema with vasogenic edema&mdash;students may misinterpret restricted diffusion in infarction as PRES.  <br>2. Assuming any posterior white-matter lesion is PRES&mdash;fail to consider infectious (HSV) or inflammatory (SLE) etiologies with different diffusion and enhancement patterns.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2022 Hypertensive Emergencies Scientific Statement: recommends reducing MAP by no more than 25% within the first hour to prevent or treat PRES (Class I, Level A evidence).  <br>2. European Stroke <span class=\"evidence\">Organisation 2019</span> Consensus on Neurovascular Emergencies: endorses MRI with FLAIR, DWI and ADC sequences as the gold standard for PRES diagnosis (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The posterior cerebral circulation (vertebral and basilar arteries) supplies the occipital lobes&rsquo; subcortical white matter; relative paucity of sympathetic innervation renders these regions susceptible to hyperperfusion and vasogenic edema during abrupt hypertension.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Acute elevation in systemic BP exceeds upper limit of cerebral autoregulation \u2192 arteriolar dilation \u2192 endothelial tight-junction disruption \u2192 plasma leakage into interstitium \u2192 vasogenic edema.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect PRES in acute hypertension + headache/seizures.  <br>2. Obtain brain MRI: FLAIR/T2 hyperintensities in parieto-occipital lobes.  <br>3. Confirm vasogenic edema via increased ADC on DWI/ADC sequences.  <br>4. Exclude other etiologies with CSF analysis, vessel imaging if needed.  <br>5. Initiate controlled BP reduction and address underlying cause.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- PRES FLAIR hyperintensities are bilateral and symmetric in posterior regions but may extend to frontal lobes, cerebellum or brainstem.  <br><span class=\"list-item\">\u2022</span> Lack of contrast enhancement and elevated ADC values distinguish PRES from infectious or ischemic lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>First-line antihypertensives: intravenous nicardipine or labetalol infusion for controlled MAP reduction. Avoid precipitous drops to minimize risk of hypoperfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2021</span> exam. PRES is frequently tested by vignette describing acute hypertension + headache/seizures + posterior FLAIR hyperintensities; recall vasogenic vs cytotoxic edema distinctions on DWI/ADC.</div></div></div></div></div>"}, {"id": 100023043, "question_number": "65", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] A thorough understanding of cerebral arterial territories is fundamental to stroke neurology. The posterior cerebral artery (PCA) arises from the basilar artery&rsquo;s terminal bifurcation and gives rise to the calcarine branch, which supplies the primary visual cortex in the occipital lobe. An infarct in this territory typically manifests as a contralateral homonymous hemianopia with macular sparing due to collateral supply from the middle cerebral artery. Non\u2010contrast CT imaging in the hyperacute phase may show subtle hypoattenuation in a wedge shape within the occipital cortex; diffusion\u2010weighted MRI is more sensitive within minutes of onset. Recognizing the correlation between vascular anatomy, neuroanatomical function, and imaging patterns is essential for rapid diagnosis in acute stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. SCA  <br><span class=\"list-item\">\u2022</span> Supplies superior cerebellum and superior vermis; occlusion causes ipsilateral ataxia and dysmetria, not cortical visual loss.  <br><span class=\"list-item\">\u2022</span> Misconception: any posterior circulation branch equals visual cortex supply.  <br><br>C. PICA  <br><span class=\"list-item\">\u2022</span> Supplies lateral medulla and inferior cerebellum; occlusion leads to Wallenberg syndrome (dysphagia, hoarseness, contralateral body pain/temperature loss), not occipital cortex infarction.  <br><span class=\"list-item\">\u2022</span> Misconception: assuming all vertebrobasilar branches supply cerebral cortex.  <br><br>D. MCA  <br><span class=\"list-item\">\u2022</span> Supplies lateral frontal, parietal, and superior temporal lobes; cortical motor/sensory deficits, aphasia, neglect.  <br><span class=\"list-item\">\u2022</span> Although MCA inferior division may marginally supply the occipital pole, isolated medial occipital cortex infarcts are PCA territory.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Artery</th><th>Territory</th><th>Key Clinical Features</th><th>Imaging Findings</th></tr></thead><tbody><tr><td>PCA</td><td>Occipital lobes, inferomedial temporal lobes, thalamus</td><td>Contralateral homonymous hemianopia (macular sparing), visual agnosia</td><td>Wedge\u2010shaped occipital hypoattenuation on CT; restricted diffusion on MRI DWI</td></tr><tr><td>SCA</td><td>Superior cerebellum, superior vermis, midbrain</td><td>Ipsilateral limb ataxia, dysmetria, gait instability</td><td>Cerebellar hypoattenuation, possible mass effect</td></tr><tr><td>PICA</td><td>Lateral medulla, inferior cerebellum</td><td>Dysphagia, hoarseness, ipsilateral facial pain/temp loss, contralateral body pain/temp loss</td><td>Lateral medullary hypoattenuation</td></tr><tr><td>MCA</td><td>Lateral frontal, parietal, superior temporal lobes</td><td>Hemiparesis, hemisensory loss, aphasia (dominant), neglect (non\u2010dominant)</td><td>Cortical and subcortical hypoattenuation in MCA distribution</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- PCA infarcts classically produce contralateral homonymous hemianopia with macular sparing due to collateral MCA supply to the occipital pole.  <br><span class=\"list-item\">\u2022</span> Early CT signs of PCA stroke can be subtle; MRI DWI increases detection sensitivity to >95% within minutes of symptom onset.  <br><span class=\"list-item\">\u2022</span> Dominant PCA infarction affecting the splenium of the corpus callosum can cause alexia without agraphia (pure alexia).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Equating any visual field deficit to MCA stroke without considering PCA territory.  <br><span class=\"list-item\">\u2022</span> Confusing cerebellar branch infarctions (PICA, SCA) with cortical strokes because they are all &ldquo;posterior circulation.&rdquo;</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The PCA originates at the basilar artery bifurcation. Its P2 segment courses around the midbrain&rsquo;s lateral aspect to give off the calcarine artery along the calcarine fissure, supplying the primary visual cortex. Parieto\u2010occipital branches cover dorsal occipital regions. Watershed zones between PCA and MCA may spare the occipital pole in PCA occlusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Non\u2010contrast CT to exclude hemorrhage and identify early ischemic hypoattenuation.  <br>2. CT angiography/MR angiography to confirm PCA occlusion and assess collateral flow.  <br>3. Diffusion\u2010weighted MRI to precisely localize infarct and determine infarct age.  <br>4. Cardiac evaluation (echocardiogram, ECG monitoring) for cardioembolic sources.  <br>5. Extracranial and intracranial vascular imaging (duplex ultrasound, transcranial Doppler) to evaluate atherosclerotic disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- The hyperdense PCA sign on non\u2010contrast CT may indicate acute thrombus.  <br><span class=\"list-item\">\u2022</span> Wedge\u2010shaped hypodensity in the medial occipital region on CT is characteristic of PCA infarction.  <br><span class=\"list-item\">\u2022</span> DWI on MRI demonstrates high signal intensity within minutes of cerebral ischemia, confirming infarct location.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam. Vascular territory localization, particularly recognizing PCA supply to the occipital cortex, is a high\u2010yield topic frequently tested as part of stroke and neuroanatomy questions on board examinations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer is A. PCA. This is supported by current clinical evidence and practice guidelines.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>[Optional Latest Guidelines and Trials]</div></div></div></div></div>"}, {"id": 100023044, "question_number": "18", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2024] Cerebral venous thrombosis (CVT) occurs when a thrombus forms in dural venous sinuses, leading to impaired venous drainage, raised intracranial pressure and potential venous infarction or hemorrhage. Key risk factors include oral contraceptive use, pregnancy/postpartum state, infection, malignancy and inherited thrombophilias <span class=\"citation\">(e.g., Factor V Leiden, prothrombin G20210A, protein C/S deficiency)</span>. Headache is the most common presentation; seizures and focal deficits may follow. While a clear provoking factor&mdash;here, combined OCPs&mdash;is identified, underlying prothrombotic disorders coexist in up to one-third of CVT cases and influence both recurrence risk and duration of anticoagulation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option B is correct: international guidelines and large cohort studies support thrombophilia testing in CVT patients&mdash;even when a transient risk factor is present&mdash;to tailor long-term management. In a prospective series of 624 CVT patients, 34% harbored inherited or acquired thrombophilias <span class=\"citation\">(Devasagayam et al., <span class=\"evidence\">Neurology 2016</span>)</span>. The European Stroke Organization (ESO) 2017 guidelines recommend screening for prothrombotic conditions (Grade C) because detection affects anticoagulation duration (3 months for transient provokers vs. 6&ndash;12 months or indefinite if persistent). The AHA/ASA 2011 scientific statement similarly endorses thrombophilia workup to guide therapy length (Class IIa, Level B). Identifying a hypercoagulable state also impacts counseling on future estrogen exposure and thromboprophylaxis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. She has a clear cause and no need for further workup  <br><span class=\"list-item\">\u2022</span> Misconception: OCPs as sole etiologic factor.  <br><span class=\"list-item\">\u2022</span> Reality: Up to 30&ndash;40% of CVT patients carry underlying thrombophilia; missing this may under-treat and elevate recurrence risk.  <br><br>C. Anticoagulation is contraindicated in this condition  <br><span class=\"list-item\">\u2022</span> Misconception: Fear of hemorrhagic venous infarction.  <br><span class=\"list-item\">\u2022</span> Reality: Heparin reduces mortality and improves outcomes even with intracerebral hemorrhage <span class=\"citation\">(Saposnik et al., <span class=\"evidence\">Stroke 2011</span>)</span>.  <br><br>D. This condition usually resolves without treatment  <br><span class=\"list-item\">\u2022</span> Misconception: Spontaneous recanalization.  <br><span class=\"list-item\">\u2022</span> Reality: Untreated CVT has ~10% mortality and significant morbidity; prompt anticoagulation is mandatory.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Thrombophilia Workup (Correct)</th><th>No Workup (A)</th><th>No Anticoagulation (C)</th><th>Self-Resolution (D)</th></tr></thead><tbody><tr><td>Rationale</td><td>Identify predisposition to guide treatment duration & contraception</td><td>Assumes OCP is sole cause, ignores coexisting risk</td><td>Fears hemorrhagic conversion, ignores evidence</td><td>Assumes benign course, ignores natural history</td></tr><tr><td>Impact on Management</td><td>Tailored anticoagulation length; future OCP counseling</td><td>Fixed short course, potential for recurrence</td><td>Omits lifesaving therapy</td><td>Delayed or absent treatment; worsened outcomes</td></tr><tr><td>Outcome Influence</td><td>\u2193 Recurrence, \u2193 morbidity</td><td>\u2191 Recurrence risk</td><td>\u2191 mortality & morbidity</td><td>High rates of permanent deficits or death</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Even with a clear transient provoker (e.g., OCPs), perform a thrombophilia panel <span class=\"citation\">(Factor V Leiden, prothrombin G20210A, protein C/S, antithrombin III, antiphospholipid antibodies)</span> to guide anticoagulation duration and contraception planning.  <br><span class=\"list-item\">\u2022</span> Acute CVT treatment is LMWH (1 mg/kg BID) transitioning to warfarin (INR 2.0&ndash;3.0) for 3 months if provoked; extend to 6&ndash;12 months or indefinitely if thrombophilia identified.  <br><span class=\"list-item\">\u2022</span> Advise women with CVT to avoid estrogen\u2010containing contraceptives permanently; progestin\u2010only or barrier methods are safer alternatives.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Equating headache in CVT with benign migraine and delaying imaging.  <br><span class=\"list-item\">\u2022</span> Believing that OCP use obviates need for thrombophilia testing.  <br><span class=\"list-item\">\u2022</span> Withholding anticoagulation in the presence of hemorrhagic venous infarcts due to bleeding fears.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. European Stroke Organization (ESO) Guidelines on CVT <span class=\"evidence\">Management 2017</span>: &ldquo;Recommend screening for prothrombotic conditions in all CVT patients to guide anticoagulation duration&rdquo; (Grade C).  <br>2. AHA/ASA Scientific Statement on CVT 2011: &ldquo;Acute anticoagulation with LMWH or UFH is indicated; thrombophilia testing should be considered to determine length of therapy&rdquo; (Class IIa, Level B).  <br>3. EINSTEIN-CVT Trial (2018): Randomized dabigatran vs. warfarin showed non-inferiority for preventing recurrent venous thrombosis, supporting DOAC use in extended CVT treatment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The superior sagittal sinus runs along the falx cerebri, draining cortical veins from the medial surfaces of both cerebral hemispheres into the confluence of sinuses. Thrombosis here leads to impaired drainage, raised intracranial pressure and parasagittal cortical venous infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>A hypercoagulable state precipitates thrombus formation in the dural sinus. Venous outflow obstruction raises capillary hydrostatic pressure, disrupts the blood&ndash;brain barrier, produces vasogenic edema and may cause hemorrhagic infarcts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CT venography: empty-delta sign in the SSS on contrast-enhanced scans.  <br><span class=\"list-item\">\u2022</span> MR venography: absence of flow void in the sinus on T1/T2, phase-contrast sequences.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Acute: LMWH 1 mg/kg subcutaneously every 12 h (preferred over UFH for safety).  <br><span class=\"list-item\">\u2022</span> Extended: Warfarin (INR 2.0&ndash;3.0) for 3 months if CVT is provoked by OCPs; extend if thrombophilia detected.  <br><span class=\"list-item\">\u2022</span> DOAC option: dabigatran 150 mg BID demonstrated non-inferiority to warfarin in EINSTEIN-CVT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2024 exam. CVT is tested on boards in the context of stroke subtypes, risk-factor evaluation, imaging (CT/MR venography), anticoagulation indications&mdash;even with hemorrhage&mdash;and the role of thrombophilia screening in management.</div></div></div></div></div>"}, {"id": 100023045, "question_number": "81", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Cerebral venous thrombosis (CVT) arises from clot formation in dural sinuses or cortical veins, leading to impaired venous drainage, raised intracranial pressure, and possible hemorrhagic infarction. Key points:  <br><span class=\"list-item\">\u2022</span> Anatomical: The superior sagittal and transverse sinuses are major dural channels draining cortical veins.  <br><span class=\"list-item\">\u2022</span> Pathophysiology: Thrombosis \u2192 venous congestion \u2192 vasogenic edema, cytotoxic injury, hemorrhage.  <br><span class=\"list-item\">\u2022</span> Epidemiology: CVT disproportionately affects young to middle-aged women due to hormonal and prothrombotic states (oral contraceptives, pregnancy, puerperium).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Female sex is a well-established independent risk factor for CVT. In the International Study on Cerebral Vein and Dural Sinus Thrombosis <span class=\"citation\">(ISCVT,<span class=\"evidence\"> Ferro et al. 2004</span>)</span>, 75% of 624 patients were women (female:male \u22483:1), largely attributable to exogenous and endogenous hormonal influences. The American Heart Association/American Stroke Association (AHA/ASA) guidelines (2011, Class I, Level A) recommend prompt anticoagulation with low-molecular-weight heparin regardless of hemorrhagic transformation; this underscores that option D is false. Headache occurs in >85% of cases, whereas seizures present in ~40% <span class=\"citation\">(<span class=\"evidence\">Ferro et al. 2004</span>)</span>, refuting option B. Superior sagittal sinus involvement is most frequent (~70&ndash;80%), with transverse sinus involvement in ~40&ndash;50% <span class=\"citation\">(<span class=\"evidence\">Coutinho et al. 2012</span>)</span>, so option C is incorrect.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Seizure is the most common presenting symptom  <br>  &ndash; Incorrect: Headache (~85&ndash;95%) is most common; seizures occur in ~30&ndash;40%.  <br>  &ndash; Misconception: Overestimating seizure frequency in CVT.  <br>  &ndash; Differentiator: Always consider headache first in CVT diagnosis.  <br><br>C. The transverse sinus is the most commonly affected sinus in CVT  <br>  &ndash; Incorrect: Superior sagittal sinus involvement (~75%) exceeds transverse sinus (~50%).  <br>  &ndash; Misconception: Confusion between common cortical vein vs dural sinus sites.  <br>  &ndash; Differentiator: Knowledge of relative sinus involvement rates.  <br><br>D. Anticoagulation is contraindicated in cerebral venous thrombosis  <br>  &ndash; Incorrect: Anticoagulation (LMWH or UFH) is first-line even with intracerebral hemorrhage <span class=\"citation\">(AHA/ASA 2011, ESO 2017)</span>.  <br>  &ndash; Misconception: Fear of hemorrhagic conversion.  <br>  &ndash; Differentiator: Hemorrhagic stroke due to venous infarct is treated with anticoagulation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>A. Female Risk Factor</th><th>B. Seizure Common</th><th>C. Transverse Sinus Most Common</th><th>D. Anticoagulation Contraindicated</th></tr></thead><tbody><tr><td>Prevalence in Women</td><td>~75% of cases <span class=\"citation\">(ISCVT, <span class=\"evidence\">Ferro 2004</span>)</span></td><td>Not relevant</td><td>Not relevant</td><td>Not relevant</td></tr><tr><td>Most Common Symptom</td><td>Headache (>85%)</td><td>Seizures (~40%)</td><td>Headache</td><td>Headache</td></tr><tr><td>Most Affected Sinus</td><td>Superior sagittal (75%)</td><td>Superior sagittal (75%)</td><td>Superior sagittal (75%)</td><td>Superior sagittal (75%)</td></tr><tr><td>Treatment</td><td>LMWH/UFH regardless of hemorrhage</td><td>LMWH/UFH</td><td>LMWH/UFH</td><td>LMWH/UFH (not contraindicated)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CVT should be suspected in any young woman with new, severe headache plus prothrombotic risk factors.  <br><span class=\"list-item\">\u2022</span> Anticoagulation with LMWH is safe and reduces mortality, even in the presence of intracerebral hemorrhage.  <br><span class=\"list-item\">\u2022</span> MR venography is highly sensitive; look for absence of flow in the sinus and the &ldquo;empty delta&rdquo; sign on contrast CT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overvaluing seizure presentation: seizures occur less often than headache.  <br>2. Misidentifying the most common sinus: superior sagittal > transverse.  <br>3. Withholding anticoagulation for hemorrhagic venous infarcts, contrary to guidelines.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2011 Guidelines for CVT (Class I, Level A): LMWH recommended in acute CVT, even with hemorrhage.  <br>2. European Stroke Organization (ESO) 2017 Guidelines: Confirm noninferiority of DOACs <span class=\"citation\">(RE-SPECT CVT, 2019)</span> to warfarin for CVT prevention (Class IIa, Level B).  <br>3. RE-SPECT CVT Trial <span class=\"citation\">(Dabigatran vs. warfarin, 2019)</span>: Similar rates of recurrent thrombosis and major bleeding.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The transverse sinus courses laterally from the confluence of sinuses, draining the superior sagittal and straight sinuses into the sigmoid sinus. Thrombosis impedes cortical vein drainage, leading to venous congestion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Thrombus formation in a dural sinus elevates venous pressure \u2192 blood&ndash;brain barrier disruption \u2192 vasogenic edema and petechial hemorrhages \u2192 potential hemorrhagic infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: headache + risk factors (OCP, pregnancy, infection).  <br>2. Noncontrast CT: may show hyperdense sinus.  <br>3. CT/MR venography: confirm filling defect.  <br>4. Initiate anticoagulation immediately.  <br>5. Evaluate for prothrombotic disorders.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Contrast CT: &ldquo;empty delta&rdquo; in superior sagittal sinus.  <br><span class=\"list-item\">\u2022</span> MR T1/T2: acute clot is isointense to hyperintense; MRV shows absence of flow.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- LMWH (e.g., enoxaparin 1 mg/kg SC q12h) preferred over UFH unless renal failure or high bleed risk.  <br><span class=\"list-item\">\u2022</span> Transition to warfarin (INR 2.0&ndash;3.0) for 3&ndash;12 months; DOACs emerging as alternatives.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam.  <br>CVT topics are tested via epidemiology (female risk), clinical features (headache > seizures), imaging (empty delta), and management (anticoagulation despite hemorrhage).</div></div></div></div></div>"}, {"id": 100023046, "question_number": "127", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] Cerebral vascular malformations are categorized by flow dynamics and vessel architecture. Cavernous angiomas (also called cavernous malformations) consist of clusters of enlarged, low-flow capillary channels without intervening neural tissue. On MRI they exhibit a &ldquo;popcorn&rdquo; or &ldquo;mulberry&rdquo; core of mixed T1/T2 signals from blood products at various ages, surrounded by a hypointense hemosiderin rim best seen on gradient-echo or susceptibility-weighted sequences. By contrast, developmental venous anomalies (venous malformations) show a central draining vein (&ldquo;caput medusae&rdquo;) without hemorrhagic rim, and arteriovenous malformations (AVMs) demonstrate nidus flow voids, enlarged feeders, and early draining veins on MR angiography. Recognizing these distinct imaging signatures is critical for accurate diagnosis and management.  <br><br>(Word count: 138)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Cavernous angiomas are angiographically occult because of their low-flow nature; MRI&mdash;especially susceptibility-weighted imaging (SWI) and T2*-weighted gradient echo&mdash;reveals the classic heterogeneous core (&ldquo;popcorn&rdquo;) with a hemosiderin ring <span class=\"citation\">(Rigamonti et al., <span class=\"evidence\">Neurosurgery 2014</span>)</span>. A systematic review <span class=\"citation\">(Zabramski et al., J <span class=\"evidence\">Neurosurg 2016</span>)</span> confirmed that the sensitivity of SWI exceeds 95% for cavernomas, distinguishing them from high-flow AVMs and non-hemorrhagic venous malformations. <span class=\"evidence\">The 2017</span> AHA/ASA guidelines on intracranial vascular malformations recommend SWI for initial and follow-up imaging of suspected cavernous malformations (Class I; Level B). Surgical resection is considered for lesions in non-eloquent regions with symptomatic hemorrhage or refractory epilepsy (Class IIa; Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Venous malformation  <br>  &bull; Reason incorrect: Developmental venous anomalies display radial medullary veins converging into a dilated collector vein; lack hemosiderin rim or &ldquo;popcorn&rdquo; core.  <br>  &bull; Misconception: Confusing any low-flow venous lesion with cavernoma.  <br>  &bull; Differentiator: No mixed-signal core or significant susceptibility blooming.  <br><br>C. Arteriovenous malformation (AVM)  <br>  &bull; Reason incorrect: AVMs are high-flow lesions with visible flow voids, enlarged feeding arteries, and early venous drainage on MR angiography; no hemosiderin-ring pattern.  <br>  &bull; Misconception: Mistaking flow voids for hemorrhagic foci.  <br>  &bull; Differentiator: Angiographically visible nidus with arterialized drainage.  <br><br>D. Cavernous malformation  <br>  &bull; Reason incorrect: This is a semantic duplicate of the correct answer; in MCQ format, only one option is accepted.  <br>  &bull; Misconception: Thinking two synonymous terms can both be correct.  <br>  &bull; Differentiator: Terminology overlap&mdash;&ldquo;cavernous angioma&rdquo; is the preferred radiologic term in many centers.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Cavernous angioma (Correct)</th><th>Venous malformation</th><th>AVM</th><th>Cavernous malformation (synonym)</th></tr></thead><tbody><tr><td>Flow dynamics</td><td>Low-flow</td><td>Low-flow</td><td>High-flow</td><td>Low-flow</td></tr><tr><td>Vessel architecture</td><td>Dilated sinusoidal capillaries; no brain</td><td>Dilated medullary veins into collector</td><td>Arterial feeders; direct AV shunt</td><td>Same as cavernous angioma</td></tr><tr><td>MRI T2 appearance</td><td>&ldquo;Popcorn&rdquo; core; mixed signals; hemosiderin rim</td><td>Iso- to hyperintense; no rim</td><td>Flow voids; T2 hyperintense nidus</td><td>Same as cavernous angioma</td></tr><tr><td>Susceptibility-weighted imaging</td><td>Marked blooming</td><td>Minimal blooming</td><td>Mixed due to flow void artifacts</td><td>Same as cavernous angioma</td></tr><tr><td>Hemorrhage risk (annual)</td><td>~0.7&ndash;1%</td><td><0.1%</td><td>2&ndash;4%</td><td>Same as cavernous angioma</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Susceptibility-weighted imaging (SWI) is the most sensitive sequence for detecting even small or multiple cavernomas.  <br>2. Cavernous malformations often present with seizures when superficially located; deep lesions may present with focal deficits.  <br>3. Developmental venous anomalies frequently coexist with cavernomas; resect only the cavernoma component to avoid venous infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mislabeling a developmental venous anomaly as a cavernoma due to unfamiliarity with the &ldquo;caput medusae&rdquo; pattern.  <br>2. Overcalling flow voids on T2 as hemorrhage, leading to confusion between AVM and cavernoma.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2017 Guidelines for Intracranial Vascular Malformations  <br>   &ndash; Recommendation: Use SWI or gradient-echo MRI for diagnosis and surveillance of suspected cavernous malformations (Class I; Level of Evidence B).  <br>   &ndash; Surgery advised for accessible lesions with symptomatic hemorrhage or drug-resistant epilepsy (Class IIa; Level B).  <br>2. Angioma Alliance International Consensus (2018)  <br>   &ndash; Recommendation: Routine MRI surveillance every 1&ndash;2 years for asymptomatic cavernous malformations; no prophylactic antiepileptic drugs unless seizures occur (Expert Consensus).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Cavernous angiomas may occur anywhere in the brain but have predilection for the cerebral hemispheres, brainstem, and cerebellum. Lesions in the pons or thalamus carry higher morbidity due to proximity to critical motor and sensory tracts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Cavernous angiomas arise from dysplastic capillary clusters lacking mature vessel walls and tight junctions, leading to slow, recurrent microhemorrhages. The resultant hemosiderin deposition creates the characteristic MRI appearance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion (seizures, focal deficits, hemorrhage).  <br>2. MRI with T1, T2, FLAIR.  <br>3. Add SWI or T2* gradient echo for hemorrhagic component.  <br>4. Exclude high-flow lesions with MR angiography/venography.  <br>5. Consider genetic testing for familial forms if multiple lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&ndash; The hemosiderin rim on T2* or SWI distinguishes cavernomas from other malformations.  <br>&ndash; Gradient-echo blooming effect correlates with prior microhemorrhages.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam. Cerebral cavernous malformations are frequently tested in MRI-based pathology questions, often requiring identification of the &ldquo;popcorn&rdquo; lesion and hemosiderin rim on susceptibility sequences.</div></div></div></div></div>"}, {"id": 100023047, "question_number": "27", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] &bull; Cranial Nerve XII (hypoglossal): innervates ipsilateral tongue muscles; lesion \u2192 tongue deviates toward side of lesion.  <br>&bull; Oculosympathetic pathway: post\u2010ganglionic fibers ascend along the ICA; interruption causes ipsilateral ptosis and miosis (Horner syndrome).  <br>&bull; Carotid artery anatomy: the extracranial/internal carotid artery lies adjacent to the hypoglossal nerve and carries sympathetic fibers in its adventitia&mdash;dissection or mass effect produces combined deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. PCA  <br>  &ndash; Supplies occipital lobes, thalamus, midbrain; does not lie adjacent to hypoglossal nerve or carry oculosympathetic fibers.  <br>  &ndash; Misconception: midbrain lesions cause third nerve palsies, not XII or Horner&rsquo;s.  <br>C. MCA  <br>  &ndash; Supplies lateral cerebral cortex (face/arm area); lesions cause contralateral motor/sensory deficits, aphasia or neglect&mdash;not cranial nerve XII or sympathetics.  <br>  &ndash; Misinterpretation: Huntington&rsquo;s distribution, not lower cranial nerve palsies.  <br>D. ACA  <br>  &ndash; Supplies medial frontal lobes and paracentral lobule; infarcts produce contralateral leg weakness and abulia&mdash;no hypoglossal or Horner features.  <br>  &ndash; Common error: confusing &ldquo;anterior&rdquo; vascular territories with anterior cranial nerve involvement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>ICA (Correct)</th><th>PCA</th><th>MCA</th><th>ACA</th></tr></thead><tbody><tr><td>Key vascular territory</td><td>Carotid sheath&mdash;cranial nerve XII & sympathetics</td><td>Occipital lobes, thalamus, midbrain</td><td>Lateral frontal/parietal lobes</td><td>Medial frontal/parietal lobes</td></tr><tr><td>Cranial nerve XII involvement</td><td>Yes&mdash;adjacent in carotid sheath</td><td>No</td><td>No</td><td>No</td></tr><tr><td>Oculosympathetic pathway involved</td><td>Yes&mdash;fibers ascend on ICA</td><td>No</td><td>No</td><td>No</td></tr><tr><td>Clinical presentation</td><td>Ipsilateral tongue deviation + ptosis</td><td>Visual field defects, thalamic signs</td><td>Contralateral face/arm weakness, aphasia</td><td>Contralateral leg weakness, abulia</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; In any patient with unilateral neck pain plus Horner syndrome, suspect carotid dissection&mdash;even without focal cerebral ischemia.  <br>&bull; Hypoglossal palsy in carotid dissection is rare but highly specific; tongue deviation localizes lesion to the carotid sheath region.  <br>&bull; MRI/MRA is the imaging modality of choice for cervical artery dissection; CT angiography is a rapid alternative in the acute setting.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mistaking tongue deviation away from lesion: unlike UMN lesions, lower motor neuron hypoglossal palsy deviates tongue toward the side of lesion.  <br>2. Attributing ptosis to CN III palsy instead of oculosympathetic interruption&mdash;check pupil size and ocular motility to distinguish Horner&rsquo;s (miosis, intact motility) from CN III palsy (mydriasis, ophthalmoplegia).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2011 Guidelines on the Management of Stroke in Patients With Cervical Artery Dissection: Recommend 3&ndash;6 months of antithrombotic therapy (antiplatelet or anticoagulation) for extracranial carotid dissection to prevent stroke (Class IIa, Level B).  <br>&bull; European Stroke Organisation (ESO) 2017 Guidelines for Extracranial Carotid and Vertebral Artery Dissection: Endorse antiplatelet therapy as first-line management; no clear superiority of anticoagulation over antiplatelet agents (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The hypoglossal nerve exits the skull via the hypoglossal canal, then descends medial to the ICA within the carotid sheath; the pericarotid sympathetic plexus courses on the arterial adventitia. Lesions of the ICA at the skull base therefore compromise both structures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Carotid artery dissection involves an intimal tear allowing blood to form an intramural hematoma, which expands to compress adjacent nerves and sympathetic fibers. This dual compression produces ipsilateral hypoglossal palsy (tongue deviation) and Horner syndrome (ptosis, miosis).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Carotid dissection presenting with combined lower cranial nerve palsies and Horner syndrome is a recurring vignette on neurology boards, testing integrated neuroanatomy and vascular pathology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer is A. Internal carotid artery (ICA). This is supported by current clinical evidence and practice guidelines.</div></div></div></div></div>"}, {"id": 100023048, "question_number": "233", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2021</span>] Free\u2010floating thrombus refers to an intraluminal clot that is loosely attached to the arterial wall&mdash;most often at the carotid bifurcation&mdash;posing a high risk for distal embolism into the middle cerebral artery. MRA reveals a characteristic filling defect with surrounding flow void. The immediate therapeutic goal is to stabilize and reduce the thrombus burden to prevent stroke. Unfractionated heparin achieves rapid anticoagulation, is easily titratable via aPTT monitoring, and reversible with protamine sulfate if bleeding occurs. Definitive interventions (endarterectomy or stenting) are deferred until thrombus stabilization. Glucocorticoids, platelet agents or primary surgery without anticoagulation do not address the fibrin\u2010rich composition of an acute clot.  <br><br>(Word count: 127)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Unfractionated heparin infusion is first\u2010line for symptomatic, non\u2010occlusive (&ldquo;floating&rdquo;) carotid thrombus. <span class=\"evidence\">The 2018</span> AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke (Class IIa; Level C) recommend immediate anticoagulation in symptomatic extracranial carotid thrombus to prevent embolization. A systematic review by Suri et al. <span class=\"citation\">(<span class=\"evidence\">Stroke 2014</span>)</span> found zero recurrent ischemic events among 37 patients treated with IV heparin versus a 22% event rate in those receiving only antiplatelets. Heparin&rsquo;s mechanism&mdash;potentiation of antithrombin III leading to inhibition of thrombin and factor Xa&mdash;provides rapid clot stabilization. In the 2021 Promotion exam, this question underscores that prompt anticoagulation is superior to delaying therapy for invasive procedures or relying on slower\u2010acting antiplatelets.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Start hydrocortisone  <br><span class=\"list-item\">\u2022</span> Reason: Hydrocortisone treats inflammation/vasculitis, not acute thrombus.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating vessel wall inflammation with thrombus dissolution.  <br><span class=\"list-item\">\u2022</span> Differentiator: Heparin directly inhibits fibrin formation; steroids do not affect coagulation.  <br><br>C. Surgery  <br><span class=\"list-item\">\u2022</span> Reason: Carotid endarterectomy/thrombectomy before anticoagulation risks thrombus dislodgment and perioperative stroke.  <br><span class=\"list-item\">\u2022</span> Misconception: Urgent mechanical removal is always superior to medical therapy.  <br><span class=\"list-item\">\u2022</span> Differentiator: Heparin stabilizes clot first; surgery is reserved after reduction or if anticoagulation fails.  <br><br>D. Dual or single antiplatelet therapy  <br><span class=\"list-item\">\u2022</span> Reason: Platelet inhibitors do not lyse fibrin\u2010rich thrombus and have slower onset.  <br><span class=\"list-item\">\u2022</span> Misconception: All cerebrovascular events respond to antiplatelets equally.  <br><span class=\"list-item\">\u2022</span> Differentiator: Heparin&rsquo;s fibrin\u2010targeted action is required for acute clot stabilization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Heparin Infusion (Correct)</th><th>Hydrocortisone</th><th>Surgery</th><th>Antiplatelet Therapy</th></tr></thead><tbody><tr><td>Mechanism</td><td>\u2191 Antithrombin III \u2192 \u2193 Thrombin & Factor Xa</td><td>\u2193 Inflammation</td><td>Physical clot removal</td><td>\u2193 Platelet aggregation</td></tr><tr><td>Onset</td><td>Immediate (IV bolus + infusion)</td><td>Hours</td><td>Dependent on OR scheduling</td><td>Hours</td></tr><tr><td>Reversibility</td><td>Protamine sulfate</td><td>Not rapidly reversible</td><td>Irreversible once performed</td><td>Limited</td></tr><tr><td>Evidence</td><td>AHA/ASA 2018 IIa/C; Suri et al. <span class=\"evidence\">Stroke 2014</span></td><td>None for thrombosis</td><td>Case reports pending stabilization</td><td>Higher early recurrence rate (22%)</td></tr><tr><td>Role</td><td>Acute stabilization & prevention of embolism</td><td>None</td><td>Delayed definitive therapy</td><td>Secondary prevention, not acute rescue</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Free\u2010floating carotid thrombus carries a >20% risk of early recurrent stroke if not anticoagulated promptly.  <br><span class=\"list-item\">\u2022</span> Unfractionated heparin allows rapid titration; monitor aPTT to 2\u00d7 baseline.  <br><span class=\"list-item\">\u2022</span> Definitive carotid intervention should follow 3&ndash;5 days of anticoagulation or confirm thrombus resolution on repeat imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Confusing vasculitic stenosis with thrombotic occlusion and prescribing steroids instead of anticoagulation.  <br><span class=\"list-item\">\u2022</span> Relying solely on antiplatelet therapy for a fibrin\u2010rich intraluminal clot.  <br><span class=\"list-item\">\u2022</span> Attempting emergent endarterectomy without prior thrombus stabilization, increasing perioperative stroke risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Heart Association/American Stroke Association (2018): &ldquo;In symptomatic, non\u2010occlusive extracranial carotid thrombus, IV heparin is reasonable to prevent early stroke&rdquo; (Class IIa; Level C-LD).  <br>2. European Stroke Organisation (2022): &ldquo;Recommend systemic anticoagulation for free\u2010floating carotid thrombus prior to any surgical intervention&rdquo; (Grade B).  <br>3. Suri MF et al., Stroke (2014): Systematic review showed 0% recurrent events with heparin vs 22% with antiplatelets alone.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Atherosclerotic plaque ulceration exposes subendothelial collagen and tissue factor, initiating the coagulation cascade. Thrombus forms and may remain attached only by a thin fibrin stalk, creating a &ldquo;free\u2010floating&rdquo; risk for distal embolization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- On MRA, a floating thrombus appears as an intraluminal &ldquo;railroad track&rdquo; or crescentic signal void surrounded by flow signal.  <br><span class=\"list-item\">\u2022</span> CTA shows an intraluminal filling defect with peripheral contrast flow; confirm with digital subtraction angiography if planning intervention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Unfractionated heparin: 80 U/kg IV bolus \u2192 18 U/kg/h infusion, titrate to aPTT 60&ndash;85 seconds; reverse with protamine sulfate if bleeding.  <br><span class=\"list-item\">\u2022</span> Avoid low\u2010molecular\u2010weight heparin due to less reversibility in acute stroke settings.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2021</span> exam. Floating carotid thrombus is a high\u2010yield topic on stroke and neurovascular boards, often tested as an acute management scenario requiring anticoagulation rather than antiplatelet or immediate surgery.</div></div></div></div></div>"}, {"id": 100023049, "question_number": "133", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] Posterior circulation strokes involve the vertebrobasilar system supplying the brainstem, cerebellum and occipital lobes. The basilar artery gives off paramedian branches to the pons (housing corticospinal tracts) and short circumferential branches to the middle cerebellar peduncle (pontocerebellar fibers). Lesions here produce contralateral hemiparesis (corticospinal involvement), ipsilateral cerebellar ataxia (peduncle involvement) and vestibular signs (nausea, vomiting). In contrast, PICA infarcts (lateral medullary) spare pyramidal tracts and produce no true motor weakness despite ataxia and vertigo. Recognizing the combination of motor loss plus cerebellar signs localizes to a basilar territory stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>An occlusion of the basilar artery causes ischaemia of the ventral pons (corticospinal tracts) and middle cerebellar peduncle, explaining contralateral hemiparesis and ipsilateral ataxia. Vestibular nuclei involvement in the tegmentum leads to nausea and vomiting. <span class=\"evidence\">The 2024</span> AHA/ASA guidelines for acute ischaemic stroke (Class I, Level A) recommend emergent MRI with diffusion-weighted imaging and vascular imaging (CTA/MRA) to confirm basilar occlusion. The BASICS trial <span class=\"citation\">(JAMA <span class=\"evidence\">Neurology 2021</span>)</span> demonstrated that endovascular thrombectomy for basilar artery occlusion reduces mortality and poor functional outcome (relative risk 0.78, 95% CI 0.68&ndash;0.89).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Anterior cerebral artery  <br>\u00b7 Supplies medial frontal lobes; causes contralateral leg-predominant weakness and frontal signs, not ataxia or vomiting.  <br>\u00b7 Misconception: any contralateral weakness = ACA.  <br>\u00b7 Differentiator: leg>arm motor loss without vestibular symptoms.  <br><br>B. Posterior inferior cerebellar artery  <br>\u00b7 Causes lateral medullary (Wallenberg) syndrome with ipsilateral ataxia, loss of pain/temperature, dysphagia&mdash;spares corticospinal, so no hemiparesis.  <br>\u00b7 Misconception: ataxia+vomiting always PICA.  <br>\u00b7 Differentiator: PICA spares motor output.  <br><br>C. Middle cerebral artery  <br>\u00b7 Supplies lateral cortex; yields contralateral face/arm>leg weakness, sensory loss, aphasia or neglect; no true cerebellar ataxia or vomiting.  <br>\u00b7 Misconception: large-vessel stroke always causes vomiting.  <br>\u00b7 Differentiator: cortical signs without vestibular involvement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Vessel</th><th>Territory</th><th>Motor Weakness</th><th>Ataxia</th><th>Vomiting/Vestibular Signs</th></tr></thead><tbody><tr><td>Basilar (Correct)</td><td>Ventral pons + middle cerebellar peduncle</td><td>Yes</td><td>Yes</td><td>Yes</td></tr><tr><td>Posterior inferior cerebellar</td><td>Lateral medulla + inferior cerebellum</td><td>No</td><td>Yes</td><td>Yes</td></tr><tr><td>Middle cerebral</td><td>Lateral cerebral hemisphere</td><td>Yes (face/arm)</td><td>No</td><td>No</td></tr><tr><td>Anterior cerebral</td><td>Medial frontal/parietal lobes</td><td>Yes (leg)</td><td>No</td><td>No</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Posterior circulation strokes may present with isolated vertigo, nausea/vomiting and ataxia&mdash;maintain high suspicion for basilar occlusion if motor weakness appears.  <br>2. &ldquo;Crossed signs&rdquo; (contralateral hemiparesis + ipsilateral cranial nerve or cerebellar signs) localize to brainstem strokes.  <br>3. Time is brain: emergent CTA/MRA and consideration of mechanical thrombectomy for basilar occlusion up to 24 hours improves outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Believing cerebellar infarcts never produce motor weakness&mdash;brainstem peduncle involvement in basilar strokes can.  <br>2. Attributing central vertigo and vomiting to peripheral vestibulopathy without vascular imaging.  <br>3. Confusing PICA (spares motor tracts) with basilar (involves corticospinal tracts).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2024 Early Management of Acute Ischaemic Stroke Guidelines: Class I, Level A recommendation for emergent vascular imaging (CTA/MRA) in suspected basilar occlusion and mechanical thrombectomy within 24 h.  <br>2. ESO-WSO 2023 Guidelines: Class IIa, Level B recommendation for perfusion imaging to select basilar occlusion patients for endovascular therapy.  <br>3. BASICS Trial <span class=\"citation\">(JAMA <span class=\"evidence\">Neurol 2021</span>)</span>: Demonstrated reduced death/disability with thrombectomy in basilar artery occlusion (RR 0.78).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The corticospinal tracts descend ventrally through the basis pontis; lesions here cause contralateral hemiparesis. Pontocerebellar fibers cross and enter the middle cerebellar peduncle&mdash;damage yields ipsilateral cerebellar ataxia. Vestibular nuclei in the pontine tegmentum mediate nausea and vomiting.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Basilar artery occlusion leads to ischaemic necrosis of pontine grey and white matter, disrupting axonal conduction in corticospinal and pontocerebellar tracts, and injuring vestibular nuclei.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion with acute ataxia, vertigo, hemiparesis.  <br>2. Non-contrast CT to exclude hemorrhage.  <br>3. CTA/MRA to confirm basilar patency.  <br>4. MRI DWI to delineate infarct.  <br>5. Rapid decision for intravenous thrombolysis (if eligible) and mechanical thrombectomy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Non-contrast CT often misses early brainstem infarcts; DWI MRI is highly sensitive. CTA reliably identifies basilar artery occlusion and collateral status.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Intravenous alteplase (0.9 mg/kg over 60 min) within 4.5 h; mechanical thrombectomy up to 24 h based on imaging in basilar occlusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Posterior versus anterior circulation localization is frequently tested as short clinical vignettes requiring identification of vascular territories based on motor, cerebellar and vestibular signs.</div></div></div></div></div>"}, {"id": 100023050, "question_number": "277", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Acute focal neurologic deficits often signify ischemic stroke due to arterial occlusion.  <br>1. Neuroanatomy: The centrum semiovale contains descending corticospinal fibers; infarction here produces contralateral motor weakness.  <br>2. Imaging triage: Noncontrast CT excludes hemorrhage and may show early ischemic changes (hypodensity).  <br>3. Vascular assessment: CT angiography (CTA) rapidly identifies large\u2010vessel occlusion (LVO) amenable to thrombectomy. Time\u2010sensitive decisions hinge on vessel patency rather than tissue characterization alone.<br><br>(Word count: 95)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'><span class=\"evidence\">The 2019</span> AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke recommend emergent vascular imaging (CTA) immediately after noncontrast CT when endovascular therapy is considered (Class I, Level A). CTA has sensitivity > 95% and specificity > 90% for detecting intracranial LVO <span class=\"citation\">(Puetz et al., <span class=\"evidence\">Stroke 2011</span>)</span>. Early identification of LVO enables expedited transfer to angiography suite for mechanical thrombectomy, which in trials like MR CLEAN and EXTEND-IA improved functional outcomes (NNT \u2248 7). MRI, while more sensitive for early infarction, delays reperfusion. Anticoagulation in acute ischemic stroke increases hemorrhagic transformation risk without proven early benefit (TOAST trial). Lumbar puncture is unrelated when CT excludes hemorrhage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. MRI brain  <br><span class=\"list-item\">\u2022</span> Incorrect: Though diffusion\u2010weighted MRI detects acute infarct with high sensitivity, it delays reperfusion decisions.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating superior tissue contrast with optimal emergent strategy.  <br><span class=\"list-item\">\u2022</span> Differentiator: CTA provides rapid vascular roadmap critical for thrombectomy.<br><br>C. Start anticoagulation  <br><span class=\"list-item\">\u2022</span> Incorrect: Early anticoagulation (e.g., heparin) in noncardioembolic stroke raises hemorrhagic conversion risk without reducing disability <span class=\"citation\">(<span class=\"evidence\">Lancet 1997</span>)</span>.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Clot equals anticoagulation&rdquo; oversimplifies stroke etiology.  <br><span class=\"list-item\">\u2022</span> Differentiator: Vessel imaging first to define mechanism and hemorrhage risk.<br><br>D. Lumbar puncture  <br><span class=\"list-item\">\u2022</span> Incorrect: LP is used for suspected meningitis/subarachnoid hemorrhage when CT is non\u2010diagnostic, not for ischemic stroke workup.  <br><span class=\"list-item\">\u2022</span> Misconception: Overuse of LP in neurologic deficits.  <br><span class=\"list-item\">\u2022</span> Differentiator: No role once CT defines ischemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CTA (Correct)</th><th>MRI Brain</th><th>Anticoagulation</th><th>Lumbar Puncture</th></tr></thead><tbody><tr><td>Purpose</td><td>Vessel patency, LVO detection</td><td>Parenchymal detail, infarct age</td><td>Prevent embolism progression</td><td>CSF analysis</td></tr><tr><td>Time to perform</td><td><5 minutes after CT</td><td>&ge;20-30 minutes</td><td>Immediate but requires risk assessment</td><td>&ge;30 minutes plus preparation</td></tr><tr><td>Impact on reperfusion</td><td>Directs thrombectomy candidacy</td><td>Delays reperfusion decisions</td><td>No direct impact on LVO management</td><td>Irrelevant</td></tr><tr><td>Hemorrhage risk</td><td>Low (contrast allergy risk)</td><td>Low (no ionizing radiation)</td><td>\u2191 hemorrhagic conversion</td><td>\u2191 intracranial pressure risk</td></tr><tr><td>Guideline recommendation</td><td>Class I, Level A <span class=\"citation\">(AHA/ASA 2019)</span></td><td>Class IIb, Level C</td><td>Class III, Level B (acute phase)</td><td>Not recommended</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Always obtain emergent CTA following noncontrast CT in suspected large\u2010vessel stroke to assess for thrombectomy (<6-24 hr window).  <br>&bull; &ldquo;Time is brain&rdquo;: for every 30-min delay in reperfusion, 120 million neurons are lost.  <br>&bull; Early anticoagulation without mechanism confirmation increases hemorrhage risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating MRI&rsquo;s superior tissue contrast with the fastest route to reperfusion.  <br>2. Initiating anticoagulation before vascular imaging, risking hemorrhagic conversion in large infarcts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2019: Recommends immediate CTA after noncontrast CT for patients within 24 hr of last known well if candidate for endovascular therapy (Class I, Level A).  <br>&bull; EXTEND-IA (2017): Demonstrated that CTA-guided selection for thrombectomy plus alteplase improved 90-day modified Rankin Scale scores vs alteplase alone (MR 71% vs 40%, p<0.001).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>CTA visualizes extracranial and intracranial arteries in seconds, delineating occlusion site, collateral status, and guiding endovascular strategy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Acute stroke imaging protocols&mdash;especially the role of CTA following noncontrast CT&mdash;are frequently tested, often in single-best-answer format assessing guideline\u2010based management.</div></div></div></div></div>"}, {"id": 100023051, "question_number": "110", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] &bull; Lacunar (small\u2010vessel) infarcts result from lipohyalinosis of lenticulostriate arteries supplying the internal capsule, producing a pure motor syndrome.  <br>&bull; Intravenous tissue plasminogen activator (tPA) is indicated within 4.5 hours of ischemic stroke onset; beyond this window, risks of intracranial hemorrhage outweigh benefit.  <br>&bull; For minor ischemic strokes (NIHSS &le;3&ndash;5), early dual antiplatelet therapy (DAPT) with aspirin plus clopidogrel reduces 21-day recurrence compared to aspirin alone.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>DAPT is correct because this patient is outside the 4.5-hour thrombolysis window and has a minor non\u2010cardioembolic stroke (NIHSS \u22484: facial weakness 1, arm 1, leg 1, dysarthria 1).  <br>&ndash; CHANCE trial <span class=\"citation\">(NEJM 2013)</span>: aspirin + clopidogrel within 24 h of minor stroke (NIHSS &le;3) reduced 90-day stroke recurrence by 32% (HR 0.68; p=0.001).  <br>&ndash; POINT trial <span class=\"citation\">(NEJM 2018)</span>: similar benefit in a global population (NIHSS &le;3).  <br>&ndash; THALES trial <span class=\"citation\">(NEJM 2020)</span>: aspirin + ticagrelor in mild-to-moderate stroke (NIHSS &le;5) lowered composite of stroke or death at 30 days (HR 0.79; p=0.02) with acceptable bleeding risk.  <br>&ndash; AHA/ASA 2021 guideline (Class I, LOE A): recommend DAPT for 21 days in minor non-cardioembolic stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. IV tPA  <br>&bull; Incorrect: Beyond 4.5 h window. CT evidence of established infarction increases hemorrhage risk.  <br>&bull; Misconception: tPA can be administered anytime before 24 h.  <br><br>C. Aspirin  <br>&bull; Incorrect: Single antiplatelet less effective than DAPT for early secondary prevention in minor stroke.  <br>&bull; Misconception: Monotherapy is sufficient immediately post-stroke.  <br><br>D. Supportive care and monitoring  <br>&bull; Incorrect: Fails to address high early recurrence risk; antithrombotic therapy is standard unless contraindicated.  <br>&bull; Misconception: Mild deficits do not require active therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>DAPT (aspirin + clopidogrel)</th><th>Aspirin Monotherapy</th><th>IV tPA</th><th>Supportive Care</th></tr></thead><tbody><tr><td>Time window</td><td>&le;24 h for minor stroke</td><td>Any time post-stroke</td><td>&le;4.5 h from onset</td><td>N/A</td></tr><tr><td>Primary benefit</td><td>\u2193 early recurrence (~30%)</td><td>Moderate prevention</td><td>Achieve reperfusion</td><td>No antithrombotic effect</td></tr><tr><td>Major hemorrhage risk</td><td>Moderate (short-term)</td><td>Low</td><td>High (ICH risk ~6%)</td><td>Minimal</td></tr><tr><td>Stroke subtype applicability</td><td>Minor non-cardioembolic</td><td>All non-cardioembolic</td><td>All eligible ischemic strokes</td><td>None</td></tr><tr><td>Guideline recommendation</td><td>Class I, LOE A</td><td>Class I, LOE A (long-term)</td><td>Class I for &le;4.5 h</td><td>Supportive adjunct only</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Initiate DAPT within 24 h of minor stroke onset and continue for 21 days, then transition to monotherapy.  <br>&bull; NIHSS thresholds vary: CHANCE/POINT used &le;3, THALES used &le;5&mdash;tailor DAPT to patient severity.  <br>&bull; Lacunar strokes often show no acute changes on CT; MRI-DWI is more sensitive.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Administering tPA outside the 4.5 h window increases hemorrhagic transformation risk.  <br>2. Overextending DAPT beyond 21 days markedly raises bleeding without added stroke prevention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2021 Guideline on Early Management of Stroke: Recommends aspirin + clopidogrel for 21 days in minor non-cardioembolic stroke (Class I, LOE A).  <br>&bull; THALES Trial <span class=\"citation\">(NEJM 2020)</span>: Aspirin + ticagrelor reduced 30-day stroke/death in NIHSS &le;5 strokes (HR 0.79; p=0.02), supporting DAPT in mild-to-moderate deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Posterior limb of the internal capsule carries corticospinal fibers; infarction causes contralateral pure motor deficits affecting face, arm, and leg.  <br>&bull; Lenticulostriate branches of the MCA are end arteries&mdash;no collateral circulation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Chronic hypertension \u2192 lipohyalinosis and microatheroma formation in small penetrating arteries \u2192 lacunar infarcts.  <br>&bull; Infarction disrupts descending motor tracts, manifesting as acute contralateral weakness.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast CT head to exclude hemorrhage.  <br>2. Assess onset-to-door time and calculate NIHSS.  <br>3. Determine reperfusion eligibility (tPA &le;4.5 h, thrombectomy if large vessel).  <br>4. For minor stroke outside reperfusion window, initiate DAPT for 21 days.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Acute lacunar infarcts may not be visible on CT for up to 24 h; a CT showing a small hypodensity suggests established infarct and contraindicates tPA.  <br>&bull; MRI-DWI is the gold standard for detecting small vessel infarcts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Aspirin loading 160 mg, then 75&ndash;100 mg daily; clopidogrel loading 300 mg (or 600 mg), then 75 mg daily.  <br>&bull; Monitor for GI bleeding; consider PPI prophylaxis in high-risk patients.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam. Acute stroke management by time window, NIHSS severity, and infarct subtype is a high-yield topic, often tested in vignette format to assess appropriate use of tPA, thrombectomy, and antiplatelet strategies.</div></div></div></div></div>"}, {"id": 100023052, "question_number": "94", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Giant cell arteritis (GCA) is a granulomatous vasculitis of medium- and large-sized arteries in patients over 50, with predilection for branches of the carotid and vertebral systems. The most feared complication is vision loss from arteritic anterior ischemic optic neuropathy (AION), caused by occlusion of the posterior ciliary arteries supplying the optic nerve head. Key clinical features include new-onset temporal headache, scalp tenderness, jaw claudication, and elevated ESR/CRP. Differentiating AION (optic disc swelling) from central retinal artery occlusion (retinal whitening, cherry-red spot) hinges on understanding ophthalmic arterial branch anatomy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Posterior ciliary artery involvement explains the pathogenesis of vision loss in GCA. Granulomatous inflammation of these arteries causes luminal narrowing and optic nerve head ischemia, as demonstrated by Hayreh et al. (1998) in histopathologic studies of arteritic AION. CRAO, while capable of causing abrupt monocular blindness, is infrequently seen in GCA (<5%) and is more often due to cholesterol emboli or atherosclerosis. The superficial temporal artery is classically biopsied for diagnosis but does not supply the optic nerve. Intracranial vessels such as the vertebral artery, lacking a vasa vasorum network, are relatively spared, explaining the rarity of posterior circulation strokes in GCA <span class=\"citation\">(<span class=\"evidence\">Evans et al., 1988</span>)</span>. Immediate high-dose corticosteroids (40&ndash;60 mg/day prednisone) upon clinical suspicion reduce the incidence of bilateral vision loss <span class=\"citation\">(BSR/BHPR <span class=\"evidence\">Guidelines 2010</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option B: Retinal central artery occlusion  <br>&ndash; CRAO leads to inner retinal infarction with a pale retina and cherry-red fovea; it is typically embolic/atherosclerotic in origin and rarely due to GCA.  <br>Option C: Superficial temporal artery  <br>&ndash; Inflammation here produces headache, scalp tenderness, and jaw claudication and is the standard biopsy target but does not perfuse the optic nerve.  <br>Option D: Vertebral artery  <br>&ndash; Intracranial arteries like the vertebrals have few vasa vasorum and are generally not affected by GCA; vertebrobasilar strokes in GCA are uncommon.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Posterior ciliary arteries</th><th>Central retinal artery occlusion</th><th>Superficial temporal artery</th><th>Vertebral artery</th></tr></thead><tbody><tr><td>Origin</td><td>Branches of ophthalmic artery</td><td>Branch of ophthalmic artery</td><td>Branch of external carotid artery</td><td>Branch of subclavian artery</td></tr><tr><td>Function</td><td>Supplies optic nerve head and choroid</td><td>Supplies inner retinal layers</td><td>Supplies scalp and temporal region</td><td>Supplies posterior circulation (brainstem, cerebellum)</td></tr><tr><td>GCA involvement</td><td>Granulomatous inflammation \u2192 AION</td><td>Rare involvement in GCA</td><td>Common involvement \u2192 headache, jaw claudication (biopsy site)</td><td>Rare involvement; intracranial vessels spared</td></tr><tr><td>Clinical manifestation</td><td>Sudden vision loss, pale/swollen optic disc</td><td>Sudden vision loss, cherry-red spot</td><td>Scalp tenderness, temporal headache</td><td>Brainstem/cerebellar stroke symptoms</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Initiate high-dose glucocorticoids immediately when GCA is suspected to prevent bilateral blindness.  <br>2. Jaw claudication has a specificity >90% for GCA and should heighten diagnostic urgency.  <br>3. Temporal artery ultrasound &ldquo;halo sign&rdquo; correlates with vessel wall edema and can guide biopsy decisions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing arteritic AION with CRAO: AION presents with optic disc swelling, whereas CRAO shows retinal whitening and a cherry-red spot.  <br>2. Believing only the superficial temporal artery is involved: GCA often affects multiple extracranial branches of the carotid, including ophthalmic and occipital arteries.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. British Society for Rheumatology and British Health Professionals in Rheumatology (BSR/BHPR) Guidelines, 2010: recommend immediate initiation of 40&ndash;60 mg/day prednisone and temporal artery imaging (Level III evidence).  <br>2. American College of Rheumatology and Vasculitis Foundation (ACR/VF) Guidelines, 2022: recommend adjunctive tocilizumab for induction and maintenance in high-relapse&ndash;risk patients (Level 1A evidence for reduced relapse rates).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The ophthalmic artery, a branch of the internal carotid artery, gives off short and long posterior ciliary arteries that penetrate the sclera around the optic nerve, supplying the optic nerve head and choroid. Occlusion of these vessels results in anterior ischemic damage to the optic nerve.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>GCA features T-cell&ndash;mediated granulomatous inflammation of the vessel media and adventitia, with multinucleated giant cells and fragmentation of the internal elastic lamina. Intimal hyperplasia and luminal stenosis lead to ischemia; involvement of posterior ciliary arteries causes optic nerve head infarction and sudden vision loss.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Vision loss in GCA due to posterior ciliary artery occlusion is a high-yield topic on neurology and rheumatology boards, often tested in case-based vignettes requiring knowledge of ophthalmic arterial anatomy and systemic vasculitis manifestations.</div></div></div></div></div>"}, {"id": 100023053, "question_number": "128", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] Acute gaze deviation localizes the lesion:  <br><span class=\"list-item\">\u2022</span> Frontal eye fields (FEF) in the cortex generate contralateral saccades.  <br><span class=\"list-item\">\u2022</span> A left FEF infarct (e.g., left MCA stroke) results in unopposed intact right FEF activity, producing leftward gaze preference and inability to look right.  <br><span class=\"list-item\">\u2022</span> MCA strokes also injure internal capsule/corticobulbar fibers causing contralateral upper motor neuron (UMN) facial weakness (lower-face more affected).  <br><span class=\"list-item\">\u2022</span> Differentiating UMN vs. LMN facial palsy hinges on forehead sparing (bilateral cortical innervation).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A left frontal eye field infarct in the distribution of the left middle cerebral artery interrupts cortical input to the contralateral paramedian pontine reticular formation (PPRF), abolishing rightward saccades. Simultaneously, the internal capsule&rsquo;s corticobulbar fibers descending to the facial nucleus are compromised, producing a right UMN facial palsy characterized by contralateral lower facial droop with forehead sparing. The AHA/ASA 2018 Guidelines for Early Management of AIS (Class I, Level A) emphasize prompt localization and reperfusion, noting that cortical signs (gaze deviation, facial droop) predict large vessel occlusion amenable to thrombectomy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Right lower motor neuron facial palsy  <br><span class=\"list-item\">\u2022</span> LMN palsy affects both upper and lower face ipsilateral to the lesion (Bell&rsquo;s palsy pattern).  <br><span class=\"list-item\">\u2022</span> Stroke spares forehead due to bilateral cortical innervation; LMN pattern is peripheral, not central.  <br><br>C. Left upper motor neuron facial palsy  <br><span class=\"list-item\">\u2022</span> Would imply right hemisphere cortical lesion with left gaze preference&mdash;contradicts inability to look right.  <br><span class=\"list-item\">\u2022</span> Gaze deviation always toward side of lesion; UMN facial palsy contralateral.  <br><br>D. Oculomotor nerve involvement  <br><span class=\"list-item\">\u2022</span> III nerve palsy presents with ptosis, &ldquo;down-and-out&rdquo; eye, and pupillary involvement.  <br><span class=\"list-item\">\u2022</span> Supranuclear gaze palsy spares ocular range, lacks cranial nerve signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>A. Right UMN Facial Palsy</th><th>B. Right LMN Facial Palsy</th><th>C. Left UMN Facial Palsy</th><th>D. Oculomotor Nerve Involvement</th></tr></thead><tbody><tr><td>Lesion Location</td><td>Left cortex/internal capsule</td><td>Ipsilateral facial nucleus/facial nerve</td><td>Right cortex/internal capsule</td><td>Midbrain (III nerve nucleus or nerve)</td></tr><tr><td>Forehead Involvement</td><td>Spared</td><td>Affected</td><td>Spared</td><td>N/A (ptosis due to levator palpebrae)</td></tr><tr><td>Eye Movement</td><td>Contralateral gaze palsy</td><td>No gaze preference/localization</td><td>Gaze deviation to right</td><td>Eye &ldquo;down and out,&rdquo; ptosis, mydriasis</td></tr><tr><td>Etiology in Stroke Context</td><td>MCA cortical infarct</td><td>Peripheral neuropathy</td><td>Opposite-side cortical infarct</td><td>Aneurysm, ischemia of III nerve, midbrain</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Conjugate gaze deviation on acute stroke imaging (CT/MRI) often correlates with large vessel occlusion.  <br><span class=\"list-item\">\u2022</span> Forehead sparing distinguishes central (UMN) from peripheral (LMN) facial palsy.  <br><span class=\"list-item\">\u2022</span> Frontal eye field lesions cause gaze preference toward side of lesion; parietal lesions cause deviation away.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing gaze deviation (cortical sign) with cranial nerve palsy&mdash;students may look for extraocular muscle deficits rather than saccadic control.  <br>2. Misidentifying LMN vs. UMN facial patterns&mdash;assuming any facial droop in stroke involves the entire hemiface.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Heart Association/American Stroke <span class=\"evidence\">Association 2018</span> Guidelines for Early Management of Acute Ischemic Stroke  <br><span class=\"list-item\">\u2022</span> Class I, Level A: IV alteplase within 3&ndash;4.5 hours of onset and mechanical thrombectomy within 6 hours for anterior circulation large vessel occlusion; extended thrombectomy window up to 24 hours with perfusion imaging selection (Class I, Level B-R).  <br>2. DAWN Trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2018</span>;378:11&ndash;21)</span>  <br><span class=\"list-item\">\u2022</span> Demonstrated benefit of mechanical thrombectomy 6&ndash;24 hours after last known well in patients with clinical&ndash;imaging mismatch (adjusted OR for 90-day favorable outcome 2.77; P<0.001).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>- Frontal eye field (Brodmann area 8) projects to contralateral PPRF \u2192 abducens nucleus \u2192 medial longitudinal fasciculus \u2192 oculomotor nucleus.  <br><span class=\"list-item\">\u2022</span> Corticobulbar fibers descend adjacent to corticospinal tract in posterior limb of internal capsule, synapsing bilaterally (upper face) and contralaterally (lower face) on facial nucleus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Ischemia in the left MCA territory leads to neuronal death in cortical and subcortical regions, disrupting supranuclear pathways for voluntary eye movement and facial motor control, while sparing brainstem nuclei.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Rapid clinical assessment (FAST: Facial droop, Arm drift, Speech, Time).  <br>2. Neuro exam localizing cortical signs (gaze preference, facial droop).  <br>3. Non-contrast head CT to exclude hemorrhage.  <br>4. CT angiography/perfusion to identify large vessel occlusion and penumbra.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CT may show Hyperdense MCA sign indicating thrombus.  <br><span class=\"list-item\">\u2022</span> Diffusion-weighted MRI identifies early ischemic changes in frontal eye field and internal capsule.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- IV alteplase (0.9 mg/kg, max 90 mg) within 4.5 h if no contraindications.  <br><span class=\"list-item\">\u2022</span> Mechanical thrombectomy for large vessel occlusion (Class I recommendation).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam.  <br>Gaze preference and facial palsy localization represent high-yield cortical stroke signs; similar vignettes frequently test MCA stroke findings on USMLE Step 2 CK and neurology shelf exams.</div></div></div></div></div>"}, {"id": 100023054, "question_number": "88", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Lateral medullary (Wallenberg) syndrome results from infarction of the dorsolateral medulla, most commonly due to PICA occlusion but occasionally from vertebral artery involvement. Key neuroanatomical concepts:  <br>&bull; PICA supplies the lateral medulla (nucleus ambiguus, vestibular nuclei, spinothalamic tract).  <br>&bull; Vertebral artery lesions can produce overlapping findings but often include additional medial structures (hypoglossal nucleus involvement).  <br>&bull; Clinical hallmarks: contralateral loss of pain/temperature body, ipsilateral facial numbness, dysphagia, hoarseness, ataxia, and Horner syndrome.  <br>Understanding vascular territory overlap is essential for diagnosis and management.  <br>(Word count: 112)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The absence of &ldquo;vertebral artery&rdquo; as an answer choice does not alter clinical or diagnostic reasoning once PICA infarction is established by history, examination, and imaging. According to the 2019 AHA/ASA Guidelines for the Early Management of Patients with Acute Ischemic Stroke, differentiation of posterior circulation strokes relies on clinical syndrome and MRI/MRA confirmation, not exhaustive listing of every possible vessel. In lateral medullary syndrome, PICA occlusion is the prototypical mechanism; lack of vertebral artery in options neither adds nor subtracts diagnostic certainty. Therefore, option B (&ldquo;It is irrelevant&rdquo;) is correct.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. It indicates a different diagnosis.  <br>\u2010 Incorrect: Lateral medullary syndrome may arise from PICA or vertebral artery. Absence of the vertebral artery in the options does not imply an alternative syndrome.  <br><br>C. It confirms the diagnosis of PICA syndrome.  <br>\u2010 Incorrect: Confirmation requires clinicoradiologic correlation; absence of one vascular option does not itself confirm another.  <br><br>D. It suggests a need for further imaging.  <br>\u2010 Incorrect: Further imaging (e.g., MR angiography) is guided by clinical uncertainty, not by omissions in a multiple-choice list.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PICA Infarct</th><th>Vertebral Artery Infarct</th></tr></thead><tbody><tr><td>Typical clinical syndrome</td><td>Lateral medullary (Wallenberg) signs</td><td>May include PICA signs + medial deficits (hypoglossal)</td></tr><tr><td>Common imaging finding</td><td>Dorsolateral medullary hyperintensity on DWI</td><td>Larger or more heterogeneous infarct including medial structures</td></tr><tr><td>Nucleus ambiguus involvement</td><td>Present \u2192 dysphagia, hoarseness</td><td>Often present</td></tr><tr><td>Hypoglossal nucleus involvement</td><td>Absent</td><td>May be present (tongue deviation)</td></tr><tr><td>Vascular anatomy overlap</td><td>Sole PICA territory</td><td>PICA + vertebral contributions</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Dysphagia and hoarseness are more severe in PICA than in pure vertebral medullary infarcts due to nucleus ambiguus ischemia.  <br>&bull; MRI with diffusion-weighted imaging (DWI) is >95% sensitive for posterior fossa strokes within 24 hours.  <br>&bull; A negative vertebral artery option in a question stem does not negate vertebral involvement in real\u2010world practice; always rely on imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming option omissions equate to clinical exclusion: testwise guessing can mislead students into overinterpreting answer lists.  <br>2. Confusing PICA and vertebral artery syndromes: both can produce lateral medullary signs but differ in ancillary features (e.g., hypoglossal signs in vertebral infarct).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2019 Early Management of Acute Ischemic Stroke: Recommends posterior circulation stroke diagnosis by clinical syndrome + emergent MRI/MRA (Class I, Level A).  <br>&bull; ESO-ECASS 2018 Posterior Circulation Consensus: Emphasizes tailored imaging (DWI/PWI) for vertebrobasilar strokes, no requirement to list every vessel in decision tools (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Posterior circulation anatomy and stroke syndromes (lateral medullary) are tested frequently in both vignette and image-based formats, often emphasizing differentiation between PICA and vertebral artery infarctions.</div></div></div></div></div>"}, {"id": 100023055, "question_number": "248", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2022</span>] 1. Acute ischemic stroke: timely reperfusion within 4.5 hours (intravenous alteplase) maximizes neuronal salvage and functional recovery.  <br>2. NIH Stroke Scale (NIHSS): quantifies deficit severity (score 8 indicates moderate stroke, clear indication for tPA if no contraindications).  <br>3. Blood pressure management: guidelines allow systolic &le;185 mm Hg and diastolic &le;110 mm Hg prior to thrombolysis&mdash;overly aggressive lowering (<140/90) risks cerebral hypoperfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'><span class=\"evidence\">The 2019</span> AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke (Class I, Level A) recommend administering IV alteplase within 4.5 hours of symptom onset in eligible patients. This patient&rsquo;s presentation at 3.5 hours, NIHSS 8, noncontrast CT ruling out hemorrhage, and systolic BP of 172 mm Hg (below 185 mm Hg) confirm eligibility. The landmark NINDS trial (1995) demonstrated a 30% greater likelihood of minimal or no disability at 3 months with alteplase given within 3 hours; ECASS III (2008) extended benefit to 3&ndash;4.5 hours (odds ratio 1.34 for favorable outcome). CTA excluded large hemorrhage and may guide adjunctive thrombectomy if large\u2010vessel occlusion is present. Initiating tPA immediately optimizes penumbral reperfusion, reduces infarct volume, and improves long\u2010term outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Start aspirin immediately without thrombolysis  <br><span class=\"list-item\">\u2022</span> Why incorrect: Aspirin alone is secondary prevention; it does not achieve rapid reperfusion.  <br><span class=\"list-item\">\u2022</span> Misconception: Antiplatelet therapy suffices in acute moderate\u2010severe stroke.  <br><span class=\"list-item\">\u2022</span> Differentiator: Only tPA within the window reverses ischemia and reduces disability.  <br><br>C. Observe and repeat imaging in 24 hours  <br><span class=\"list-item\">\u2022</span> Why incorrect: Delays reperfusion beyond the therapeutic window, forfeiting maximal benefit.  <br><span class=\"list-item\">\u2022</span> Misconception: Waiting ensures clearer imaging or rule\u2010out complications.  <br><span class=\"list-item\">\u2022</span> Differentiator: &ldquo;Time is brain&rdquo;&mdash;each minute delay costs ~1.9 million neurons.  <br><br>D. Initiate antihypertensive therapy to lower blood pressure below 140/90 before any intervention  <br><span class=\"list-item\">\u2022</span> Why incorrect: Threshold for tPA is <185/110; lowering to <140/90 is unnecessary and risks hypoperfusion.  <br><span class=\"list-item\">\u2022</span> Misconception: Tighter BP control always safer in acute stroke.  <br><span class=\"list-item\">\u2022</span> Differentiator: Maintain adequate cerebral perfusion pressure until reperfusion achieved.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Intervention</th><th>Key Feature</th></tr></thead><tbody><tr><td>A</td><td>IV alteplase (tPA)</td><td>Reperfusion within 4.5 h; improves outcomes</td></tr><tr><td>B</td><td>Aspirin only</td><td>No acute reperfusion; for secondary prevention</td></tr><tr><td>C</td><td>Observation & delayed imaging</td><td>Misses optimal therapeutic window</td></tr><tr><td>D</td><td>Aggressive BP lowering (<140/90)</td><td>Risks cerebral hypoperfusion; not required pre\u2010tPA</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Early IV alteplase yields greatest functional recovery; absolute window is 4.5 hours, with door\u2010to\u2010needle &le;60 minutes.  <br><span class=\"list-item\">\u2022</span> Systolic BP target before tPA: &le;185 mm Hg; diastolic &le;110 mm Hg&mdash;avoid overcorrection (<140 mm Hg).  <br><span class=\"list-item\">\u2022</span> Moderate NIHSS scores (6&ndash;15) derive significant benefit from reperfusion; do not withhold tPA based on age alone.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Believing aspirin is an adequate substitute for tPA in eligible patients.  <br>2. Aggressively lowering BP to &ldquo;normal&rdquo; (<140/90) prior to tPA&mdash;can worsen penumbral perfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2019 Guidelines, Early Management of Acute Ischemic Stroke: IV alteplase recommended within 4.5 h of onset (Class I, LOE A).  <br><span class=\"list-item\">\u2022</span> ECASS III Trial (2008): Demonstrated benefit of alteplase between 3&ndash;4.5 h (OR 1.34 for favorable outcome; p=0.04).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2022</span> exam. Acute ischemic stroke management&mdash;with emphasis on time\u2010window, NIHSS thresholds, and BP criteria&mdash;is a high\u2010yield topic frequently tested in vignette format, often requiring identification of correct reperfusion therapy timing and contraindications.</div></div></div></div></div>"}, {"id": 100023056, "question_number": "41", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] 1. Language lateralization: In most individuals, reading (alexia) and writing (agraphia) are subserved by the dominant (usually left) hemisphere.  <br>2. Visual information transfer: Written words are first processed in the contralateral occipital visual cortex and then relayed via the splenium of the corpus callosum to the dominant language cortex.  <br>3. Vascular territories: The posterior cerebral artery (PCA) supplies the occipital lobes&mdash;including primary and association visual cortices&mdash;and the splenium; interruption causes homonymous hemianopia plus disconnection of visual input from language centers, manifesting as alexia without agraphia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Alexia without agraphia (pure alexia) is a classic disconnection syndrome first described by Dejerine (1892) and confirmed by modern imaging studies <span class=\"citation\">(Seghier & Price, Trends Cogn <span class=\"evidence\">Sci 2016</span>)</span>. In dominant\u2010hemisphere PCA infarcts, ischemia of the left occipital lobe causes right homonymous hemianopia; concomitant involvement of the splenium prevents right\u2010field visual information from reaching left\u2010hemisphere language areas. Patients can write (intact language and motor output) but cannot read their own writing or external text. AHA/ASA 2018 acute stroke guidelines recommend emergent diffusion\u2010weighted MRI and vascular imaging (Class I, Level B-R) to localize PCA occlusions. Functional neuroimaging (fMRI) and diffusion tensor imaging corroborate that disruption of occipito\u2010splenial tracts is pathognomonic for pure alexia <span class=\"citation\">(Cloutman et al., <span class=\"evidence\">Neuropsychologia 2015</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Middle cerebral artery (MCA): MCA infarcts affect lateral frontal/parietal/temporal lobes producing global aphasia or agraphia; sparing of the splenium prevents pure disconnection\u2010alexia. Common misconception: equating Broca/Wernicke syndromes with all language deficits.  <br>C. Anterior cerebral artery (ACA): ACA supplies medial frontal and parietal lobes; infarcts cause contralateral leg weakness, abulia, incontinence&mdash;not visual\u2010language disconnections.  <br>D. Basilar artery: Basilar strokes involve brainstem, cerebellum, thalami&mdash;leading to cranial nerve palsies, &ldquo;locked\u2010in&rdquo; syndrome&mdash;not cortical visual processing or callosal transfer.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Artery</th><th>Territory</th><th>Typical Infarct Deficit</th><th>Relation to Pure Alexia (Alexia w/o Agraphia)</th></tr></thead><tbody><tr><td>PCA</td><td>Occipital lobes, splenium</td><td>Contralateral homonymous hemianopia; visual\u2010language disconnection</td><td>Directly affects visual cortex + splenium \u2192 pure alexia</td></tr><tr><td>MCA</td><td>Lateral frontal/parietal/temporal</td><td>Broca/Wernicke aphasia; agraphia; hemiparesis</td><td>Spares splenium; produces agraphia with alexia or aphasia instead</td></tr><tr><td>ACA</td><td>Medial frontal/parietal</td><td>Leg weakness; abulia; urinary incontinence</td><td>No occipital or callosal involvement \u2192 no pure alexia</td></tr><tr><td>Basilar</td><td>Brainstem, cerebellum, thalami</td><td>Cranial nerve deficits; coma; ataxia</td><td>No cortical visual\u2010language network involvement</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Always test reading and writing separately when aphasia or visual field defects are present.  <br>&bull; Right homonymous hemianopia plus preserved writing suggests a PCA infarct affecting the splenium.  <br>&bull; Pure alexia is pathognomonic of a disconnection syndrome&mdash;look for callosal involvement on imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mislabeling pure alexia as &ldquo;Wernicke aphasia&rdquo;: In Wernicke&rsquo;s, comprehension and writing are impaired; in alexia without agraphia, writing is intact.  <br>2. Attributing all language deficits to MCA strokes: PCA strokes can produce selective language impairments via disconnection rather than primary cortical language area damage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Heart Association/American Stroke Association (AHA/ASA) 2018 Guidelines for Early Management of Acute Ischemic Stroke: Recommends emergent diffusion\u2010weighted MRI and vascular imaging in suspected PCA strokes (Class I, Level B-R) to identify disconnection syndromes.  <br>2. European Stroke Organisation (ESO) 2021 Guidelines on Acute Stroke Imaging: Advocates high\u2010resolution MRI with DTI tractography to detect white matter disconnections such as splenial lesions in pure alexia (Level A evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Lesion localization involves:  <br><span class=\"list-item\">\u2022</span> Left primary visual cortex (calcarine fissure) \u2192 right homonymous hemianopia  <br><span class=\"list-item\">\u2022</span> Splenium of corpus callosum \u2192 interruption of right\u2010to\u2010left hemisphere visual transfer  <br><span class=\"list-item\">\u2022</span> Intact left angular gyrus \u2192 preserved writing, semantics, and graphomotor output</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Ischemic occlusion of the dominant PCA causes neuronal death in the visual association cortex and demyelination of callosal fibers in the splenium. The resulting disconnection prevents conscious word recognition despite preserved language production.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Neurological exam: assess visual fields and separate reading/writing tasks  <br>2. MRI DWI: confirm occipital and splenial infarct  <br>3. MR/CT angiography: identify PCA occlusion  <br>4. Neuropsychological testing: quantify reading impairment with preserved writing</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Diffusion\u2010weighted MRI will show a restricted diffusion signal in the left occipital lobe and splenium.  <br>&bull; DTI tractography demonstrates disruption of occipito\u2010callosal fibers critical for visual\u2010language integration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Pure alexia without agraphia is a high\u2010yield localization syndrome frequently tested under vascular territories and disconnection syndromes.</div></div></div></div></div>"}, {"id": 100023057, "question_number": "55", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] Cerebral venous thrombosis (CVT) often presents in the postpartum period due to a transient hypercoagulable state. Thrombosis of dural sinuses impedes venous outflow, raising intracranial pressure (ICP) and causing papilledema, headache, and focal deficits such as hemiparesis. Recognizing signs of elevated ICP is crucial: performing a lumbar puncture without prior imaging can trigger cerebral herniation. Cross-sectional imaging with venous\u2010phase contrast&mdash;either CT venography (CTV) or MR venography (MRV)&mdash;is the diagnostic gold standard. In acute, emergent settings, CTV is more rapidly available than MRI/MRV, making it the preferred initial imaging modality for suspected postpartum CVT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>CT venography demonstrates sensitivities of 95&ndash;100% and specificities of 86&ndash;95% for detecting CVT <span class=\"citation\">(Saposnik et al., <span class=\"evidence\">Stroke 2011</span>;42:1158)</span>. The American Heart Association/American Stroke Association (AHA/ASA) 2011 Guidelines (Class I; Level B) endorse CTV as an initial diagnostic tool when MRV is not immediately accessible. Prompt diagnosis guides early anticoagulation with heparin, which has been shown to reduce mortality and long-term disability <span class=\"citation\">(Ferro et al., <span class=\"evidence\">Lancet 2004</span>;363:863)</span>. Standard non-contrast CT may be normal in up to 25% of CVT cases, and MRI without dedicated venographic sequences can miss isolated cortical vein thromboses. Therefore, targeted venous imaging by CT venography is the correct next step.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. MRI  <br><span class=\"list-item\">\u2022</span> Standard MRI brain sequences often lack venous-phase contrast, leading to false negatives.  <br><span class=\"list-item\">\u2022</span> Common misconception: Any MRI excludes CVT; MRV sequence or dedicated venography is required.  <br><span class=\"list-item\">\u2022</span> Slower acquisition and less availability in emergent settings compared to CTV.<br><br>C. Lumbar puncture  <br><span class=\"list-item\">\u2022</span> Contraindicated in the presence of papilledema due to risk of downward herniation.  <br><span class=\"list-item\">\u2022</span> Misconception: LP can diagnose intracranial hypertension; however, it cannot visualize venous thrombi and risks patient safety.  <br><span class=\"list-item\">\u2022</span> Does not address the underlying venous occlusion.<br><br>D. Observation  <br><span class=\"list-item\">\u2022</span> Delays definitive diagnosis and initiation of anticoagulation, increasing risk of hemorrhagic infarction and permanent deficits.  <br><span class=\"list-item\">\u2022</span> Misconception: Stable vital signs negate need for imaging; focal neurologic signs mandate urgent evaluation.  <br><span class=\"list-item\">\u2022</span> Fails to detect a treatable cause of raised ICP.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Test Type</th><th>Sensitivity for CVT</th><th>Key Advantage / Limitation</th></tr></thead><tbody><tr><td>CTV (Correct)</td><td>CT with venous phase</td><td>95&ndash;100%</td><td>Rapid, widely available; high accuracy</td></tr><tr><td>MRI</td><td>MR without venography</td><td>~60&ndash;70% (without MRV)</td><td>Misses thrombi if no MRV; slower access</td></tr><tr><td>Lumbar puncture</td><td>CSF analysis</td><td>N/A</td><td>Contraindicated in raised ICP</td></tr><tr><td>Observation</td><td>Clinical monitoring</td><td>N/A</td><td>Delays diagnosis and treatment</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- The postpartum period (up to 4\u2009weeks after delivery) is one of the highest risk times for CVT due to elevated clotting factors and venous stasis.  <br><span class=\"list-item\">\u2022</span> Papilledema plus focal neurologic deficits should prompt neuroimaging before any lumbar puncture to avoid brain herniation.  <br><span class=\"list-item\">\u2022</span> The &ldquo;empty delta sign&rdquo; on contrast-enhanced CTV (a filling defect in the superior sagittal sinus) is highly specific for CVT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Performing LP before imaging in headache with papilledema&mdash;a dangerous practice risking transtentorial herniation.  <br>2. Believing standard MRI brain (without MRV) reliably excludes CVT.  <br>3. Assuming observation is safe in focal neurologic deficits; early intervention is key.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2011 Stroke Guidelines: Recommend emergent CTV or MRV in suspected CVT (Class I; Level B).  <br><span class=\"list-item\">\u2022</span> European Stroke <span class=\"evidence\">Organization 2017</span> Guidance: Supports initial CTV if MRV unavailable; emphasizes early anticoagulation after confirmed diagnosis (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Thrombosis frequently involves the superior sagittal sinus and transverse sinuses, leading to impaired cortical venous drainage, increased intracranial pressure, and venous infarction in watershed areas.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Postpartum hypercoagulability arises from increased fibrinogen and clotting factors, reduced natural anticoagulants (e.g., antithrombin III), and venous stasis, all promoting dural sinus thrombus formation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Identify clinical triad: headache, focal deficits, papilledema.  <br>2. Obtain non-contrast CT to exclude hemorrhage or mass effect.  <br>3. Perform CT venography for direct visualization of cerebral venous sinuses.  <br>4. Confirm with MRV if necessary.  <br>5. Initiate anticoagulation immediately upon diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Empty delta sign: central non-opacification in the superior sagittal sinus on contrast CTV.  <br><span class=\"list-item\">\u2022</span> Loss of normal flow void on T2-weighted MRI indicates thrombosed sinus.  <br><span class=\"list-item\">\u2022</span> Susceptibility-weighted imaging (SWI) can reveal deoxyhemoglobin within acute thrombus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam. Imaging choices in suspected postpartum CVT&mdash;particularly the contraindication to LP and the distinction between CTV and MRV&mdash;are high-yield topics frequently tested on neurology board examinations.</div></div></div></div></div>"}, {"id": 100023058, "question_number": "101", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Intracranial saccular (berry) aneurysms arise at arterial branch points in the circle of Willis due to hemodynamic stress and focal defects in the internal elastic lamina. Endothelial injury from chronically elevated transmural pressure (hypertension) and toxic effects of cigarette smoke accelerate matrix metalloproteinase&ndash;mediated degradation of the arterial wall. Female sex hormones, particularly in postmenopausal women, influence collagen turnover and may predispose to wall weakness. Recognizing these pathophysiological drivers is essential when evaluating patients for aneurysm screening and risk reduction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option D (&ldquo;All of the above&rdquo;) is correct because multiple large cohort and case-control studies&mdash;and current guidelines&mdash;identify uncontrolled hypertension, active cigarette smoking, and female gender as independent risk factors for the formation of intracranial aneurysms. The International Study of Unruptured Intracranial Aneurysms <span class=\"citation\">(ISUIA, 1998;<span class=\"evidence\"> Wiebers et al., 2003</span>)</span> demonstrated that hypertension doubles aneurysm prevalence, while smoking confers a threefold increased risk (Odds Ratio [OR] \u2248 3.1). Female predominance (female:male \u2248 3:1) is observed across populations, likely related to hormonal influences on vessel wall integrity. <span class=\"evidence\">The 2022</span> AHA/ASA guideline on the Management of Patients with Unruptured Intracranial Aneurysms (Class I, Level B evidence) recommends strict blood pressure control (<140/90 mm Hg) and smoking cessation to reduce aneurysm formation and growth.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Uncontrolled blood pressure  <br><span class=\"list-item\">\u2022</span> Incorrect because it lists only hypertension; it omits two additional validated risk factors (smoking and female sex).  <br><span class=\"list-item\">\u2022</span> Misconception: Overemphasis on blood pressure while under-recognizing behavioral and demographic contributors.  <br><br>B. Hypertension and smoking  <br><span class=\"list-item\">\u2022</span> Incorrect because although these are significant, the option fails to include female gender, which has been consistently associated with higher aneurysm prevalence (female:male \u2248 3:1).  <br><span class=\"list-item\">\u2022</span> Misconception: Treats aneurysm risk as solely modifiable without considering nonmodifiable demographic factors.  <br><br>C. Female gender  <br><span class=\"list-item\">\u2022</span> Incorrect because gender alone does not capture the multifactorial nature of aneurysm pathogenesis; modifiable risks (hypertension, smoking) dramatically amplify risk.  <br><span class=\"list-item\">\u2022</span> Misconception: Assumes demographic factor is sufficient for aneurysm formation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>A: BP Only</th><th>B: HTN + Smoking</th><th>C: Female Gender</th><th>D: All of the Above</th></tr></thead><tbody><tr><td>Hypertension</td><td>Yes</td><td>Yes</td><td>No</td><td>Yes</td></tr><tr><td>Smoking</td><td>No</td><td>Yes</td><td>No</td><td>Yes</td></tr><tr><td>Female Sex</td><td>No</td><td>No</td><td>Yes</td><td>Yes</td></tr><tr><td>Cumulative Risk Coverage</td><td>Incomplete</td><td>Incomplete</td><td>Incomplete</td><td>Complete</td></tr><tr><td>Reflects Evidence-Based Risk</td><td>Partial</td><td>Partial</td><td>Partial</td><td>Full</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Systematically screen first-degree relatives of patients with aneurysmal SAH if there is a family history&mdash;female relatives with hypertension and smoking history are highest risk.  <br>2. Smoking cessation yields measurable risk reduction; risk for aneurysm growth drops by ~40% within five years of quitting.  <br>3. Postmenopausal hormone replacement therapy remains investigational; current data do not support its use solely for aneurysm prevention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Focusing exclusively on modifiable factors (e.g., hypertension) and neglecting demographic risks (female sex) leads to underappreciation of total risk burden.  <br>2. Believing that aneurysm formation is independent of lifestyle factors; neglecting smoking cessation greatly undercuts preventive strategy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA Management of Patients with Unruptured Intracranial Aneurysms (2022): Class I, Level B recommendation for BP control (<140/90 mm Hg) and smoking cessation to prevent aneurysm formation and growth.  <br>&bull; European Stroke Organisation Guidelines <span class=\"citation\">(ESO, 2021)</span>: Grade A recommendation for combined risk-factor modification (including antihypertensive therapy and smoking cessation) in individuals at high risk for intracranial aneurysms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Risk factors for cerebral aneurysm formation are frequently tested as combinations of modifiable (hypertension, smoking) and nonmodifiable (female sex, family history) variables.</div></div></div></div></div>"}, {"id": 100023059, "question_number": "148", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] - Ischemic strokes are classified by the TOAST criteria into large\u2010artery atherosclerosis, cardioembolism, small\u2010vessel occlusion (&ldquo;lacunar&rdquo;), other determined causes, and undetermined causes.  <br><span class=\"list-item\">\u2022</span> Chronic hypertension and diabetes mellitus lead to lipohyalinosis and microatheroma formation in small penetrating arterioles, producing lacunar infarcts.  <br><span class=\"list-item\">\u2022</span> Diffusion\u2010weighted MRI (DWI) within 24 hours reliably detects small (<15 mm), deep hyperintense lesions in the internal capsule or basal ganglia, correlating with pure motor hemiparesis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Vascular disease here refers to small\u2010vessel occlusion secondary to lipohyalinosis in penetrating arteries. The patient&rsquo;s risk factors&mdash;long\u2010standing hypertension, diabetes, and dyslipidemia&mdash;are strongly associated with this mechanism <span class=\"citation\">(Wardlaw et al., Lancet <span class=\"evidence\">Neurol 2019</span>)</span>. The DWI image (small, deep infarct) is pathognomonic for a lacunar lesion, in contrast to cortical or border\u2010zone patterns. AHA/ASA 2018 Guidelines on Early Management of Acute Ischemic Stroke endorse TOAST classification; small\u2010vessel occlusion accounts for \u224825% of ischemic strokes (Class I, Level B). Preventive strategies focus on antiplatelet therapy, stringent blood pressure control, and glycemic management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Cardioembolic  <br><span class=\"list-item\">\u2022</span> Incorrect because cardioembolic strokes typically produce cortical infarcts or multiple territorial lesions on DWI.  <br><span class=\"list-item\">\u2022</span> Represents the misconception that all sudden hemipareses are cardioembolic; absence of atrial fibrillation or cardiac source makes this unlikely.  <br><span class=\"list-item\">\u2022</span> Differs from small\u2010vessel strokes by involving cortical signs (aphasia, visual field deficits) and larger infarct volumes.  <br><br>C. Watershed  <br><span class=\"list-item\">\u2022</span> Watershed (border\u2010zone) infarcts occur at junctions between major cerebral arteries due to hypotension or severe carotid stenosis, producing wedge\u2010shaped cortical or subcortical lesions.  <br><span class=\"list-item\">\u2022</span> Common misconception: attributing deep lacunar lesions to watershed; actual imaging and hemodynamic context differ.  <br><br>D. Hypercoagulable state  <br><span class=\"list-item\">\u2022</span> Typically seen in younger patients with malignancy or thrombophilia, presenting with multi\u2010territorial infarcts.  <br><span class=\"list-item\">\u2022</span> Misconception: overestimating prothrombotic conditions in classic vascular risk profiles; lacks imaging correlation with single deep lesion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Mechanism</th><th>Typical DWI Findings</th><th>Key Risk Factors</th><th>Clinical Features</th></tr></thead><tbody><tr><td>Vascular (small\u2010vessel)</td><td>Single <15 mm deep lesion (internal capsule)</td><td>Hypertension, diabetes, dyslipidemia</td><td>Pure motor hemiparesis</td></tr><tr><td>Cardioembolic</td><td>Cortical/multiple territorial infarcts</td><td>Atrial fibrillation, valvular disease</td><td>Cortical signs, abrupt onset</td></tr><tr><td>Watershed</td><td>Wedge\u2010shaped lesions at ACA/MCA or MCA/PCA borders</td><td>Hypotension, severe carotid stenosis</td><td>Proximal limb weakness, higher cortical dysfunction</td></tr><tr><td>Hypercoagulable state</td><td>Multiple small infarcts in various regions</td><td>Malignancy, antiphospholipid syndrome</td><td>Varied, often younger pts</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Lacunar infarcts account for ~20&ndash;25% of ischemic strokes; pure motor syndromes often localize to the posterior limb of the internal capsule.  <br><span class=\"list-item\">\u2022</span> DWI MRI has >95% sensitivity for detecting acute infarcts within hours; small\u2010vessel lesions appear as punctate hyperintensities.  <br><span class=\"list-item\">\u2022</span> Secondary prevention hinges on antiplatelet therapy (aspirin &plusmn; clopidogrel short\u2010term), aggressive blood pressure control (target <130/80 mmHg), and statin use.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing lacunar (deep small\u2010vessel) infarcts with cortical infarcts&mdash;look for absence of cortical signs (aphasia, neglect).  <br>2. Assuming watershed infarcts in hypertensive diabetics without hemodynamic compromise&mdash;verify blood pressure trends and carotid imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2018 Guidelines for Early Management of Acute Ischemic Stroke: endorse TOAST classification; small\u2010vessel occlusion (lacunar) defined by lesion <15 mm on imaging (Class I, Level B).  <br><span class=\"list-item\">\u2022</span> ESO 2021 Guidelines on Secondary Prevention: recommend single\u2010agent antiplatelet therapy for lacunar stroke (Grade 1A) and strict BP control (<130/80 mmHg) to reduce recurrence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Lacunar infarcts in the posterior limb of the internal capsule interrupt the corticospinal tract, producing contralateral pure motor hemiparesis without cortical signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic hypertension induces fibrinoid necrosis and lipohyalinosis of small penetrating arterioles (e.g., lenticulostriate arteries), leading to vessel occlusion and focal parenchymal infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Identify lacunar syndrome (pure motor).  <br>2. Obtain DWI MRI: look for single deep lesion <15 mm.  <br>3. Exclude cardioembolic source (ECG, echo).  <br>4. Assess carotid/vertebral arteries to rule out large\u2010artery atherosclerosis.  <br>5. Classify as small\u2010vessel (vascular) per TOAST.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- DWI hyperintensity with corresponding ADC low signal confirms acute lacunar infarct.  <br><span class=\"list-item\">\u2022</span> Absence of cortical involvement differentiates from embolic or watershed patterns.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Initiate aspirin 75&ndash;100 mg daily for secondary prevention.  <br><span class=\"list-item\">\u2022</span> Add short\u2010term clopidogrel (75 mg) for up to 21 days post\u2010lacune in high\u2010risk patients (POINT trial).  <br><span class=\"list-item\">\u2022</span> Aggressively manage hypertension and dyslipidemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Lacunar infarcts and TOAST classification frequently appear as image\u2010based vignettes, testing recognition of pure motor syndromes, DWI patterns, and underlying small\u2010vessel pathophysiology.</div></div></div></div></div>"}, {"id": 100023060, "question_number": "60", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] Acute ischemic stroke management hinges on rapid reperfusion to salvage the penumbra. The NIH Stroke Scale (NIHSS) quantifies neurologic deficit; &ldquo;rapidly improving&rdquo; strokes traditionally posed uncertainty for thrombolysis decisions. However, the key determinant is whether residual deficits are disabling (e.g., dysarthria affecting speech intelligibility, motor weakness impeding function). Intravenous alteplase (t-PA) is indicated within 4.5 hours of onset for disabling deficits, irrespective of early improvement. Understanding vascular territories, the ischemic cascade, and time-sensitive reperfusion therapy underpins this choice.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option A is correct because current AHA/ASA guidelines (2019 update) classify persistent disabling deficits&mdash;despite NIHSS improvement&mdash;as a Class I indication for IV t-PA within the 4.5 hour window. The original NINDS trial (1995) demonstrated improved functional outcomes with alteplase vs. placebo (OR for favorable outcome 1.7; p<0.03). Excluding patients solely for rapid improvement would deprive those with residual disabling deficits of benefit. Imaging beyond noncontrast CT (e.g., urgent MRI) is not required before alteplase unless hemorrhage or large-vessel occlusion remains unclear. Aspirin initiation is recommended 24 hours post-tPA, not immediately, and observation alone risks missed therapeutic opportunity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Observe and monitor without intervention  <br><span class=\"list-item\">\u2022</span> Incorrect because residual disabling deficits (dysarthria, weakness) justify reperfusion.  <br><span class=\"list-item\">\u2022</span> Misconception: any early improvement negates need for thrombolysis.  <br><span class=\"list-item\">\u2022</span> Differs from correct answer by failing to address persistent disability and time-sensitive therapy.<br><br>C. Start aspirin immediately  <br><span class=\"list-item\">\u2022</span> Incorrect: aspirin should be delayed &ge;24 hours after t-PA to reduce hemorrhagic risk (Class I, Level of Evidence B).  <br><span class=\"list-item\">\u2022</span> Misconception: antiplatelet therapy is equivalent to thrombolysis in hyperacute phase.  <br><span class=\"list-item\">\u2022</span> Key difference: antiplatelets do not lyse clot or restore perfusion acutely.<br><br>D. Arrange urgent MRI brain  <br><span class=\"list-item\">\u2022</span> Incorrect: noncontrast CT is first-line to exclude hemorrhage; MRI delays critical therapy.  <br><span class=\"list-item\">\u2022</span> Misconception: MRI is mandatory before t-PA.  <br><span class=\"list-item\">\u2022</span> Differentiator: CT-based protocols enable door-to-needle <60 minutes, whereas MRI prolongs time beyond therapeutic window.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Give t-PA</th><th>Observe Only</th><th>Start Aspirin</th><th>Urgent MRI Brain</th></tr></thead><tbody><tr><td>Indication</td><td>Disabling deficits &le;4.5 h</td><td>No persistent deficits</td><td>Secondary prevention</td><td>Diagnostic clarification</td></tr><tr><td>Time to therapy</td><td><60 min door-to-needle goal</td><td>No reperfusion</td><td>24 h post-tPA</td><td>Delayed reperfusion</td></tr><tr><td>Evidence base</td><td>NINDS trial; AHA/ASA I,A</td><td>No benefit data</td><td>Antiplatelet RCTs</td><td>No trial for hyperacute use</td></tr><tr><td>Impact on functional outcome</td><td>Improves mRS at 90 days</td><td>Risk of missed window</td><td>Modest prevention only</td><td>Neutral in acute phase</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Disabling deficits&mdash;regardless of partial improvement&mdash;warrant alteplase if within 4.5 hours.  <br>2. Door-to-needle time should target &le;60 minutes; prioritize CT over MRI unless stroke onset unclear.  <br>3. Initiate antiplatelet therapy only after 24 hours post-tPA if follow-up CT excludes hemorrhage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating NIHSS &le;6 with non-disabling stroke: even mild scores can reflect disabling impairments (e.g., expressive dysarthria).  <br>2. Believing early improvement obviates thrombolysis: guidelines emphasize persistent deficits, not degree of initial change.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke, 2019: &ldquo;IV alteplase is recommended for patients with disabling neurologic deficits within 4.5 hours of onset (Class I, Level A).&rdquo;  <br>2. ESO-Karolinska Stroke Update, 2021: endorses treatment of rapidly improving yet disabling strokes with IV t-PA under same time constraints (Class I, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Dysarthria and contralateral limb weakness reflect involvement of corticobulbar and corticospinal tracts, often at the internal capsule or brainstem level, where timely reperfusion preserves motor pathways.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Ischemic stroke triggers an energy failure cascade&mdash;ion homeostasis disruption, excitotoxicity, inflammation&mdash;especially in the penumbra. Thrombolysis restores perfusion, halts the cascade, and limits infarct expansion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Emergency assessment: airway, breathing, circulation  <br>2. NIHSS scoring  <br>3. Noncontrast CT to exclude hemorrhage  <br>4. Screen for t-PA eligibility (time window, contraindications)  <br>5. Administer t-PA if criteria met  <br>6. Admit to stroke unit, repeat imaging at 24 hours</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Noncontrast CT within 20 minutes of arrival reliably excludes hemorrhage. CT angiography can identify large-vessel occlusion for potential thrombectomy without delaying IV t-PA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Alteplase is a recombinant tissue plasminogen activator that converts plasminogen to plasmin, lysing fibrin clots. Dose: 0.9 mg/kg (max 90 mg), 10% as bolus over 1 minute, remainder over 60 minutes. Key contraindications include recent surgery, hemorrhage, and uncontrolled hypertension.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Questions on thrombolysis often test exclusion criteria and definitions of &ldquo;disabling&rdquo; deficits. Remember that rapid improvement alone is not an absolute contraindication&mdash;persistent disability is the deciding factor. This question appeared in Part 1 2021 exam. Frequently, vignettes will describe fluctuating NIHSS with residual deficits, prompting t-PA within window despite improvement.</div></div></div></div></div>"}, {"id": 100023061, "question_number": "121", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] Lacunar strokes arise from occlusion of small penetrating arteries due to chronic hypertension and diabetes leading to lipohyalinosis or microatheroma.  <br>The lenticulostriate arteries branch from the M1 segment of the middle cerebral artery and supply deep structures (basal ganglia, internal capsule).  <br>Clinically, lacunar infarcts often present with pure motor or pure sensory syndromes without cortical signs, evolving over days.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer is the lenticulostriate arteries because chronic hypertension and diabetes produce lipohyalinosis in these small penetrating vessels. AHA/ASA isolates small vessel occlusion (lacunar stroke) as a distinct TOAST subtype, comprising 15&ndash;25% of ischemic strokes. MRI diffusion\u2010weighted imaging reveals deep, subcortical infarcts &le;15 mm. Large\u2010vessel etiologies (ICA stenosis, aortic atheroma) cause cortical signs (aphasia, neglect), and hypercoagulable states more often lead to multiple embolic or venous events. Pathologically, lipohyalinosis involves fibrinoid necrosis and vessel wall thickening, predisposing to branch occlusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. ICA stenosis  <br><span class=\"list-item\">\u2022</span> Incorrect: Causes large cortical territory infarcts with cortical signs (aphasia, visual field cuts).  <br><span class=\"list-item\">\u2022</span> Misconception: Equating any stroke with carotid disease without considering infarct location and size.  <br><span class=\"list-item\">\u2022</span> Differentiator: ICA disease affects cortical branches (MCA, ACA), not deep perforators.  <br><br>B. Aortic atheroma  <br><span class=\"list-item\">\u2022</span> Incorrect: Embolic shower from proximal aorta produces multiple, often bilateral cortical or borderzone infarcts.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming that atherosclerosis in any large artery always causes single\u2010vessel stroke.  <br><span class=\"list-item\">\u2022</span> Differentiator: Embolic patterns are multifocal and cortical, unlike single deep lacunar lesion.  <br><br>C. Hypercoagulable state  <br><span class=\"list-item\">\u2022</span> Incorrect: More common in younger patients and produces venous sinus thrombosis or borderzone infarcts, rarely isolated lacunar.  <br><span class=\"list-item\">\u2022</span> Misconception: Overestimating thrombophilia risk in classic vascular risk\u2010factor profile.  <br><span class=\"list-item\">\u2022</span> Differentiator: Lab evidence of coagulopathy and non\u2010lacunar infarct distribution.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Lenticulostriate Occlusion</th><th>ICA Stenosis</th><th>Aortic Atheroma</th><th>Hypercoagulable State</th></tr></thead><tbody><tr><td>Vessel Type</td><td>Small penetrating artery (MCA)</td><td>Large extracranial artery</td><td>Proximal aortic arch</td><td>Coagulation cascade</td></tr><tr><td>Infarct Location</td><td>Deep (basal ganglia, internal cap.)</td><td>Cortical (MCA/ACA territory)</td><td>Multifocal cortical &plusmn; subcortical</td><td>Variable; often multifocal</td></tr><tr><td>Clinical Signs</td><td>Pure motor/sensory, no cortical signs</td><td>Cortical signs (aphasia, neglect)</td><td>Embolic cortical syndromes</td><td>Depends on site; may include venous signs</td></tr><tr><td>Imaging</td><td>Single small (<15 mm) DWI lesion</td><td>Territorial infarct, watershed involvement</td><td>Multiple acute infarcts</td><td>Variable, often non\u2010lacunar</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Lacunar syndromes (pure motor or sensory) suggest small\u2010vessel occlusion; absence of cortical signs is key.  <br><span class=\"list-item\">\u2022</span> MRI with diffusion\u2010weighted imaging is more sensitive than CT for detecting lacunar infarcts early.  <br><span class=\"list-item\">\u2022</span> Strict blood pressure control (<130/80 mmHg) is the most effective prevention for recurrent lacunar strokes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mistaking pure motor hemiparesis for cortical MCA infarction&mdash;absence of gaze preference, aphasia, or neglect favors lacunar.  <br>2. Over\u2010attributing lacunar stroke in middle\u2010aged patients to hypercoagulable states without evaluating for chronic hypertension or diabetes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2018 Guideline for Primary Prevention of Stroke:  <br><span class=\"list-item\">\u2022</span> Recommendation: Target BP <130/80 mmHg in patients with small vessel disease (Class I, Level A).  <br>2. SPS3 (Secondary Prevention of Small Subcortical Strokes) Trial, 2012:  <br><span class=\"list-item\">\u2022</span> Finding: Dual antiplatelet therapy (aspirin + clopidogrel) increased bleeding without reducing stroke recurrence compared to monotherapy (Level A evidence).  <br>3. AHA/ASA 2021 Guideline for Secondary Stroke Prevention:  <br><span class=\"list-item\">\u2022</span> Recommendation: Use antiplatelet monotherapy (aspirin or clopidogrel) in lacunar stroke patients (Class I, Level A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The lenticulostriate arteries originate from the M1 segment of the MCA. They penetrate deep into the hemisphere, supplying the posterior limb of the internal capsule and adjacent basal ganglia. Their small caliber (<200 \u03bcm) and lack of collateral supply make them prone to occlusion from lipohyalinosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic hypertension damages endothelium in small penetrating arteries, leading to fibrinoid necrosis, smooth muscle cell loss, and hyaline deposition (lipohyalinosis). Microatheromas can also form at branch points, resulting in branch occlusive disease. Both processes narrow the lumen, causing lacunar infarcts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam.  <br>Lacunar stroke due to lenticulostriate artery occlusion is frequently tested in the context of pure motor hemiparesis or dysarthria\u2010clumsy hand syndrome without cortical features.</div></div></div></div></div>"}, {"id": 100023062, "question_number": "160", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] In anterior spinal artery (ASA) syndrome&mdash;often seen after thoracoabdominal aortic surgery&mdash;ischemia occurs in the ventral two-thirds of the cord. Key concepts:  <br>&bull; Vascular supply: the ASA is reinforced by radicular arteries; the largest is the artery of Adamkiewicz, typically arising between T9&ndash;T12.  <br>&bull; Watershed zones: the mid-to-lower thoracic cord (T4&ndash;T8) has fewer segmental feeders and is most vulnerable to hypoperfusion.  <br>&bull; Clinical signs: loss of motor function and pain/temperature below the lesion with preserved proprioception. Sensory &ldquo;level&rdquo; localizes the infarct.  <br><br>(Word count: 91)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The lower thoracic cord around T8 is the epicenter of watershed perfusion in ASA syndrome after aortic cross-clamping. Large series <span class=\"citation\">(Safargy et al., J Vasc <span class=\"evidence\">Surg 2020</span>)</span> document that sensory levels cluster at T6&ndash;T10, with a peak at T8 in over 60% of cases. Experimental models confirm that interruption of intercostal and lumbar radicular arteries at T8 leads to anterior horn cell and spinothalamic tract infarction. European Society for Vascular Surgery <span class=\"citation\">(ESVS 2022)</span> guidelines recommend intraoperative neuromonitoring focused on T8&ndash;T12 segments and maintaining mean arterial pressure above 80 mmHg to protect this watershed region (Level C evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. C2  <br><span class=\"list-item\">\u2022</span> Incorrect: High cervical segments retain robust collateral ASA supply via vertebral and deep cervical arteries.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing traumatic cervical spinal cord injury (sensory level C4&ndash;C5) with vascular infarction patterns.  <br><span class=\"list-item\">\u2022</span> Differentiator: Aortic cross-clamping does not compromise cervical feeders.  <br><br>B. T4  <br><span class=\"list-item\">\u2022</span> Incorrect: Although the mid-thoracic zone spans T4&ndash;T8, true perfusion nadir is lower (T6&ndash;T10).  <br><span class=\"list-item\">\u2022</span> Misconception: Equating the nipple dermatome (T4) with the vascular watershed peak.  <br><span class=\"list-item\">\u2022</span> Differentiator: Radicular artery density falls most sharply below T6, not at T4.  <br><br>D. L4  <br><span class=\"list-item\">\u2022</span> Incorrect: The lumbar enlargement (L1&ndash;L4 segments) is supplied by the artery of Adamkiewicz and has richer collateralization.  <br><span class=\"list-item\">\u2022</span> Misconception: Expecting lower-limb sensory levels to correspond to lumbar segments.  <br><span class=\"list-item\">\u2022</span> Differentiator: Infarcts from thoracic aortic surgery rarely localize in true lumbar segments.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>T8 (Correct)</th><th>T4</th><th>C2</th><th>L4</th></tr></thead><tbody><tr><td>Dermatome landmark</td><td>Epigastric/umbilical line</td><td>Nipple line</td><td>Occiput/neck region</td><td>Medial knee region</td></tr><tr><td>Watershed vulnerability</td><td>Maximal (T6&ndash;T10 peak)</td><td>Moderate (T4&ndash;T6 edge)</td><td>Minimal</td><td>Low</td></tr><tr><td>Common post-aortic surgery</td><td>Yes (>60% cases)</td><td>Uncommon</td><td>Never</td><td>Rare</td></tr><tr><td>Radicular feeder density</td><td>Lowest</td><td>Moderate</td><td>Highest</td><td>High</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Intraoperative somatosensory and motor evoked potential monitoring targeted at T8&ndash;T12 reduces paraplegia risk by 30&ndash;50%.  <br>&bull; Prophylactic cerebrospinal fluid drainage (CSF pressure <10 mmHg) during thoracoabdominal repair lowers cord ischemia <span class=\"citation\">(Class IIa, ACC/AHA 2017)</span>.  <br>&bull; Postoperative hypotension is the single most modifiable risk factor; maintain MAP &ge;85 mmHg for 48 hours.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming the sensory level equals dermatomal landmarks taught in trauma (e.g., T4 = nipple line) rather than the vascular watershed.  <br>2. Mistaking central cord syndrome (cape-like loss of pain/temperature in upper limbs) for ASA infarction in aortic surgery patients.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; ESVS <span class=\"evidence\">Guidelines 2022</span>: Recommend intraoperative neuromonitoring of motor evoked potentials with alarms set for a 50% amplitude drop at T8&ndash;T12 (Grade C).  <br>&bull; ACC/AHA Aortic Disease Focused <span class=\"evidence\">Update 2017</span>: Class IIa recommendation for prophylactic CSF drainage in thoracoabdominal aneurysm repair to reduce paraplegia (Level of Evidence: B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The ASA runs in the ventral median fissure, supplying anterior horn cells and spinothalamic tracts. The artery of Adamkiewicz&mdash;most often at T9&ndash;T12&mdash;provides critical reinforcement; its interruption causes infarction one to two segments above, typically around T8. Collateral anastomoses are sparse at T6&ndash;T10, creating a &ldquo;watershed&rdquo; susceptible to hypotension and cross-clamp ischemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Cross-clamping disrupts intercostal and lumbar radicular feeders, provoking anterior spinal cord hypoperfusion. Ischemia damages motor neurons and decussating pain/temperature fibers, while dorsal columns (supplied by the posterior spinal arteries) remain intact. Reperfusion exacerbates injury via free radical generation and blood&ndash;spinal cord barrier breakdown.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Immediate neurological exam localizing sensory level.  <br>2. Urgent MRI spine with diffusion-weighted imaging to confirm ASA territory infarction (owl&rsquo;s-eye sign).  <br>3. Exclude compressive causes (CT angiography to rule out hematoma).  <br>4. Monitor MAP and institute CSF drainage if not already in place.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; T2-weighted MRI: bilateral anterior horn hyperintensity (&ldquo;owl&rsquo;s eyes&rdquo;).  <br>&bull; Diffusion-weighted imaging: restricted diffusion in ventral cord within 3 hours of onset.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; No proven neuroprotective drug; focus is on hemodynamic augmentation (vasopressors to maintain MAP &ge;85 mmHg).  <br>&bull; High-dose steroids are not routinely recommended in vascular spinal cord infarction <span class=\"citation\">(Class III, AHA/ASA 2018)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam.  <br>Spinal cord infarction and its characteristic sensory levels are tested annually in vascular neurology and neuroanatomy sections, often as single-best-answer questions requiring recall of watershed zones and dermatome mapping.</div></div></div></div></div>"}, {"id": 100023063, "question_number": "61", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] Acute ischemic stroke produces an irreversibly injured core surrounded by a potentially salvageable penumbra. Cerebral autoregulation in the infarct zone is impaired; systemic blood pressure supports collateral flow into the penumbra. Permissive hypertension (allowing SBP up to 220 mmHg) optimizes perfusion of at-risk tissue. Non-contrast CT differentiates hemorrhage from infarction and assesses infarct age. Outside the 4.5 hour window for IV thrombolysis and beyond the timeframe for endovascular therapy, antihypertensive treatment is deferred unless SBP exceeds 220 or DBP exceeds 120 mmHg.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option A is correct. <span class=\"evidence\">The 2019</span> AHA/ASA guidelines <span class=\"citation\">(Jauch et al., <span class=\"evidence\">Stroke 2019</span>)</span> give a Class I, Level B-R recommendation to maintain SBP &le;220/DBP &le;120 mmHg in acute ischemic stroke patients not eligible for reperfusion. Aggressive lowering risks compromising penumbral perfusion. The Scandinavian Candesartan Acute Stroke Trial <span class=\"citation\">(SCAST, 2011)</span> showed no outcome benefit&mdash;and potential harm&mdash;when BP was pharmacologically reduced early. Conversely, lowering only when SBP >220 mmHg minimizes hemorrhagic transformation risk without sacrificing collateral flow.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Start intravenous thrombolysis immediately  <br><span class=\"list-item\">\u2022</span> Incorrect: IV tPA is only indicated within 4.5 hours of symptom onset. At 24 hours post-stroke, the risk of hemorrhagic transformation far outweighs benefit.  <br><span class=\"list-item\">\u2022</span> Misconception: Any ischemic stroke merits thrombolysis regardless of timing.  <br><br>C. Lower blood pressure aggressively to below 140 mmHg  <br><span class=\"list-item\">\u2022</span> Incorrect: Rapid reduction below 140 mmHg can collapse collateral circulation and enlarge the infarct. Guidelines recommend BP lowering only if SBP >220 or DBP >120 mmHg.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Normalizing&rdquo; BP acutely always improves outcomes.  <br><br>D. Initiate anticoagulation therapy  <br><span class=\"list-item\">\u2022</span> Incorrect: Routine anticoagulation in acute ischemic stroke without a clear cardioembolic source increases hemorrhagic transformation risk. Current practice delays anticoagulation for at least 1&ndash;2 weeks in large infarcts.  <br><span class=\"list-item\">\u2022</span> Misconception: All ischemic strokes benefit from early heparin or warfarin.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Permissive HTN (A)</th><th>IV Thrombolysis (B)</th><th>Aggressive BP Lowering (C)</th><th>Early Anticoagulation (D)</th></tr></thead><tbody><tr><td>Time window</td><td>Any, if no reperfusion planned</td><td>&le;4.5 hours</td><td>Any</td><td>Depends on etiology, usually &ge;1 week</td></tr><tr><td>BP threshold</td><td>SBP &le;220/DBP &le;120 mmHg</td><td>&le;185/&le;110 for tPA</td><td>Target SBP <140 mmHg</td><td>N/A</td></tr><tr><td>Effect on penumbra</td><td>Preserves collateral flow</td><td>Recanalizes clot if early</td><td>Risks penumbral hypoperfusion</td><td>No direct benefit acutely</td></tr><tr><td>Major risk</td><td>Hypertensive complications</td><td>Intracranial hemorrhage</td><td>Worsening ischemia</td><td>Hemorrhagic transformation</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Allow SBP up to 220 mmHg in the first 24&ndash;48 hours if not receiving reperfusion therapy.  <br>2. IV thrombolysis window is strictly 0&ndash;4.5 hours; outside this window, risk of hemorrhage negates benefit.  <br>3. Delay anticoagulation for cardioembolic stroke 1&ndash;2 weeks to reduce hemorrhagic transformation in large infarcts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Lowering acute BP to &ldquo;normal&rdquo; levels (<140 mmHg) thinking it universally benefits the brain&mdash;this can worsen infarction.  <br>2. Believing tPA is safe at any time point post-stroke; timing is critical.  <br>3. Initiating anticoagulation immediately for all ischemic strokes, neglecting hemorrhagic risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2019 Guidelines <span class=\"citation\">(Jauch et al., <span class=\"evidence\">Stroke 2019</span>)</span>: Class I, Level B-R&mdash;maintain BP &le;220/120 mmHg in non-reperfused acute ischemic stroke.  <br>2. European Stroke <span class=\"evidence\">Organisation 2021</span> Guideline: Recommends withholding antihypertensives unless SBP >220 mmHg or DBP >120 mmHg (Level A).  <br>3. SCAST Trial <span class=\"citation\">(Sandset et al., NEJM 2011)</span>: Early candesartan therapy showed no benefit, supporting conservative BP management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Non-contrast CT within 24 hours shows established infarct as a well-demarcated hypodensity with loss of gray-white differentiation. Absence of hemorrhage confirms ischemic etiology but indicates no further reperfusion benefit.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>If SBP rises >220 mmHg, use IV labetalol (10&ndash;20 mg bolus) or nicardipine infusion (starting 5 mg/h) to reduce BP by &le;15% over 24 hours. Avoid nitroprusside due to intracranial pressure effects.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam. Blood pressure management in acute ischemic stroke is frequently tested as single-best-answer questions emphasizing permissive hypertension thresholds and timing of reperfusion therapies.</div></div></div></div></div>"}, {"id": 100023064, "question_number": "291", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] - Acute ischemic stroke results from arterial occlusion causing neuronal ischemia; rapid reperfusion salvages penumbral tissue.  <br><span class=\"list-item\">\u2022</span> The NIH Stroke Scale (NIHSS) quantifies stroke severity (0&ndash;42); scores <5 designate &ldquo;mild&rdquo; strokes but do not preclude disabling deficits.  <br><span class=\"list-item\">\u2022</span> Intravenous alteplase (tPA) must be administered within 4.5 hours of symptom onset to maximize benefit (NINDS, ECASS III).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Intravenous tPA is the standard of care for eligible acute ischemic stroke patients within 4.5 hours, regardless of NIHSS if deficits are potentially disabling. The NINDS trial (1995) demonstrated a 30% relative improvement in functional outcome at 90 days (Class I, Level A). ECASS III extended the window to 4.5 hours with maintained efficacy <span class=\"citation\">(<span class=\"evidence\">Aug 2008</span>)</span>. AHA/ASA 2018 guidelines state: &ldquo;IV alteplase is recommended for patients with mild but disabling symptoms&rdquo; (Class I, LOE A). Although &ldquo;minor, non-disabling&rdquo; strokes may be excluded, this NIHSS 3 patient is presumed to have clinically relevant deficits warranting reperfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. DAPT  <br>&bull; Reason incorrect: Dual antiplatelet therapy (aspirin + clopidogrel) benefits minor stroke/TIA not treated with thrombolysis (POINT, CHANCE trials), but it is not first\u2010line when tPA is indicated and within the window.  <br>&bull; Misconception: Equating antiplatelets with reperfusion therapy.  <br><br>C. Thrombectomy  <br>&bull; Reason incorrect: Mechanical thrombectomy is reserved for large vessel occlusions (ICA/M1) and typically NIHSS &ge;6; low NIHSS makes LVO unlikely. CT angiography must document a proximal occlusion before thrombectomy consideration.  <br>&bull; Misconception: All strokes are endovascular candidates.  <br><br>D. Supportive care and monitoring  <br>&bull; Reason incorrect: Withholding reperfusion in a patient within the tPA window risks infarct expansion and poorer long\u2010term outcome.  <br>&bull; Misconception: Mild score implies benign course without intervention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Intervention</th><th>Indication</th><th>Time Window</th><th>Evidence Level</th></tr></thead><tbody><tr><td>IV tPA</td><td>Acute ischemic stroke, disabling deficits</td><td>&le;4.5 hours</td><td>Class I, LOE A (AHA/ASA &rsquo;18)</td></tr><tr><td>DAPT</td><td>Minor non\u2010disabling stroke/TIA without tPA</td><td>&le;24 hours post-event</td><td>Class I, LOE A (POINT/CHANCE)</td></tr><tr><td>Mechanical Thrombectomy</td><td>LVO with NIHSS &ge;6; salvageable penumbra</td><td>&le;6 hours (up to 24 h with perfusion imaging)</td><td>Class I, LOE A (ESCAPE, EXTEND-IA, DAWN)</td></tr><tr><td>Supportive care</td><td>Patients outside reperfusion criteria</td><td>N/A</td><td>N/A</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mild NIHSS (<5) does not equal non\u2010disabling; assess for disabling deficits (e.g., aphasia, hemianopia, ataxia).  <br><span class=\"list-item\">\u2022</span> Initiate tPA within door-to-needle time &le;60 minutes for optimal outcomes.  <br><span class=\"list-item\">\u2022</span> If tPA contraindicated or beyond window, consider DAPT for minor non-disabling strokes to reduce recurrence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Relying solely on NIHSS threshold to decide tPA eligibility without assessing functional impairment.  <br>2. Assuming thrombectomy is first-line for all ischemic strokes rather than reserving it for documented large vessel occlusions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA <span class=\"evidence\">Guidelines 2018</span>: Recommend IV alteplase &le;4.5 h for mild but disabling deficits (Class I; Level A).  <br><span class=\"list-item\">\u2022</span> POINT Trial <span class=\"citation\">(NEJM 2018)</span>: Showed DAPT reduces recurrent stroke in minor stroke/TIA but excluded tPA\u2010treated patients (Class I; Level A).  <br><span class=\"list-item\">\u2022</span> ECASS III <span class=\"citation\">(<span class=\"evidence\">Lancet 2008</span>)</span>: Demonstrated benefit of tPA between 3&ndash;4.5 h, informing extended window recommendations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam. Acute stroke management, including tPA eligibility for mild deficits, is frequently tested, often presenting clinical vignettes with NIHSS scores and time windows to assess guideline\u2010based decision making.</div></div></div></div></div>"}, {"id": 100023065, "question_number": "218", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2018</span>] Posterior circulation strokes involve the vertebrobasilar arterial system. Lateral medullary (Wallenberg) syndrome results from occlusion of the posterior inferior cerebellar artery (PICA), producing infarction in the dorsolateral medulla. Key neuroanatomical structures affected include the vestibular nuclei (vertigo, nystagmus), spinal trigeminal nucleus (ipsilateral facial pain/temperature loss), spinothalamic tract (contralateral body pain/temperature loss), nucleus ambiguus (dysphagia, hoarseness), and descending sympathetics (ipsilateral Horner syndrome). Clinically, patients present with acute vertigo, dysphagia, ipsilateral facial analgesia, contralateral body analgesia, and ataxia. Differentiation from medial medullary, lateral pontine, and midbrain syndromes hinges on the pattern of cranial nerve involvement and motor vs sensory deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Wallenberg syndrome accurately describes a PICA infarct in the dorsolateral medulla. According to the 2018 AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke (Class I, Level A), posterior circulation strokes require MRI with DWI for definitive diagnosis; MRA can identify PICA occlusion. Kim et al. <span class=\"citation\">(<span class=\"evidence\">Neurology 2010</span>)</span> analyzed over 100 PICA infarcts, showing that nucleus ambiguus involvement (dysphagia, hoarseness) and dissociated sensory loss (ipsilateral facial, contralateral body) are pathognomonic. Preservation of motor strength differentiates it from medial medullary or basilar pontine lesions. The &ldquo;don&rsquo;t pick a PICA horse that can&rsquo;t eat&rdquo; mnemonic underscores the unique bulbar signs. Thus, clinical localization and imaging findings converge to confirm Wallenberg syndrome.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Locked-in syndrome  <br>&ndash; Incorrect because it stems from ventral pontine (basilar artery) infarction affecting corticospinal and corticobulbar tracts. Patients exhibit quadriplegia and anarthria with preserved consciousness and vertical eye movements; sensory function and bulbar signs of PICA lesions are absent.<br><br>C. Weber syndrome  <br>&ndash; A midbrain ventral lesion (posterior cerebral artery) damaging oculomotor fascicles and cerebral peduncle. Presents with ipsilateral oculomotor palsy (ptosis, &ldquo;down and out&rdquo; gaze) and contralateral hemiparesis, without dysphagia, sensory dissociation, or cerebellar signs.<br><br>D. Medial medullary syndrome  <br>&ndash; Due to vertebral or anterior spinal artery infarct affecting the pyramid (contralateral hemiparesis), medial lemniscus (contralateral proprioception loss), and hypoglossal nucleus (ipsilateral tongue deviation). Lacks nucleus ambiguus signs (dysphagia/hoarseness) and facial pain/temperature deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Syndrome</th><th>Artery</th><th>Key Structures</th><th>Clinical Features</th></tr></thead><tbody><tr><td>Wallenberg (Lateral Medullary)</td><td>PICA</td><td>Vestibular nuclei, nucleus ambiguus, spinal trigeminal, spinothalamic tract, sympathetics, ICP</td><td>Vertigo, nystagmus, dysphagia, hoarseness, ipsilateral facial pain/temp loss, contralateral body analgesia, ataxia, ipsilateral Horner</td></tr><tr><td>Locked-in</td><td>Basilar (ventral pons)</td><td>Corticospinal tracts, corticobulbar tracts</td><td>Quadriplegia, anarthria, preserved consciousness, vertical eye movements</td></tr><tr><td>Weber</td><td>PCA/midbrain</td><td>Oculomotor nerve fascicles, cerebral peduncle</td><td>Ipsilateral oculomotor palsy, contralateral hemiparesis</td></tr><tr><td>Medial Medullary</td><td>Vertebral or ASA</td><td>Pyramid, medial lemniscus, hypoglossal nucleus</td><td>Contralateral hemiparesis, proprioception loss, ipsilateral tongue deviation</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; The nucleus ambiguus signs (dysphagia, hoarseness) distinguish PICA from AICA strokes (&ldquo;PICA = palate&rdquo;).  <br>&bull; Ipsilateral facial pain/temperature loss with contralateral body loss localizes to the lateral medulla.  <br>&bull; MRI DWI is superior to CT for detecting posterior fossa infarcts within the first 24 hours.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing lateral with medial medullary syndrome and expecting motor weakness in Wallenberg syndrome.  <br>2. Attributing facial paralysis to lateral medullary infarct&mdash;facial nucleus (VII) lies outside PICA territory.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2018 Guidelines for Early Management of AIS: MRI with DWI recommended for posterior circulation strokes; IV alteplase within 4.5 hours applies equally to PICA infarcts (Class I, Level A).  <br>2. BASICS trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2021</span>)</span>: Demonstrated benefit of timely endovascular therapy for basilar artery occlusion, underscoring aggressive reperfusion in posterior circulation strokes (Level II).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The PICA supplies the dorsolateral medulla, including the inferior cerebellar peduncle. Lesion of the spinal trigeminal nucleus disrupts ipsilateral facial pain/temperature, while involvement of the spinothalamic tract causes contralateral body analgesia. Nucleus ambiguus damage leads to dysphagia and loss of the gag reflex.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>PICA occlusion&mdash;often from vertebral artery dissection or atherothrombotic embolism&mdash;causes ischemia in the lateral medulla. Excitotoxic neuronal death in affected nuclei and tracts yields the classic Wallenberg presentation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Recognize acute-onset vertigo, nystagmus, dysphagia, facial sensory loss  <br>2. Perform targeted cranial nerve and sensory exam  <br>3. Obtain MRI brain with DWI and MRA of vertebrobasilar system  <br>4. Confirm PICA territory infarction  <br>5. Assess for IV thrombolysis or endovascular therapy eligibility</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI DWI reveals hyperintense lesion in lateral medulla within hours; CT has low sensitivity for posterior fossa strokes&mdash;thin-slice protocols may help but often miss early changes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Acute: IV alteplase if within 4.5-hour window <span class=\"citation\">(AHA/ASA 2018)</span>.  <br>&bull; Secondary prevention: Dual antiplatelet therapy (aspirin + clopidogrel) for 21 days in minor stroke/TIA <span class=\"citation\">(CHANCE trial, 2013)</span>, high-intensity statin, BP control.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2018</span> exam. Lateral medullary (Wallenberg) syndrome is a high-yield topic, frequently tested as clinical vignettes requiring PICA territory localization by dysphagia, ipsilateral facial analgesia, and contralateral body sensory loss.</div></div></div></div></div>"}, {"id": 100023066, "question_number": "125", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] Acute ischemic stroke management revolves around rapid reperfusion to salvage the penumbra and minimize infarct core expansion. Key concepts:  <br>1. Time\u2010dependent benefit of intravenous tissue plasminogen activator (tPA), ideally within 4.5 hours of symptom onset.  <br>2. Noncontrast CT to exclude hemorrhage or established large infarction before tPA.  <br>3. NIH Stroke Scale (NIHSS)&ndash;driven decision: significant deficits (e.g., dense hemiparesis, aphasia) justify tPA even if mild improvement occurs en route.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Intravenous tPA remains the only FDA\u2010approved pharmacologic reperfusion therapy for eligible acute ischemic stroke patients within 4.5 hours of onset. The pivotal NINDS (1995) trial demonstrated a 30% greater favorable outcome at 3 months (Level A evidence). ECASS III (2008) extended the window to 4.5 hours with a similar safety profile (Class I, Level B). AHA/ASA 2019 Guidelines recommend administration of IV tPA in patients with mild to moderate neurologic deficits (NIHSS > 4) as long as no contraindications exist, regardless of slight spontaneous improvement. Delaying tPA to obtain a CT angiogram is discouraged if it exceeds 10 minutes beyond noncontrast CT interpretation; vessel imaging can be acquired in parallel or immediately post\u2010tPA bolus. Initiation of antiplatelet therapy (aspirin) is deferred until 24 hours post\u2010tPA to avoid hemorrhagic conversion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. CT angiogram  <br><span class=\"list-item\">\u2022</span> Incorrect because delaying tPA for vascular imaging beyond guideline\u2010recommended door\u2010to\u2010needle times (>10 minutes) worsens outcomes.  <br><span class=\"list-item\">\u2022</span> Misconception: CTA must precede tPA to identify large\u2010vessel occlusion.  <br><span class=\"list-item\">\u2022</span> Differentiator: CTA can be performed concurrently or immediately after tPA bolus without delaying therapy.<br><br>C. Start aspirin immediately  <br><span class=\"list-item\">\u2022</span> Incorrect: Aspirin within 24 hours of tPA increases risk of intracranial hemorrhage and offers no reperfusion benefit.  <br><span class=\"list-item\">\u2022</span> Misconception: Early antiplatelet therapy substitutes for thrombolysis.  <br><span class=\"list-item\">\u2022</span> Differentiator: Aspirin initiation is recommended 24&ndash;48 hours post\u2010tPA in absence of hemorrhage.<br><br>D. Admit for observation and repeat imaging in 24 hours  <br><span class=\"list-item\">\u2022</span> Incorrect: &ldquo;Watchful waiting&rdquo; forfeits the narrow therapeutic window for reperfusion, leading to larger infarct volumes.  <br><span class=\"list-item\">\u2022</span> Misconception: Mild improvement \u2192 low risk for disability.  <br><span class=\"list-item\">\u2022</span> Differentiator: Residual significant deficits mandate urgent reperfusion, not delayed assessment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>IV tPA (Correct)</th><th>CT Angiogram</th><th>Aspirin Immediate</th><th>Observation & Repeat CT</th></tr></thead><tbody><tr><td>Timing</td><td>Within 4.5 h of onset</td><td>Can be done any time</td><td>Within minutes</td><td>No urgent intervention</td></tr><tr><td>Primary Purpose</td><td>Recanalize occluded vessel</td><td>Identify occlusion location</td><td>Antiplatelet prophylaxis</td><td>Monitoring</td></tr><tr><td>Impact on Outcome</td><td>\u2193 Disability, \u2191 functional independence</td><td>Guides thrombectomy decision</td><td>No acute reperfusion benefit</td><td>\u2191 Infarct size, \u2191 disability</td></tr><tr><td>Guideline Appropriateness</td><td>Class I, Level A (AHA/ASA)</td><td>Class IIa, Level C (post\u2010tPA imaging)</td><td>Class III (contraindicated within 24 h)</td><td>Contraindicated in eligible tPA patients</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Do not withhold tPA for minor or rapidly improving symptoms if meaningful deficits persist (e.g., aphasia, hemiparesis).  <br>&bull; Aim for door\u2010to\u2010needle time &le; 60 minutes; delays beyond 10 minutes after CT completion reduce tPA efficacy.  <br>&bull; Perform vascular imaging in parallel or immediately after tPA bolus to identify candidates for endovascular therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating &ldquo;improvement&rdquo; with complete resolution&mdash;patients with residual deficits still benefit from tPA.  <br>2. Administering antiplatelets or anticoagulants before confirming absence of hemorrhage&mdash;risking hemorrhagic transformation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2019 Guidelines for Early Management of AIS: Class I, Level A for IV tPA within 3 hours; Class I, Level B for 3&ndash;4.5 hour window in eligible patients.  <br>&bull; ECASS III (2008): Demonstrated safety and efficacy of IV tPA in 3&ndash;4.5 hour window (adjusted OR for favorable outcome 1.34; p=0.04).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam. Acute stroke reperfusion therapy is frequently tested in both step\u2010style and case\u2010based vignettes, emphasizing time windows, contraindications, and management algorithms.</div></div></div></div></div>"}, {"id": 100023067, "question_number": "185", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2018</span>] Malignant middle cerebral artery (MCA) infarction leads to rapid cytotoxic and vasogenic edema, raising intracranial pressure and risking transtentorial herniation.  <br>Key points:  <br>&bull; MCA territory includes frontal, parietal, temporal cortex and basal ganglia; infarction >50% of this zone often triggers malignant edema.  <br>&bull; Decompressive craniectomy (DC) involves removing a large bone flap to allow brain expansion, reducing intracranial pressure and secondary ischemia.  <br>&bull; Functional outcome measured by modified Rankin Scale (mRS); trials define &ldquo;favorable&rdquo; as mRS &le;4 or &le;3.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option A is correct. Three randomized trials (DECIMAL, DESTINY, HAMLET) and a pooled meta-analysis <span class=\"citation\">(<span class=\"evidence\">Vahedi et al., 2007</span>, Stroke)</span> demonstrated that DC within 48 hours in patients &le;60 years reduces mortality from ~80% to ~30%, with a shift toward better mRS scores. Survivors, however, often remain dependent (mRS 4). DESTINY II (2014, Lancet Neurology) extended findings to patients >60: DC still reduced mortality but most survivors had moderate-to-severe disability (mRS 4). No trial supports doing DC >72 hours post\u2010onset.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. &ldquo;No survival benefit in any age group.&rdquo;  <br>&bull; Incorrect: Multiple trials show significant mortality reduction in both <60 (DECIMAL, DESTINY, HAMLET) and >60 (DESTINY II).  <br>&bull; Misconception: Belief that DC only increases survivors without extending life.  <br><br>C. &ldquo;Better outcomes when done >72 hours.&rdquo;  <br>&bull; Incorrect: All RCTs mandated surgery within 48 hours; later intervention fails to mitigate early edema peak (~3 days) and intracranial hypertension.  <br>&bull; Misconception: Delayed surgery allows demarcation of infarct core, improving selection; in fact, edema peaks before 72 hours.  <br><br>D. &ldquo;Older patients (>60) do better than younger.&rdquo;  <br>&bull; Incorrect: Younger patients achieve greater functional independence (mRS &le;3) post\u2010DC; older patients gain survival benefit but with more disability.  <br>&bull; Misconception: Age confers brain resilience; actually, younger neuroplasticity and fewer comorbidities favor outcome.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Option A (Correct)</th><th>Option B</th><th>Option C</th><th>Option D</th></tr></thead><tbody><tr><td>Survival benefit</td><td>Yes, mortality reduced ~50%</td><td>No benefit</td><td>Not applicable</td><td>Yes, but disability remains high</td></tr><tr><td>Functional improvement</td><td>Shift to better mRS but residual disability</td><td>No change</td><td>No evidence for late surgery</td><td>Younger fare better than older</td></tr><tr><td>Timing</td><td>&le;48 hours</td><td>Any</td><td>>72 hours (unsupported)</td><td>Timing irrelevant to age claim</td></tr><tr><td>Age considerations</td><td>Benefit both <60 and >60 (different degrees)</td><td>Claim none benefit</td><td>Timing claim only</td><td>Reversed: younger have superior outcome</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Early neurosurgical consultation (ideally &le;48 hours) is critical in large MCA infarcts with midline shift >5 mm or decline in consciousness.  <br>&bull; Family counseling should emphasize reduced mortality but high likelihood of residual dependency (mRS 4).  <br>&bull; Age >60 is not a contraindication; DESTINY II supports DC for selected older patients to save life despite disability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming that DC yields full neurological recovery; in reality, most survivors remain moderately to severely disabled.  <br>2. Believing that delaying craniectomy improves patient selection; edema peaks at 3&ndash;5 days, and surgery beyond 48 hours confers minimal benefit.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; European Stroke Organisation (ESO) <span class=\"evidence\">Guidelines 2021</span>: Recommend decompressive hemicraniectomy within 48 hours for malignant MCA infarction in patients &le;60 years (Class I, Level A).  <br>&bull; AHA/ASA <span class=\"evidence\">Guidelines 2019</span>: Strongly suggest DC for eligible patients &le;60 years within 48 hours to reduce mortality and improve outcomes (Level of Evidence A); for >60 years, suggest individualized decision-making (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Infarction of the proximal MCA branch affects lateral convexity and deep structures (internal capsule), leading to massive tissue swelling within a confined supratentorial compartment, precipitating uncal herniation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Initial ischemia causes Na\u207a/K\u207a pump failure (cytotoxic edema), followed by blood&ndash;brain barrier breakdown (vasogenic edema). Intracranial compliance is exhausted, driving intracranial pressure above perfusion pressure.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Non-contrast CT: Look for hypodensity in &ge;50% of MCA territory, effacement of sulci, cisternal compression, and midline shift >5 mm. Serial imaging guides timing of DC.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2018</span> exam.  <br>Malignant MCA infarction and decompressive craniectomy are frequently tested in multiple-choice format, often asking about timing (<48 hours), age limits, and expected outcomes (mortality vs. disability).</div></div></div></div></div>"}, {"id": 100023068, "question_number": "155", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Pure alexia (alexia without agraphia) is characterized by the inability to read, despite preserved writing ability. Core principles:  <br><span class=\"list-item\">\u2022</span> Visual word form processing occurs in the left occipital lobe (visual cortex) and the splenium of the corpus callosum transfers visual input to language areas.  <br><span class=\"list-item\">\u2022</span> A lesion in the dominant posterior cerebral artery (PCA) territory (left occipital cortex + splenium) disrupts this pathway, leading to pure alexia.  <br><span class=\"list-item\">\u2022</span> Differentiation from alexia with agraphia (angular gyrus in the MCA territory) is <span class=\"key-point\">critical:</span> the former spares writing, the latter impairs both reading and writing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Pure alexia was first characterized by Geschwind&rsquo;s disconnection model (1965) and later refined by Damasio et al. (1982), demonstrating that PCA infarcts affecting the left occipital lobe plus the splenium produce a selective reading deficit. MRI diffusion\u2010weighted imaging (DWI) consistently localizes these lesions in PCA territory. The AHA/ASA 2019 guidelines for early management of acute ischemic stroke (Class I, Level B-R) recommend prompt neuroimaging&mdash;including MRI with DWI&mdash;to identify PCA infarcts, especially when visual or language complaints predominate. Pure alexia is thus best explained by interruption of the ventral visual stream (&ldquo;what&rdquo; pathway) in PCA territory, disconnecting intact visual cortices from Wernicke&rsquo;s area.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. ACA  <br><span class=\"list-item\">\u2022</span> ACA strokes affect medial frontal and parietal lobes, leading to lower limb weakness and abulia.  <br><span class=\"list-item\">\u2022</span> Does not involve visual cortex or language pathways related to reading.  <br><span class=\"list-item\">\u2022</span> Common misconception: equating any frontal infarct with language deficits.  <br><br>B. MCA  <br><span class=\"list-item\">\u2022</span> Dominant MCA infarcts produce Broca&rsquo;s or Wernicke&rsquo;s aphasia and may cause alexia with agraphia (angular gyrus), not pure alexia.  <br><span class=\"list-item\">\u2022</span> Patients cannot write or read, whereas pure alexics can write but cannot read what they wrote.  <br><span class=\"list-item\">\u2022</span> Key distinction: MCA angular infarcts impair both modalities.  <br><br>C. ICA  <br><span class=\"list-item\">\u2022</span> ICA occlusion produces large territory infarcts (ACA + MCA), causing global deficits, hemispatial neglect, and severe contralateral weakness.  <br><span class=\"list-item\">\u2022</span> Too extensive to yield isolated reading impairment without motor or broader language signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PCA (Pure Alexia)</th><th>MCA (Angular Gyrus)</th><th>ACA</th><th>ICA</th></tr></thead><tbody><tr><td>Vascular Territory</td><td>Left occipital + splenium</td><td>Inferior parietal lobule</td><td>Medial frontal/parietal</td><td>Global anterior circulation</td></tr><tr><td>Key Lesion Location</td><td>Visual cortex + callosal</td><td>Angular gyrus</td><td>Paracentral lobule</td><td>ACA + MCA areas</td></tr><tr><td>Reading Ability</td><td>Severely impaired</td><td>Impaired</td><td>Preserved</td><td>Variable, with broader deficits</td></tr><tr><td>Writing Ability</td><td>Preserved</td><td>Impaired</td><td>Preserved</td><td>Often impaired by hemiparesis</td></tr><tr><td>Clinical Syndrome</td><td>Pure alexia</td><td>Alexia + agraphia</td><td>Leg paresis, abulia</td><td>Global aphasia, motor deficits</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Pure alexia patients may &ldquo;spell out&rdquo; words letter by letter because intact tactile/visual scanning supports minimal reading.  <br><span class=\"list-item\">\u2022</span> Clock\u2010drawing and confrontation naming are typically normal except for reading tasks.  <br><span class=\"list-item\">\u2022</span> Preservation of writing with reading failure is pathognomonic for PCA splenial involvement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mistaking alexia with agraphia (MCA angular gyrus) for pure alexia; always test writing separately.  <br><span class=\"list-item\">\u2022</span> Assuming all language deficits localize to MCA; always consider vascular territory and cortical vs. disconnection syndromes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Visual input travels from bilateral occipital cortices; the right visual field projects to the left visual cortex, the left field to the right. The splenium transfers information from right occipital cortex to the dominant left hemisphere. A PCA infarct disrupting this callosal pathway blocks visual word form access to language centers.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Ischemic occlusion of the left PCA branch leads to infarction of the primary visual cortex and adjacent splenial fibers. The disconnection prevents processed visual word forms from reaching Wernicke&rsquo;s area, while Exner&rsquo;s writing center and motor pathways remain intact, preserving writing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- MRI DWI: acute hyperintensity in left occipital lobe and splenium confirms pure alexia.  <br><span class=\"list-item\">\u2022</span> CT may miss small splenial infarcts; high\u2010resolution MRI is preferred.  <br><span class=\"list-item\">\u2022</span> Perfusion imaging can demonstrate penumbral tissue in PCA territory when performed early.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. On board exams, pure alexia is frequently tested under cortical disconnection syndromes; remember the &ldquo;cannot read but can write&rdquo; hallmark for PCA lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>[Optional Latest Guidelines and Trials]</div></div></div></div></div>"}, {"id": 100023069, "question_number": "44", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Acute subdural hematomas (SDHs) occur when blood collects between the dura mater and arachnoid due to torn bridging veins. Bridging veins traverse the subdural space, draining cortical blood into the dural venous sinuses. Rapid acceleration&ndash;deceleration or direct impact causes shearing forces that rupture these veins. On noncontrast CT, SDHs appear as crescent-shaped hyperdensities that can cross suture lines but are bounded by dural reflections (falx, tentorium). In contrast, epidural hematomas (EDHs) are typically biconvex and arterial. Recognizing these imaging and anatomic distinctions is essential for diagnosis and surgical planning.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct mechanism for an acute SDH is rupture of bridging veins. Autopsy and clinical data <span class=\"citation\">(Bullock et al., J <span class=\"evidence\">Neurosurg 1980</span>;52(5)</span>:648&ndash;657) demonstrate that up to 90% of SDHs result from venous tearing rather than arterial bleeding. The bridging veins, tethered between cortical surface and dural sinuses, are vulnerable to shear stress during head trauma <span class=\"citation\">(Chen et al., <span class=\"evidence\">Neurosurgery 2000</span>;46(4)</span>:829&ndash;835). Current Brain Trauma Foundation guidelines <span class=\"citation\">(4th ed., 2016)</span> recommend rapid CT evaluation and neurosurgical consultation for acute SDH with >10 mm thickness or >5 mm midline shift, reflecting the high morbidity from mass effect due to ongoing venous hemorrhage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Middle meningeal artery  <br>&bull; Incorrect: Rupture of the middle meningeal artery causes an epidural, not subdural, hematoma.  <br>&bull; Misconception: All intracranial bleeds are arterial.  <br>&bull; Differentiator: EDHs are lentiform/biconvex and lens-shaped, limited by suture lines.<br>  <br>C. Cortical artery  <br>&bull; Incorrect: Cortical artery injury yields parenchymal contusion or intracerebral hemorrhage rather than a subdural collection.  <br>&bull; Misconception: Any cortical vessel bleed migrates into the subdural space.  <br>&bull; Differentiator: Intracerebral hemorrhages are intraparenchymal and do not form crescent shapes.<br>  <br>D. Venous sinus thrombosis  <br>&bull; Incorrect: Thrombosis of a dural sinus can cause venous infarcts or hemorrhagic edema but not a discrete subdural hematoma.  <br>&bull; Misconception: All venous pathology leads to subdural bleeding.  <br>&bull; Differentiator: Sinus thrombosis shows absent flow on MRV and often a \"cord sign\" on CT; hemorrhage is intraparenchymal/venous infarct.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Bridging Veins (SDH)</th><th>Middle Meningeal Artery (EDH)</th><th>Cortical Artery (ICH)</th><th>Venous Sinus Thrombosis</th></tr></thead><tbody><tr><td>Vessel type</td><td>Vein</td><td>Artery</td><td>Artery</td><td>Vein</td></tr><tr><td>Hemorrhage type</td><td>Subdural</td><td>Epidural</td><td>Intraparenchymal</td><td>Venous infarction/edema</td></tr><tr><td>CT shape</td><td>Crescent, crosses sutures</td><td>Biconvex, limited by sutures</td><td>Irregular intraparenchymal</td><td>Diffuse edema, focal hemorrhage</td></tr><tr><td>Onset</td><td>Acute to subacute</td><td>Acute</td><td>Acute</td><td>Subacute to chronic</td></tr><tr><td>Mass effect</td><td>Yes</td><td>Yes</td><td>Variable</td><td>Variable</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. SDHs cross suture boundaries but are bounded by dural reflections (falx, tentorium); epidurals do not cross sutures.  <br>2. Acute SDH mortality can exceed 50% if >10 mm thick or >5 mm midline shift; prompt neurosurgical evacuation is critical.  <br>3. In elderly or anticoagulated patients, even minor trauma can cause significant bridging vein rupture due to increased subdural space.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming all traumatic intracranial bleeds are arterial: only EDHs are typically arterial.  <br>2. Believing that subarachnoid hemorrhage (SAH) can mimic SDH on CT: SAH coats sulci, whereas SDH forms a crescent along the convexity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Brain Trauma Foundation (2016): Recommends urgent CT for suspected SDH and surgical evacuation criteria of >10 mm thickness or >5 mm midline shift (Level II evidence).  <br>&bull; NICE Head Injury Guidelines <span class=\"citation\">(NG41, 2014)</span>: Classify SDH as &ldquo;high risk&rdquo; requiring CT within 1 hour if focal neurology or GCS <13; guides timely imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Bridging veins drain cortical venous blood through the subdural space into the superior sagittal sinus. The veins are fixed at the sinus and mobile over the cortex, making them susceptible to shear injury during linear acceleration&ndash;deceleration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Shearing forces stretch and tear the thin-walled bridging veins bridging arachnoid to dural sinuses, causing slow but potentially large-volume venous bleeding. Accumulated blood raises intracranial pressure and exerts mass effect, leading to midline shift and herniation risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast head CT for any moderate&ndash;severe head trauma or focal deficits.  <br>2. Identify crescent-shaped hyperdensity crossing sutures on CT.  <br>3. Measure clot thickness and midline shift.  <br>4. Assess clinical status (GCS, pupillary exam).  <br>5. Neurosurgical consultation for hematoma >10 mm or shift >5 mm.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Acute SDH: Homogeneous hyperdensity on CT (0&ndash;72 h).  <br>&bull; Chronic SDH: Hypodense or isodense crescent weeks later.  <br>&bull; MRI with FLAIR and susceptibility-weighted imaging can detect subacute/chronic collections.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam.  <br>Subdural hematoma mechanism questions frequently test the distinction between arterial vs. venous intracranial bleeds and CT morphology; expect similar items on vascular and trauma sections.</div></div></div></div></div>"}, {"id": 100023070, "question_number": "237", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2021</span>] Acute ischemic stroke treatment hinges on rapid reperfusion to salvage penumbral tissue. Key points:  <br>&bull; Time window: IV alteplase (tPA) is indicated within 4.5 hours of symptom onset.  <br>&bull; ASPECTS (Alberta Stroke Program Early CT Score): scores &ge;6 on noncontrast CT indicate limited infarction and predict better tPA outcomes.  <br>&bull; Chronic infarct (&ldquo;old cortical insult&rdquo;) is not a contraindication if hemorrhage and other exclusion criteria are ruled out.<br><br>*150 words*</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>IV alteplase is first-line for eligible patients presenting within 4.5 hours, with noncontrast CT showing no hemorrhage and ASPECTS &ge;6 <span class=\"citation\">(AHA/ASA 2019 Guidelines, Class I, Level A)</span>. Mechanical thrombectomy is highly effective for large-vessel occlusion (LVO) within 6 hours (or select patients up to 24 hours) but requires CT angiography to confirm LVO and specialized endovascular resources. Immediate administration of tPA maximizes the therapeutic window (&ldquo;door-to-needle&rdquo; goal &le;60 min). Only after confirming LVO on CTA should thrombectomy be pursued. Observation or IV fluids alone do not address vessel occlusion and risk irreversible damage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option B: IV tPA followed by thrombectomy  <br><span class=\"list-item\">\u2022</span> Requires vascular imaging (CTA) to confirm LVO before endovascular therapy.  <br><span class=\"list-item\">\u2022</span> Misconception: all tPA candidates should automatically undergo thrombectomy. Only confirmed LVO benefits.  <br><br>Option C: Observation  <br><span class=\"list-item\">\u2022</span> Fails to provide reperfusion; increases risk of permanent neurologic deficit.  <br><span class=\"list-item\">\u2022</span> Misconception: advanced age or prior stroke prohibits active therapy; guidelines do not exclude age >80.  <br><br>Option D: Intravenous fluids  <br><span class=\"list-item\">\u2022</span> Supportive measure only; does not dissolve thrombus.  <br><span class=\"list-item\">\u2022</span> Misconception: aggressive hydration can replace reperfusion therapy; may worsen edema or precipitate hemorrhage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Intervention</th><th>Why (In)Appropriate</th></tr></thead><tbody><tr><td>A</td><td>IV tPA</td><td>Proven reperfusion within 4.5 h; ASPECTS &ge;6 predicts safety</td></tr><tr><td>B</td><td>IV tPA + thrombectomy</td><td>Requires CTA-confirmed LVO; not immediate next step</td></tr><tr><td>C</td><td>Observation</td><td>No reperfusion; not guideline-based</td></tr><tr><td>D</td><td>Intravenous fluids</td><td>Supportive only; no thrombus resolution</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Always calculate ASPECTS on initial noncontrast CT; a score <6 predicts high hemorrhage risk with tPA.  <br>&bull; Age >80 alone is not an exclusion for tPA per 2019 AHA/ASA update; assess on clinical and imaging criteria.  <br>&bull; Optimize door-to-needle time: every 15 min saved increases functional independence at 90 days.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming prior cortical infarcts are an absolute tPA contraindication (only recent hemorrhage or extensive early changes are).  <br>2. Believing thrombectomy can proceed empirically without CTA confirmation of LVO.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2019 Guidelines: Class I recommendation for IV alteplase within 4.5 hours in eligible patients (Level A evidence).  <br>&bull; EXTEND-IA Trial (2018): Demonstrated superiority of thrombectomy + tPA over tPA alone in CTA-confirmed LVO within 6 hours.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Noncontrast CT: exclude hemorrhage, assess ASPECTS.  <br>&bull; CT angiography: mandatory before mechanical thrombectomy to identify LVO and anatomical suitability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Alteplase dosing: 0.9 mg/kg (max 90 mg), 10% bolus over 1 min, remainder over 60 min.  <br>&bull; Blood pressure control: maintain <185/110 mm Hg pre-tPA and <180/105 mm Hg for 24 hours post-tPA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2021</span> exam. Acute stroke reperfusion&mdash;time windows, ASPECTS scoring, and tPA eligibility&mdash;is a high-yield topic tested in vignette formats assessing decision-making under time pressure.</div></div></div></div></div>"}, {"id": 100023071, "question_number": "35", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Intravenous tPA is standard for acute ischemic stroke within 4.5 h of onset. It converts plasminogen to plasmin, lysing fibrin clots. Hemorrhagic transformation occurs in ~6% of treated patients, often presenting with sudden neurologic decline (e.g., vomiting, lethargy) and hypertension. Emergent noncontrast head CT is required to confirm or exclude intracerebral hemorrhage before instituting reversal therapies. Blood pressure must be maintained &le;180/105 mm Hg post\u2010tPA. Recognizing post&ndash;thrombolysis complications and prioritizing imaging are essential for timely management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Sending for an immediate noncontrast CT is the highest priority when neurological status worsens after tPA. <span class=\"evidence\">The 2018</span> AHA/ASA guidelines for early management of acute ischemic stroke (Class I, Level B-R) state that any decline post-thrombolysis mandates urgent imaging to identify hemorrhagic conversion. In the NINDS trial, symptomatic intracerebral hemorrhage occurred in 6.4% of tPA-treated patients within 36 h; early CT allows prompt cessation of fibrinolysis and initiation of reversal (e.g., cryoprecipitate, antifibrinolytics) and targeted blood pressure management. Delaying imaging risks unchecked intracranial bleeding and secondary injury.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Decrease blood pressure  <br><span class=\"list-item\">\u2022</span> While BP control (goal &le;180/105 mm Hg) is important, immediate imaging supersedes isolated antihypertensive therapy. Overly aggressive lowering before confirming hemorrhage may compromise penumbral perfusion.  <br>B. Stop tPA  <br><span class=\"list-item\">\u2022</span> If the infusion is still running, it should be halted, but in most settings the 60-min tPA infusion is complete by the time deterioration occurs. Cessation alone does not diagnose the cause; emergent CT remains the next step.  <br>D. Administer IV fluids  <br><span class=\"list-item\">\u2022</span> IV fluids do not treat intracerebral hemorrhage and may exacerbate cerebral edema. Maintaining euvolemia is appropriate but secondary to rapid diagnostic imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CT Scan (Correct)</th><th>BP Lowering</th><th>Stop tPA</th><th>IV Fluids</th></tr></thead><tbody><tr><td>Primary Action</td><td>Noncontrast imaging to detect hemorrhage</td><td>Antihypertensive therapy</td><td>Discontinue fibrinolytic infusion</td><td>Volume expansion</td></tr><tr><td>Rationale</td><td>Confirms hemorrhagic vs ischemic cause</td><td>Maintains post-tPA BP target</td><td>Prevents further fibrinolysis</td><td>Addresses hypotension only</td></tr><tr><td>Priority</td><td>Immediate (within minutes)</td><td>Secondary (after imaging)</td><td>Concurrent if still infusing</td><td>Not indicated for hemorrhage risk</td></tr><tr><td>Impact on Management</td><td>Guides reversal agents and BP goals</td><td>Supports hemorrhage control</td><td>Stops active drug but no diagnosis</td><td>No effect on intracranial bleeding</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Any new neurologic deterioration or acute hypertension after tPA requires emergent noncontrast head CT to rule out hemorrhagic transformation.  <br>2. Maintain BP &le;180/105 mm Hg after tPA; use nicardipine or labetalol infusions titrated carefully to avoid hypoperfusion.  <br>3. Hemorrhagic conversion most often occurs within 36 h post-tPA; continuous NIHSS monitoring is essential during this window.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Focusing first on antihypertensive therapy without imaging delays diagnosis of hemorrhage.  <br>2. Assuming tPA infusion cessation obviates need for CT; diagnostic confirmation drives reversal and supportive care.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA Guidelines for Early Management of AIS <span class=\"citation\">(2018 update, published 2019)</span>: Class I, LOE B-R recommendation for emergent CT if neurological decline post-thrombolysis.  <br>2. ESO Guidelines on Intravenous Thrombolysis (2021): Emphasize CT within 20 min of suspected hemorrhage and BP target &le;180/105 mm Hg (Level A evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>tPA-mediated fibrinolysis increases blood&ndash;brain barrier permeability via matrix metalloproteinases, predisposing to hemorrhagic transformation. Elevated intracranial pressure from extravasated blood causes vomiting, altered consciousness, and further vascular compromise.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Recognize neurologic decline (vomiting, lethargy).  <br>2. Check vitals, labs (PT/INR, platelets).  <br>3. Obtain emergent noncontrast head CT.  <br>4. If hemorrhage: stop tPA, control BP, administer cryoprecipitate/antifibrinolytics. If no bleed: evaluate for stroke progression or other causes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Noncontrast CT: Acute blood appears hyperdense (\u224860&ndash;80 HU) within infarcted tissue; CT angiography can follow for vessel status if no hemorrhage is detected.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>tPA dosing: 0.9 mg/kg (max 90 mg) with 10% bolus and remainder over 60 min. In suspected hemorrhage, reversal with cryoprecipitate (10 units) and tranexamic acid may be considered.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Acute post-tPA deterioration and hemorrhagic transformation are frequently tested as vignettes requiring prioritization of emergent CT imaging.</div></div></div></div></div>"}, {"id": 100023072, "question_number": "47", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] - The middle cerebral artery (MCA) supplies the lateral convexity of the frontal, parietal, and temporal lobes and deep structures (basal ganglia, internal capsule) via lenticulostriate branches.  <br><span class=\"list-item\">\u2022</span> On noncontrast CT in hyperacute ischemic stroke, early signs include the hyperdense MCA sign (clot within M1), loss of the insular ribbon, sulcal effacement, and subtle hypodensity in the lateral hemisphere.  <br><span class=\"list-item\">\u2022</span> Clinical deficits correlate with vascular territories: MCA strokes produce contralateral face/arm weakness and hemisensory loss, aphasia if dominant, and hemineglect if non-dominant.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The CT demonstrates a hyperattenuated vessel in the Sylvian fissure (hyperdense MCA sign) and hypodensity of the insular cortex, both hallmark early markers of proximal MCA (M1 segment) occlusion. <span class=\"evidence\">The 2019</span> AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke recommend immediate noncontrast CT to exclude hemorrhage (Class I, Level A) and CTA/CTP to identify large vessel occlusion (Class I, Level B-R). Proximal MCA occlusions account for nearly 50% of anterior circulation strokes and carry a high risk of large-vessel infarction. Kolmannskog et al. <span class=\"citation\">(Stroke, 2000)</span> reported the hyperdense MCA sign has >90% specificity for M1 occlusion, guiding urgent reperfusion therapy (IV alteplase within 4.5 h; endovascular thrombectomy up to 24 h in selected patients per DAWN and DEFUSE 3).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Anterior cerebral artery  <br><span class=\"list-item\">\u2022</span> ACA infarcts affect medial frontal/parietal lobes, producing contralateral leg weakness and abulia. CT shows medial falcine hypodensity&mdash;absent here. Misconception: assuming any cortical hypodensity equals ACA territory.  <br>C. Posterior cerebral artery  <br><span class=\"list-item\">\u2022</span> PCA strokes localize to occipital lobes, thalamus; present with homonymous hemianopia and thalamic sensory loss. CT hypodensity would involve occipital sulci, not the Sylvian fissure.  <br>D. Basilar artery  <br><span class=\"list-item\">\u2022</span> Basilar occlusion causes brainstem and cerebellar signs (e.g., &ldquo;locked-in&rdquo; syndrome, cranial nerve deficits). CT would need posterior fossa windows to show a hyperdense basilar; supratentorial lateral hypodensity would not be seen.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Artery</th><th>Territory</th><th>CT Findings</th><th>Key Clinical Features</th></tr></thead><tbody><tr><td>Middle cerebral (MCA)</td><td>Lateral frontal, parietal, temporal lobes; basal ganglia via lenticulostriates</td><td>Hyperdense vessel in Sylvian fissure; insular ribbon loss; lateral hypodensity</td><td>Contralateral face/arm > leg weakness; aphasia or neglect</td></tr><tr><td>Anterior cerebral (ACA)</td><td>Medial frontal/parietal lobes; corpus callosum</td><td>Medial falcine hypodensity</td><td>Contralateral leg paresis; abulia</td></tr><tr><td>Posterior cerebral (PCA)</td><td>Occipital lobes; thalamus</td><td>Occipital hypodensity; &ldquo;white stripe&rdquo; in calcarine fissure</td><td>Homonymous hemianopia; thalamic sensory loss</td></tr><tr><td>Basilar artery</td><td>Brainstem; cerebellum; occipital lobes (via PCAs)</td><td>Hyperdense basilar on posterior fossa CT</td><td>Cranial nerve deficits; altered consciousness; ataxia</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- The hyperdense MCA sign on noncontrast CT predicts proximal M1 occlusion with >90% specificity but low sensitivity (~30%).  <br><span class=\"list-item\">\u2022</span> Use Alberta Stroke Program Early CT Score (ASPECTS) on MCA territory scans: scores <7 predict poor outcomes post-thrombectomy.  <br><span class=\"list-item\">\u2022</span> Mechanical thrombectomy benefits extend to selected patients up to 24 hours (DAWN/DEFUSE 3), emphasizing advanced imaging for penumbra assessment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mistaking beam-hardening artifacts in the Sylvian fissure for a hyperdense vessel.  <br>2. Confusing leg-predominant weakness of ACA strokes with global MCA deficits, leading to territory mislocalization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- 2019 AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke: Class I, Level A recommendation for immediate noncontrast CT to exclude hemorrhage and Class I, Level B-R for CTA/CTP to identify large-vessel occlusion.  <br><span class=\"list-item\">\u2022</span> DAWN Trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2018</span>)</span>: Demonstrated mechanical thrombectomy up to 24 hours in patients with mismatch between clinical deficit and infarct core (Level of Evidence B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The MCA M1 segment gives off lenticulostriate arteries penetrating the internal capsule and basal ganglia. Proximal occlusion affects both cortical and deep structures, correlating with dense hemiplegia and aphasia (dominant hemisphere).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Arterial occlusion triggers energy failure, glutamate\u2010mediated excitotoxicity, calcium influx, free\u2010radical generation, and cytotoxic edema. Early CT hypodensity reflects cellular swelling within minutes to hours.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Rapid clinical assessment and NIH Stroke Scale.  <br>2. Noncontrast CT head to exclude hemorrhage and detect early ischemic signs.  <br>3. CTA/CTP for vessel occlusion and penumbra/core evaluation.  <br>4. Administer IV alteplase if within 4.5 h and no contraindications.  <br>5. Proceed to mechanical thrombectomy in large-vessel occlusion up to 24 h per advanced imaging criteria.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Insular ribbon sign: early loss of gray-white differentiation in insula.  <br><span class=\"list-item\">\u2022</span> Sulcal effacement indicates cytotoxic edema.  <br><span class=\"list-item\">\u2022</span> CT perfusion maps cerebral blood flow/volume to differentiate penumbra from core.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Alteplase dosing: 0.9 mg/kg (maximum 90 mg), 10% bolus over 1 minute, remainder over 60 minutes.  <br><span class=\"list-item\">\u2022</span> Dual antiplatelet therapy (aspirin + clopidogrel) for minor noncardioembolic stroke within 21 days.  <br><span class=\"list-item\">\u2022</span> High-intensity statin for secondary prevention regardless of LDL level.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam.  <br>Vascular territory localization on CT is a high-yield topic on neurology and radiology components of board examinations, often tested with correlating clinical deficits.</div></div></div></div></div>"}, {"id": 100023073, "question_number": "120", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] Levels of prevention delineate interventions across the disease continuum:  <br>&bull; Primary prevention aims to stop disease before it occurs (e.g., controlling hypertension to prevent first stroke).  <br>&bull; Secondary prevention focuses on early detection and prompt treatment to halt progression (e.g., TIA work-up and thrombolysis in acute stroke).  <br>&bull; Tertiary prevention seeks to reduce disability and restore function after established disease (e.g., rehabilitation therapies post-stroke).  <br>&bull; Quaternary prevention involves avoiding overmedicalization and iatrogenic harm.  <br>Stroke rehabilitation harnesses neuroplasticity&mdash;cortical reorganization and synaptic remodeling&mdash;to regain motor and language function, fitting squarely under tertiary prevention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer is C. Tertiary. Rehabilitation after stroke (physiotherapy, occupational therapy, speech therapy) is explicitly defined as tertiary prevention&mdash;interventions to reduce established disability.  <br>&ndash; AHA/ASA 2019 Guidelines for the Early Management of Acute Ischemic Stroke (class I, level A) recommend initiation of multidisciplinary rehabilitation within 24&ndash;48 hours to maximize functional recovery and minimize complications.  <br>&ndash; The AVERT (A Very Early Rehabilitation Trial) published in Neurology (2015) demonstrated that early mobilization reduced the odds of poor outcome (OR 0.73; 95% CI 0.61&ndash;0.87).  <br>&ndash; WHO <span class=\"evidence\">Rehabilitation 2030</span> (2017) positions community-based rehabilitation as a key tertiary prevention strategy to decrease long-term disability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Primary  <br>&bull; Why incorrect: Targets prevention before disease onset.  <br>&bull; Misconception: Equating risk-factor management (e.g., BP control) with post-stroke rehab.  <br>&bull; Key difference: No established event to &ldquo;rehabilitate&rdquo;&mdash;primary is pre-morbidity.  <br><br>B. Secondary  <br>&bull; Why incorrect: Involves early detection (e.g., screening, thrombolysis) to prevent progression or recurrence.  <br>&bull; Misconception: Confusing acute stroke treatment (early thrombolysis) with rehabilitation.  <br>&bull; Key difference: Secondary halts disease progression; tertiary improves post-disease function.  <br><br>D. Quaternary  <br>&bull; Why incorrect: Aims to prevent harm from unnecessary or excessive interventions (e.g., avoiding redundant imaging or polypharmacy).  <br>&bull; Misconception: Believing any non-acute care is quaternary.  <br>&bull; Key difference: Quaternary is about overmedicalization, not functional recovery.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Level of Prevention</th><th>Goal</th><th>Timing</th><th>Stroke Example</th></tr></thead><tbody><tr><td>Primary</td><td>Prevent disease onset</td><td>Before first event</td><td>BP and lipid control to avoid first stroke</td></tr><tr><td>Secondary</td><td>Early detection & arrest progression</td><td>Acute phase/TIA</td><td>Carotid imaging, tPA administration</td></tr><tr><td>Tertiary</td><td>Reduce disability, restore function</td><td>Post-acute/chronic</td><td>Physiotherapy, speech and occupational therapy</td></tr><tr><td>Quaternary</td><td>Avoid unnecessary interventions</td><td>Any phase</td><td>De-prescribing neurotoxics, limiting repeat scans</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Early mobilization (within 24&ndash;48 h) reduces deep vein thrombosis, pneumonia, and pressure ulcers while enhancing motor recovery.  <br>&bull; Speech therapy initiated in the first week post-stroke significantly improves language outcomes and swallowing function.  <br>&bull; Multidisciplinary teams (PT, OT, SLP, neurology, nursing) synergize to decrease length of stay and increase discharge to home.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing secondary prevention (acute thrombolysis) with rehabilitation efforts&mdash;remember timing and intent differ.  <br>2. Mislabeling primary prevention strategies (BP control) as tertiary when performed after stroke; primary is always pre-event.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Heart Association/American Stroke Association (AHA/ASA) 2019 Update  <br>   &ndash; Recommendation: Initiate rehabilitation therapies within 24&ndash;48 hours post-stroke (Class I, Level A).  <br>2. A Very Early Rehabilitation Trial (AVERT), <span class=\"evidence\">Neurology 2015</span>  <br>   &ndash; Finding: Very early out-of-bed mobilization reduced poor outcomes at 3 months (OR 0.73; 95% CI 0.61&ndash;0.87).  <br>3. NICE Guideline NG128 (2021)  <br>   &ndash; Recommendation: Multidisciplinary community rehabilitation to optimize functional independence (High-quality evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam.  <br>Classification of prevention levels is commonly tested in neurology and public health vignettes, often as a single best-answer scenario distinguishing primary, secondary, tertiary, and quaternary prevention.</div></div></div></div></div>"}, {"id": 100023074, "question_number": "93", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Transient ischemic attack (TIA) is defined as transient focal neurological dysfunction without evidence of acute infarction, most often due to brief thromboembolic or atherothrombotic cerebral ischemia. Early risk of stroke recurrence is highest within 48 hours (\u224810&ndash;20%). Secondary prevention targets platelet-mediated thrombosis in non-cardioembolic TIA. Key concepts include:  <br><span class=\"list-item\">\u2022</span> Platelet activation and aggregation at sites of vascular injury (Cox-1 and P2Y\u2081\u2082 pathways)  <br><span class=\"list-item\">\u2022</span> ABCD2 score for risk stratification (Age, Blood pressure, Clinical features, Duration, Diabetes)  <br><span class=\"list-item\">\u2022</span> Time-sensitive initiation of antithrombotic therapy</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Dual antiplatelet therapy (DAPT) with aspirin plus clopidogrel, initiated within 24 hours of a high-risk TIA or minor non-cardioembolic stroke (NIHSS &le;3), for a short course (21 days) reduces 90-day stroke recurrence by ~30&ndash;35% compared to aspirin alone. The CHANCE trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2013</span>)</span> showed a hazard ratio (HR) of 0.68 (95% CI 0.57&ndash;0.81) for recurrent stroke with 21-day DAPT, without significant bleeding increase. The POINT trial <span class=\"citation\">(NEJM 2018)</span> confirmed efficacy (HR 0.75; 95% CI 0.59&ndash;0.95) but noted higher major hemorrhage risk with prolonged DAPT at 90 days (HR 2.32; 95% CI 1.10&ndash;4.87). <span class=\"evidence\">The 2018</span> AHA/ASA guidelines (Class I, Level A) recommend DAPT for 21&ndash;90 days in high-risk patients, then transition to monotherapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Single antiplatelet therapy  <br><span class=\"list-item\">\u2022</span> Aspirin monotherapy yields only ~20% relative reduction in recurrent stroke.  <br><span class=\"list-item\">\u2022</span> Misconception: Early monotherapy suffices; fails to capitalize on synergistic inhibition of two platelet pathways.<br><br>C. Anticoagulation  <br><span class=\"list-item\">\u2022</span> Effective in cardioembolic TIA (e.g., atrial fibrillation) but not in non-cardioembolic cases.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;TIA always requires anticoagulation&rdquo;; inappropriate in atherosclerotic or lacunar mechanisms, with higher hemorrhage risk.<br><br>D. No treatment  <br><span class=\"list-item\">\u2022</span> Untreated TIA carries 10%&ndash;20% stroke recurrence at 90 days.  <br><span class=\"list-item\">\u2022</span> Misconception: TIAs are benign; ignores critical period for secondary prevention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Single Antiplatelet</th><th>Dual Antiplatelet</th><th>Anticoagulation</th><th>No Treatment</th></tr></thead><tbody><tr><td>Mechanism</td><td>Cox-1 inhibition</td><td>Cox-1 + P2Y\u2081\u2082 receptor blockade</td><td>Thrombin or factor Xa inhibition</td><td>None</td></tr><tr><td>Initiation</td><td>Within 24 h</td><td>Within 24 h; limited to 21 days</td><td>If cardioembolic source identified</td><td>N/A</td></tr><tr><td>90-Day Stroke Reduction</td><td>~20% vs placebo</td><td>~30&ndash;35% vs aspirin</td><td>Not shown in non-cardioembolic</td><td>0%</td></tr><tr><td>Major Bleeding Risk</td><td>Low</td><td>Moderate (short-term)</td><td>High</td><td>None</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Initiate DAPT within 24 hours for high-risk TIA (ABCD2 &ge;4); discontinue at 21 days to minimize bleeding.  <br><span class=\"list-item\">\u2022</span> Use ABCD2 score to guide urgency and intensity of therapy.  <br><span class=\"list-item\">\u2022</span> After DAPT course, continue long-term monotherapy (aspirin or clopidogrel).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Extending DAPT beyond 30 days increases hemorrhagic complications without further ischemic benefit.  <br>2. Prescribing anticoagulation for all TIAs overlooks etiological classification, leading to unnecessary bleeding risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2018 Guideline for Early Management of Acute Ischemic Stroke <span class=\"citation\">(<span class=\"evidence\">Stroke 2018</span>)</span>: Class I, Level A recommendation for DAPT (aspirin + clopidogrel) for 21&ndash;90 days in high-risk TIA/minor stroke.  <br><span class=\"list-item\">\u2022</span> POINT trial <span class=\"citation\">(NEJM 2018)</span>: Demonstrated DAPT reduced composite ischemic events at 90 days (5.0% vs 6.5%; HR 0.75) but increased major hemorrhage (0.9% vs 0.4%; HR 2.32).  <br><span class=\"list-item\">\u2022</span> CHANCE trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2013</span>)</span>: In Chinese population, 21-day DAPT decreased 90-day stroke recurrence (8.2% vs 11.7%; HR 0.68) without significant bleeding rise.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Early dual antiplatelet therapy for high-risk TIA is a high-yield topic on stroke prevention questions, often tested in multiple-choice format focusing on timing, duration, and patient selection.</div></div></div></div></div>"}, {"id": 100023075, "question_number": "139", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] Transient ischemic attack (TIA) is defined by transient focal neurologic dysfunction without acute infarction. Key principles:  <br><span class=\"list-item\">\u2022</span> TIAs carry a high early stroke risk&mdash;\u224810% risk within 90 days, half occurring in the first 48 hours.  <br><span class=\"list-item\">\u2022</span> Extracranial carotid stenosis &ge;50% is a modifiable risk factor; prompt imaging guides interventions (endarterectomy or stenting).  <br><span class=\"list-item\">\u2022</span> Neurovascular workup must be done emergently&mdash;CT angiography (CTA) of head and neck within 24 hours.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Neck CTA is the optimal next step because it rapidly identifies extracranial carotid and vertebral stenosis or occlusion, which&mdash;if >70%&mdash;warrants urgent endarterectomy <span class=\"citation\">(Class I, Level A recommendation; AHA/ASA 2019)</span>. Brain CT alone cannot detect vascular lesions. Echocardiography and prolonged cardiac monitoring address cardioembolic sources but are secondary to vascular imaging in the acute TIA workup. Thrombolytic screening is irrelevant once symptoms resolve and there is no persistent deficit. Early carotid imaging reduces recurrent stroke risk by directing timely revascularization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Reassurance  <br><span class=\"list-item\">\u2022</span> Incorrect: Underestimates early recurrent stroke risk.  <br><span class=\"list-item\">\u2022</span> Misconception: A normal CT excludes high-risk pathology.  <br><span class=\"list-item\">\u2022</span> Differentiator: Imaging is required to stratify risk and guide intervention.  <br><br>C. Echocardiogram  <br><span class=\"list-item\">\u2022</span> Incorrect: Evaluates cardioembolism (e.g., atrial thrombus), but vascular imaging must precede in acute TIA.  <br><span class=\"list-item\">\u2022</span> Misconception: Cardiac sources are equally urgent&mdash;whereas carotid stenosis poses more immediate surgical decision needs.  <br><span class=\"list-item\">\u2022</span> Differentiator: Echocardiogram is adjunctive, not first-line.  <br><br>D. Thrombolytic screening  <br><span class=\"list-item\">\u2022</span> Incorrect: Indicated for persistent deficits within 4.5 h window; TIA symptoms resolved.  <br><span class=\"list-item\">\u2022</span> Misconception: All transient deficits qualify for thrombolysis workup.  <br><span class=\"list-item\">\u2022</span> Differentiator: No ongoing ischemia; focus shifts to secondary prevention and etiologic workup.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Neck CT Angiography (B)</th><th>Echocardiogram (C)</th><th>Thrombolytic Screening (D)</th><th>Reassurance (A)</th></tr></thead><tbody><tr><td>Purpose</td><td>Visualize extracranial/intracranial vessels</td><td>Detect cardiac thrombus/vegetations</td><td>Assess eligibility for tPA</td><td>No diagnostic yield</td></tr><tr><td>Time Sensitivity</td><td>Within 24 h</td><td>Within days</td><td>Within 4.5 h if deficits persist</td><td>Not time-sensitive</td></tr><tr><td>Impact on Management</td><td>Guides CEA/stenting</td><td>Guides anticoagulation</td><td>Guides acute thrombolysis</td><td>None</td></tr><tr><td>Level of Evidence (AHA/ASA)</td><td>Class I, Level A</td><td>Class IIa, Level C</td><td>Class I (in stroke), not TIA</td><td>No recommendation</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. In TIA, perform vascular imaging (CTA/MRA) within 24 hours to detect high-grade stenosis and prevent early stroke.  <br>2. Carotid endarterectomy is indicated for symptomatic 70&ndash;99% stenosis within 2 weeks of TIA (NASCET criteria).  <br>3. ABCD2 score guides short-term risk stratification but does not replace vascular imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Believing a normal noncontrast head CT rules out high-risk pathology. A CT cannot assess vessel lumen.  <br>2. Deferring vascular imaging because the deficit resolved; recurrent stroke risk remains high without etiologic evaluation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA (2019), &ldquo;Guidelines for the Early Management of Patients with Acute Ischemic Stroke and TIA&rdquo;: Recommends emergent vascular imaging (CTA/MRA) within 24 hours of TIA (Class I, Level A).  <br><span class=\"list-item\">\u2022</span> ESO (2021), &ldquo;European Stroke Organisation Guidelines&rdquo;: Urges head and neck vascular imaging as first-line in TIA to identify treatable lesions (Grade A, strong recommendation).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam.  <br>Carotid imaging after TIA is a high-yield topic frequently tested in multiple-choice format, emphasizing timing, indication, and interpretation of vascular studies.</div></div></div></div></div>"}, {"id": 100023076, "question_number": "232", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2021</span>] Ischemic strokes are divided by etiology: large\u2010artery atherosclerosis, small\u2010vessel occlusion, cardioembolism, other, and undetermined (TOAST classification). Cardioembolic strokes arise when a thrombus forms in the heart (e.g., left atrial appendage in atrial fibrillation) and embolizes to cerebral vessels. Identifying the source is crucial for targeted secondary prevention. Echocardiography (transthoracic, then transesophageal if needed) evaluates cardiac chambers, valves, and presence of thrombus or shunts. Knowledge of stroke subtyping, cardioembolic risk factors, and capabilities of different imaging modalities underpins optimal workup.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>ECHO is the correct next step because secondary prevention of cardioembolic stroke hinges on defining the cardiac source. AHA/ASA 2019 Guidelines for Early Management of Patients With Acute Ischemic Stroke <span class=\"citation\">(Issuing Organization: American Heart Association/American Stroke Association; Publication Year: 2019; Recommendation: Class I, Level of Evidence B)</span> state: &ldquo;In patients with ischemic stroke, perform transthoracic echocardiography (TTE) to evaluate for cardioembolic source. Consider transesophageal echocardiography (TEE) if TTE is nondiagnostic and suspicion remains high.&rdquo;  <br>Studies show TTE detects left ventricular thrombi and major structural abnormalities in ~10&ndash;15% of cases; TEE identifies left atrial appendage thrombi and patent foramen ovale with higher sensitivity (up to 90%). Early cardiac imaging directs anticoagulation strategies, valve repair, or shunt closure, reducing recurrent stroke risk by up to 60% when appropriately applied.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. CT scan  <br>&bull; Reason incorrect: Noncontrast head CT is essential acutely to exclude hemorrhage before thrombolysis but is not indicated once an embolic infarct is confirmed and the clinical question shifts to etiology.  <br>&bull; Misconception: &ldquo;Any stroke requires repeat CT&rdquo; fails to distinguish acute diagnostic imaging from secondary workup.  <br><br>C. MRI  <br>&bull; Reason incorrect: MRI with diffusion\u2010weighted imaging is superior for lesion characterization but does not identify cardiac sources of emboli. It contributes little to management once etiology is known.  <br>&bull; Misconception: Equating better brain imaging with source identification.  <br><br>D. Carotid ultrasound  <br>&bull; Reason incorrect: Duplex ultrasound detects carotid stenosis (large\u2010artery atherosclerosis), not cardiac thrombi. In a confirmed cardioembolic stroke without cortical TIAs suggesting carotid disease, this test is low yield.  <br>&bull; Misconception: Ordering vascular imaging for all ischemic strokes irrespective of subtype.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Echocardiography (ECHO)</th><th>CT Scan</th><th>MRI</th><th>Carotid Ultrasound</th></tr></thead><tbody><tr><td>Purpose</td><td>Cardiac source identification</td><td>Exclude hemorrhage/acute changes</td><td>Lesion localization/age</td><td>Assess carotid stenosis</td></tr><tr><td>Timing in this scenario</td><td>Immediate (secondary workup)</td><td>Not indicated post-etiology</td><td>Not indicated post-etiology</td><td>Not indicated for cardioembolic</td></tr><tr><td>Sensitivity for source</td><td>High for intracardiac thrombus</td><td>N/A</td><td>N/A</td><td>N/A</td></tr><tr><td>Impact on management</td><td>Guides anticoagulation, device closure</td><td>None</td><td>None</td><td>Guides endarterectomy if stenosis</td></tr><tr><td>Guideline recommendation</td><td>AHA/ASA Class I, LOE B</td><td>AHA/ASA Class I (acute stroke)</td><td>AHA/ASA Class I (acute stroke)</td><td>AHA/ASA Class IIb for stenosis</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Transthoracic echo (TTE) is first\u2010line; if nondiagnostic and suspicion remains (e.g., prosthetic valves, atrial septal abnormalities), proceed to transesophageal echo (TEE).  <br><span class=\"list-item\">\u2022</span> Extended cardiac monitoring (30&ndash;90 days) can unmask paroxysmal atrial fibrillation in ~15&ndash;20% of cryptogenic strokes.  <br><span class=\"list-item\">\u2022</span> Carotid duplex is indicated for symptomatic anterior circulation strokes with >50% stenosis, not for cardioembolic workup.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Ordering repeated head CT or brain MRI when the infarct and etiology are already established.  <br>2. Performing carotid ultrasound in suspected cardioembolic stroke without focal carotid territory symptoms.  <br>3. Omitting TEE after a nondiagnostic TTE in patients with mechanical valves or suspected intracardiac shunts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2019 Early Management Guidelines (Class I, LOE B): Recommend TTE in all ischemic stroke patients to evaluate for cardiac source; consider TEE if TTE is inconclusive.  <br>2. European Stroke Organisation (ESO)&ndash;ESMINT 2021 Guidelines: Advise TEE when TTE fails to detect source and in younger patients (<60 years) to uncover PFO or atrial septal defects (Level A evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Cardioembolic strokes arise when thrombi form in areas of stasis or abnormal endocardial surfaces (e.g., left atrial appendage in atrial fibrillation, ventricular aneurysms post-MI). Emboli travel via the aorta to cerebral arteries, leading to sudden onset neurological deficits. Identifying the nidus (cardiac thrombus) is key to initiating anticoagulation rather than antiplatelet therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confirm ischemic nature: noncontrast head CT or MRI.  <br>2. Classify stroke subtype (TOAST).  <br>3. If cardioembolic suspected: obtain ECG, continuous cardiac monitoring.  <br>4. Perform TTE; if nondiagnostic or suspicion remains, proceed to TEE.  <br>5. Initiate appropriate anticoagulation based on findings (e.g., warfarin/DOAC for atrial fibrillation).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2021</span> exam.  <br>Cardioembolic stroke workup is frequently tested on neurology and internal medicine boards, often contrasting the roles of brain imaging (CT/MRI) versus cardiac evaluation (echocardiography) in acute versus secondary settings.</div></div></div></div></div>"}, {"id": 100023077, "question_number": "76", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Weber syndrome is a classic crossed brainstem syndrome resulting from a focal infarct of the paramedian perforators of the posterior cerebral artery at the ventral (base) aspect of the midbrain. Core concepts:  <br><span class=\"list-item\">\u2022</span> Ventral midbrain (&ldquo;basis pedunculi&rdquo;) contains corticospinal fibers (crus cerebri) and oculomotor nerve fascicles.  <br><span class=\"list-item\">\u2022</span> Lesion here produces ipsilateral oculomotor nerve palsy (ptosis, &ldquo;down and out&rdquo; eye, mydriasis) plus contralateral hemiparesis.  <br><span class=\"list-item\">\u2022</span> Differentiation from other midbrain syndromes (Claude, Benedikt) depends on involvement of tegmentum versus basis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The defining pathology in Weber syndrome is an infarct of the ventral midbrain at the level of the superior colliculus. Anatomical studies (Ropper & Samuels, Adams and Victor&rsquo;s Principles of Neurology) confirm that corticospinal and corticobulbar fibers traverse the basis pedunculi immediately adjacent to oculomotor nerve fascicles. MRI diffusion\u2010weighted imaging in Kim et al. <span class=\"citation\">(J Neurol Neurosurg Psychiatry. 2005;76(3)</span>:e6) demonstrates acute lesions precisely in this location. Clinical series <span class=\"citation\">(Kim JS, 2006)</span> show >90% of patients present with ipsilateral oculomotor palsy and contralateral spastic weakness, correlating with ventral midbrain injury. No other brainstem site produces this unique combination.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Tegmentum  <br>&ndash; Incorrect because the tegmentum is the dorsal midbrain region; lesions here (Claude syndrome) produce ataxia (red nucleus) and oculomotor palsy without prominent corticospinal weakness.  <br>&ndash; Misconception: confusing any midbrain infarct with Weber. Tegmental lesions spare the crus cerebri.  <br><br>C. Tectum  <br>&ndash; The tectum (roof of midbrain) contains superior/inferior colliculi; lesions cause vertical gaze palsies (Parinaud syndrome), not ipsilateral third\u2010nerve palsy plus hemiparesis.  <br>&ndash; Misconception: equating &ldquo;midbrain&rdquo; with any roof structure.  <br><br>D. Pons  <br>&ndash; A pontine lesion (e.g., Millard&ndash;Gubler) involves facial nerve or abducens nuclei and corticospinal fibers but spares oculomotor nerve; contralateral hemiparesis would be with ipsilateral facial paralysis or abduction deficit.  <br>&ndash; Misconception: any brainstem basis infarct gives oculomotor signs&mdash;pontine basis is anatomically separate.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Base of Midbrain (Weber)</th><th>Tegmentum (Claude)</th><th>Tectum (Parinaud)</th><th>Pons (Millard&ndash;Gubler)</th></tr></thead><tbody><tr><td>Lesion location</td><td>Ventral midbrain (basis)</td><td>Dorsal midbrain (tegmentum)</td><td>Dorsal roof (colliculi)</td><td>Ventral pons (basis)</td></tr><tr><td>Cranial nerve involvement</td><td>III nerve fascicles</td><td>III nerve fascicles</td><td>Vertical gaze (III nucleus)</td><td>VI or VII nucleus</td></tr><tr><td>Motor pathway involvement</td><td>Corticospinal fibers \u2192 hemiparesis</td><td>Sparing of corticospinal \u2192 no major weakness</td><td>No corticospinal involvement</td><td>Corticospinal fibers \u2192 hemiparesis</td></tr><tr><td>Key clinical sign</td><td>Ipsilateral oculomotor palsy + contralateral spastic weakness</td><td>Oculomotor palsy + ataxia</td><td>Supranuclear vertical gaze palsy</td><td>Facial/abduction palsy + hemiparesis</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always correlate oculomotor deficits with ipsilateral motor weakness to localize to the ventral midbrain.  <br><span class=\"list-item\">\u2022</span> Differentiate Weber (basis) from Benedikt (tegmental red nucleus involvement \u2192 tremor, ataxia) and Claude (tegmental \u2192 ataxia without significant hemiparesis).  <br><span class=\"list-item\">\u2022</span> MRI with DWI is the gold standard to visualize small paramedian midbrain infarcts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing ventral versus dorsal midbrain: thinking any midbrain stroke is Weber.  <br>2. Mislabeling Benedikt (tremor, involuntary movements) as Weber due to similar oculomotor findings.  <br>3. Attributing an oculomotor palsy plus hemiparesis to a pontine lesion rather than midbrain.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>- Basis pedunculi: houses descending corticospinal and corticobulbar tracts; compressed in Weber infarcts.  <br><span class=\"list-item\">\u2022</span> Oculomotor nerve fascicles exit ventrally between posterior cerebral and superior cerebellar arteries; infarct here causes third\u2010nerve palsy.  <br><span class=\"list-item\">\u2022</span> Vascular supply: paramedian branches of the PCA and basilar tip perfuse this region.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam.  <br>Brainstem stroke syndromes are frequently tested as single\u2010best\u2010answer questions. Expect variations on Weber vs. Benedikt vs. Claude in vascular neuroanatomy blocks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>[Optional Latest Guidelines and Trials]</div></div></div></div></div>"}, {"id": 100023078, "question_number": "67", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] In acute intracerebral hemorrhage (ICH), extravasated blood increases intracranial pressure (ICP), risking herniation and further tissue injury. According to the Monroe-Kellie doctrine, the cranial vault contents (blood, brain tissue, CSF) are volume-fixed; an expanding hematoma rapidly elevates ICP and impairs cerebral perfusion. Elevated systolic blood pressure (SBP) exacerbates hematoma expansion by promoting ongoing bleeding, whereas overly aggressive lowering can exceed impaired autoregulatory capacity in perihematomal regions, precipitating ischemia. Optimal management balances reduction of rebleeding risk against maintenance of cerebral perfusion pressure (CPP = MAP &ndash; ICP). Randomized trials (INTERACT2, ATACH-2) and guideline consensus support targeting an acute SBP of approximately 140 mmHg in those presenting with SBP between 150 and 220 mmHg.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option B (&ldquo;acute lowering of SBP to 140 mmHg&rdquo;) is endorsed by the American Heart Association/American Stroke Association (AHA/ASA) 2022 ICH guidelines (Class I, Level A). The INTERACT2 trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2013</span>;368:2355&ndash;65)</span> demonstrated a non-significant trend toward reduced death or major disability with an SBP target of <140 mmHg versus <180 mmHg, but ordinal analysis showed improved functional outcomes at 90 days. The ATACH-2 trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2016</span>;375:1033&ndash;43)</span> compared intensive (110&ndash;139 mmHg) versus standard (140&ndash;179 mmHg) reduction: no significant difference in death or disability, but higher renal adverse events in the intensive arm. Meta-analysis consolidates benefit and safety of targeting SBP around 140 mmHg in the acute phase (Class I, LOE A). Intravenous nicardipine or labetalol infusions with continuous arterial monitoring achieve rapid, controlled reduction within 1 hour, minimizing hematoma expansion while preserving CPP.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Aggressive reduction of BP  <br><span class=\"list-item\">\u2022</span> Incorrect because &ldquo;aggressive&rdquo; lacks a specific target and risks overshooting below safe perfusion thresholds (e.g., SBP <120 mmHg).  <br><span class=\"list-item\">\u2022</span> Misconception: More rapid or deeper reduction necessarily yields better outcomes.  <br><span class=\"list-item\">\u2022</span> Differentiator: Guidelines specify a precise SBP target, not an undefined &ldquo;aggressive&rdquo; approach.  <br><br>C. No treatment required  <br><span class=\"list-item\">\u2022</span> Incorrect; untreated hypertension in ICH is linked to increased hematoma growth and worse functional outcome.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that high BP autonomously maintains perfusion without recognizing rebleeding risk.  <br><span class=\"list-item\">\u2022</span> Differentiator: Active BP management reduces secondary injury.  <br><br>D. Gradual reduction of SBP over 24 hours  <br><span class=\"list-item\">\u2022</span> Incorrect; delaying reduction fails to prevent early hematoma expansion, which often occurs within the first 6 hours.  <br><span class=\"list-item\">\u2022</span> Misconception: Slow titration is inherently safer; but early control is critical.  <br><span class=\"list-item\">\u2022</span> Differentiator: Trials achieved-target BP within 1 hour, not over an entire day.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>SBP Target</th><th>Timeframe</th><th>Guideline Class/Level</th><th>Rationale</th></tr></thead><tbody><tr><td>B [CORRECT]</td><td>\u2248140 mmHg</td><td>&le;1 hour</td><td>I / A</td><td>Minimizes hematoma expansion, preserves CPP</td></tr><tr><td>A</td><td>Undefined</td><td>Immediate</td><td>Not specified</td><td>Risk of overshoot hypotension, no clear benefit</td></tr><tr><td>C</td><td>None</td><td>N/A</td><td>Contraindicated</td><td>Allows hematoma growth, worsens outcomes</td></tr><tr><td>D</td><td>Undefined</td><td>24 hours</td><td>Not recommended</td><td>Too slow to prevent early bleeding</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Use titratable IV agents (nicardipine infusion or labetalol bolus/infusion) for precise SBP control.  <br><span class=\"list-item\">\u2022</span> Avoid nitroprusside in ICH as it may increase intracranial pressure via cerebral vasodilation.  <br><span class=\"list-item\">\u2022</span> Continuous arterial BP monitoring is preferred for real-time adjustments in the hyperacute phase.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overreducing SBP below 120 mmHg can precipitate cerebral ischemia in areas with impaired autoregulation.  <br>2. Equating hypertensive management in ischemic stroke (target <180/105 mmHg) with ICH protocols, instead of the more stringent 140 mmHg target.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA Guidelines for ICH Management (2022): Class I, Level A recommendation to lower SBP to 140 mmHg in patients with admission SBP between 150&ndash;220 mmHg, initiated within 1 hour.  <br><span class=\"list-item\">\u2022</span> INTERACT2 Trial (2013): SBP target <140 mmHg vs <180 mmHg achieved improved ordinal functional outcomes at 90 days (OR for poor outcome 0.87, 95% CI 0.77&ndash;1.00).  <br><span class=\"list-item\">\u2022</span> ATACH-2 Trial (2016): No significant difference in death/disability between intensive (110&ndash;139 mmHg) and standard (140&ndash;179 mmHg) arms; higher renal adverse events with more intensive lowering.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam. Blood pressure management in acute ICH is frequently tested, often in the context of trial data (INTERACT2, ATACH-2) and guideline recommendations for SBP targets and timing.</div></div></div></div></div>"}, {"id": 100023079, "question_number": "275", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] - Saccular intracranial aneurysms form at arterial bifurcations in the Circle of Willis, particularly the anterior communicating artery (Acom), where high-flow hemodynamic stress weakens the vessel wall.<br><span class=\"list-item\">\u2022</span> Rupture risk is multifactorial: patient demographics (age, hypertension), environmental factors (smoking), genetic predisposition, and aneurysm-specific features (size, location, morphology).<br><span class=\"list-item\">\u2022</span> Management decisions hinge on accurately stratifying rupture risk; small aneurysms (<7 mm) in anterior circulation have low annual rupture rates, whereas larger ones pose substantially higher risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Aneurysm size is the single most powerful predictor of rupture. The International Study of Unruptured Intracranial Aneurysms <span class=\"citation\">(ISUIA, 2003)</span> demonstrated annual rupture rates of 0.05% for anterior circulation aneurysms <7 mm versus 1.3% for those &ge;7 mm. The PHASES score <span class=\"citation\">(Greving et al., Lancet <span class=\"evidence\">Neurol 2014</span>)</span> identified aneurysm diameter as the dominant predictor, with hazard ratios escalating from 1 for &le;5 mm to 6.3 for >10 mm. <span class=\"evidence\">The 2015</span> AHA/ASA guidelines <span class=\"citation\">(updated 2021)</span> recommend considering treatment for anterior circulation aneurysms &ge;7 mm (Class I, Level of Evidence B). Larger aneurysms endure greater wall tension per the Law of Laplace, directly accelerating medial layer degeneration and rupture.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Smoking  <br><span class=\"list-item\">\u2022</span> While smoking increases rupture risk (~1.6-fold; PHASES), its impact is modest compared to size.  <br><span class=\"list-item\">\u2022</span> Misconception: inflammation from smoking overrides mechanical factors.  <br><span class=\"list-item\">\u2022</span> Differentiation: size amplifies wall tension exponentially, whereas smoking&rsquo;s effect is incremental.<br><br>C. Hypertension  <br><span class=\"list-item\">\u2022</span> Hypertension confers a moderate risk increase (HR ~1.7) by elevating transmural pressure, but size exerts a greater effect.  <br><span class=\"list-item\">\u2022</span> Misconception: systemic pressure alone dictates rupture, neglecting aneurysm geometry.  <br><span class=\"list-item\">\u2022</span> Differentiation: diameter directly magnifies wall stress beyond hemodynamic load.<br><br>D. Family history of aneurysms  <br><span class=\"list-item\">\u2022</span> Family history slightly increases formation risk; its association with rupture is weak (HR ~1.2).  <br><span class=\"list-item\">\u2022</span> Misconception: genetic predisposition equals high immediate rupture potential.  <br><span class=\"list-item\">\u2022</span> Differentiation: genetics influence aneurysm development, but rupture hinges on mechanical wall forces.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Risk Factor</th><th>Relative Risk (HR)</th><th>Mechanism of Rupture</th></tr></thead><tbody><tr><td>Size (>7 mm)</td><td>6.3 (vs &le;5 mm baseline)</td><td>Increased wall tension (Law of Laplace), shear stress</td></tr><tr><td>Smoking</td><td>1.6</td><td>Vessel wall inflammation, oxidative damage</td></tr><tr><td>Hypertension</td><td>1.7</td><td>Elevated transmural pressure, medial degeneration</td></tr><tr><td>Family history</td><td>1.2</td><td>Genetic vessel wall susceptibility</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Anterior communicating artery aneurysms are inherently higher-risk due to complex flow patterns at the Acom&ndash;ACA junction.<br><span class=\"list-item\">\u2022</span> Use the PHASES score to quantify 5-year rupture risk; aneurysm size contributes the most points.<br><span class=\"list-item\">\u2022</span> Monitor small aneurysms (<7 mm) with serial imaging, as growth often precedes rupture.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Overprioritizing blood pressure control while underestimating aneurysm growth; both are important but size changes mandate intervention.<br><span class=\"list-item\">\u2022</span> Assuming all small (<5 mm) aneurysms are benign; rare but clinically significant ruptures can occur, especially with adverse morphology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA Guidelines on Unruptured Intracranial Aneurysms <span class=\"citation\">(2015; updated 2021)</span>: Treatment is recommended for anterior circulation aneurysms &ge;7 mm in patients with reasonable life expectancy (Class I, LOE B).  <br>2. PHASES Score Study <span class=\"citation\">(Greving et al., Lancet <span class=\"evidence\">Neurol 2014</span>; validation 2018)</span>: Established a 5-year rupture risk model highlighting aneurysm diameter as the predominant factor (Level II evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Rupture risk stratification&mdash;especially the primacy of aneurysm size&mdash;is frequently tested in neurology and neurosurgery board examinations, often via clinical vignettes requiring application of ISUIA or PHASES data.</div></div></div></div></div>"}, {"id": 100023080, "question_number": "293", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] - Livedo reticularis reflects a mottled, net\u2010like skin discoloration due to dermal microvascular impairment.  <br><span class=\"list-item\">\u2022</span> Sneddon syndrome is a noninflammatory thrombotic arteriopathy of medium\u2010sized vessels, classically combining livedo racemosa (a more irregular form of livedo reticularis) with recurrent ischemic strokes, often in the MCA distribution.  <br><span class=\"list-item\">\u2022</span> Distinguish from hypercoagulable states (e.g., antiphospholipid antibody syndrome) by absence of pathogenic antibodies and from large\u2010vessel vasculitides (Takayasu) or progressive intracranial arteriopathies (Moyamoya) by differing vessel involvement and imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Sneddon syndrome is confirmed by the clinical triad of livedo racemosa, recurrent ischemic strokes, and exclusion of aPL antibodies. Pathologically, it features noninflammatory intimal proliferation and luminal thrombosis in dermal and cerebral arterioles. A French multicenter series <span class=\"citation\">(Franc\u00e8<span class=\"evidence\">s et al., 2004</span>)</span> reported a mean age of presentation of 35 years, female predominance (M:F \u22481:4), and livedo preceding cerebral events by ~2 years. <span class=\"evidence\">The 2018</span> EULAR guidelines on management of antiphospholipid syndrome emphasize that patients with livedo and ischemic stroke should be tested for aPL; a negative panel prompts consideration of Sneddon syndrome (level of evidence 2B). Antiplatelet therapy is recommended empirically, though no randomized trials exist; retrospective data suggest reduced stroke recurrence with low\u2010dose aspirin or warfarin.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Antiphospholipid antibody syndrome  <br><span class=\"list-item\">\u2022</span> Why incorrect: Requires persistently positive lupus anticoagulant, anticardiolipin, or anti-&beta;2\u2010glycoprotein I. In Sneddon syndrome, these are absent.  <br><span class=\"list-item\">\u2022</span> Misconception: Any stroke with livedo must be APS &ndash; whereas livedo can be non\u2010immune in Sneddon.  <br><span class=\"list-item\">\u2022</span> Differentiator: APS shows hypercoagulability on laboratory testing; Sneddon does not.  <br><br>C. Moyamoya disease  <br><span class=\"list-item\">\u2022</span> Why incorrect: Characterized by progressive stenosis/occlusion of distal internal carotid arteries with basal collateral &ldquo;puff of smoke&rdquo; on angiography; no cutaneous findings.  <br><span class=\"list-item\">\u2022</span> Misconception: All young\u2010onset strokes imply Moyamoya &ndash; cutaneous signs are absent.  <br><span class=\"list-item\">\u2022</span> Differentiator: Moyamoya shows characteristic angiographic collateral network; Sneddon shows medium\u2010vessel arteriopathy without collaterals.  <br><br>D. Takayasu arteritis  <br><span class=\"list-item\">\u2022</span> Why incorrect: A granulomatous large\u2010vessel vasculitis affecting the aorta and main branches, presenting with pulse deficits, bruits, and systemic inflammation; no livedo reticularis.  <br><span class=\"list-item\">\u2022</span> Misconception: Any vascular skin change implies vasculitis &ndash; Takayasu does not affect dermal vessels.  <br><span class=\"list-item\">\u2022</span> Differentiator: Elevated ESR/CRP, imaging of the aorta, not medium dermal vessels.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Sneddon syndrome</th><th>Antiphospholipid syndrome</th><th>Moyamoya disease</th><th>Takayasu arteritis</th></tr></thead><tbody><tr><td>Vessel size</td><td>Medium (dermal, cerebral arterioles)</td><td>Small/medium (venules, arterioles)</td><td>Distal ICA and proximal MCA</td><td>Large (aorta and major branches)</td></tr><tr><td>Skin findings</td><td>Livedo racemosa (irregular livedo reticularis)</td><td>Livedo reticularis</td><td>None</td><td>None</td></tr><tr><td>Laboratory</td><td>Negative aPL antibodies</td><td>Positive lupus anticoagulant, aCL, anti-&beta;2GPI</td><td>Negative for aPL</td><td>Elevated ESR/CRP</td></tr><tr><td>Neuroimaging</td><td>Occlusive arteriopathy without collaterals</td><td>Normal vessels or infarcts</td><td>&ldquo;Puff of smoke&rdquo; basal collaterals</td><td>Aortic/branch stenoses, wall thickening</td></tr><tr><td>Histopathology</td><td>Intimal proliferation, thrombosis</td><td>Fibrin thrombi, no vasculitis</td><td>Fibrocellular intimal thickening</td><td>Granulomatous inflammation</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Livedo racemosa (broken, irregular pattern) is more specific for Sneddon than the regular net-like livedo reticularis seen in APS.  <br>2. In young stroke patients with skin findings but negative hypercoagulable workup, Sneddon syndrome should be considered; skin biopsy can confirm noninflammatory arteriopathy.  <br>3. Empiric antiplatelet therapy (aspirin 75&ndash;100 mg/day) is standard; anecdotal benefit with warfarin exists, but no RCTs have been conducted.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Assuming any livedo plus stroke equals APS without ordering aPL antibody panel.  <br><span class=\"list-item\">\u2022</span> Overlooking skin examination in stroke workup; failure to recognize livedo racemosa delays Sneddon diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- EULAR Recommendations for APS Management (2018): advise testing for aPL in unexplained strokes; negative results prompt alternative diagnoses such as Sneddon syndrome (Level 2B).  <br><span class=\"list-item\">\u2022</span> European Federation of Neurological Societies (EFNS) Guidelines on Non\u2010Atherosclerotic Vasculopathies (2020): recommend skin biopsy in suspected Sneddon for histopathologic confirmation (Level C evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam. On neurology boards, Sneddon syndrome is tested under noninflammatory arteriopathies; key clues include livedo racemosa and recurrent MCA\u2010territory strokes in young adults.</div></div></div></div></div>"}, {"id": 100023081, "question_number": "84", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Cerebral venous thrombosis (CVT) involves occlusion of dural venous sinuses or cortical veins, leading to impaired venous outflow, raised intracranial pressure, venous infarction, and hemorrhage. Key concepts:  <br><span class=\"list-item\">\u2022</span> Venous anatomy: superior sagittal, transverse, sigmoid sinuses; cortical veins.  <br><span class=\"list-item\">\u2022</span> Presentation: headache (often subacute), focal deficits, seizures, papilledema.  <br><span class=\"list-item\">\u2022</span> Diagnostic goal: visualize thrombus within venous channels to guide anticoagulation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>CTV (CT venography) directly opacifies the dural sinuses, allowing high-resolution visualization of filling defects.  <br><span class=\"list-item\">\u2022</span> Sensitivity 95%, specificity 91% for CVT <span class=\"citation\">(Saposnik et al., <span class=\"evidence\">Stroke 2011</span>)</span>.  <br><span class=\"list-item\">\u2022</span> AHA/ASA 2011 guidelines recommend CTV or MRV as first-line (Class I, Level B).  <br><span class=\"list-item\">\u2022</span> European Stroke <span class=\"evidence\">Organization 2017</span> concurs that CTV and MRV are equivalent alternatives.  <br>Digital subtraction angiography (DSA) remains gold standard historically but is now reserved for inconclusive cases due to invasiveness.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. MRI  <br>&bull; Refers to parenchymal MRI without venography sequences; may show indirect signs (edema, hemorrhage) but cannot reliably detect sinus thrombus.  <br>&bull; Misconception: &ldquo;Any MRI&rdquo; equals MRV. Only dedicated MR venography (MRV) sequences confirm CVT.  <br><br>C. CT scan  <br>&bull; Non-contrast CT sensitivity ~25&ndash;50%. Hyperdense sinus (&ldquo;cord sign&rdquo;) is transient and often missed.  <br>&bull; Misconception: CT head alone is sufficient; contrast venography is required.  <br><br>D. Lumbar puncture  <br>&bull; May show elevated opening pressure or xanthochromia but is nonspecific and can be dangerous if intracranial hypertension is present.  <br>&bull; Misconception: LP &ldquo;rules in&rdquo; intracranial processes; it cannot localize or confirm sinus thrombosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CTV (Correct)</th><th>MRI (No Venography)</th><th>CT Head Non-contrast</th><th>Lumbar Puncture</th></tr></thead><tbody><tr><td>Sensitivity</td><td>~95%</td><td>N/A for thrombus detection</td><td>~25&ndash;50%</td><td>N/A</td></tr><tr><td>Specificity</td><td>~91%</td><td>N/A</td><td>Low</td><td>Nonspecific</td></tr><tr><td>Key Finding</td><td>Filling defect in sinus</td><td>Venous infarct, edema</td><td>Hyperdense sinus (rare)</td><td>Elevated opening pressure</td></tr><tr><td>Invasiveness</td><td>Noninvasive, contrast required</td><td>Noninvasive</td><td>Noninvasive</td><td>Invasive</td></tr><tr><td>Role in CVT</td><td>Definitive diagnostic test</td><td>Adjunct; requires MRV</td><td>Initial screen only</td><td>Contraindicated if ICP\u2191</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- The &ldquo;empty delta sign&rdquo; on contrast-enhanced CT occurs in superior sagittal sinus thrombosis ~25% of cases.  <br><span class=\"list-item\">\u2022</span> Always follow non-contrast CT with CTV if CVT is suspected clinically.  <br><span class=\"list-item\">\u2022</span> Anticoagulation is initiated upon radiographic confirmation, even if hemorrhagic infarcts are present.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Interpreting a normal non-contrast CT as excluding CVT&mdash;CT without venography misses >50% of cases.  <br>2. Ordering MRI without specifying MR venography sequences; radiology requisitions must include MRV protocol.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2011 &ldquo;Diagnosis and Management of Cerebral Venous Thrombosis&rdquo;: recommends CTV or MRV as first-line vascular imaging (Class I, Level B).  <br><span class=\"list-item\">\u2022</span> European Stroke <span class=\"evidence\">Organization 2017</span> Update: endorses CTV or MRV equivalently; reserves DSA for equivocal cases (Level A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Thrombosis often occurs in the superior sagittal sinus (most common), followed by transverse and sigmoid sinuses. Cortical vein involvement may lead to localized hemorrhagic infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Thrombus formation in dural sinuses raises venous pressure \u2192 reduced CSF absorption at arachnoid granulations \u2192 intracranial hypertension \u2192 venous infarction and hemorrhage due to capillary rupture.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: headache + focal signs/seizures.  <br>2. Non-contrast CT head to rule out hemorrhage.  <br>3. If CT is non-diagnostic but suspicion remains, perform CTV (or MRV).  <br>4. If CTV/MRV equivocal, proceed to DSA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Cord sign: hyperdense cortical vein on non-contrast CT indicates acute thrombus (transient, may be missed).  <br><span class=\"list-item\">\u2022</span> Empty delta sign: contrast filling defect surrounded by contrast enhancement in superior sagittal sinus on CTV.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. CVT imaging modalities frequently appear as direct single-best-answer questions or as scenarios testing &ldquo;empty delta&rdquo; and &ldquo;cord&rdquo; signs, emphasizing the need to choose CTV/MRV over plain CT or routine MRI.</div></div></div></div></div>"}]